1117|Clinical and social outcomes,Total cost of treatment,measures of symptoms, overall functioning, and social functioning,Median direct costs,Cost effectiveness,Psychopathology, treatment satisfaction, subjective quality of life, and social disabilities,patient satisfaction,Indirect costs,symptoms, functioning, social adjustment, quality of life, and satisfaction with clinical services upon admission to the study, at discharge from the index admission,psychopathologic symptoms, treatment satisfaction, and quality of life,psychopathology, social functioning, interpersonal functioning, social network and social support,clinical, functional, social adjustment, quality of life, and satisfaction outcome measures,social functioning,clinical symptoms, social functioning, and burden on relatives|Day hospital care was as effective as conventional inpatient care with respect to psychopathologic symptoms, treatment satisfaction, and quality of life.
70|visual health,mean myopia progression,myopia progression,demographic factors, visual health knowledge, visual acuity, and refractive error,visual health knowledge, visual acuity, and refractive error,axial length elongation (ALE) of eye|After the intervention, the experimental group demonstrated improvements in visual health knowledge, visual acuity, and refractive error.
                
60|Immediate success,success rates,Recurrence rates|One-week success rates were 25 out of 27 (93%) in the intention-to-treat manual aspiration group and 28 out of 33 (85%) in the chest tube drainage group (p = 0.4).
142|One- and 2-year survival rates,One- and 2-year event-free survival rates,Therapeutic effect, residual foci of untreated disease, and complications of RF ablation and PMC,Major complications,One- and 2-year local recurrence-free survival rates,residual foci of untreated disease,number of treatment sessions per nodule,rates of residual foci of untreated disease,Complete therapeutic effect,local recurrence-free survival rates|One- and 2-year local recurrence-free survival rates were 98% and 96% in the RF group and 83% and 62% in the PEI group, respectively (univariate RR = 0.17;
89|visual analogue score (VAS), the Sinonasal Outcome Test-20 (SNOT-20), the Short Form 36 Health Survey (SF-36), nitric oxide (NO), acoustic rhinometry, saccharine clearance time (SCT), and nasal endoscopy,total nasal volume in CRS,subjective and objective parameters of CRS|Treatment consisting of sinus irrigation alone prevented surgery in 58% of all patients for 1 year.
369|outcome--desire to stop smoking,odds of point abstinence from smoking,Smoking state,relapse rate,maternal smoking and relapse,12-month abstinence rates,Prolonged abstinence rates,abstinence outcomes,abstinence rates,continuous abstinence rate,smoking cessation counseling,cessation rate,baseline desire to quit,urinary concentrations of cotinine,Quit rates and smoking behaviors,risk of relapse,Success rates,Smoking abstinence,actually quit smoking,7-day point prevalence abstinence,stopping smoking,number of days quit,Patient participation rates,prevalence of smoking,success rates,Smoking cessation,rates of abstinence,Assist-provide referral,quit attempts,relapse,quit smoking,Assist-discuss medication,urinary cotinine concentrations,cigarette consumption,standardized measure of breathlessness,quitting, self-reported quit rates,rate of decline,Mortality,readiness to quit and attitude toward and knowledge of ETS,stop smoking,Subjects' smoking status,mortality range,prevalence of sputum production and dyspnoea; ventilatory function,quit attempt,success rate,cessation rates,6-month abstinence included number of previous quit attempts, quitting for 24 hr in the past year, desire to quit, confidence in quitting, perceived health benefits, and lower nicotine dependence,blood pressure levels,maternal quitting or relapse,Advise,percentage of smokers who stopped smoking,sustained cessation rates,sustained abstinence,myocardial infarction,rate of misreporting,antismoking behavior (quit, quit and relapse, or cut down,point prevalence of quitting,stopped smoking,Measurement of breath carbon monoxide (CO) and urinary cotinine, a metabolite of nicotine,attempts to quit,quit rates,number of quit attempts,breath CO,6-month prolonged abstinence,mean symptoms score for depression,prevalence abstinence rate,Lack of power, contamination, and low attendance,smoking abstinence|None of the interventions had any effect on point prevalence of quitting as determined 8-9 months later by self-report.
47|skeletal change, alignment, and occlusion of the teeth, or length and complexity of treatment,overjet and severity of malocclusion,skeletal and dental changes,inclination of the upper incisors to the maxillary plane,Anteroposterior skeletal and dental changes,lower failure-to-complete rate,reduction of overjet, correction of molar relationships, and reduction in severity of malocclusion,final occlusal result and skeletal discrepancy,least forward movement of point,PAR index,dental movement,greatest proclination of the lower labial segment,sagittal skeletal relationship,favourable growth responses,PAR scores,lateral cephalometric radiographs taken,posterior facial heights,horizontal mandibular growth development,Peer Assessment Rating (PAR) Index,mandibular length|The Bionator and Twin Block groups showed statistically significant reductions in the inclination of the upper incisors to the maxillary plane (P < 0.05).
595|process-of-care measures,overall understanding of epilepsy,quality of care,level of advice recorded as having been given on drug compliance, adverse drug effects, driving, alcohol intake, and self help groups,patients' levels of knowledge of epilepsy,Frequency of clinic attendance, mean seizure frequencies, and mean serum levels of phenobarbitone,quality of life (QOL,knowledge,seizure rates,medication-related side-effects,medication compliance,behavioral (QOLIE-89, POMS, PSDQ, Self-Esteem) and clinical (seizure activity, antiepileptic drug (AED) concentrations) outcomes,seizure frequency,SF-36 health-related quality-of-life instrument,generic questionnaires (SF-36, self-esteem,AEP scores,communication and satisfaction,Patient compliance and clinical control,behavioral outcomes,blood levels of antiepileptic drugs (AEDs,50-item true-false test specifically designed to evaluate the SEE program, the Washington Psychosocial Seizure Inventory, the Beck Depression Inventory, Lubin's Depression Adjective Checklist, the State-Trait Anxiety Inventory, the Acceptance of Disability Scale, and Sherer's Self-Efficacy Scale,Questionnaire responses,Seizure frequency and satisfaction,patient quality of life or quality of epilepsy care,Clinical and Behavioral Outcomes,risk of depression,Physical Role Limitations,Medication Effects,quality of life,knowledge levels,seizure outcome,QOL,seizure activity,QOLIE-89 score,battery of prevalidated epilepsy-specific quality-of-life instruments,overall quality of life and two domain scores,average duration of epilepsy,questionnaire assessing patients' knowledge of epilepsy, the Hospital Anxiety and Depression Scale, and patients' reported satisfaction with the advice and explanations provided on key epilepsy-related topics,plasma anticonvulsant levels and prescription refill frequencies), and seizure frequency,depression scores,knowledge scores,fear of seizures,hazardous medical self-management practices,Compliance and seizure frequency,knowledge of epilepsy scores,Seizure frequency,knowledge, anxiety, and depression,proportion of seizure,active seizures,generic instruments (SF-36, Rosenberg self-esteem Scale, von Zerssen Depression Scale), and epilepsy-specific scales (Restrictions in Daily Life, Epilepsy-Related Fears, Coping with Epilepsy and Adaptation,Knowledge scores,physical self-concept and vigor that improved and total mood disturbance,doctor-held card practices,tolerability of antiepileptic drug (AED) therapy, fewer side effects,Mean change in Quality of Life in Epilepsy Inventory (QOLIE)-89 total scores|Users of the new service were significantly more likely than non-users to have discussed 8 of 11 topics asked about epilepsy [odds ratios (ORs) ranging from 2.42 to 7.91] with their general practitioner (GP), and 2 of the 11 topics with the hospital doctor (ORs 5.59, 5. 74).
not found|Survival,Hospital admissions,Length of stay and intensive care unit use,inpatient mortality,unmet need for supportive services, medical care utilization (ambulatory visits, emergency department visits, and hospitalizations), and use of HIV medication (receipt of antiretroviral therapy and prophylaxis against Pneumocystis carinii pneumonia and toxoplasmosis,relative hazard of death,survival,Experience and survival,average length of a hospital inpatient stay,timing of starting anti-Pneumocystis medications,adjusted odds of hospitalization,Hospitalization,functional status and patients' self-ratings of physical condition at hospital discharge,health insurance,health insurance status and hospital characteristics,low birth weight infants and preterm deliveries,emergency department visits ,HIV specialty care,baseline CD4+ cell counts,process of care for PCP and short-term mortality rates,longer survival,Utilization of services, health-related quality of life, preventive and screening measures, and antiretroviral use,Patient satisfaction,home health care,emotional counseling,inpatient mortality and (2) 30-day mortality,30-day mortality,Mortality,AORs of adherence,Relative risk of mortality,Prenatal Care Utilization Index (APNCU,Adjusted odds ratios (AORs) of acceptable antiretroviral therapy,activated patient problems,number of visits,CD4+ T-cell counts,hospitalization,use and timing of bronchoscopy, the type and timing of PCP therapy, and in-hospital mortality,adjusted odds ratio (AOR) of repeated ED visits,median CD4+ T-cell count,social workers' services,survival rates,intensive care,percentages of acquired immunodeficiency syndrome (AIDS,definitive diagnosis rates,continuity, referral services, and behavioral risk reduction counseling,survival probability,length of stay,adjusted odds ratios (AORs) of treatment,utilization of ambulatory care,mean cost of HIV-related drugs,Length of stay, cost, and intensive care unit use,mortality|There were no significant differences in patient outcome as measured by functional status and patients' self-ratings of physical condition at hospital discharge.
15|Body weight,severity of disturbed behavior,euphoria, somnolence and tiredness,anorexia and disturbed behavior,Adverse reactions,serious intercurrent infections|Dronabinol treatment decreased severity of disturbed behavior and this effect persisted during the placebo period in patients who received dronabinol first.
3088|wound infections,Surgical site infection rates,general surgery wound infection rates,Postoperative wound infections and surgical face masks,number of Streptococci,pre-operative stay,surgical site infections|This difference was not statistically significant (p greater than 0.05) and the bacterial species cultured from the wound infections did not differ in any way, which would have supported the fact
261|having quit smoking,CO-confirmed prolonged abstinence rates,smoking cessation outcomes,Mean compliance,number of times quit,percentage who achieved 6-month prolonged smoking abstinence,Sustained abstinence, reflecting 7-day abstinence,7-day abstinence and duration since last cigarette,Point prevalence abstinence, quit attempts, changes in smoking rate and longest quit attempt,7-day abstinence rates,habit of cigarette smoking,retention rates,mean saliva cotinine concentrations,30-day prolonged abstinence (carbon monoxide level,Mean smoking rates,Health Risk Appraisal (HRA,quit smoking,cigarette consumption,safety and efficacy,duration of smoking and number of cigarettes smoked daily (P<.05,smoking reduction (CPD and thiocyanate concentrations,feasibility, acceptability, and effectiveness,smoking rates,refusal self-efficacy,attitudes toward smoking,cotinine levels,prolonged abstinence, assessed through self-report and verified with exhaled carbon monoxide (CO) levels,Self-reported smoking rate,Positive change in stage and smoking status,survival curves,change smoking behaviour (upon hospital discharge), and self efficacy for smoking cessation,smoking cessation,Cessation rates,quantity and frequency of smoking relative to standard care,point prevalence rates,Safety and efficacy,Abstinence rates,30-day, point-prevalence smoking abstinence rates for BOI and SOS,Cotinine-confirmed 7-day point prevalence abstinence rates,cessation rates,prevalence abstinence rates,NOT smoking cessation and reduction outcomes,numbers of cigarettes smoked,successful quit attempts,tolerated, and adverse events,smoking cessation rate,CO or thiocyanate concentrations,6-months prolonged abstinence from smoking,cessation attempts and point abstinence,carbon monoxide-validated quit and reduction rates for NOT and BI schools|Although treated participants improved more in tobacco related knowledge relative to controls (p = 0.002), there were no group differences in changes in attitudes toward smoking.
not found|mean fit and treatment interval,laboratory parameters and serum magnesium levels,maternal age; gestational age; systolic and diastolic blood pressures,magnesium levels,MgSO4 treatment,Glasgow Coma Scale (GCS,PGF1alpha levels,recurrent convulsion rate,prostacyclin (PGI(2)) and thromboxane A(2,Plasma levels of 6-keto-PGF1alpha and TXB(2), stable metabolites of PGI(2) and TXA(2,Maternal blood pressures,diastolic blood pressure,average serum magnesium concentrations,maternal blood pressure,type of eclampsia,proteinuria,severe preeclampsia,insulin-requiring diabetes,return of consciousness,systolic blood pressure,enzyme-linked immunosorbent assay (ELISA,TXB(2) levels,number of convulsions,seizures, MgSO4 toxicity, or intolerance,fit and delivery interval,Case fatality rate,frequency of progression to severe disease,blood pressures,Venous blood,rate of recurrent convulsion,Prostacyclin and thromboxane levels,prostacyclin and thromboxane levels,systolic and diastolic pressures,Platelet counts|Similar average serum magnesium concentrations were produced by the regimens the only significant difference was that fluctuations in magnesium levels were greater with the IM than the i.v.
70|ESR,normal hematocrit level,hematologic response,serious adverse effects,excellent hematologic responses to recombinant erythropoietin, without toxicity,efficacy and secure safety,secondary disease activity measures Ritchie index, number of swollen joints, pain score, ESR, and patients' global assessment of disease activity,anaemia and disease activity,haemoglobin,energy level,decrease, or omission of the erythropoietin dosage,hematocrit,normal haemoglobin levels,meaningful hematologic response,C reactive protein concentrations,activities of daily living or pain levels,adverse effects|Significant differences in favour of the Epo group were also observed in the secondary disease activity measures Ritchie index, number of swollen joints, pain score, ESR, and patients' global assessment of disease activity.
100|child coping or decreased distress,distress,pain and behavioral distress,pain using a 4-point pain scale,children's coping, distress, pain, and need for restraint; nurses' and parents' coaching behavior; and parents' and nurses' distress,preprocedural anxiety ratings,nurse coaching and child coping and less child distress,pain, and radial pulse rates,level of hypnotizability,pain relief,pain using a visual analog scale (VAS,Self-reported pain and fear,crying,anxiety,Pain, subjective evaluation of experience,pain and fear; parents and child life specialists (CLS) rated the child's fear, and CLS rated the child's distress,distraction,practical and cost-effective,procedural distress,injection pain,Faces Pain Scale, and rated their anxiety about the procedure using the Children's Anxiety and Pain Scale,anticipatory anxiety and less procedure-related pain and anxiety,needle pain severity,VAS scores,pain and pain-related anxiety,pain severity scores,Satisfaction ratings,child distress,low distress despite reporting moderate anxiety and pain,behavioral distress,anticipatory physiological and self-report ratings relative,pain and anxiety,self-report ratings of pain,ratings of pain-related behaviour,child behavioral distress or self-report of pain,pain and distress,nurse or parent visual analog scale scores,VAS pain scores,children's pain, fear, and distress,heart rate,pain,pain, fear, and distress,pain behaviors,procedural coping and distress behavior,relief of pain|Prepared children reported significantly less pain, and radial pulse rates confirmed that they were less distressed by the procedure.
24|EMDR condition,number of nightmares,reduced PTSD and depression,posttreatment symptoms of PTSD and dissociation,clinical severity,depression and guilt and substantial increases in self-esteem,PTSD symptoms, rape-related distress, general anxiety, and depression,apparent habituation effect,efficacy, speed, and incidence of symptom worsening,PTSD symptom severity,psychiatric symptoms, functional status, quality of life, physical health, and service utilization,SIT and PE-SIT,number of self-report, psychometric, and standardized interview measures,trauma-related symptoms,degree of intrusion symptoms, EMDR,Nightmare Frequency Questionnaire (NFQ), Pittsburgh Sleep Quality Index (PSQI), PTSD Symptom Scale (PSS), and Clinician-Administered PTSD Scale (CAPS,numbing and hyperarousal symptoms,dropout rate,EMDR and relaxation,Clinician-Administered PTSD Scale, the PTSD Symptom Scale, the Structured Clinical Interview for DSM-IV, the Beck Depression Inventory, and the Trauma-Related Guilt Inventory,avoidance and numbing and, possibly, PTSD symptoms,standard clinician- and self-administered PTSD and related psychopathology scales,total mood disturbance,PTSD scores,Subjective Units of Distress (SUDS) ratings,posttraumatic stress disorder,PTSD symptoms,Posttraumatic stress symptoms,Postsession SUDS,chronic nightmares, improve sleep quality,outcome measure (Beck Depression Inventory, State-Trait Anxiety Inventory, Penn Inventory for Posttraumatic Stress Disorder, Impact of Event Scale, Tennessee Self-Concept Scale,severity of PTSD and depression,traumatic stress symptoms,Comparative efficacy, speed, and adverse effects,PTSD,Profile of Mood States total mood disturbance,affect regulation problems, interpersonal skills deficits, and PTSD symptoms,self-report and observer-rated measures of PTSD, and self-report measures of depression,success rate,PTSD and depression,PTSD and depression symptoms,PTSD and maladaptive cognitive styles,PTSD severity,NFQ and improved sleep,nightmares, sleep, and PTSD,PTSD severity, depression, and anxiety,frequency of disturbing dreams, improves sleep quality|On global PTSD measures, there were no significant differences between the treatments at the end of therapy.
not found|Serum gonadotropin levels,spermatogenesis suppression and safety,Serum luteinizing hormone (LH,sperm concentrations,Serum HDL levels,suppression of pituitary and testicular function,serum LNG levels,testosterone, LH, and FSH levels,suppressing LH, FSH, and sperm production,blood count, lipid profile, liver function tests, prostate-specific antigen (PSA), sex hormone binding globulin (SHBG), prolactin or cortisol,dosage of LNG,stable, physiological T levels,Spermatogenic suppression,pretreatment gonadotropin levels,Serum gonadotropins levels and sperm concentration,gonadotrophin secretion without adverse metabolic or behavioural effects,Severe oligoazoospermia,serum gonadotropins and androgens and sperm concentration,lipoprotein or haemoglobin concentrations,Time to azoospermia,azoospermia,weight and decline in high-density lipoprotein cholesterol,Spermatogenesis,liver enzymes,Severe oligospermia or azoospermia,mean LH and FSH levels,Gene expression,pituitary-testicular functions,Monthly LH and FSH levels by RIA and twice monthly sperm counts,weight, hematocrit, clinical chemistry, or prostate-specific antigen levels,Serum levels of HDL cholesterol,suppression of spermatogenesis to oligozoospermia,Efficacy of suppression,contraceptive efficacy,Serum free T levels,DHT concentrations fell,proportions achieving azoospermia,weight gain or HDL suppression,azoospermic; gonadotropin levels,spermatogenesis suppression,weight gain and suppression of serum high-density lipoprotein (HDL) cholesterol levels,adverse events such as weight gain, mood changes, acne, sweating, or libido change,Mean haemoglobin levels,Average weight gain,Serum levels of LH,Accumulation ratios of serum total and free T levels,Steady-state serum LNG levels,Prostate volumes,Serum low-density lipoprotein cholesterol levels,additional suppression of gonadotropins or sperm concentration,serum chemistry,spermatogenesis and azoospermia,serum T levels,weight gain,HDL levels,Serum dihydrotestosterone levels,body weight, hemoglobin, hematocrit, or high-density lipoprotein cholesterol concentrations,spermatogenesis and circulating gonadotropin levels,Sperm concentration fell,mean serum levels,Consistent azoospermia or severe oligozoospermia,sperm concentration,Sperm counts, serum testosterone (T), luteinizing hormone, follicle-stimulating hormone, and LNG,weight and cholesterol,body weight, erythrocytes, hemoglobin, and hematocrit and decrease in high-density lipoprotein cholesterol and alkaline phosphatase,suppression of spermatogenesis,T levels,hematocrit and hemoglobin,weight gain and suppression of serum high-density lipoprotein cholesterol (HDL) levels,suppression of spermatogenesis, pituitary-testicular axis, and lipid metabolism,serum LH and T,suppression of spermatogenesis with azoospermia,Inhibin-alpha and the spermatocyte marker acrosin-binding protein,serum SHBGs,Mean trough testosterone concentrations,serum SHBG,serum LH and FSH,LH, FSH, and sperm production,marked suppression of spermatogenesis,weight gain and HDL cholesterol suppression,spermatogenesis, reproductive hormones, testis, and prostate,reduced expression of 5alpha-reductase type,Sex hormone-binding globulin levels,Total cholesterol, high density lipoprotein cholesterol, and low density lipoprotein cholesterol,adverse metabolic side effects,recovery of sperm counts and gonadotropins to normal levels,Plasma epitestosterone,suppression of gonadotropins,Testosterone concentrations,maximum concentration and area under the curve (AUC) for serum total and free testosterone (T,Suppression,suppression of serum high-density lipoprotein cholesterol,Severe oligospermia,body composition, lipids, prostate-specific antigen, haematological or biochemical variables,sperm production,azoospermia rates,testosterone concentrations,complete suppression of gonadotropins,Total and free testosterone,maximal suppression of spermatogenesis,severe oligozoospermia,high density lipoprotein cholesterol,efficiency of suppression to severe oligozoospermia,suppression of sperm density,Serum HDL cholesterol levels,serum FSH and LH levels,induction of azoospermia or severe oligospermia,serum total T,expression of steroidogenic enzymes,tolerated,serum MENT levels,High-density lipoprotein cholesterol fell,Gonadotropin and testosterone concentrations,efficacy, hormone profiles, and safety,average concentration and AUC of serum total and free T,serious adverse effects,azoospermia, weight gain, and serum high-density cholesterol (HDL) suppression,Median recovery time,serum sex hormone-binding globulin,gonadotropin, sperm suppression, and prostatic effects,density lipoprotein (HDL) suppression and weight gain,effective suppression of sperm output,luteinizing hormone and follicle-stimulating hormone,Serum high density lipoprotein cholesterol,hemoglobin,sperm density,mild truncal acne, weight gain,loss of libido,Plasma LH and FSH,Peak testosterone concentrations,LH and FSH levels and sperm counts,Gonadotropins,Serum FSH,gain weight,Plasma total and free testosterone levels,Sperm concentrations,luteinizing hormone, follicle-stimulating hormone, and sperm production,sperm output,uniform severe oligoazoospermia,Serum T levels,azoospermic or severely oligozoospermic,weight gain and HDL suppression,Faster suppression,sperm counts,T implant extrusion,Trough serum LNG levels,Serum oestradiol concentrations (S-E(2,peak MENT levels,Serum levels of dihydrotestosterone (DHT,attainment of azoospermia,Hemoglobin concentrations rose, and high density lipoprotein-cholesterol (HDL-C,suppression of spermatogenesis to severe oligozoospermia,peak plasma oestradiol,Semen analyses, blood drawings, physical examinations, and prostate ultrasounds,persistent sperm concentrations,frequent escape from gonadotrophin suppression,lipid metabolism,suppression of gonadotropins and sperm production,hematocrit,Azoospermia,Serum testosterone concentrations (S-T,spermatogenic suppression,mixed antiglobulin reaction (MAR)-IgG, MAR-IgA or tray agglutination test (TAT,hematology or chemistry profiles,trough testosterone levels,LH and FSH,Suppression to severe oligozoospermia,Acne and increased hemoglobin,erythrocyte count, hematocrit, and hemoglobin and a decrease in SHBG,Weight gain, development of acne,Prostate-specific antigen and lipids (total, low or high density lipoprotein cholesterol, and triglycerides,weight gain and high-density lipoprotein suppression,lipoproteins, fibrinogen or sexual behaviour during treatment, and minor falls in haematocrit and haemoglobin concentration,total serum T|In all groups marked suppression of gonadotropins resulted in a significant decrease of spermatogenesis and azoospermia in 13/14, 11/12, and 12/14 men in groups I to III, respectively.
160|menstrual blood loss and pelvic pain,lighter blood loss,excessive menstrual bleeding,MBL,Pain,Efficacy of pain relief,dysmenorrhoea and/or increased menstrual bleeding,severe side effects,mean menstrual loss,IUD removal within 12 months of insertion,menstural blood loss,mean menstrual blood loss,pain alleviation,intensity of dysmenorrheic pain,IUD associated uterine bleeding,heavier blood loss,menstrual blood loss (MBL) and pain,excessive IUD-induced bleeding,menstrual bleeding,blood loss,Menstrual blood loss (measured by pictorial blood loss assessment chart) and uterine artery resistance,duration and amount of the menstrual blood flow,overall relief,pelvic discomfort,menstrual bleeding and pain,Menstrual blood loss,menstrual loss,change menstrual blood loss,IUD-induced pain,menstrual blood loss and pains,hazard ratio for removal for these IUD-induced side effects,uterine artery pulsatility index,bleeding time,menstrual blood loss,excessive menstrual blood loss,bleeding time and basal menstrual blood loss,dysmenorrhea and premenstrual uterine pain,menstrual blood losses,pain intensity,pain and reduced bleeding,Dysmenorrhea,pain scores|T.A. relieved pain and reduced bleeding after insertion and during three subsequent menstruations without serious side-effects.
not found|lung inflammation and pulmonary microvascular permeability,inflammatory mediators, albumin, and oxygen requirements,levels of interleukin-8, elastase alpha1 proteinase inhibitor, free elastase activity, and albumin,Pulmonary inflammation and lung permeability,oxygen requirements,concentrations of the inflammatory mediators and of albumin,concentrations of interleukin-8, elastase alpha1 proteinase inhibitor, and albumin,lung inflammation|Pulmonary inflammation and lung permeability were assessed by analyzing the levels of interleukin-8, elastase alpha1 proteinase inhibitor, free elastase activity, and albumin in tracheal aspirates on days 10 and 14 of life.
75|time required for canine eruption,successful eruption,Successful or unsuccessful canine eruption,Cervical vertebral maturation,success rate,prevalence rates of successful canine eruption, and the amount of time for canine eruption|The cephalometric superimposition study showed a significant mesial movement of the upper first molars in the CG and EG when compared with the EHG.
34|stroke scores,ischemic damage,neurological deficits,efficacy, safety, and feasibility,Orgogozo scale,myocardial infarction,percentage of patients with improvement at 24 hours (National Institutes of Health Stroke Scale [NIHSS]) and 90 days (NIHSS, Barthel Index, modified Rankin Scale, Glasgow Outcome Scale,complications of treatment and mortality at 90 days,modified Rankin Scale,pretherapeutic and posttherapeutic scores,time from stroke onset to randomization, and Orgogozo scale scores,therapeutic efficacy of HBO,Orgogozo scale score,Neurological deterioration,Rankin score|Moreover, no statistically significant improvement was observed in the HBO group at 6 months and 1 year according to Rankin score (P < .78) and our own 10-point scale (P < .50).
                
27||At 30 minutes following treatment, 81% of the patients treated with haloperidol but only 36% treated with droperidol required a second injection (p less than .05).
393||There were seven cases of endomyometritis in the group given no antibiotic and none in the cefotetan group, a statistically significant difference (P less than .01).
not found|incidence of complication,Broberg and Morrey scores and postoperative complication rate,Postoperative complication rate,Functional status,Broberg and Morrey Elbow Score,favourable joint function|Mean follow-up of the eight cases in the ORIF group was 14 months (range 10-21 months), with good results in one case, fair in four, and poor in three.
20|safety and efficacy,various pain scores,mean pain scores,pain relief and side effects|However, there was no statistically significant difference in mean pain scores between the groups.
                
326|condom failures,acceptability and efficacy,Questionnaire data,HIV/AIDS-related knowledge, protective attitudes, and self-efficacy for HIV risk reduction,self-reported condom use,emotional distress,HIV/AIDS-related knowledge and risk reduction self-efficacy,risk reduction behavior,HIV prevention information, motivation, behavioral skills and behavior,HIV risk,readiness to change "risky" partner-selection behavior,situational self-efficacy,knowledge about sexually transmitted diseases (STDs), (b) self-reported sexual risk behavior, and (c) STD acquisition,general knowledge, greater condom negotiation self-efficacy,mean distress measures,decision-making knowledge and behavior, assertiveness knowledge and behavior, and interpersonal communication knowledge, attitude, and behavior,scales measuring physical outcome motivation and social outcome motivation,HIV/acquired immune deficiency syndrome (AIDS) knowledge, self-efficacy and outcome expectancies,scales measuring autoimmune deficiency syndrome (AIDS) knowledge, self-evaluative outcome motivation, and intention to practice HIV preventive behaviors with current partner|Regarding the effects of the intervention, results indicate that students in the experimental school were less likely to initiate sexual activity and had greater general knowledge, greater condom negotiation self-efficacy, more favorable attitudes toward waiting to have sex, and greater situational self-efficacy than in the control school.
88|QoL score and functional severity index,quality of life (QoL) and functional severity index; asthma knowledge and understanding of asthma action plans (AAPs); and school days missed because of wheezing,unscheduled visits to hospital or a doctor caused by asthma exacerbation,school days because of wheezing,primary outcome (number of unscheduled medical visits for asthma,frequency of asthma exacerbations|Significantly more carers in the intervention group could answer questions about asthma medication, knew where their AAP was kept (84% v 56%), and were able to describe the plan (67% v 40%).
17|adverse events,energy intake, but vegetables,Subsequent growth velocity,maintenance of remission,energy intake,Lloyd-Still disease activity index, erythrocyte sedimentation rate, C reactive protein and albumin concentrations, and body weight,aminotransferase activity,height velocity,Growth,mean energy intake,duration of steroid use,mild leukopenia,disease activity and duration of remission|The elemental diet was equally effective in inducing an improvement in Lloyd-Still disease activity index, erythrocyte sedimentation rate, C reactive protein and albumin concentrations, and body weight as the high dose steroid regimen.
not found|Analgesic effect,pain intensity and relief on categorical scales and pain half-gone on a dichotomous nominal scale; a categorical overall evaluation,analgesic activity,pain intensity and pain relief,Sum Pain Intensity Difference (SPID,relief of postpartum episiotomy pain,frequency or intensity of side effects,pain intensity and pain relief and summary measures,pain intensity differences, peak pain intensity differences, total relief, peak relief, and hours of 50% relief,overall pain relief,sum pain half-gone, and overall evaluation,rapid analgesia,Assay-sensitivity and test power,efficacy variables,relative analgesic efficacy and safety,Pain intensity difference (PID) and sums of pain intensity difference (SPID,parameters (pain relief, pain intensity, patient's global evaluation, duration of analgesia,degree of pain relief and tolerance,pain relief and pain intensity difference,Overall pain scores,Remedication time,moderately severe baseline pain intensity; post-treatment pain relief,additional pain relief,pain scores,acetaminophen analgesia,pain intensity or relief,pain intensity difference and summed pain intensity differences,onset of meaningful relief,time to rescue analgesic,pain intensity and pain relief measurements,Drug tolerability,local adverse events,number of patients requiring rescue medication,Ratings of pain intensity and pain relief,pain relief, pain intensity difference, total pain relief (TOTPAR), and summed pain intensity difference (SPID,small additive effects,peak pain intensity difference (visual analog scale), summed pain intensity differences, total pain relief, peak pain relief, time to reduction of pain,pain intensity differences,postoperative pain,severe postoperative pain,median time to onset of analgesia,Pain relief,relative analgesic efficacy,frequency of adverse effects,later time to taking escape analgesics,remedication time,level of pain and pain relief,Severe pain,effective analgesic activity,meaningful relief,median time to meaningful pain relief,Analgesic efficacy,analgesia,SPID, TOTAL, and global ratings,efficacy (sum of pain intensity differences, largest pain intensity difference, total pain relief, largest pain relief, and time to remedication,side effects,intensity of pain, relief of pain, and side effects,time to onset of relief and overall analgesic efficacy,visual analogue pain scale and a pain score,Visual analogue pain intensity score (VAS 0-100 mm) and categorical pain relief score,serious adverse events,postoperative dental pain,Analgesia,sum pain intensity difference, total relief of pain, and overall evaluation parameters,mean response with zomepirac,adverse reaction,pain intensity and relief and stopwatch onset of meaningful relief,relief of postoperative pain,adverse reactions,overall pain scores (AUC(0,360 min), maximum pain relief, pain relief at 1 h after dosage and the number of patients taking escape analgesics,peak analgesia,overall analgesic effect,median times to onset of relief,postsurgical dental pain,Pain intensity, pain relief, and side effects,analgesic response,incidence of adverse events,tolerated,maximum pain relief,peak and overall analgesic effects,total or peak analgesia,pain severity and relief on categorical scales,relative onset of analgesic response, overall analgesic efficacy, duration of effect, and safety,adverse effects,number of hours until remedication,serious adverse effects,mean scores,Total Pain Relief (TOTPAR,rapid onset to meaningful relief,Side effects,analgesic effects,standard verbal rating and visual analog scales,duration of analgesic effect,patient self-rating of pain intensity, pain relief, time to meaningful pain relief, need for additional analgesic medication, and patient global evaluation,additive analgesic efficacy,pain relief,intensity of pain,efficacy and safety,analgesic efficacy,Adverse events,intensity of their pain,PID and SPID scores,analgesic effect,analgesic effectiveness,tolerability,onsets of first perceptible relief and meaningful relief,pain intensity difference, total pain relief, and reduction of pain,pain intensity difference, pain relief, and global evaluation,total pain relief during the first 3 and 6 h, global evaluation score,total and peak analgesia,analgesic efficacy and safety,Pain intensity,pain intensity,analgesic efficacy and tolerability,pain,faster relief and superior overall efficacy,Analgesic efficacy and safety|Both doses of diflunisal were significantly more effective than acetaminophen alone and produced peak analgesia comparable to that of the acetaminophen-codeine combination.
not found|progression of disability,Mini-Mental State Examination,disability, dependency, behavioural and psychological symptoms, carers' psychological wellbeing, or delay in institutionalisation,nausea,incidence of drug-related adverse events,Alzheimer Disease Assessment Scale-cognitive subscale,caregiver-rated global impression,levels of caregiver stress with a modified, multiple-item Caregiver Stress Scale (CSS,CSS total and individual domain scores,functional skills,overall distribution of caregiver ratings,entry to institutional care and progression of disability, defined by loss of either two of four basic, or six of 11 instrumental, activities on the Bristol activities of daily living scale (BADLS,Disability Assessment for Dementia (DAD), the modified instrumental activities of daily living (IADL) scale (IADL+), and the modified Physical Self Maintenance Scale (PSMS,Efficacy,subscale scores,efficacy and safety,cognitive performance test, the Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog) and a global evaluation, the Clinician's Interview-Based Impression of Change with caregiver input (CIBIC plus,Alzheimer's Disease Assessment Scale-cognitive subscale scores,IADL+ and PSMS+ mean change,Computerized Memory Battery Test subscales: facial recognition,cognition and global function,effective and well tolerated,behavioural and psychological symptoms, carer psychopathology, formal care costs, unpaid caregiver time, adverse events or deaths,cognitive performance test, the Japanese version of the Alzheimer's Disease Assessment Scale - cognitive subscale (ADAS-J cog, p = 0.003) and a clinical global assessment, the Japanese version of the Clinical Global Impression of Change,specific tests of explicit memory or verbal fluency,safety and efficacy,caregiving competence, personal gain, and management of distress,safe and well tolerated,diarrhea,Mini-Mental State Examination, the Computerized Memory Battery Test, the Clinical Dementia Rating Scale-Sum of the Boxes, the Patient Global Assessment Scale, and the Apathy Scale,Change in Alzheimer's Disease Assessment Scale cognitive subscale scores,Sum of the Boxes of the Clinical Dementia Rating (CDR-SB), the Mental Function Impairment Scale (MENFIS) and the caregiver-rated modified Crichton scale (CMCS,modified Alzheimer Disease Assessment Scale-cognitive subscale,Caregiver time spent assisting patients with basic and instrumental ADLs,caregiving time and lower levels of caregiver stress,Sum of the Boxes of the Clinical Dementia Rating Scale (CDR-SB), a modified Interview for Deterioration in Daily living activities in Dementia (IDDD) and a patient rated quality of life assessment,Alzheimer's Disease Assessment Scale-cognitive subscale and the Clinical Dementia Rating-Sum of the Boxes,activities of daily living (ADLs) and social functioning,cognitive and global function,relative risk of progression of disability or entering institutional care,relative risk of entering institutional care|There was no associated change in caregiver-rated global impression (donepezil vs placebo: proportion improved, 0.24 vs 0.22; proportion worsened, 0.27 vs 0.35; P = .34) or on specific tests of explicit memory or verbal fluency.
not found||Injuries to the medial collateral ligament could not be demonstrated to benefit from surgical treatment in any respect--with or without surgery the results were excellent.
96|Ovarian response,cancellation rate,duration of ovarian stimulation,number of follicles,clinical pregnancies,implantation rate,rate of decline in E(2,number of ampules and units of FSH,Cancellation rate,number of MII oocytes,duration of stimulation and consumption of gonadotrophins,number of metaphase (M) II oocytes, the number of embryos transferred, and the pregnancy rate,PRs per cycle and per transfer,higher pregnancy rates,number of oocytes retrieved,number of mature oocytes,serum luteinizing hormone (LH) levels,fertilization rate,lower estradiol (E(2,Mean follicular phase serum luteinizing hormone (LH) and progesterone (P) levels,higher E(2) level,numbers of mature oocytes retrieved and of top-quality embryos transferred,LH, serum E(2) levels,number of oocytes,number of mature oocytes retrieved, embryo quality, fertilization, implantation, and pregnancy rates,implantation and pregnancy rate,cancellation rates, more oocytes per pickup (OPU), more embryos transferred per patient, and a higher pregnancy rate,number of ampoules of gonadotrophins required,rate of folliculogenesis,ovulation), pregnancy rate,Number of oocytes retrieved, pregnancy rate (PR) per cycle, PR per transfer, and implantation rate|There was significantly reduced duration of stimulation and consumption of gonadotrophins in the antagonist group when compared to the agonist group.
30|disease-specific quality of life,subjective response, tinnitus questionnaire, tinnitus severity index and the loudness perception,Tinnitus Handicap Inventory score,Serum levels,severe idiopathic subjective tinnitus,tinnitus annoyance,questionnaires and visual analog scales,Tinnitus Handicap Inventory; secondary measures include the Profile of Mood States (POMS) rating scale, subjective tinnitus severity,sensation of subjective idiopathic tinnitus,questionnaires, visual analog scales, and a battery of audiologic measurements,Perceived intensity and intrusiveness of tinnitus|There was not a significant subjective improvement in tinnitus annoyance for the patients (37%) versus controls (42%).
64|Sinonasal Outcome Test-20 (SNOT-20), measurements of peak nasal inspiratory flow, saccharine transit time, olfactory function, nasal endoscopic scoring, and nasal lavage assays for interleukin-8, fucose, and a2-macroglobulin,olfactory function, peak nasal inspiratory flow, or lavage levels for fucose and a2-macroglobulin,SNOT-20 score, nasal endoscopy, saccharine transit time, and IL-8 levels in lavage fluid (P<.05|No significant improvements were noted for olfactory function, peak nasal inspiratory flow, or lavage levels for fucose and a2-macroglobulin.
18|night-time symptom relief and sleep satisfaction assessments,nasal congestion/runny nose/cough/pain relief scores,symptom improvement,nasal congestion, sneezing, postnasal drainage, and nasal discharge,Nasal patency measurements,severity (moderate/severe) and center as main strata,degree of relief,Nervousness,patient, evolution of symptoms, disposition of the patient to take the medication again, and variation in nasal peak flow,SEM overall sinus symptom assessment score,Rhinorrhea,efficacy and tolerability,satisfaction on sleep,severity of signs and symptoms,moderate nasal congestion score (NCS,nervousness,sedative effects,Safety,pain relief,5-point verbal rating scale (VRS) and pain intensity and nasal congestion on a 4-point VRS,Nasal airflow conductance (NAC) and pain relief,efficacy and safety,severe nasal congestion score,proportion of children considered "better" overall,complication rate,global clinical efficacy,excellent therapeutic response,severity of rhinorrhea, sneezing, nasal obstruction, sore throat, cough, and headache and reduced nasal mucus production, nasal tissue use, and virus concentrations in nasal secretions,frequency of drowsiness,nasal congestion score,URI symptoms,Clinic scores,nasal congestion and pain intensity scores,overall night-time relief,safe and well tolerated,child's runny nose, nasal congestion, cough, and sleep status,Pain relief,tolerated,insomnia,SEM weighted average of sinus symptoms,overall sinus symptom assessment and a weighted composite assessment of sinus pressure, pain, and congestion (sinus symptoms,relief of nasal congestion,tolerability,Efficacy and tolerability,frequencies of infection, colds occurrence, and viral shedding,Sneezing, nasal obstruction, and overall response to treatment,severity of cough, nasal obstruction, nasal discharge, and throat-clearing,A score of common cold symptoms (headache, throat pain, extremities and joint pain, cough, blocked nose, and disturbances of sleep quality,cough,NAR and pain relief/intensity scores,overall therapeutic response,sum of scores for nasal and ocular symptoms (p<0.006) or total symptoms,Total symptom scores,symptoms of upper respiratory tract infection,nasal secretion weights,nasal congestion scale,Nasal symptom scores,nasal resistance,daily mean total symptom score,cough severity,individual symptoms,percentage of subjects showing a good or excellent treatment efficacy,headache and rhinorrhea,virus isolation rate,pain reduction|The decongestive effect of Rhinopront syrup was assessed in 18 adults and 18 children with acute rhinitis, by comparison to a matching placebo syrup and to a commercial standard decongestant (Triaminic tablets or drops).
23|blood glucose variability,CSII blood glucose levels,risk of hypoglycemia,metabolic control,treatment satisfaction,glucose standard deviation, mean amplitude of glycaemic excursions (MAGE), lability index and average daily risk range (ADRR,glycemic control and health-related quality of life,baseline C-peptide,nocturnal and 24-hour hypoglycemia,CSII,physical discomfort,quality of life assessed at 9 months using the Diabetes Quality of Life (DQOL) questionnaire,PedsQL and impact scores,oscillatory potentials and lengthened macular recovery time,mean blood glucose values, glycosylated hemoglobin (HbA1), retinopathy, blood pressure levels, or duration of diabetes,oscillatory potentials (electroretinography [ERG]) and macular recovery time (nyctometry,severe hypoglycemia,frequency of hypoglycemic episodes,AUC glucose ,mean glycemic values,24-hour duration and area under the curve for hyperglycemia,HbA(1c) levels,HbA(1c), total daily insulin dose (TDD), self-monitored blood glucose readings, and adverse events,glycemic control, hypoglycemic events, and quality of life,Scores on the Short-Form 36-Item subscales 'general health' and 'mental health,proteinuria,frequency of blood glucose values,SD of all the BG values,glucose levels,microaneurysms and hemorrhages (CSII and CIT,mean duration of postprandial within-target glucose levels,Mean insulin doses,lability index,Overall mean blood glucose,diameter of retinal veins,blood glucose peaks,Hemoglobin A(1c) levels and glucose level profiles,patient reports of hypoglycemic events,hyperglycaemic episodes,TDD,Fasting self-monitored blood glucose,Oscillatory potentials, macular recovery time, and diabetic retinopathy,Mean plasma glucose and hemoglobin A1c concentrations and the frequency of hypoglycemic reactions,Standardized quality-of-life Pediatric Quality of life Inventory (PedsQL) and impact of disease scores,hypoglycemic events,macular recovery time,frequency of hypoglycemic events,nerve conductivity and a decreased protein excretion,metabolic control, frequency of severe hypoglycaemia,quality of life and impact of disease scores,kidney function,glucose variability,Treatment satisfaction,Severe episodes of hypoglycemia and ketoacidosis,Major hypoglycemia,smaller 24-hour area under the curve for hypoglycemia,frequency of hypoglycaemic episodes,HbA(1c,glycemic control, reported hypoglycemic events, or quality of life,quality of life,DQOL subscales,Mean serum fructosamine levels,glycaemic control and kidney function,metabolic control [insulin dose, hemoglobin A1c (HbA1c), and C-peptide,episodes of ketoacidosis,Mean blood glucose, M-value and 24-h glycosuria,Prestudy preprandial/postprandial glucose levels,Lower HbA(1c) and premeal glucose levels,glomerular filtration rate (GFR) and renal plasma flow (RPF,hemoglobin A1c, insulin doses, weight, and height,postprandial hypoglycemia and hyperglycemia,need of insulin, the maternal body weight gain, the week and mode of delivery, the neonatal weight and the maternal and fetal complications,rate of diurnal hypoglycemic events,Blood glucose (BG,number of mild hypoglycemic episodes,Glycemic patterns,creatinine and blood pressure,symptomatic hypoglycaemia and lowered haemoglobin A1c,quality of life and impact of disease,sural nerve conductivity,urinary albumin excretion (UAE,Glycaemic control,shorter duration of nocturnal hypoglycemia,Symptomatic hypoglycemia,HbA1c,blood glucose levels,HbA(1c), self-reported hypoglycemic events, and blood glucose memory meter read outs,blood glucose profile, HbA(1c), number of episodes of hypo- and hyperglycaemia, lipid profile, free fatty acids (FFA), growth hormone and treatment satisfaction,hypoglycemic episodes,Mean insulin requirement,lowering HbA(1c) levels,Diabetes Treatment Satisfaction Questionnaire,mean (SD) hemoglobin A(1c) levels,rate of hyperglycemia,blood glucose and glycosylated hemoglobin,mean blood glucose (MBG), fasting plasma ketone bodies, fasting plasma free fatty acids (FFA), fasting plasma human growth hormone (HGH), fasting plasma glucagon or serum fructosamine,eventual presence of urinary keton bodies and hypoglycemic crisis,HbA1c values,oscillatory potentials or nyctometry,Mean blood glucose concentration and urinary glucose excretion,Glycemic control (HbA(1c) level,glycated haemoglobin (HbA(1c)) 7.6 ,Weight gain,plasma glucose concentration,rate and magnitude of hypoglycemia,number of hypoglycaemic episodes,Stability of blood glucose self-measurement values,BG levels,glycaemic control,amplitudes of oscillatory potentials|Areas under the curve were significantly larger during MDI for nocturnal and 24-hour hypoglycemia (P =.01 and.04, respectively) and for postprandial hypoglycemia and hyperglycemia (P =.03 and.05, respectively).
4524|smoking susceptibility,risk of taking up smoking,cigarette use, receptivity to cigarette promotions, and confounding factors, including grade, parental education, peer smoking, and family smoking,odds of smoking progression,knowledge of smoking hazards,Smoking status,moderate visit frequency,smoking behaviour,demographic characteristics, smoking behavior, tobacco advertising receptivity, novelty-seeking personality, depressive symptoms, family and peer smoking, alcohol use, and marijuana use,smoking progression,response rate,prevalence rate of smoking,levels of time 2 smoking,adolescent smoking initiation,novelty seeking, the odds of being more receptive to tobacco advertising,higher smoking uptake,susceptibility to smoking and ever smoking,smoking uptake,levels of brand-specific advertising exposure,parental smoking, best friends' smoking, perceived positive values of smoking, perceived negative values of smoking, correct health knowledge, cigarette-brand awareness, having a favourite cigarette advertisement,prevalence rates of the uptake of smoking relative,knowledge scores,uptake of smoking,life-time and current smoking,prevalence rate,Initial attitude scores,rate of established smoking,tobacco marketing receptivity,adolescent smoking onset and progression|Among experimental smokers, the majority (64%) were receptive to tobacco marketing, which had a multivariate association with higher level of lifetime smoking (movie smoking did not).
36|angiographic and hemodynamic variables,mean relative improvement in the perfusion defect,reduction of systolic and mean pulmonary arterial pressures,systemic systolic blood pressure recordings,perfusion defect,recurrent pulmonary embolism,risk of death or treatment escalation,efficacy and safety,vascular obstruction,Bleeding,Massive bleeding,hospital death or clinical deterioration requiring an escalation of treatment, which was defined as catecholamine infusion, secondary thrombolysis, endotracheal intubation, cardiopulmonary resuscitation, or emergency surgical embolectomy or thrombus fragmentation by catheter,Miller index at pulmonary angiography,angiographic evidence of thrombolysis,major bleeds,fatal bleeding or cerebral bleeding,probability of 30-day event-free survival,since mortality,total pulmonary resistance,lung scan resolution,Mean pulmonary artery pressure,transfusion requirements,initial pulmonary angiographic scores,bleeding episodes,Minor bleeding|The vascular obstruction, assessed by the Miller index at pulmonary angiography, decreased significantly in alteplase-treated patients (p less than 0.01) from a baseline of 28.3 +/-
not found|frequency of vaginal and cesarean delivery,mean postpartum stay,shorter neonatal hospital stay,mean number of febrile days,mean peak postpartum temperature,microbiologic results, the gestational age, or the birth weight,neonatal morbidity or mortality,incidence of endometritis,neonatal sepsis|There was no significant difference in the incidence of endometritis between the two groups (10 of 69 versus 5 of 64; p = NS).
130|effective relief of pain,pain rating assessments,peak analgesia,hourly pain scores,total and peak analgesia,peak and total analgesia,Pain intensity,duration of analgesia,total analgesia,Adverse effects,Pain indices,analgesic efficacy,interval scale and a visual analogue scale,pain severity,total or peak analgesia,analgesic effect,side effects,pain relief|Suprofen 200 mg and suprofen 400 mg were found to be as efficacious as diflunisal 750 mg in a single-dose, double-blind randomized study of 130 hospitalized patients with pain following meniscectomy.
219|relapse rate,therapeutic efficacy,mortality rate,relapse rates,duration of defervescence and the bacteriological response,overall mortality rate,cumulative mortalities,total antibiotic treatment duration,acute mortality rate,bacteremia, respiratory failure, and renal failure,Culture-confirmed relapse,duration of oral therapy,Mortality,Clinical and bacteriologic responses,overall therapeutic failure rate,unsatisfactory clinical response,tolerated,Adverse effects,culture-confirmed relapse,efficacy and tolerance,death or treatment failure,Mortality rates,hospital mortality rate,relapse or death,culture-proven relapse in melioidosis,duration of survival,Bacteriological responses,survival overall,Treatment failure,overall mortalities from melioidosis, septicemic melioidosis, and disseminated septicemic melioidosis,death rate,mortality|Mortality rates were not significantly different between the 2 groups: 18% in the cefoperazone-sulbactam group versus 14% in the ceftazidime group.
97000|contact rates,Mean overall time,home visits,out of hours and accident and emergency attendance,attendance rate,Costs,safety and effectiveness,Type of consultation (telephone, appointment, or visit), time taken for consultation, presenting complaints, use of services,subsequent use of investigations and of services in the two-week period following consultation, frequency of blood pressure measurement and antibiotic prescriptions, and number of problems considered at consultation,number of adverse events,total number of contacts,Safety and effectiveness,hospitalizations or ER visits,number of scheduled and unscheduled visits,doctor time for the index telephone or face-to-face consultation,lower PEI scores,overall workload of general practitioners,Patient Enablement Instrument (PEI) and reported willingness to use telephone consultations,nursing time,telephone bill,mean number of contacts with casualty wards,mean general practitioner time,Blood pressure,patient attendance,Deaths|Statistical equivalence was observed in the number of deaths within seven days, in the number of emergency hospital admissions, and in the number of attendances at accident and emergency departments.
10|Plasma testosterone levels,hair diameter,complete gonadotropin inhibition,plasma estrogen and androgen levels,hirsutism scores,basal and stimulated gonadotropin levels,Hirsutism scores,Ferriman-Gallwey scores,Plasma estradiol, estrone, testosterone, and androstenedione levels,urinary 3 alpha-androstanediol and plasma dehydroepiandrosterone sulfate levels,hirsutism score,Ferriman-Gallwey score, hepatic function, and gonadal and adrenal steroid profiles,diameter of the hair medulla fell,levels of total and free T, A, dihydrotestosterone, and 3alpha-androstanediol glucuronide,free testosterone levels,levels of testosterone,Ferriman-Gallwey score,total hair diameter fell,serum lipid concentrations,sex hormone-binding globulin,total T levels,side-effects, hirsutism scoring, and lipid and hormonal levels,milder side effects,Levels of total and free T, androstenedione (A), DHEAS, sex hormone-binding globulin, dihydrotestosterone, and 3alpha-androstanediol glucuronide,dehydroepiandrosterone sulfate fell into the castrate range urinary 3 alpha-androstanediol excretion,Hirsutism,basal plasma gonadotropin levels,high-density lipoprotein-cholesterol levels,hair growth and androgen levels,acne and seborrhoea and normalization of ovarian size,decrement level in hirsutism scoring|Plasma estradiol, estrone, testosterone, and androstenedione levels significantly decreased, but urinary 3 alpha-androstanediol and plasma dehydroepiandrosterone sulfate levels did not change significantly.
400|bodyweight and body mass index,airway Pa density,changes in respiratory symptoms (CF Questionnaire-Revised [CFQ-R] Respiratory Scale), pulmonary function (FEV(1)), and sputum PA density,Pseudomonas aeruginosa (Pa) density,Safety,forced vital capacity,delay P. aeruginosa pulmonary infection,clinical symptom score, maintenance of pulmonary function and inflammatory parameters,renal or auditory toxicity,ototoxicity nor nephrotoxicity,proportion of patients with drug-related adverse events,changes in sputum P. aeruginosa density, tobramycin/colistin minimum inhibitory concentrations and safety assessments,P. aeruginosa susceptibility, minimum concentration required to inhibit 90% of strains (MIC(90)), rates of P. aeruginosa-negative culture, P. aeruginosa persistence and superinfection, need for hospitalization and parenteral antipseudomonal antibiotics, loss of school/working days due to the disease, and nutritional status (bodyweight and body mass index,hospitalization, antibiotic use, school days missed, and nutritional status,density of P. aeruginosa,Mean peak expiratory flow on ceftazidime, 299 litres/min, and on gentamicin and carbenicillin, 297 litres/min,mean forced expiratory volume,detectable ototoxic or nephrotoxic effects,clinical indices, markers of inflammation, or incidence of adverse events,pulmonary function and microbiologic outcome, decreased hospitalizations, increased nutritional status, and was well tolerated,antibiotic usage, days in hospital or clinical symptoms,safety and efficacy,sputum P. aeruginosa density,nephro- or ototoxicity,deterioration in lung function,worsening of respiratory symptoms,rate of lung function decline (as measured by forced expiratory volume in 1 sec; FEV(1)), hospitalization, and concomitant antibiotic use,serum creatinine or audiometry and no episodes of significant bronchospasm,Pulmonary function (forced expiratory volume in 1 second [FEV(1)], forced vital capacity [FVC], and forced expiratory flow at the midportion of vital capacity [FEF(25-75%)]), P. aeruginosa susceptibility, microbiologic results, and in vitro minimum inhibitory concentration for 90% of strains (MIC(90,Clinical symptoms, deterioration in pulmonary function, antibiotic usage, days in hospital and development of Pseudomonas aeruginosa,Pulmonary function, the density of P. aeruginosa in sputum, ototoxicity, nephrotoxicity, and the emergence of tobramycin-resistant P. aeruginosa,concentration of tobramycin attained in sputum,Personal preference,pulmonary function and microbiology,tolerated and improved pulmonary function,Pa density; no Pa,incidence of respiratory tract infections or hospital admissions, clinical scores, radiologic scores, or rate of change of pulmonary function,Forced vital capacity (FVC), forced expiratory flow,median time to need for additional antipseudomonal antibiotics for symptoms of pulmonary exacerbation,respiratory symptoms and pulmonary function,tolerability and safety of TSI,adverse events, audiometry (bone conduction at 250-8,000Hz frequency), laboratory tests, physical examination and general health condition,efficacy and tolerability,forced expiratory volume,Carriage of Haemophilus influenzae,general progression of cystic fibrosis,time to need for additional inhaled or intravenous antipseudomonal antibiotics,forced expiratory flow at the midportion of the vital capacity,tolerated,Rates of carriage of Staphylococcus aureus,Efficacy, safety, and local pharmacokinetics,density of P. aeruginosa in sputum,pulmonary function and clinical status,bacterial load,deterioration,lung function,Forced expiratory volume in 1 second (FEV(1)) percentage of predicted normal,FEV(1,mean CFQ-R respiratory scores,pulmonary function and microbiologic outcome,colistin, forced expiratory volume,Mean sputum concentrations of tobramycin,need for parenteral antipseudomonal antibiotics,Lung function parameters and markers of inflammation,Adverse events reporting, audiometry, and renal function,lung function decline rate,pulmonary function, the density of P. aeruginosa in sputum, and hospitalization,efficacy and safety,Adverse events,MIC of isolated P. aeruginosa strains,adverse events,antibiotic efficacy,microbiologic outcomes,sputum PA density,time to conversion from a P. aeruginosa-positive to a P. aeruginosa-negative respiratory culture,serum creatinine and auditory function,risk of hospitalization,evaluation of the relative change in lung function,Mean forced vital capacity,respiratory hospitalizations, concomitant antibiotic use|An interim safety review showed a 2.42-fold risk of respiratory hospitalization for control group subjects (P = 0.020), and the study was terminated.
26|adverse events,number of pulmonary exacerbations,number of days of oral antibiotics,Antibiotic treatment,Plasma Zn, Cu, inflammatory cytokines and ex vivo generation of IL-2,rate of respiratory tract infections (RTIs), use of antibiotics and plasma cytokines,total antioxidant capacity,plasma IL-6 and IL-8,pulmonary exacerbations,plasma beta-carotene concentration, total antioxidant capacity, malondialdehyde (MDA) as a marker of lipid peroxidation, and clinical parameters (Shwachmann-Kulczycki score, body mass index (BMI), height, and lung function (FEV(1,plasma concentration of beta-carotene,respiratory tract infections,Shwachmann-Kulczycki score, lung function, and BMI|The number of days of oral antibiotics was lower in Zn treated patients compared to placebo (P = 0.05).
140|noninfective complications,incidence of urinary tract infection (UTI) and complications,asymptomatic bacteriuria,bacteriological and clinical success rates,morbidity rates,incidence of minor complications,Fever,incidence of infections,Urine cultures,frequency of fever or bacteremia,bacteremia rate,Urinary Tract Infection,infectious complications,postoperative fever, bacteremia and bacteriuria,Microbiological success (no bacteriuria > 10(5) organisms/mL, or bacteraemia, after TPB,Urinary tract infection rates,postbiopsy infectious complications,TPB,complications of fever and urinary tract infections,infective complications,rate of infectious complications,incidence of fever and urinary tract infections,efficacy and safety,bacteriologic response (bacteriuria [more than 10(4) colony-forming units (CFU)/mL] versus no bacteriuria,Urine and blood cultures,positive urine cultures,positive MSUs,urinary infection,net costs of treating infectious complications,clinical signs and symptoms of a urinary tract infection (UTI,postbiopsy bacteriuria,actual rate of bacteriuria,clinical success rate,major complications requiring hospitalization,rectal bleeding, haematuria and pain,pre-existing bacteriuria,incidence of infective complications,Pyrexia,Blood cultures,Bacteriuria,urinary tract infection,self-recording of body temperature,bacteremia,hospitalization rate,rate of positive MSUs,urinary infection rate,urinary tract infection and fever,Midstream urine (MSU) samples,fever,incidence of infectious complications,rates of bacteriuria,urinary tract symptoms, rectal bleeding, haematuria and perineal pain,bacteriuria|Efficiency control was determined by the incidence of urinary tract infection (UTI) and complications in both groups after statistical analysis.
                
not found|Global scores for quality of antenatal and delivery care,overall testing rate,proportion of clients requesting an HIV test,proportion of treatment-eligible pregnant women enrolling into HIV care within 60 days of HIV diagnosis,Overall uptake of HIV testing,HIV infection,Episiotomy rates,VCT,Pregnancy incidence,HIV prevalence,incident pregnancy,pregnancy incidence,mean CYP,Sexual and reproductive health,number of VCT facilities,Contraceptive prevalence,quality of PMTCT services,attendance rates,uptake of HIV testing, and recovery, relapse, and growth rates of HIV-positive,HIV transmission,Contraceptive use and pregnancy incidence,Quality of antenatal and delivery care services,Adjusted odds ratios (AORs) and confidence intervals (CIs) for enrollment and initiation proportions,Quality of antenatal and delivery care,annualized attrition rate,pregnancy intentions, contraceptive use, and pregnancy incidence,death of the index child and the end of breastfeeding,adult HIV prevalence rate,Rates of oral and injectable contraceptive use,CD4 cell count testing,quality of antenatal and delivery care,unwanted pregnancy incidence,Mean attendance at family planning clinics,contraceptive uptake,risk of MTCT,RPR screening,discharge Weight-For-Height (WFH,Service ratios,average staff workload,prevalence odds ratios (PORs) and 95% confidence intervals (CIs) for documented RPR screening,time-to-treatment initiation,high attendance rates,HIV prevalence rate,Contraceptive use|HIV transmission between discordant couples was 0 infections/100 follow-up years (95% CI, 0-3.2); vertical transmission from mother to child was 11 infections/100 live births (95% CI, 4.6-21.9); These rates are significantly lower than expected rates of transmission in Haiti.
                
not found|suspicion of intrauterine fetal growth retardation,acute fetal distress,rate of abnormal values,hospital until delivery,acidotic pH|The prevalence of low-birth-weight infants for their gestational age was 47.73% in the treatment group and 40.74% in the control group.
not found|five-item Arizona Sexual Experience Scale (ASEX) assessed sexual functioning,total testosterone levels,hyperprolactinemia and reproductive comorbidities,efficacy and tolerability,free testosterone levels,low-density lipoproteins and standing blood pressure,sexual functioning,Sexual function,sexual dysfunction,reproductive morbidities and sexual dysfunction,menstrual cycling,satisfactory sexual intercourse,Adjusted mean ASEX total scores,resolution of galactorrhea and gynecomastia, and sexual functioning,tolerated,mean serum prolactin levels,serum prolactin and improvement in sexual and reproductive comorbid symptoms,Baseline prolactin levels,number of adequate erections, satisfaction with sexual intercourse, and the duration of erections,mean ASEX total scores,baseline prolactin levels,eosinophil counts,prolactin levels,ASEX total scores and ASEX sub-items,odds ratios for adequate erections|Treatment Group effects were not significantly different in any of the prospective weeks for ASEX total scores and ASEX sub-items.
106|mean daily combined wound scores,Pneumonia,Major complications,peristomal wound infections of degree III,Stomal infection,systemic infection,wound infection rates,infectious complications,incidence of peristomal and other infections,neurological disease,Peristomal wound infection,Wound infection scores,serious comorbidity,wound reaction,peristomal wound infections,total procedure-related complication rate,percutaneous endoscopic gastrostomy site and systemic infections,clinically important wound infections,percutaneous endoscopic gastrostomy site infection,prophylactic antibiotics,risk of peristomal pain,complication rate,severe complications,Patients systemic infection rates,non-wound infections,Wound infection,values of infection scores,percutaneous endoscopic gastrostomy site or systemic infection and death,disturbance of healing, minor or major wound infection,Erythema and exudate,rate of infection including major wound infection,stomal infection,Cumulative infections,death,dysphagia due to oropharyngeal tumors,overall infection rates,peristomal infections,risk of peristomal wound infection,peritonitis,wound infection,risk of infectious complications,Antibiotic and application costs,occurrence of a peristomal wound infection at any time within one week of PEG insertion,overall peristomal wound infection|Antibiotic prophylaxis with a single dose of co-amoxiclav significantly reduces the risk of infectious complications after percutaneous endoscopic gastrostomy and should be recommended.
218|Mobilisation,mortality|There is no significant difference in the mortality of the internal fixation and posterior arthroplasty groups.
not found|mild esophageal squamous dysplasia,peroxidation of low-density lipoprotein cholesterol,incidence of basal-cell and squamous-cell carcinomas,skin-cancer rates,Cumulative tumor-free survival and cumulative survival rate,Snellen equivalent visual acuity,prevalence of precancerous gastric lesions,mean levels of LDL and HDL cholesterol,ascorbic acid, vitamin E, or beta carotene on cardiovascular events,total cardiovascular events,Plasma alpha-tocopherol concentrations,Alcohol ingestion and hospitalization rates,total stroke,immune function,Death, nonfatal MI, or stroke,serum concentrations of vitamins A, C, D3, E, folate, and selenium,median plasma beta carotene level,incidences of lung, colorectal, and prostate cancers,dysplasia grade overall,cancer incidence and total and cause-specific mortality,changes in Barthel activities of daily living, length of stay, and mental test score (MTS,total cancer incidence,death, non-fatal myocardial infarction, and stroke,incidence rate ratio of acute respiratory tract infection for multivitamin-mineral supplementation,mean (SD) interval,rates of regression: Relative risks,adverse experiences and serious adverse events,average stenosis progressed,Immune function,cancer and cardiovascular events,cancer rates,Severity and rate of worsening of parkinsonism and response to levodopa,overall incidence of malignant neoplasms or cardiovascular disease, or in overall mortality,Plasma ascorbic acid, total vitamin C and vitamin E,recurrence of colorectal polyps,cause mortality and total cancer mortality, total cancer incidence, and the incidences of lung, prostate, and colorectal cancers,HDL cholesterol,mean serum total tocopherol (TOC) concentration,selenium toxicity,fatigue,low plasma vitamin status,Progression rates,Immune response,stomach cancer,IMT change rates,closure rate,mean number of falls,mental test score, Barthel score, or length of stay,change in systemic arterial compliance and low-density lipoprotein (LDL) oxidative susceptibility over time,total mortality,vitamin E intake and cardiovascular disease (CVD) risk,Adverse effects,vitamin E levels,LVEF,risk of death,Incidence of respiratory tract infections, number of persons and number of days with respiratory tract infections (upper and lower), and number of new antibiotic prescriptions,occurrence of new skin cancers,major cardiovascular events,fatal events,precancerous gastric lesions,incidence of malignant neoplasms and cardiovascular disease,incidence of basal-cell carcinoma,Plasma malondialdehyde,cardiovascular events and cancer,colorectal adenoma,slope of mean CCA-IMT,antibody response,atherosclerosis progression,serum vitamin E levels,carotid intima-media thickness (IMT) and systemic arterial compliance (SAC,incidence of lung cancer,lipids and peroxidation,treadmill walking duration,thiobarbituric reactive substances,Oxidative stress,Serum tocopherol,intima-media thickness,atherosclerosis progression and CVD events,serum aminotransferases and serum bilirubin,cardiovascular events,number of patients without respiratory tract infections,fatigue scores,illness severity,hazard ratio of first new BCC,plasma selenium,FMD and vWF and PAI-1 levels,LV volumes,rate of change in the common carotid artery far-wall intima-media thickness (IMT) assessed by computer image-processed B-mode ultrasonograms,cardiovascular disease mortality,QUS,mean level of smoking-related B(a)P-DNA adducts,number of cases of lung cancer,nutritional status and bone quality,change in lipid peroxidation,area, 'increase % pixels opaque' (IPO,CCA-IMT progression,time to first new SCC or BCC,carotid atherosclerosis,cancer incidence and cause-specific mortality,neurological severity or in disability,composite cardiovascular disease endpoints and myocardial infarction,oxidative stress and antioxidant defense and endothelial function,vitamin E,rate of cataract extraction,Cumulative cancer incidence rates,combination of cardiovascular death and non-fatal MI as well as non-fatal MI alone,baseline CCA-IMT values,risk of cardiovascular disease (CVD,dry ARMD,POMS-BI questionnaires,cause mortality,type 2 diabetes mellitus,T cells, CD4 cells, and CD4: CD8 ratio,serum pepsinogen (PG) level, Helicobacter pylori (H. pylori ) infection, and cytotoxin-associated gene A (Cag A) status,restriction of activity,B(a)P-DNA adducts,total mood or mood-subscale scores,incidence of squamous-cell carcinoma,Quality of life,cardiovascular deaths,combined prevalence of dysplasia or gastric cancer,clinically possible or probable Alzheimer's disease; secondary outcomes were cognition and function,risk of non-fatal MI,incidence of urogenital infections,risks of prostate cancer,rates of either type of skin cancer,nutritional status, quantitative heel ultrasound (QUS), mobility, muscle strength and falls,tumour necrosis factor-alpha and its soluble receptors TNFR-1 and TNFR-2,vitamin and trace element serum levels,total cancer incidence, ischemic cardiovascular disease incidence and total mortality,episodes of infection,incidence of lung cancer, other cancers, and death,relative risk (RR) for total cancer incidence,rate of deterioration of function assessed by the modified Norris limb and bulbar scales, manual muscle testing (BMRC), spasticity scale, ventilatory function and the Sickness Impact Profile (SIP ALS/19,subjects' ratings of perceived leg pain,Nutritional status and cell-mediated immune function,upper respiratory tract infections,antibody titers,change of PGI/II ratio,walking ability and perceived quality of life (QOL,left ventricular (LV) function, levels of pro-inflammatory cytokines, and quality-of-life (QoL,excess risks of lung cancer,dysplasia progression,Fisk scores,Endothelial function,mean serum concentration of alpha-tocopherol,suboptimal ascorbic acid,individuals receiving vitamin E,LDL + VLDL fraction,ascorbic acid,blood biochemistry, low-density lipoprotein (LDL) subfractions and lipid peroxidation,gastric cancer incidence,Biochemical markers of oxidative stress,slight deterioration,myocardial infarction, stroke, and cardiovascular death,antibiotic prescriptions, hospital admissions, adverse events, and compliance,likelihood of progression to Alzheimer's disease,Prothrombin time,flow-mediated dilatation (FMD) of the brachial artery and plasma concentration of von Willebrand factor (vWF) and plasminogen activator inhibitor type 1 (PAI-1,Tibial cartilage volume,colds,ALS Health State scale,CD57 natural killer cells,Severe bleedings,serum pepsinogen level and Helicobacter pylori infection,risk of hemorrhagic stroke,cancer incidence, cancer deaths, and major cardiovascular events,Delayed-type hypersensitivity skin response, humoral response,incidences of total cancer,Mean absolute healing rates,severity of parkinsonism and rate of worsening of parkinsonism,Median duration,composite variable consisting of: myocardial infarction (fatal and non-fatal), ischaemic stroke, peripheral vascular disease (excluding the arteriovenous fistula), and unstable angina,Severity of infections,cancer or major cardiovascular events,low-density lipoprotein cholesterol/total TOC ratio, a parameter of the inhibition of peroxidation of low-density lipoprotein cholesterol,oxidative stress markers and antioxidant levels,quality of life,esophageal/gastric cardia cancer,net subjective improvement,performance of serial maximal exercise treadmill tests, serial systolic time interval measurements, and daily angina diaries,mean (SD) total mood scores,gastric mucosal atrophy,changes in allantoin and antioxidant levels and change in endothelial function,risk of cancer, cancer death, and major cardiovascular events,frequency of chest pain,symmetry of parkinsonism, gait dysfunction as an initial symptom, severity of parkinsonism, and rate of worsening of parkinsonism,LDL oxidative susceptibility,Overall regression rates,infection rates,Risk of total mortality,higher risk of heart failure,progression of IMT,incidence of adenomas; the relative risk for beta carotene,incidences of basal and squamous cell carcinomas of the skin,Ratings of perceived claudication pain,lung cancer and cardiovascular disease mortality,exercise capacity, improve left ventricular function,cardiovascular death,composite end point of first major cardiovascular event (nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death) and total invasive cancer,rate of infections,low serum values in vitamin C, folate, zinc and selenium,Site-specific cancer incidence and total and cause-specific mortality and calendar time-specific risk for lung cancer incidence and total mortality,cartilage volume,mood and quality of life,rate of progression to Alzheimer's disease,atherosclerotic progression,ischemic cardiovascular disease incidence and mortality,B(a)P-DNA adducts (high-performance liquid chromatography), plasma cotinine, vitamin levels, and GSTM1 genotype,immunity and infections,incidence of or progression of nuclear, cortical, or posterior subcapsular cataracts,cardiovascular disease, or total mortality,Alpha-tocopherol levels,endothelial function,cardiovascular disease outcomes,Platelet count, serum albumin, ALT, and total cholesterol,lower respiratory tract infections,incidence of death and a higher rate of cardiovascular disease mortality,Incidence of cancers, ischemic cardiovascular diseases and mortality,total mortality but vitamin E,respiratory tract infections,total cancer mortality,rate of change in systemic arterial compliance,number of men with myocardial infarction,Adequate 25(OH)D concentrations,incidence of basal cell or squamous cell skin cancer,218 new squamous cell skin cancers,mean number of new nonmelanoma skin cancers,nurse (telephone contact), home visits, and microbiological and serological testing in subsets of patients,Six-minute walk test and inflammatory cytokine levels,Loss of medial and lateral tibial cartilage,adverse gastrointestinal symptoms,myocardial infarction, stroke, coronary revascularization, or CVD death,lung, colorectal, and overall primary cancer,total cancer incidence and total mortality,hazard ratio,vitro peroxidation,Cumulative esophageal/gastric cardia death rates,cerebrovascular disease,survival and motor function,regression rate,hepatic laboratory parameters, mortality or hospitalization rates,serum vitamin B12 and folate concentrations and increased serum 25(OH)D,low-density lipoprotein oxidation,Decreased intake of cardioprotective nutrients (vitamin E, zinc, magnesium, B6 and folate,heart failure, unstable angina, and revascularizations,active vitamin E,incidence of first new skin cancers,dysplasia regression,Antibody titers,total mortality, and cardiovascular-disease mortality,number of deaths from cancer,myocardial infarction,esophageal squamous carcinogenesis,acute respiratory tract infections,subsequent risk of myocardial infarction (MI) and cardiovascular death,infectious events,482 major cardiovascular events,rate of deterioration of function assessed by the modified Norris limb scale,Median plasma vitamin levels,Survival,risk of lung cancer and total mortality,Dropout rates,colon cancers,Atherosclerotic progression,number of infections per subject,cancer deaths,normal gastric mucosa,gastric juice ascorbic acid and total vitamin C,incidence of malignant neoplasms, cardiovascular disease, or death,liver function, suppress hepatocarcinogenesis,arteriographic evidence of a change in coronary stenosis and the occurrence of a first cardiovascular event (death, myocardial infarction, stroke, or revascularization,lower mortality,Progression of atherosclerosis,Overall posttrial relative risk (RR) for lung cancer incidence,Annualized mean (SD) change in minimum lumen diameter (MLD,Gastric juice ascorbic acid and total vitamin C levels,cardiovascular death and non-fatal MI,total cancer mortality and total cancer incidence,absolute number of T cells,coronary atherosclerosis,glutathione peroxidase activity in plasma,incidence or number of days with infection for all, upper, or lower respiratory tract infections,Mood (Profile of Moods States - Bipolar Form [POMS-BI] questionnaire), "quality of life" (Short Form 36 [SF-36] questionnaire) and plasma selenium,mean CCA-IMT,gastric juice, plasma and mucosal measurements of vitamin levels and markers of DNA damage,number of hospital visits,polycyclic aromatic hydrocarbon-DNA adducts and oxidative DNA damage (8-oxo or hydroxydeoxyguanosine) in mononuclear and oral cells,initial plasma beta carotene level,biochemical markers of oxidative stress,contacts with primary care for infections, self reported days of infection, and quality of life,gastric cancer,exercise tolerance,mood or quality of life,vitamin C,vital signs (heart rate and blood pressure), an ECG and VEP's,relative risk of polyp occurrence,Progression of cortical cataract,probability of progression to Alzheimer's disease,Coronary progression,moderate esophageal squamous dysplasia,mean eye macular pigment optical density,malondialdehyde (MDA) and allantoin,regression rates,infectious morbidity,Serum levels of alpha-tocopherol, albumin, alanine aminotransferase (ALT), and total cholesterol and platelet count,Self perceived stabilization of vision,rate of non-fatal MI,serum creatinine,Serum cholesterol and triglycerides,standardized mortality ratios,Monocyte nuclear nuclear factor-kappa B binding activity,Mild cognitive impairment,LV volumes and LVEF and QoL scores,suboptimal alpha-tocopherol plasma concentration,plasma MDA,Smoking habits and blood samples,exercise tolerance and perceived QOL,incidences of myocardial infarction,Incidence of cancer and mortality,antibiotic use,Survival analysis,relative risks of lung cancer mortality,risk of major cardiovascular events,plasma levels of thiobarbituric acid reactive species,wound closure probability per unit time,serum level of alpha-tocopherol,VFO-14 questionnaires conceming subjective glare recovery,progression rate,total myocardial infarction,infectious episodes,basal cell skin cancer,antibiotic usage,lowering of lipids and plasma malondialdehyde,erythrocyte superoxide dismutase and glutathione peroxidase, plasma total antioxidant power (as FRAP value), and ascorbic acid and vitamin E concentrations,Mortality and cancer incidence,cardiovascular mortality,raised plasma vitamin E levels,B(a)P-DNA adduct levels,oxidative stress,reduced LDL oxidative susceptibility,delayed-type hypersensitivity skin response,DNA damage,Plasma levels,hospitalization for heart failure,patients given alpha-tocopherol,morbidity from infections,seroconversion,serum 25(OH)D,survival, calculating time to death, tracheostomy or permanent assisted ventilation, according to the WFN-Criteria of clinical trials,Relative healing rates and healing velocities,progression of carotid atherosclerosis determined by intima-media thickness of the right common carotid artery,incidence of cancer,Mini-Mental State Examination,oxidative stress markers and endothelial function,QoL score,progression of atherosclerosis,progression of carotid atherosclerosis,proliferation of lymphocytes in response to phytohaemagglutinin,Cataract severity,quality-of-life and left ventricular function,cumulative survival,lipid peroxidation,mean 2-year progression,time to the occurrence of any of the following: death, institutionalization, loss of the ability to perform basic activities of daily living, or severe dementia (defined as a Clinical Dementia Rating of 3,incidence of major cardiovascular events,wound survival, healing rates of wound surfaces, and clinimetric changes over 12 weeks,vitamin B12 (178.0+/-40.3 pmol l(-1,incidence or rate of progression of age-related cataracts,severe state B,nuclear cataract,healing of pressure ulcers,cortical opacification of the right lens,major cardiovascular events (nonfatal myocardial infarction, nonfatal stroke, and cardiovascular disease death,humoral response,lipoprotein peroxidation and composition,antibiotic use and hospitalization rates,risk of lung cancer,circulating oxidized LDL,lung cancer incidence,1024 respiratory tract infection episodes,Curing the H. pylori infection,cancer mortality,Height and weight,4-year cumulative incidence rate,rate of regression of the precursor lesions,mortality,relative risk of cardiovascular disease mortality,functional status,distance LogMAR visual acuity,weight and > 3 g/l increase in serum albumin,Overall rate ratios,cardiovascular disease and cancer,ischemic or hemorrhagic stroke,rate of occurrence of the first new nonmelanoma skin cancer,severe chronic atrophic gastritis, intestinal metaplasia, dysplasia, or gastric cancer,Mucosal malondialdehyde, chemiluminescence and DNA damage levels,cancer incidence, cancer deaths, and major cardiovascular events (myocardial infarction, stroke, and cardiovascular death,incidence and severity of acute respiratory tract infections,Perceived distance and walking speed (Walking Impairment Questionnaire) and perceived physical function (Rand Short Form-36,incidence of infection,cancer incidence,constant work-rate and incremental treadmill tests,plasma ascorbic acid and alpha-tocopherol concentrations,heart failure and hospitalizations for heart failure,reduced risk of total cancer incidence and total mortality,Serum micronutrients, body weight, QUS, rate of falls, hand grip strength, and the timed up and go test,Hazard ratios,alpha-tocopherol,Incidence and severity of self-reported acute respiratory tract infections,mortality rates,serum hyaluronic acid,total number of infections,cartilage volume loss,Cancer deaths|Among treated women, B(a)P-DNA adducts decreased by 31% compared with women on placebo (P = 0.03).
not found|pain and decreased ambulation and required assistive devices,peri-operative data, general and hip-specific complications, hip function and health-related quality of life,worst hip-rating-questionnaire and EuroQol scores,hip-rating questionnaire and the EuroQol health status measure,radiographic evidence of acetabular erosion,Displaced Femoral (neck fracture,mortality rate,mean Oxford hip score,mean survival time,quality of life and functional outcomes,Merete, Berlin, Germany], total arthroplasty ,mean duration of surgery,health-related quality of life measure,pain relief and gait function,least pain and most mobility,local complications,SF-36 mental health subscale,direct health service costs,Musculoskeletal Functional Assessment instrument and Short Form-36 health survey,rate of complications,estimated blood loss, length of hospital stay, mortality rate, number of dislocations, postoperative complications, or ambulatory status,incidence of postoperative complications, the early mortality rate and the operating time and blood loss,Harris hip score,experiencing pain,revision rate,complication rate,functional outcome scores,postoperative Short Form-36 or Musculoskeletal Functional Assessment instrument scores,Short Form-36 (SF-36), Western Ontario and McMaster Osteoarthritis Index (WOMAC), and the Harris Hip Score and the Timed "Up & Go" Test,Barthel Index and EQ-5D scores,rate of secondary surgery,rates of complications and mortality,superior WOMAC function scores,Hip function,mean Harris hip score,range of passive hip motion,SF-36 subscale,cardiac or pulmonary disease, cancer, alcoholism, or psychosis,mortality and complications,endurance capability,lower (better) Oxford hip score,Quality of life and functional outcomes,Oxford hip score, and final radiographs,level of pain, ambulation, or aids required,mean intraoperative blood loss,duration of surgery,general complications,acetabular erosion severe enough to indicate revision,mean patient survival,Harris Hip Scores,degree of return to the preinjury state,mortality rates,Barthel Index and Harris Hip Score,Barthel Index scores,complications or mortality,pain,intra-operative blood loss,mean walking distance,mortality|Two years after operation there was no statistical difference between the rate of complications in the two groups.
56|flow rate,patient's speech fluency, language content, overall degree of aphasia severity, or nonverbal cognitive abilities,efficacy and tolerance,patient's language and nonverbal cognitive skills|Analysis of the recorded computer tomography map gave an improvement coefficient >2 (flow rate marginally or better improved) for 23 piracetam patients as compared with 5 placebo patients (P < 0.001, Uleman test).
not found|frequency of grade 3 and grade 4 hemorrhages,mild intraventricular hemorrhage,Moderate or severe hemorrhage,mortality rate,incidence and severity of intracranial hemorrhage,intracerebral hemorrhage,blood levels,Moderate and severe hemorrhages,neonatal intracerebral hemorrhage,Hemorrhage,Conjugated bilirubin levels,severity of periventricular-intraventricular hemorrhage,mild SE/IVH,IVH,frequency of SE/IVH,Severe hemorrhages,neonatal intraventricular hemorrhage,total incidence of periventricular-intraventricular hemorrhage,incidence of any grade of hemorrhage,intracranial hemorrhage,Maternal demographics, pregnancy complications, antenatal management, and route of delivery,overall ICH,phenobarbital serum concentrations,Antenatal phenobarbital and bilirubin metabolism,mild and severe intraventricular hemorrhage,severe hemorrhage,SE/IVH frequency,neonatal intracranial hemorrhage (ICH,severe intraventricular hemorrhage,incidence of all grades of ICH,moderate and severe ICH,Intraventricular hemorrhage,Incidence of neonatal ICH,intraventricular hemorrhage,mortality|Moreover no severe hemorrhage (grade 3-4) occurred in the treated babies: 0 of 21 versus 5 of 18 (27.7%; p less than 0.01).
not found|respiratory or cardiovascular function,percentage of cocaine-negative urine samples,bioavailability, tolerability, and potential efficacy,retention index,Pharmacokinetics, safety, and tolerability,hepatic toxicity,hepatitis C infection,Troublesome tissue reactions,heavy drinking,tissue reactions,serious adverse events,safety and tolerability of the Naltrexone Depot formulation, blood levels of naltrexone and its main metabolite 6-beta naltrexol, and self-reported alcohol use,Overall, rate and time to treatment discontinuation,NTX plasma concentrations,6beta-naltrexol concentrations,efficacy and tolerability,abstinence reactions,Discontinuation due to adverse events,naltrexone plasma concentrations,feasibility, efficacy, and tolerability,Subjective, performance, and physiological effects,Patient satisfaction, side effects and unwanted medical events,Total exposure (AUC(0-infinity,duration judged by naltrexone plasma levels,Adverse events,safety and efficacy,frequency of heavy drinking days,plasma levels,number of drinks per day, heavy drinking days and proportion of drinking days,subjective ratings,time course, safety, and effectiveness,opiate effects,Plasma levels,Subjective ratings of withdrawal,Adverse effects,sedative "overdoses,mean trough pupil diameter,Efficacy and tolerability,opioid overdoses,number of opioid overdoses,transaminases,typical blood NTX levels,blood naltrexone levels,untoward side-effects,event rate of heavy drinking days,Side effects|For those previously treated with oral naltrexone, more opioid overdoses occurred in both the 6-months prior to and after oral compared to the 6-months post-implant treatment.
                
not found|procedural pain,success rates,Motor and sensory blocks,general anesthesia,success rate of a perivascular axillary plexus block,quality of popliteal sciatic nerve block,quality of the sensory block and the tolerance to the pneumatic tourniquet,success rate of popliteal sciatic nerve block,quality and the onset of the sensory block,number of needle passes,quality of sensory and motor blockade,proportion of successful blocks, decrease block execution time,quality of ulnar block,quality of the sensory block,Procedure-related pain,axillary bruising and pain,patient acceptance,block success rate,success rate of axillary brachial plexus block,Overall success,quality of brachial plexus anaesthesia,success of sciatic nerve location,complete motor or sensory loss,success rate of performing the block,Axillary nerve,onset of sensory blockade,time needed for block performance and procedural pain,success rate of sciatic nerve block,quality and the onset time,Surgical anesthesia,Block performance time,complete block of all nerve territories,Surgical anesthesia without supplementation,Block success,Block time,Performance time and onset time of complete sensory block,onset and completeness of sensory,onset of motor block,onset of motor and sensory block for the musculocutaneous, median, radial, and ulnar nerves,number of attempts to obtain an adequate motor response, success rate of nerve location at the first attempt, quality and duration of both sensory and motor blocks, and anesthetic distribution,Onset time,Secondary catheter failure,partial or complete sensory block of all nerve territories,onset of sensory block,quality of supraclavicular block,needle redirections,time until readiness for surgery,Obturator motor block (hip adduction,Sensory, motor, and extent of blockade,satisfactory sensory and motor blockades,Ultrasound guidance,incidence of femoral,threshold stimulating current and resulting response, spread of drug on re-injection,secondary catheter failure,incidence of adverse events,block procedure time, or complications,Complete loss of sensation in the anterior, medial, and lateral aspects of the thigh,Onset time of complete sensory block,Median discomfort,Onset time for sensory block,higher success, faster onset, and progression of sensorimotor block,Femoral motor block (knee extension,nerve blocks,primary block success,sensory block and onset time,incidence of sensory loss,median tourniquet pain,frequency of femoral and obturator motor block,pain relief,frequency of sensory loss,median (range) number of needle passes,Sensory and motor blockade parameters,analgesic effect,Quality of sensory block,incidence of paraesthesia,quality, safety, and execution time of supraclavicular block,time until readiness for surgery, quantified discomfort during the block, and pain related to tourniquet ischemia on a numeric rating scale (0-10,Heart rate, noninvasive blood pressure, and oxygen saturation,success rate,Sensation and motor function,success of sciatic nerve block,Block success rate,Incidental arterial puncture,block time,success rate of interscalene brachial plexus blockade,Median time,Sensory and motor function,major complication|Combined ultrasound and neurostimulation guidance does not decrease block time but increases the success rate of popliteal sciatic nerve block observed at 30 min.
not found|self-reported frequency of illicit opioid use, the percentage of opioid-negative urine specimens, and the maximum number of consecutive weeks of abstinence from illicit opioids,duration of sustained abstinence,longer durations of abstinence (LDA,unsafe sexual practices,frequency of DSM-IV opiate and cocaine dependence diagnoses,standardized psychological tests, independent observer ratings, and continuous records of licit and illicit drug use,rate of counseling attendance,stimulant abstinence,child maltreatment (self-reported) and cocaine abuse based on urinalyses,cocaine abstinence,anxiety, depression, and situational non-assertiveness,HIV-Risk Taking Behaviour Scale,adherence,counseling attendance,counseling attendance and some indication of lower psychosocial impairment,abstinence reinforcement,lower rate of poor treatment response,percentages of urine specimens negative for heroin, cocaine, and both simultaneously,Lower DMI plasma levels,Total number of stimulant- and alcohol-negative samples provided, percentage of stimulant- and alcohol-negative samples provided, longest duration of abstinence, retention, and counseling attendance,HRBS scores,retention, proportion of opioid-negative urine tests, self-reported drug use, and self-reported HIV risk behaviors,Weekly urinalysis drug screens and Addiction Severity Index (ASI) scores,self-efficacy,reductions of HIV risk behaviors and illicit opiate use and treatment retention,injection-related drug-taking behaviors,HIV risk behaviors,rates of simultaneous cocaine/opiate-positive urine specimens,average cost of prizes,percentage of opiate-negative urine specimens,HIV risk-taking behaviour,Overall opioid use,total weeks of abstinence,emotional adjustment and depression,proportion of opioid-negative urine tests,opiate-negative urine specimens (thrice weekly urinalysis,sexual risk quiz,frequency of illicit opioid use,overall proportions of opiate negative urine toxicology tests,reduced self-reported frequency of use and self-reported craving,competitive employment or total earnings,Opioid withdrawal symptoms|The experimental intervention increased attendance in subjects with low and high levels of psychopathy and with and without other psychiatric comorbidity.
not found|direct cost savings,odds ratio for returning to work,Functional status and pain,male gender, lower distress, lower levels of reported ergonomic exposure, and receipt of ICM,patient satisfaction,Time until return to work for workers with workplace intervention,total duration of sick leave,time until return to work, pain intensity, functional disability, and general health perception,Patient satisfaction,Pain and disability scales,lasting return to work, pain intensity and functional status,symptom severity and functional limitations,time for doing this,total mean number of sick days|Time until return to work for workers with workplace intervention was 77 versus 104 days (median) for workers without this intervention (P = 0.02).
39876|incidence of or progression of nuclear, cortical, or posterior subcapsular cataracts,Incidence of cataract operations,area, 'increase % pixels opaque' (IPO,change in nuclear opalescence over time,Cataract severity,total cardiovascular events,cardiovascular death,smoking duration, visual acuity, and total cholesterol,Progression of cortical cataract,number of cases,rate of cataract extraction,incidence or rate of progression of age-related cataracts,nuclear cataract,cataract extraction,overall incidence of cataract,posterior subcapsular cataract,incidence of cataract extractions,cortical and posterior subcapsular opacities and nuclear colour changes; best corrected visual acuity change; myopic shift; and failure of treatment,beta carotene,incidence of cataract,4-year cumulative incidence rate,Severe bleedings|There was no significant difference between the vitamin E and placebo groups in the incidence of cataract (1159 vs. 1217 cases; relative risk [RR], 0.96; 95% confidence interval [CI], 0.88-1.04).
272|colorectal cancer incidence or mortality,extent of colorectal polyposis,risk of colorectal adenomas,RR of developing colorectal cancer,mucosal prostaglandin levels,colorectal adenoma recurrence,mean (+/-SD) number of adenomas,number and size of new adenomas and side effects of therapy,Compliance,severe dysplasia, or invasive cancer,colorectal adenomas,rectal bleeding and early stage at diagnosis,adverse events,mean number of colorectal polyps,stage or prevalence of rectal bleeding,polyp burden,adjusted relative risk of any recurrent adenoma,average rate of compliance,mean number,incidence of colorectal adenomas,absence of personal history of adenoma,time to the detection of a first adenoma,decreasing RR,adenoma recurrence,Unadjusted relative risks of any adenoma,polyp regression or size,levels of five major prostaglandins,number of colorectal polyps,incidence of one or more adenomas|At least one adenoma of more than 5 mm diameter was observed in 13 patients (10%) in the aspirin group and 26 (23%) in the placebo group (P = 0.01).
173|self efficacy for pain,levels of disability,back performance scale and Prolo scale,Radiographic range of motion,implant or implant/surgical procedure-related adverse events,Disability and pain,patient self-assessments, physical and neurologic examinations, and radiographic evaluation,hospital stay,VAS,rate of satisfaction,Overall neurologic success,safety and effectiveness,overall success superiority,Oswestry score,hospitalization stays,rate of reoperations,global assessment (GA), VAS for back and leg pain, Oswestry Disability Index, SF36 and EQ5D at 1 and 2 years,average estimated blood loss,complication rate,average hospital stay,gain in function,Oswestry Low Back Pain Disability Questionnaire (Oswestry Disability Index [ODI,mean Oswestry Disability Index scores,blood loss,patients' satisfaction,Oswestry disability index,return to work, SF-36 mental component score, EQ-5D, fear avoidance beliefs, Hopkins symptom check list, drug use, and the back performance scale,rate of excellent outcome,SF-36 Health Survey scores,pain and disability scores,physical function, reduced pain, and earlier return to work,maximum recovery,pedicle screw removal,Visual Analog Scale assessing back pain, the Oswestry Disability Index questionnaire, and the SF-36 Health Survey,low back pain, satisfaction with life (SF-36 and EuroQol EQ-5D), Hopkins symptom check list (HSCL-25), fear avoidance beliefs (FABQ), self efficacy beliefs for pain, work status, and patients' satisfaction and drug use,GA,visual analog scale pain assessment,score on the Oswestry disability index,mean Visual Analog Scale scores,favour of surgery for low back pain,Complications and reoperations,longer surgical times,overall success, a composite measure of safety and effectiveness as recommended by the Food and Drug Administration and defined in the protocol,Visual analog scale patient satisfaction,patient satisfaction,totally pain-free,SF-36 physical component score,Oswestry Disability Index, back pain, and Short Form-36 Physical Component Summary scores,A visual analog scale (VAS,Prolo scale,Oswestry Disability Index and the Visual Analog Scale,Disc height and segmental angular motion,leg amputation,average operative time (skin to skin|There were no significant differences in return to work, SF-36 mental component score, EQ-5D, fear avoidance beliefs, Hopkins symptom check list, drug use, and the back performance scale.
253|safety and efficacy,pain intensity,number of days with the severest pain score, overall duration of painful crisis, and duration of hospitalization|Analysis revealed a statistically significant reduction in number of days with the severest pain score, overall duration of painful crisis, and duration of hospitalization (p < 0.05 for each comparison of tinzaparin vs. placebo).
not found|elevated level of EMG activity,pain, discomfort, interference, and time loss,symptoms of dysmenorrhea,level of EMG activity,EMG activity,symptom severity, general discomfort, resting time, and medication use|Following treatment, these subjects reported significant reductions in pain, discomfort, interference, and time loss due to dysmenorrheic symptoms relative to their own baselines and to an untreated control group.
20|average pain relief (diary) and the maximum pain intensity,Pain scores,dry mouth, insomnia, headache, gastrointestinal upset, tremor, constipation, and dizziness,pain rate,pain intensity and pain relief,drug concentrations,escape medication,severe depressive reactions,effect and plasma concentration,serum concentration,pain and paresthesia associated with diabetic neuropathy,pin-prick hyperalgesia, allodynia, detection and pain thresholds to electrical and heat stimuli, temporal summation of repetitive electrical and heat stimuli,withdrawal symptoms,edema, phantom pain, or sensory changes,Pain and pain-related symptoms,neuropathic pain,Side-effect ratings,Baseline pain intensity,Neurologic examination and assessment of side effects,degree of the temporal summation to electrical and heat stimuli,mean average pain score,HbA1, fasting serum glucose, and safety tests,worst pain,intensity and quality of pain,depression scores,paresthesia scores,Quid and depression-anxiety symptoms with the Hamilton Rating Scale (HAMD,Drowsiness, confusion and dry mouth,clinically important ECG changes,Mean VAS-PR scores,visual analog scales (VAS), the McGill Pain Questionnaire (MPQ), and a side-effects scale,efficacy and tolerance,pain reduction, mood disturbance, and quality of life,complete remission of lower extremity pains,pain and depression,daily ratings of pain intensity on a 10-step verbal scale (0 = no pain and 10 = worst thinkable pain,mean pain scores,Overall pain,individual pain scores,pain measures,global rating of the analgesic effect on a 5-step verbal scale (pain relief scale,Plasma concentration,neuropathic component of pain,Spitzer's quality of life score,pain quality and intensity,cognitive measure,burning mouth symptoms,pain relief globally,pain reduction,pain symptoms,pain intensity, hours of sleep, hours standing and lying, side effects, mood, anxiety, weakness,intensity and overall quality of pain deteriorated,Visual analogue and verbal rating scales,pain score,venlafaxine concentrations and excellent pain relief,Depression,anticholinergic effects,anxiety and depression,Anxiety, depression, and adverse effects,severe side effects,diabetic neuropathy symptoms,global rating of pain relief,particular pain quality,pain or pain-related symptoms,substantial degrees of depression during psychiatric interview and by Kupfer-Detre test scores,axilla pain,sleeping and walking,side effects and no withdrawal symptoms,mean values of the daily ratings of pain intensity,global improvement,incidence of side effects,relieve burning mouth pain,chronic pain and improving pain-related physical and psychosocial dysfunction,Sensitivity and depression parameters,effective and well tolerated,allodynia and pin-prick hyperalgesia,safety and efficacy,shorter response latency,pain with opioids,median blood level,rated pain paroxysms, constant pain, and touch- and pressure-evoked pain by use of 0- to 10-point numeric rating scales,VAS scores,Nausea and somnolence,interference of pain on quality of life,Psychogenic facial pain,incidence of chest wall pain,average daily pain intensity,Comprehensive Psychopathological Rating Scale (CPRS,Pain relief,depression ratings,mean values of pain reduction,Moderate or greater pain relief,Adverse effects,Pain prevalence,Dysesthetic pain,chronic facial pain,musculoskeletal pain,symptomatic peripheral diabetic neuropathy,pain in polyneuropathy,peripheral nerve function,depressive symptoms,pain free,initial pain scores,pain and paresthesia,Greater relief,systemic side effects,plasma concentration of citalopram,analgesia,saliva flow,pain intensity or pain-related disability,neuropathic cancer pain,relief of steady, brief, or skin pain by visual analog scales for pain and pain relief; mood; disability; satisfaction,Side effect ratings,median total ami- and nortriptyline concentrations,postoperative opioid use,individual pain ratings,Complete, good or moderate pain relief,number of daily activities disturbed by the pain, the Finnish McGill Pain Questionnaire, adverse effects, anxiety, depression, pressure threshold and grip strength,Average (SE) time to pain,low venlafaxine concentrations,scores on the daily 100 mm Visual Analog Pain Intensity (VAS-PI) and Pain Relief (VAS-PR) scales,serious adverse events,pain, paresthesia, dysesthesia, numbness, and nocturnal aggravation,neuropathic pain relief,intolerable side effects,analgesic effect of tricyclic antidepressants,Desipramine levels,efficacy and tolerability,systemic side effect,Opioid consumption, pain intensity, symptoms and adverse effects, mood, sleep, patient's preference, quality of life,phantom breast pain,arm pain,analgesic profile and the quality (global or neuropathic) of pain,visual analogue scale of pain intensity and measurements of interference by pain with functional activities,level of analgesia,Psychiatric interview,pain and no subjectively noticeable mouth dryness,polyneuropathy pain,pain intensity and escape medication,Significant relief of both pain and paresthesia,therapeutic analgesic efficacy,sensitivity and shooting pain,incidence of adverse events,change in pain intensity between baseline and the final visit,pain scale,tolerated,central poststroke pain,pain prevalence,McGill Pain Questionnaire, Sternbach Pain Intensity Scale, and Zung Pain and Distress Index,adverse effects,excellent pain relief,global rating of the analgesic effect on a 5-step verbal scale,steady-state plasma concentration,primary outcomes (average pain intensity) and secondary outcome measures (disability, satisfaction with life, handicap,pain ratings,symptoms in peripheral diabetic neuropathy,individual pain scores for pain paroxysms, constant pain, and pressure-evoked pain,pain or paresthesia,detection thresholds (electrical and heat,daily basis overall pain, shooting, burning, paraesthesia and numbness using a 0-10 visual analogue scale,plasma levels of imipramine and its metabolite desipramine,Side effects,Opioids and TCA reduced pain ,relief of pain,postherpetic neuralgia,pain threshold and the summation threshold to electrical stimuli and the summation threshold to heat stimuli,incidence of PMPS,VAS, HAM-D, and HAM-A scores) and qualitative,least pain intensity or the pain,analgesic effects,pain ,plasma concentration,Venous blood samples,weekly pain intensity and paresthesia intensity, measured on two categorical scales,pain intensity reduction,average pain level of 'moderate' to 'very severe,Pain,pain and produced unpleasant mouth dryness,depression and anxiety level,quality of life and mood disturbance,Pain relief measured by pain scale with verbal descriptors and global pain score assessment,side effects (nausea and vomiting or gastric upset and diarrhea,Hamilton depression scores, amitriptyline reduced pain,pain relief,psychogenic facial pain,adverse side effects,Anxiety and depression scores,touch-evoked pain,10-step verbal scale,patients' ratings of the intensity of experimental heat stimuli,Intolerable side effects,efficacy and safety,pain and increased saliva flow,dizziness and drowsiness,relief of pain or paresthesia,symptoms of neuropathy,analgesic efficacy,Adverse events,Clinical Global Impressions scale (CGI,interference with daily activities by pain,reduced pain,serum tricyclic levels,Anxiety and depression,Burning pain,number of tablets,pain intensity (0 to 10 scale), pain relief (0 to 100%), and cognitive function,visual analogue scale (VAS) for pain intensity, the Hamilton Rating Scale for Depression (HAM-D), the Hamilton Rating Scale for Anxiety,Clinical Global Impressions-Severity of Illness and the Clinical Global Impressions-Improvement, Patient Global Rating of Pain Relief, and percentage of patients achieving 50% reduction in pain intensity,pain reductions,Pain intensity and pain relief,rated constant pain, lancinating pain paroxysms, touch-evoked pain and pain on pressure by use of 0--10 point numeric rating scales,daily ratings of pain intensity on a 10-step verbal scale,pain status,depression and return of depression test scores,Chronic pain,Pain intensity,global pain intensity,Relief of steady pain, brief pain and pain on tactile stimulation,painful polyneuropathy,relieving pain,pain relief, mean pain score and global pain score,plasma concentrations,ongoing pain intensity (VAS), patient satisfaction, side effects, global efficacy and tolerance,lower total pain score,analgesic efficacy and tolerability,pain intensity,pain,side effects|Pain relief tended to be greater in depressed patients, but relief was also observed in patients who did not show an antidepressant effect.
244|time to cord separation, cord-related morbidities, or cord-related urgent care,shortest attachment time,Infant vital status,risk of omphalitis and neonatal mortality,Costs of alcohol drying,Separation of the umbilical cord,Time to cord separation, rates of colonization, and species of organisms that colonized,neonatal mortality,occurrence of umbilical granuloma,adverse event,Staphylococcal colonization,longest attachment time,cord separation time,occurrence of severe cord infection (redness with pus,Cord separation time,cord separation time and other secondary outcomes: omphalitis, sepsis, death, cord bleeding, compliance, satisfaction or dissatisfaction with regard to the type of treatment, umbilical cord colonization,Parents' treatment satisfaction,colonization rates,cord infection,slight cord scar bleeding,Severe omphalitis in chlorhexidine clusters,Higher rate of cord-related adverse events,Umbilical cord care,efficacy and safety,risk of omphalitis with CHX application,Rates of skin colonization,Umbilical stump cultures,Incidence of omphalitis,Omphalitis,rate of infections,signs of infection (pus, redness, or swelling,high colonization rate,time to umbilical cord separation and any discomfort such as infection, hemorrhage, and granuloma formation,sex, gestation period, birthweight, APGAR score or delivery method,Umbilical infection, cord separation time, maternal comfort, and cost,Bacterial colonization and neonatal infections,rate of positive umbilical swabs,omphalitis or skin infection,similar comfort with cord care and relief with cord separation,omphalitis, granuloma of the umbilical ground, adverse events and parents' treatment satisfaction,local umbilical infection,infection, and monetary savings,umbilical cord separation time,incidence of neonatal omphalitis and neonatal mortality,gender, gestational age, birthweight or length, gravidity, meconium staining, maternal age or presence of discharge,Neonatal mortality,Infections (pemphigus, paronychia, conjunctivitis, umbilical infection,catheterization of umbilical vessels,median cord detachment time,minimum killing concentration (MKC) of CHD and EtOH,Total infection rates,Cord separation time, changing of the programmed cord-care regimen, death, omphalitis, sepsis, cord bleeding, nurses' opinion on treatments efficacy, and UC colonization,relative incidence rate,Separation time,sepsis or died,mean duration for cord detachment,umbilical cord separation time (UCST,infection rates,Complete information,rates of different types of infections (conjunctivitis, pyoderma, paronychia, omphalitis,Frequency of omphalitis,separation time,umbilical colonization,infection or mortality risk,infants' gender, mode of delivery, gravidity, gestational age, birth weight, or hospital stay,mean cord separation time,omphalitis and neonatal mortality,shorter cord separation time,rate of negative umbilical swabs,Umbilical care and cord separation,mortality|A significantly higher percentage of nurses were satisfied with the salicylic sugar powder treatment (98%) than with the chlorhexidine treatment (67%), notwithstanding a more frequent occurrence of slight cord scar bleeding in the salicylic sugar group (7.8%) than in the chlorhexidine group (4%).
52|HbA(1c) level,Baseline hemoglobin HbA1c,incidence of hypoglycaemia,DTSQ , DSC type 2, WHO-5 or SF -36, except for the SF -36 dimension 'health change,or weight,HbA1c level,glycaemic control and psychological indices,SMBG or urine glucose testing,decrease of HbA1c,mean (SD) age,HbA(1c), psychological indices, use of oral hypoglycaemic drugs, body mass index (BMI), and reported hypoglycaemia rates,HbA(1c) levels,target level of HbA(1c,higher baseline BMI,HbA1c,glycemic control,mean fasting plasma glucose,mean change in HbA(1c) levels,BMI,Treatment satisfaction,stability or worsening,fasting plasma glucose,number of blood glucose strips,Weight loss,changes in body weight, lipids, and microalbumin and changes in treatment satisfaction and well-being,diabetes regression,body mass index,subitems depression,median HbA1c,Short-form 36 Health Survey Questionnaire (SF-36), the Type 2 Diabetes Symptom Checklist (DSC-r), the Diabetes Treatment Satisfaction Questionnaire (DTSQ) and the WHO -Wellbeing Index (WHO-5,change in HbA(1c) level,SMBG and HbA1c levels,glycosylated hemoglobin,change in HbA(1c) levels,mean HbA(1c) reduction,incidence of symptomatic hypoglycaemia,Body weight, total cholesterol, and microalbumin,change in HbA(1c,Body weight reduction,percentage of patients achieving a lifestyle score,Furthermore, health-related quality of life and treatment satisfaction,duration of diabetes,fasting glucose value and three postprandial glucose values,depression subscale,glycosylated hemoglobin values|Also, there were no significant changes between groups on the DTSQ , DSC type 2, WHO-5 or SF -36, except for the SF -36 dimension 'health change' which was lower in the SBMG group (mean difference:
6|Visual feedback,visual feedback|The results indicated that visual feedback for tongue placement and frication was especially useful in the treatment of defective /s/ sounds in patients with cleft palate who exhibited abnormal posterior tongue posturing during the production of dental or alveolar sounds.
not found|akathisia scores,Akathisia|Clonazepam may be a safe and effective treatment for neuroleptic-induced akathisia in this age group.
44|elderly mobility scale score,trajectories of recovery,strength, functional motor performance and balance and reduced fall-related behavioural and emotional problems,muscle strength, walking speed, balance, and perceived health but not bone mineral density or fat-free mass,need high-level care,Isometric lower-extremity force, 6-minute-walk distance, free gait speed, mental status, and physical function,Functional mobility (Elderly Mobility Scale), disability (Barthel Index) and health status (Nottingham Health Profile,leg extensor power, or reduce disability,strength, functional performance and emotional state,temporal-distance gait parameters and mobility level (house-bound, limited, or unlimited,indoor mobility ability,Quadriceps strength, postural sway, functional reach, weight-bearing ability, walking velocity, and self-rated fall risk,sustained palpable or visible contractions with no leg movement,function and quality of life,strength,walking speed,physical ability,Significant weight loss,postoperative cardiovascular instability,weight,heart rate,feasibility, safety and efficacy,tolerated sufficient stimulation intensity to produce repetitive knee extension,knee extensor muscle strength in the fractured leg and walking speed, measured at 4 and 16 weeks,hip ROM, strength, walking velocity, Harris hip score, and health-related quality of life (HRQOL,Muscle strength and range of movement of the lower limb,PPT and FSQ scores,physical domain score,visual analogue scale for pain, the brief pain inventory and Ketorolac for post-operative control of pain, and an overall assessment of outcome by the surgeon,morbidity and mortality rates,measures of balance and functional performance,duration of physical rehabilitation until the patient was able to (1) walk 50 metres in less than 2 minutes, (2) manage stair climbing to the first floor, (3) manage sit-to-stand transfer, (4) move in and out of bed, (5) manage bathing, dressing and lavatory visits,Mean change (SD) in PPT score for physical therapy,walking velocity,Isometric force,strength and walking velocity,strength and functional performance,Weight change, quadriceps strength, gait speed, quality of life and health care utilization,duration of physical rehabilitation,Leg extensor power,strength, postural control, and mobility,standardized measures of skeletal muscle strength, gait, balance, quality of life, and body composition,weight-bearing ability,energy subscore of the Nottingham Health Profile,6-minute-walk distance and gait speed,overall trajectory of time in exercise,weight loss,acute hospital length of stay and destination at discharge,physical function and quality of life and reduce disability,discharge mobility level,physical ability (strength, balance, gait, functional performance,Adherence,physical function and reduces disability,leg extensor power (Nottingham Power Rig), functional mobility (elderly mobility score), disability (Barthel Index) and quality of life (Nottingham Health Profile,Barthel score,change in leg extensor power (Nottingham Power Rig,Mortality,psychologic domain of HRQOL,leg extensor power and reduced disability,Depressive symptoms,strength, balance, gait and functional performance,faster recovery of mobility,muscle strengthening, range of motion (ROM), balance, and functional training,subjective falls risk,distance walked, force produced, gait speed, and physical function,risk of weight loss,Recovery of walking speed and ability, postural stability, lower-limb muscle power, and pain,total scores on a modified Physical Performance Test (PPT), the Functional Status Questionnaire physical function subscale (FSQ), and activities of daily living scales,Mean change (SD) in FSQ score for physical therapy,strength and mobility,mobility level,medical problems,quadriceps strength,Fractured leg extensor power,discharged directly home from the acute care,leg extensor power,functional performance,health outcomes,Strength, balance, gait, and functional performance,time spent exercising,Functional levels,leg extensor power and decreases disability,leg extensor power and reduces disability,recovery of walking speed,Wound infections|No difference between the two groups was demonstrated in the duration of physical rehabilitation by a per protocol analysis of the patients who completed the trial.
                
60|letter deletion and memory tests,State-Trait Anxiety Inventory (STAI,Arterial desaturation during induction of anaesthesia and insertion of a laryngeal mask airway,anxiety scores,anxiety and produced sedation,Digit- Symbol Substitution Test score,worsening of psychomotor skill,time interval between arrival in the postanesthesia care unit and discharge to home (discharge time,Patient acceptability,Sedation,Complete recovery,time to awaken, the level of postoperative sedation and the ability to walk unaided,PACU time and time to discharge-readiness,Postoperative sequelae,Postoperative cognitive recovery,Sedation scores, extubation time, and discharge times,anxiolytic effects,Patient acceptance,Awakening time,TDT score,Indices of anxiety and alertness,STAI anxiety levels,incidence of intraoperative airway difficulties such as coughing,psychological variables,anxiety,preoperative anxiety,postanesthesia care unit and recovery of psychomotor function,recall abilities,Haemodynamic differences,heart rate and systolic arterial pressure immediately before induction of anaesthesia,anxiolytic properties,Psychomotor function,preoperative discomfort and apprehension,NRS anxiety scores,incidence of pain,numerical rating scale (NRS,anxiolysis, sedation or recovery,sedation score,postoperative nausea, vomiting and other side effects,ASA physical status, duration of surgery, basal NRS score, sedation at the preset time intervals, and discharge time,anxiolysis or sedation,vomiting,discharge times,anxiety score,VAS or STAI score,anxiety levels,delayed recovery times,cognitive function,anxiety level,return of psychomotor function,effectiveness and side effects,anxiolysis, sedation, amnesia and psychomotor performance,postoperative nausea,postoperative sedation and recovery times,higher sedation level,Anxiety,Psychomotor performance assessed by digital-symbol substitution tests,mean heart rate and blood pressure,100-mm visual analogue scales (VAS) and The State-Trait Anxiety Inventory (STAI) psychometric questionnaire,blood pressure and heart rate,postoperative sedation,psychomotor function,discharge time,Psychomotor performance assessed by 'n' deletion test,situational anxiety,patient self-assessment linear analogue scales and observer scores,Effective anxiolysis,excellent (Grade I) conditions for insertion of a laryngeal mask airway,anxiolysis and sedation|Haemodynamic differences between the groups were not clinically significant, and return of psychomotor function was not delayed by timolol.
300|condom failures,behavioral risk and preventing STIs and UPs,behaviors, sexual risk knowledge, attitudes toward condoms, and condom use negotiation skills,proportion of condom-protected sex acts,STI incidence,subsequent chlamydial or gonorrheal infection,number of sexual partners,postintervention STI or UP [odds ratio,vaginal intercourse,intercourse episodes,risky sexual behaviors,chlamydial infection,consistent condom use, defined as condom use during every episode of vaginal intercourse; other outcome measures were sexual behaviors, observed condom application skills, incident STD infection, self-reported pregnancy, and mediators of HIV-preventive behaviors,rates of chlamydial and gonorrheal infection,several risk behaviors,sexual risk behaviors, sexually transmitted diseases (STDs), and pregnancy and enhance mediators of HIV-preventive behaviors,percentage of women using condoms during the previous 3 months (overall and by partner type) and proportion of total episodes of intercourse,rate of recurrent STD,Incident chlamydial infections,rates of reinfection with C. trachomatis,recurrent chlamydial infection,AIDS knowledge and intentions to use condoms, and fewer sex partners,chlamydia infections and self-reported pregnancy,sexually transmitted infection (STI) incidence, repeat pregnancy, sexual risk behavior, and psychosocial risks,sexual risk knowledge and more positive attitudes toward condoms,rates of incident STI or unintended pregnancy,likely to report use of dual contraceptive methods,psychosocial mediators of STD/HIV-preventive behaviors,STD-related knowledge,pregnancy, Chlamydia trachomatis, Neisseria gonorrhoeae, and Trichomonas vaginalis,condom use and decreased unprotected sexual intercourse,knowledge about sexually transmitted diseases (STDs), (b) self-reported sexual risk behavior, and (c) STD acquisition,percentage of sexual acts,female condom use and protected sexual acts,rate of participation,condom use and recurrent sexually transmitted disease (STD,male condom use,awareness of, attitudes toward and use of female,infection rates,reduced biological, behavioral, and psychosocial risks for HIV,Rates of subsequent infection,HIV transmission knowledge, condom attitudes, and self-efficacy to use condoms,benefits, acceptance of sexuality, control over the sexual encounter, attitudes toward condoms, and self-efficacy,multiinstrument questionnaire measuring sexual behavior, condom practices, attitudes and beliefs, cognitive complexity, sociodemographics, and motivation,rates of retention,higher cognitive complexity,sexual risk behavior|Self-reports revealed that those assigned to the interactive video were significantly more likely to be abstinent in the first 3 months following initial exposure to the intervention, and experienced fewer condom failures in the following 3 months, compared to controls.
140|wound infection, healing time, time off work and the recurrence rate,length of hospital stay,Disease recurrence,median healing time,hospital stay,time to resumption of work shorter,times of healing,no recurrence,excision of recurrences,disease recurrence,duration of hospitalization,visual analog scale and the McGill Pain Questionnaire,morbidity,removal of sutures,post-operative complications,Morbidity and recurrence rates,longest healing time,time to healing,numbers of late complications,pain perception,complications, time to suture removal,Early mobility and recurrence,healing failure and early bridging,quality of life and patient comfort,infection rate,wound breakdown,Time to return to work and to complete healing,social functioning,complications, need for analgesia and wound dressing, periods of time off work and off driving,duration of operation and hospital stay, shorter time periods to walk, return to daily activities, or sit without pain and to return to work or school, and fewer complications,postoperative complications,Shorter hospital stay, earlier healing, shorter time off work, lower ratio of complications, lower pain perception, and improved general health perception,mean hospital stay,recurrence,Incidence of early complications (bleeding that needed treatment, wound breakdown, infection, haematoma, or wound pain), number of postoperative visits required, and length of sick leave taken,early complications,postoperative pain,mean postoperative Visual Analogue Scale scores,bleeding, hematoma, infection, and recurrence,clinical outcomes and quality of life,time off work and off driving and also the Visual Analogue Scale scores,healing time,general health perception,mean healing time and time off work,Morbidity,quality of life scores,mean healing time,time to complete healing (P<.001), time off work (P<.001), and wound infection rate,heal and proceeded to cleft closure,wound infection rate,healing failure and hematoma,healing of the wound and disease recurrence,return to normal activity,healing time and duration of sick-leave,Recurrence rates,median length of the postoperative hospital stay,total time of healing,complete healing of the wound,recurrence rates, Duration of operation,quality of life,Recurrence,cure rate,Duration of operation, postoperative pain, duration of hospital stay, postoperative complications, and time to recurrence,wound healing,operating time, hospital-stay, time off from work and wound healing time,infection rates,wound infection,recurrence rate,time off from work,mobilization earlier,postoperative complications regarding bleeding, hematoma, infection, or recurrence,flap necrosis, local haematomas or seromas,vacuum effect,median time before return to work,longer hospital stays,Total hospitalization period,length of hospital stay, length of time to return to work, wound infection rate, and recurrence rate,shortest hospital stay, operative blood loss and post-operative pain,operative time,operating time, healing time, time before return to work, morbidity rate, and recurrence rate,Initial primary healing,Time to final healing,healed their wounds primarily,Mean wound healing,Wound healing and the return to normal activity,Duration of operation, postoperative pain, time to first mobilization, length of hospital stay, postoperative complications, time to resumption of work, recurrence and time to recurrence,rate of recurrence,Demographic data, operative time, hospital stay, operative blood loss, post-operative pain, wound healing time and patient's satisfaction,shortest wound healing time,Healing,duration of hospital stay shorter,Times to sitting on toilet and walking without pain,Postoperative pain,method of excision and open wound healing,pain,Duration of operation|Time to final healing was significantly shorter and quality of life scores on the CWIS were higher in patients receiving RELP than in those receiving UM.
239|hematologic, renal or hepatic parameters, neurologic function or use of antibiotics,transfusion requirements or wound complications,No sepsis, transfusion reactions or coagulopathies,median blood requirement,bank blood requirements,circulating D-dimers,mean volume of homologous blood transfused,demographic data, drain output, total blood loss, and mean postoperative haemoglobin levels,Hb, RBC, HCT and PLT,intraoperative mediastinal blood loss,haemoglobin at the time of hospital discharge,autologous blood transfused,fibrinogen concentrations,demographics, comorbidity, risk stratification, or operative details,Median (interquartile range) blood loss,safety and effectiveness,Patient bleeding times,allogeneic transfusion,blood loss and postoperative hemoglobin values,haemoglobin concentration,mean body weight,Hb, HCT, PLT or length of cardiopulmonary bypass (CPB,number of red cells, hemoglobin, hematocrit, platelets, white blood cells, values of potassium, sodium, free hemoglobin and acid base status,clinical infections,Postoperative chest tube drainage,Homologous blood transfusion,homologous blood,morbidity,Blood salvage,blood loss, hemoglobin levels, complications, and costs,operative and postoperative blood losses--hence, the total blood loss,lung perfusion postoperatively,coagulation parameters,volume of reinfused blood,mean number of units of allogeneic blood transfused,postoperative morbidity,mean Hb concentration,intravascular hemolysis,postoperative hemoglobin levels,total postoperative bleeding,mean preoperative hematocrit,hospital mortality,platelet function and fibrin deposition,mean volume of shed mediastinal blood reinfused,HBT,Efficacy, safety and user-friendliness,platelet aggregation, von Willebrand factor (vWF) multimetric analysis or clotting profiles,Hemoglobin and hematocrit changes,substantial financial savings,postoperative haematocrit and haemoglobin values,serum PCT concentration,C-reactive protein, erythrocyte sedimentation rate, troponin-T, and hemoglobin levels,inflammatory activation, myocardial injury, bleeding, and hemoglobin levels,blood losses,Fibrin split products,blood transfusion,thromboelastograph values or laboratory measures of clotting pathway function (prothrombin time, activated partial thromboplastin time, fibrinogen, and fibrinogen D-dimer levels,No infection, renal dysfunction, or coagulation disorders,blood loss and homologous blood transfusion requirements,incidence of re-exploration,Mean intraoperative blood loss,postoperative homologous blood transfusions,Prothrombin time (PT) and activated partial thromboplastin time (APTT,Safety and therapeutic effectiveness,blood loss and homologous blood usage,blood gas and hemoglobin measurements,postoperative blood,transfusion of homologous blood,total cost per patient,levels of the biochemical markers of myocardial injury,Postoperative blood loss,C-reactive protein, erythrocyte sedimentation rate, and troponin-T,total operation, hospitalization, and management costs,number of patients requiring homologous blood transfusion,small overall cost saving,postoperative segmental perfusion defect,volume of collected blood,preoperative hemoglobin values, estimated blood loss, Cell Saver return volumes, intraoperative and postoperative homologous blood transfused, postoperative hemoglobin values on the day of surgery and on postoperative days 1 and 4, complications, and length of hospital stay,postoperative blood requirements,units of homologous blood transfused,median amount of homologous blood,hemoglobin concentration,incidence of post-operative complications, such as wound infection, deep-vein thrombosis and chest infection,plasma-free haemoglobin and bacterial contamination,hemoglobin and hematocrit values, drainage volume and transfusions (homologous and autologous), range of knee motion, knee swelling and hospital stay,Postoperative blood salvage,adverse effects of blood transfusion,safety, efficacy and user-friendliness,TAT and FPA levels,2,3-DPG levels,homologous transfusion requirements,postoperative SIRS and infective complications,preoperative and operative variables,average preoperative hemoglobin concentration,allogeneic blood use,mean allogeneic red cell utilization,blood aspirate,Haematological effects,C-reactive protein concentration,complications or episodes of hypotension, confusion, cardiac or pulmonary compromise, febrile reaction, or coagulopathy,haemoglobin,Plasma concentrations of tumor necrosis factor-alpha, interleukin-6, and C3a,excessive bleeding,frequency of homologous blood product use,Total intra-hospital homologous blood replacement,incidence of infection requiring intervention,total knee and total hip arthroplasty,mean mediastinal drainage,drained blood loss,safety and efficacy,Hb, Hct level, and leucocyte count,Transfusion requirements, and incidence of systemic inflammatory response syndrome (SIRS) and infection,mean length of stay in hospital,Intraoperative and postoperative hemodilution,cost,Mean volume of blood autotransfused,postoperatively blood salvage,Blood conservation,homologous blood consumption,lack of septic, hematological, pulmonary, renal, or hepatic complications,postoperative hemoglobin/hematocrit levels, and complications,number of infective episodes,banked blood utilisation,requirements for transfusion of stored bank blood,protein C level,perioperative mortality,Postoperative hemoglobin and hematocrit values,Excellent quality of the autologous FFP,hemoglobin levels and drainage volumes,allogeneic blood transfusion,mean postoperative blood replacement,salvaged mediastinal blood available for autologous transfusion,chest tube drainage,number of re-explorations for excessive bleeding,allogeneic blood transfusion requirements,clotting pathway function (prothrombin time, activated partial thromboplastin time, and fibrinogen levels), increased postoperative bleeding, fluid requirements, or adverse clinical events,hemoglobin levels,Hematologic and coagulation parameters,Postoperative autotransfusion of drainage blood,cost of the blood management,mean amount of blood transfused,homologous blood transfusion,homologous blood transfusions,allogenic blood requirement,efficacy and financial cost,lung perfusion scintigraphy, chest X-rays, ABG, and D-dimer values,Allogeneic blood,hemoglobin level,total knee replacement,postoperative systemic inflammatory response,complications leading to transfusion,fibrin degradation products,Leucocyte count, Hb, Hct values, C-reactive protein, and procalcitonin concentration,blood transfusions,Safety, efficacy, and cost,volume of salvaged and autotransfused blood,Pre- and postoperatively prothrombin time and partial thromboplastin time,allogeneic blood requirements,Homologous transfusion requirements,total homologous blood requirements,blood loss and Cell Saver return volumes,use of homologous blood,blood utilization,Total patient costs,salvaged blood,mean homologous blood replacement,preoperative and postoperative haemoglobin levels,infective complications,Lung X-rays, arterial blood gases (ABG), D-dimer values, and lung perfusion scintigraphies,transfused blood and the preoperative and postoperative hemoglobin levels,Volume of intraoperative autologous blood transfusion, postoperative mediastinal blood loss and homologous blood transfusion requirements,Risk of SIRS,adverse reactions,oxygen transport capacity,transfusion reactions, infectious complications, or coagulopathies,intraoperative blood salvage,Mean haemoglobin concentration,Haemoglobin levels and drain output,proportion of patients receiving allogeneic blood, and average number of units per patient,Total homologous blood product exposure,allogeneic blood transfusions,allogeneic blood,levels of haemoglobin,serum levels of CK-MB, cardiac troponin T (cTnT), and H-FABP,risk of infection,Plasma concentrations of the cytokines tumor necrosis factor-alpha and interleukin-6 and complement factor C3a,potassium concentrations,higher level of cTnT,mean blood loss,Hemoglobin levels and costs,mean immediate and 24-hour postoperative hemoglobin values,total postoperative blood loss,high hemoglobin, white blood cell, and plasma hemoglobin content and MCV,need for donor blood transfusion,number of patients requiring any blood transfusion,Postoperative drainage volumes,chest infection,body surface, preoperative and postoperative hematocrits, number of grafts, bypass duration, and postoperative mediastinal blood loss,Safety and efficacy,mean volume of autologous blood reinfused,complications or adverse effects,plasma free haemoglobin concentrations,adverse effects,values of haemoglobin, haematocrit and platelets,estimated blood loss (EBL), allogeneic blood transfusion (units administered intraoperatively, postoperatively, and total), proportion of patients not receiving allogeneic blood,Intravascular fibrin degradation,Global coagulation tests, antithrombin III, and total serum protein,postoperative renal dysfunction, coagulopathy or mortality,mean post-operative haemoglobin levels,Postoperative hemoglobins,allogeneic blood transfusions, total volume of blood collected in the bag used for retransfusion, perioperative Hb levels, febrile reaction, and other complications,units of allogeneic red blood cells,bank blood,peak delta values,clinical outcome, overall blood loss, use of platelets, fresh frozen plasma and colloids, haematological indices, renal and hepatic functions, or clotting mechanism,transfusion-related complications,Packed red cells,average mediastinal blood losses,postoperative haemoglobin levels and homologous blood requirements,mean volume autotransfused,blood coagulation,intraoperative and postoperative Cell-Saver (Haemonetics, Braintree, MA,mean 24-hours postoperative blood loss,haemoglobin levels,Median transfusion requirements,total blood,blood parameters (hemoglobin, hematocrit, thrombocytes), clotting status (prothrombin time, plasma thromboplastin time, thrombin time, fibrinogen, plasminogen, and antithrombin III), and immunological methods such as fibrinopeptide A (FPA), thrombin-antithrombin III (TAT), and protein C,serum levels of cTnT or H-FABP,length of postoperative in-hospital stay,bleeding tendency and systemic inflammatory response,need for bank blood,average volume of autotransfusion blood,banked blood requirement,postoperative febrile reaction,Drainage and transfusion volume,efficacy and safety,Transfused and circulating blood,mediastinal re-exploration for bleeding,autologous blood transfusion,values of red blood cells,Packed red blood cells,need for allogenic blood,hemodynamic parameters, oxygen delivery or oxygen extraction,Blood losses,number of HBTs,platelet count,intravascular fibrin degradation,blood loss, and Hb concentration,Patient blood samples and bleeding times,D-dimer levels,bleeding,Coagulation parameters analyzed and complication rates,24-hour postoperative hemoglobin concentration,prothrombin time,febrile reactions,Exposure to banked blood,highest postoperative D-dimer levels,Postoperative morbidity and blood loss,postoperative hemoglobin concentrations,postoperative transfusions,mean number of allogeneic red cell concentrates required and the number of patients in each group who required no transfusion,average requirement of bank blood,postoperative homologous transfusions,Cryoprecipitate and fresh frozen plasma utilization,homologous transfusion,retransfusions and postoperative febrile reactions,hematocrit,total amount of infusion, intraoperative blood loss, autologous transfusion, and blood parameters,red blood cells,Postoperative bleeding,coagulation-fibrinolytic profile,percentage of patients not requiring allogeneic red cells,SIRS,postoperative blood loss, fluid requirements, blood product requirements, or in the incidence of adverse clinical events,intraoperative blood loss and homologous blood transfusion,discharge hemoglobin level,Haemoglobin (Hb), haematocrit (Hct), C-reactive protein values, and leucocyte count,blood hemoglobin and total protein content,homologous blood requirements,Postoperative bleeding and hemoglobin levels,postoperative haemoglobin level,Volume of homologous blood transfusion,length of stay,serum procalcitonin (PCT) concentration,no supplementary blood transfusion,fibrinogen level,intraoperative net blood loss,reduction and avoidance of donor blood requirements,volume of blood collected,mean volume of banked packed RBCs transfused per patient,D-dimer generation,predonation hemoglobin (Hb) concentration,serum level of CK-MB,transfusion requirements, no adverse clinical or coagulopathic effects,febrile transfusion reaction,Platelet utilization,postoperative autologous blood salvage|The median amount of homologous blood required after operation by the study group was reduced by 74% from the amount required by the control group (mean, 67 ml vs 256 ml, respectively; P less than .0001).
861|incidence of delivery with an intact perineum,instrumental deliveries,frequency of sutured vulvar and vaginal tears, women's sense of control, and satisfaction with the delivery experience,tear rates,perineal massage diaries|Comparison of the group assigned to massage with the group assigned to no massage showed a reduction of 6.1% in second or third degree tears or episiotomies.
26|binding activity,Mean fasting and post-breakfast blood glucose levels,mean insulin antibody titer,duration of diabetes, insulin dose, and daily carbohydrate intake,Quality of life,Warning symptoms of hypoglycaemia,metabolic control,overall diabetic control,Hunger and sweating without concomitant neuroglycopenic symptoms,frequency of severe hypoglycaemia,Mean fasting plasma glucose,anti-human insulin antibodies,total frequency of hypoglycaemia,Total reported symptomatic episodes,mean adrenaline response,Hypoglycaemic episodes,antibody values,Metabolic control, insulin dosage and B-cell function,frequency and intensity of hypoglycaemic episodes,fasting concentrations of glycerol and non-esterified fatty acids,blood-glucose responses,glycaemic control, insulin dose and anti-insulin antibodies,Serum insulin-binding antibodies,Hypoglycaemia,incidence of hypoglycemic reactions,nocturnal blood glucose,frequency of mild hypoglycemia,onset time and faster peak action time of human insulin,24-hour blood glucose profiles,delayed rise of insulin antibodies,adverse reactions, injection-site anomalies, or drug-related biochemical abnormalities,insulin binding activity,fasting blood glucose concentration,hemoglobin A1 levels,blood glucose profiles and HbA1c values,neuroglycopenic symptoms,severe hypoglycemia,symptoms of hypoglycaemia,glycated hemoglobin values,mean percentage of hypoglycaemic episodes,maternal hyperglycemia or hypoglycemia,Immunogenicity,Concentrations of antibody reactive with porcine and human insulins,Glycated haemoglobin,number of episodes,daily insulin doses,blood glucose daily profiles, insulin doses, hemoglobin Alc,symptomatic response to hypoglycaemia,Episodes of hypoglycaemia,136 hypoglycaemic episodes,Mean levels of fasting plasma glucose, glycohemoglobin, and daily insulin dosages,glycosylated haemoglobin levels,awareness of hypoglycaemia,SEM), and glycosylated haemoglobin,severe unwarned hypoglycemia,clinical symptoms, glycosylated haemoglobin, and home blood glucose monitoring,anxiety level,Daily insulin dose,insulin per kilogram of body weight,numbers of episodes of nocturnal or reported hypoglycaemia,level of antibodies,Mean IABC, bound insulin, RIF, and percentage of B, P, and H bound,IgG insulin antibody levels,capillary blood glucose concentration,occurrence of asymptomatic biochemical hypoglycaemia,glycohemoglobin levels,incidence of hypoglycaemia,episodes of mild hipoglycemia,Immunological and metabolic responses,Insulin antibody levels,Insulin antibody determinations,frequency, severity, and symptomatology of hypoglycaemia,Total and ultralente daily insulin doses,Sex ratio, age, body mass index, duration of diabetes, C-peptide concentrations, baseline metabolic control and initial insulin requirements,total frequency of symptomatic hypoglycaemia,severe hypoglycemic attacks or skin reactions,adverse reaction,Fasting blood glucose level,mean preprandial capillary blood glucose, glycosylated haemoglobin or insulin dose,HbA1c) values,Insulin doses and blood glucose, glycated haemoglobin A1c, and fructosamine concentrations,frequency and severity of hypoglycaemia,Biochemical hypoglycaemia,hypoglycaemic events,capillary blood glucose series, M-values, HbA1c, and fasting lipids,insulin requirements,fasting and 1-h postprandial blood glucose, HbA1c, and daily insulin dosage,anamnestic immunological response and deterioration of metabolic control,fasting and postprandial plasma glucose levels, the concentration of glycosylated haemoglobin, serum lipid levels, insulin dose, and body weight,restlessness,Higher fasting blood glucose concentrations,efficacy and immunogenicity,blood glucose control,duration of diabetes,local or systemic adverse reactions,mean HbA1c,Significant insulin antibody,fasting blood sugar levels,human (semisynthetic) insulin and porcine insulin,Mean insulin dosage (U/day,Mean HbA1c,glycated hemoglobin and fasting blood sugar values,Glycosylated haemoglobin values,frequency, timing, severity, or awareness of hypoglycaemia,symptoms and awareness of hypoglycaemia,M-values, mean HbA1c or fasting lipids,biochemical hypoglycaemia,pre-lunch blood glucose,glucose excursions,Glycaemic control and frequency of hypoglycaemic episodes,fasting blood glucose level,Questionnaire recording "autonomic" and "neuroglycopenic" symptoms,hypoglycaemia,report hunger,log insulin binding values,report lack of concentration,level of IgG insulin binding or the percentage of patients with insulin antibodies,blood glucose levels,insulin antibodies (IA,fasting blood sugar (FBS), 24 hour glucosuria and glycated protein (GP,insulin antibody values,efficacy and safety,hypoglycaemia awareness,anti-bovine insulin antibodies,blood glucose,pre-breakfast blood glucose,modified M index, and total daily insulin requirement,mean glucose level and the modified M index,overall mean blood glucose concentrations,Hypoglycaemic symptoms, the total daily insulin dose, and the ratio of short- to intermediate-acting insulin,severe hypoglycaemic events,Frequency, severity and symptomatology of hypoglycaemia,mean insulin antibody levels,occurrence of hypoglycemia,HbA1c values,severe hypoglycaemia,Blood glucose level, glycosylated haemoglobin, insulin requirements, and frequency of hypoglycaemic events,Insulin dosage/day, fasting plasma glucose, percentage HbA1, insulin antibody binding capacity (IABC), bound insulin (BI), percentage binding of 125I-labeled B, P, and H insulins, and receptor inhibition factor (RIF,fasting blood glucose,insulin antibody levels,mean glucose level,total HbA1,hypoglycaemia while taking BHI,glycaemic control|Mean fasting plasma glucose (12.1 mM) and HbA1 (11%) were significantly higher on B than on P, H, and SB.
59|graft patency and limb salvage rate,distal anastomosis interposition vein cuff,Operative mortality,primary patency,reoperation for wound complications,need revision or reoperation for wound complications,12-month patency rates,limb salvage rates,patency rate,Patency and limb salvage,acute ischemia,primary patency rate,secondary patency rate,cumulative rates of primary patency and limb salvage,Leg salvage,secondary patency and limb salvage rates,overall survival rate,patency rates,mean postoperative ankle-brachial index (ABI,graft patency or limb salvage,limb salvage rate,2-year patency rates|The primary and secondary patency rate at 2 years was 29 and 40% for the AVFG and 36 and 40% for the CG (NS).
not found|faster weight gain,Weight loss,Poor weight gain,growth parameters (weight, length, and head circumference), serum total protein levels, feeding-related complications, duration of intravenous fluid supplementation, and length of hospitalization,abnormalities of blood chemistry or significant complications,gestational age, birth weight, and morbidity,mean incremental weight velocity during NJ feeding,mean weight velocity and mean occipitofrontal circumference velocity,delivery mean body weight and mean occipitofrontal circumference,Cumulative weight gain, caloric and fluid intake, percent weight lost, blood chemistry values, and complications,average weight gain,bodyweight or occipitofrontal circumference,mean caloric intake,calorie intake or growth rates,weight gain, caloric intake, and fluid intake,growth rate, oral energy input,practicality, effectiveness, and safety,caloric intake|At expected date of delivery mean body weight and mean occipitofrontal circumference were significantly smaller in the NJ group.
69|mean (+/-SD) length of hospitalization,Delayed laparotomy,survival,total parenteral nutrition,delayed laparotomy or died,dependence on parenteral nutrition 90 days postoperatively and length of hospital stay,Six-month survival,6-month survival|Six-month survival was 18/35 (51.4%) with a drain and 21/33 (63.6%) with laparotomy (P = 0.3; difference 12% 95% CI, -11, 34%).
47|clinical efficacy and safety,plateau value fall in forced expiratory volume,evening PEFR,ophthalmic parameters (glaucoma and posterior subcapsular cataracts,adrenal responses,plasma cortisol levels,hypothalamic-pituitary-adrenal axis, bone density, or ophthalmic parameters,lumbar spine (L1 to L4 ) bone density,Recurrence of symptoms,Bronchoalveolar lavage (BAL) and airway biopsy studies,bone mineral density,efficacious and well tolerated,percentage of nights with no awakenings,Hypothalamic-pituitary-adrenal axis suppression,Diskus to Diskhaler ratio for Cmax,HPA axis function and ophthalmic evaluations,Secondary pulmonary function end points and asthma symptoms,BHR and the different indices of the methacholine dose-response (MDR) curve,cortisol response,progressive increase in PD20AMP,Cortisol excretion,Mean 8-hour area under the plasma cortisol concentration-time curves and peak plasma cortisol concentrations,serum cortisol levels,Baseline mean morning peak expiratory flow,cortisol excretion,bronchoconstriction and airway inflammation,compliance rates,24-h cortisol secretion,BHR,hypothalamic-pituitary-adrenal (HPA) axis function,late-response allergen-induced sputum eosinophilia,urinary leukotriene E4 excretion,airway responsiveness or sputum eosinophilia,MDR curve,FP formulations,safety and efficacy,number of cells expressing intracellular adhesion molecule-1 (ICAM-1) and MAC-1,forced expired volume in 1 sec (FEV(1)) ,Exhaled NO levels (ppb,effective and safe,Efficacy and tolerability,airway hyperresponsiveness, sputum eosinophils, and exhaled nitric oxide levels,Morning and evening peak expiratory flow (PEF), asthma symptoms, and supplemental albuterol use,asthma, inflammation, and smooth muscle dysfunction (e.g., bronchoconstriction,tolerated and effective,morning peak expiratory flow rates (PEFR,morning PEF,Salivary and urinary cortisol data,morning and evening peak expiratory flow, need for rescue albuterol, and asthma symptom scores,Efficacy parameters,evening peak expiratory flow,sputum eosinophils and exhaled NO levels,BMD,morning plasma cortisol concentrations,pulmonary function and asthma symptom control,pulmonary function and asthma stability,mean plasma cortisol responses,safety measurement,Markers of bone formation (serum osteocalcin) and resorption (urinary N-telopeptide,PC20,cortisol suppression,FEV1 and peak expiratory flow rates,Partial protection,lung function and the immunopathology of asthma over time,24-h urinary cortisol excretion and PC20 for adenosine,Lower leg length,symptom recurrence,number of nighttime awakenings,FP plasma concentrations,serum and urinary cortisol,incidence and severity of adverse events,AUC,nocturnal symptoms,frequency of inhaled albuterol use,stimulated plasma cortisol concentrations,airway responsiveness,nighttime awakenings,numbers of T cells, macrophages, and eosinophils in the bronchial wall,EIB,HPA axis function,morning peak expiratory flow,forced expiratory volume in one second (PC20) = sensitivity), slope (reactivity) and maximal response (plateau,incidence of potentially drug-related adverse events,Growth rate,sputum eosinophilia prechallenge,numbers of (CD3+) T-lymphocytes, (CD4+) T-helper cells, (CD45RO+) activated T-helper cells and eosinophils,area under the 12-h serial FEV(1) curve relative,cortisol secretion and airway responsiveness,maximal airway narrowing response,Mean change in FEV(1,sputum cell counts and measures of eosinophil activation at 7 h and 24 h, and methacholine airway responsiveness,geometric mean % fall in FEV(1,Baseline median urinary cortisol excretion values,mean morning PEF,probability of remaining in the study without being withdrawn because of worsening asthma,fluticasone propionate effect,MDR curves,maximum plasma FP concentration (Cmax,reversibility,early asthmatic response,exhaled NO levels,cortisol production,late asthmatic response,changes in pulmonary function, asthma symptoms, rescue albuterol use, nighttime awakenings due to asthma, and quality of life,asthma exacerbation rates,eosinophilia (P<0.005) and activated eosinophils,Asthma symptom scores, supplemental rescue albuterol use, and number of nighttime awakenings due to asthma requiring treatment,Compliance,basement-membrane thickness,clinic morning peak expiratory flow,adverse events and basal plasma cortisol,mean FEV(1) AUC(bl,plasma fluticasone propionate and cortisol concentrations,control forced expiratory volume in one second (FEV1), and maximal flow at 50% of control FVC during forced expiration after a maximal (V'max,50) and a partial inspiration (V'p,50,poststimulation mean peak plasma cortisol concentrations,withdrawal due to lack of efficacy,24-hour urinary free-cortisol excretion,SEM maximum percentage fall in FEV1,hypothalamic-pituitary-adrenal axis,Airway hyperresponsiveness, induced sputum eosinophils, and exhaled nitric oxide (NO) levels,time without developing signs of exacerbating asthma,efficacy and tolerability,steady-state plasma FP concentrations,Mean forced expiratory volume in 1 second, forced vital capacity, and forced expiratory flow,morning peak expiratory flow rates,quality of life,mean plasma cortisol response to cosyntropin,incidence of possibly drug-related adverse events,area under the curve of serum cortisol versus time (AUC0-20,forced expiratory volume in 1 second (FEV(1,late response,lung function,serum-cortisol suppression,asthma exacerbations, adverse events, and clinically significant laboratory test results,adjusted mean PEF,allergen-induced airway responses and sputum inflammatory markers,parent global evaluation, absolute values of FEV1 nor PD20,morning peak flow rate,tolerability of FSC,inspiratory vital capacity,Mean morning predose percent predicted forced expiratory volume,peak expiratory flow and symptom scores,area under serum cortisol concentration curve for 22 hours (AUC(0-22h)); 24-hour urinary cortisol level; and 8 AM salivary cortisol level,night awakenings and less use of rescue albuterol,Adverse events,adverse events,clinic forced expiratory flow,FEV(1), albuterol use, and withdrawal due to lack of efficacy,urinary free cortisol and urinary 17-hydroxy steroids,urine cortisol excretion,Supplemental rescue albuterol use,mean height, mean growth velocity, or mean skeletal age,symptom scores,FEV1 and PC20-histamine,PD(20,exhaled nitric oxide,lumbar spine,PC20 to histamine, sputum eosinophil numbers, and exhaled NO levels,tolerated and improved lung function,24-hour daily asthma symptom scores,asthma control and quality of life,Tolerability assessments included electrocardiograms, routine clinical laboratory tests, vital signs, oropharyngeal examinations, and physical examinations,lung function and quality of life,PEFR values,symptoms and peak flow recordings (PEFR,incidence of adverse events and 24-hour urine cortisol excretion rates,suppression of HPA axis,airway responsiveness or the sputum eosinophilia,urinary cortisol,FEV1, evening PEF, and asthma symptoms,morning and evening peak expiratory flow,systemic effect,mean overall individual compliance rates,hypothalamic-pituitary-adrenal axis and bone mineral density,asthma symptom scores,Bronchial responsiveness to methacholine,forced expiratory volume in 1 sec (FEV1), patient-measured peak expiratory flow (PEF), total symptom scores, and rescue bronchodilator use,morning PEF and nighttime awakenings,Oral candidiasis rates,exacerbation requiring oral corticosteroids,hypothalamic-pituitary-adrenal axis function,plasma FP concentrations,mean log2 PC20 for methacholine,severity of EIB,tryptase level in BAL,Systemic effects,Comparative efficacy and safety,effective and well tolerated,unspecified oropharyngeal plaques,Serum cortisol,Mean increase in FEV1,Efficacy and safety,demographic characteristics,airway hyperresponsiveness,sputum eosinophilia,percentage of eosinophils and soluble intercellular adhesion molecule-1,FEV1 and morning peak expiratory flow rate (PEFR,clinic PEF,efficacy variables, such as FEV(1), morning and evening peak expiratory flow (PEF), asthma symptom scores, nighttime awakenings, albuterol use, and duration of study participation,mean FEV1 AUC(bl,sputum eosinophils,skeletal system,dynamic cortisol response,FEV1,mean values of forced expiratory volume,cortisol secretion,pulmonary function and quality of life,Daily symptom score and peak expiratory flow,morning peak expiratory flow rate, physician overall assessments and patient-rated assessment of symptoms, and albuterol use for symptom control,FEV1 and PEF,FEV(1,worsening asthma,lung function and asthma control,mean log2 provocative concentration,Steady-state kinetics,8-hour plasma cortisol area under the curve values,diary card symptom scores, beta 2-agonist rescue and clinic lung function,lung function, adrenal function, and asthma-specific quality of life,safety profile of FSC,morning predose forced expiratory volume,Daytime asthma symptom scores and albuterol use,Bone mineral density (BMD,efficacy and safety,ENO, spirometry, need for rescue medication, quality of life (QOL), and diary scores (DS,pulmonary function indexed by forced expiratory volume,eosinophil cationic protein (ECP) level,pulmonary function,ENO, spirometry, QOL, DS, and beta2 use,spirometric indices, airway inflammation, airway remodelling, and bronchial hyperreactivity (BHR,peak expiratory flow rate, beta2 need, DS, and QOL measurements,candidiasis of the mouth/throat,throat irritation,FEV1, delta FEV1, FEF25-75, and FEV1/FVC,Maximal improvement in FEV1,BAL fluid eosinophils, mast cells, and epithelial cells,early responses, airway eosinophilia, and allergen-induced airway hyperresponsiveness,baseline FEV1,BHR to histamine,mean ENO,peak expiratory flow, and asthma symptom scores,plasma concentration-time curve (AUC) and 8-hour peak plasma cortisol concentrations,Perceived effectiveness,Forced expiratory volume,mucosal inflammation,number of night awakenings and symptomatic albuterol,asthma stability, pulmonary function tests, physician and patient assessments, and rescue bronchodilator use,Patient-rated data (peak expiratory flow, asthma symptom scores, percent of days with no asthma symptoms,provocative dose of methacholine,PC20 histamine,systemic effects,Incidence of adverse events and low morning plasma cortisol concentrations,Symptom scores, use of rescue medication, wheezing, parent global evaluation and pulmonary function tests including forced expiratory volume in one second (FEV1), peak expiratory flow (PEF) and bronchial responsiveness (provocation dose of methacholine causing a 20% fall in FEV1 (PD20,BAL inflammatory cells,mean changes in FEV1 and morning PEF recorded at clinic visits,percentage of symptom-free days and nights and airways hyperresponsiveness,percentage symptom-free days, use of beta2-mimetics, morning and evening PEF, FEV1 % pred and wheezing,clinical parameters (symptom scores, percentages of symptom-free and albuterol-free days, albuterol use, and nighttime awakenings,nighttime symptom scores,bronchial hyperresponsiveness,FEV1, morning and evening peak expiratory flow, asthma symptoms, albuterol use, and nighttime awakenings,excretion of urinary leukotriene E4,response to NKA,24-hour urinary free cortisol levels,Incidence and severity of adverse events,Subepithelial reticular basement membrane (rbm) thickness,nocturnal PEFR,plasma cortisol AUC(0-24,nighttime awakenings and albuterol use to treat symptoms,safety variables and pulmonary function,efficacy,numbers of neutrophils in bronchial biopsy samples and the concentrations of myeloperoxidase and soluble E-selectin,24-hour urinary cortisol excretion rates,morning peak expiratory flow rate (PEFR,forced expiratory volume,area under the plasma FP concentration-time curve,sputum eosinophils (geometric mean (SD,baseline PD(20) geometric mean,Pulmonary function,FEV,CD4:CD8 ratio and numbers of activated (EG2+) eosinophils,airway hyperresponsiveness to histamine, eosinophil counts in induced sputum, and exhaled nitric oxide levels,ratios of Cmax and AUClast,tolerated,mean low- and high-dose peak serum cortisol levels,24-hour daily (composite of daytime and nighttime) asthma symptom scores,efficacy parameters,Diurnal pattern of serum cortisol suppression,Patient quality of life assessed by means of the Asthma Quality of Life Questionnaire,provocative dose of methacholine causing a 20% fall in FEV(1,mean area under the 12-hour serial FEV(1) curve relative to the prerandomization baseline (FEV(1,suppression of HPA-axis function,pulmonary function and symptom control,leg growth rate,mean morning peak expiratory flow (PEF), as recorded by patients prior to the use of bronchodilator or study medication, and the rate of investigator-recorded asthma exacerbations,headache,plasma cortisol concentration time curves and peak cortisol concentrations,Stabilization,bone, hypothalamic-pituitary-adrenal (HPA) axis function,increase in PD(15)FEV(1,lung function and diary card parameters,eosinophil count,clinical and functional data, and in sputum eosinophil percentages,Rbm thickness,Patient-rated asthma symptoms,area under the plasma cortisol concentration-time curve over 24 h (plasma cortisol AUC(0-24), relative to placebo,exacerbation rates,number of eosinophils and mast cells in the lamina propria in bronchial biopsies specimens,side effects,tolerated and the safety profile|Both significantly decreased airway responsiveness compared to placebo (p < 0.001), and also significantly increased lung function with no difference between the two active groups.
not found|duration of general illness, sore throat, weight loss, or absence from school or work,visual analog scale,diary of symptoms and rated their pain on a visual analog scale,Oropharyngeal Epstein-Barr virus (EBV) shedding,pain relief|Oropharyngeal Epstein-Barr virus (EBV) shedding was significantly inhibited during the treatment period (P = .02, Mann-Whitney rank test).
87|monosymptomatic nocturnal enuresis,prostaglandin E2 (PGE2) concentrations,diuresis and solute excretion,serum and urine PGE2 concentrations,efficacy, tolerability and side effects,nightly excretion of sodium,number of dry nights,prostaglandin production,Efficacy,cystometric bladder capacity and disappearance of uninhibited detrusor contractions,nocturnal enuresis,bladder capacities,mean number of wet nights,dry nights,free water reabsorption and solute clearance,therapeutic effects,risk of a wet episode,adverse events,number of wet nights,average percentage of wet nights,tolerated,Tolerability and side effects,nocturnal enuretic frequency,Prostaglandins increase detrusor pressure, decrease urethral pressure and lead to sodium excretion,glomerular filtration rate,efficacy of IBU,serum PGE2 and urine PGE2 concentrations,mean serum and urine PGE2 concentrations,night-wetting frequency,Dry Night Log-Parent Report (DNL-PR), a daily parent diary,Complete and partial responses,average number of dry nights,Nocturnal enuresis,mean bladder capacities,side effects|Compared with placebo, atomoxetine treatment was associated with a significant increase in dry nights in children with nocturnal enuresis.
42|total catheter patency,restoration of catheter function to all treated lumens (i.e., total catheter patency,fibrin sleeves,incidence of non-hemorrhagic events,safety and efficacy,restoring total CVAD function,major hemorrhagic or embolic events,restoring catheter function,occurrence of hemorrhagic and non-hemorrhagic events,function of the VADs,serious study-drug-related adverse events, no intracranial hemorrhage, no major hemorrhage, and no embolic events,highest patency rate,full function,restoration of the ability to withdraw and infuse through the catheter,Catheter function,function,patency restoration rates,major hemorrhagic events|Forty-two patients with VAD occlusions refractory to routine urokinase instillations were documented by x-ray (cathetergram) to have fibrin sleeves at the catheter tips.
not found|Acute Biliary Pancreatitis,severe acute biliary pancreatitis (SABP,Respiratory failure,overall morbidity,severe complications,incidence of complication, length of hospitalization and cost,incidence of bile duct stones,changes in organ failure score and computed tomography (CT) severity index during the first week after admission, incidence of local complications, and overall morbidity and mortality,systemic and local inflammation,Hospital stay,deaths,ES [1 death,Overall mortality, mortality due to pancreatitis, and complications,persisting bile duct stones,mean CT severity index,jaundice,mean organ failure score,stone removal,overall rate of complications,incidence of local complications,Acute Physiology and Chronic Health Evaluation II score,Decreased Acute Physiology and Chronic Health Evaluation II score,acute biliary pancreatis,mortality|The incidence of complication, length of hospitalization and cost were markedly lower in patients with severe acute GP in the ERCP group than those in the non-ERCP group (P<0.05), in contrast to the 2 mild subgroups of the ERCP and non-ERCP groups (P>0.05).
                
460|attendance,Mammogram screening rates,mammogram screening rate,Attendance,Sociodemographic factors, health behaviours, and attitudes, beliefs, and intentions,Exercise, smoking, diet change, and breast self-examination,perceived importance of regular screening for cervical and breast cancer and intentions to go for breast screening,Pap smears,Attitudes, beliefs, and intentions,screening mammography,receive Pap smears,average attendance rate,adherence|The most dramatic difference was in the higher odds that women in the intervention group would obtain a mammogram within 2 months (odds ratio = 10.5).
                
not found|moderate cervical intraepithelial neoplasia (CIN) II or severe CIN,Toxicity,disease response,human papillomavirus-positive,progression to high-grade SIL or cervical cancer,Compliance and side effects,complete histologic regression rate of CIN,rate of histologic regression,invasive cancer,Baseline CD4 levels,vaginal and vulvar side effects,rate of histological regression,Side effects,toxicity, headache,mild local self-reported and clinician-detected toxicities,systemic adverse events|Toxicity was not significant in either arm.
                
15|clinical, radiographic, angiographic, and pathologic parameters|In the MTX-CF arm there were four responses (three complete responses, one partial response) whereas in the I/A CDP arm there were nine responses (seven complete responses, two partial responses).
990|plasma levels of E2, P, FSH, and LH; uterine volume; calcium and phosphorus in spot urine specimens; and bone mineral accretion,plasma levels of E2 and P,postnatal bone mineral accretion,bone mineral accretion rates,chronic lung disease,uterine volumes increased, and FSH and LH as indicators for biological effectiveness|The bone mineral accretion rates tended to be higher, and the incidence of chronic lung disease tended to be lower (0% vs. 29%; P = 0.097).
43|nausea,median survival time,toxicity, objective response rates, time to progression (TTP) and overall survival (OS,global QOL,response (primary), survival, toxicity, and quality of life (QOL,toxic effects,Quality of life,FAM combination CR rate,Duration of response and survival,discontinuation for toxicity,stomatitis,improved survival,Grades 3-4 toxicity,TTP or OS superiority,Increased pain,overall survival,time to treatment failure,time to progression or overall survival,Objective remissions,longest survival,overall response rates,overall response rates (complete responses [CRs] and partial responses [PRs,hematologic toxicity,complete responses (CR,ORR,progressive disease (PD,time-to-progression (TTP,Gastrointestinal disturbances,response rate, HRQOL and survival,response rates,tolerated, the main grade 3/4 toxicities being diarrhoea,hematologic toxicity and serious infections,median progression-free survival,survival or palliation, unrewarded toxicity, and excessive cost,Time to progression,Severe toxicity rates,median duration of survival,partial remission (overall response rate [ORR,grade 3/4 neutropenia and grade 2 alopecia,TTP, survival, and response rate,median time to progression, duration of response, and duration of survival,baseline HRQOL scores,Toxicities,survival difference,median PFS for XP,febrile neutropenia,patients survival,year survival rates,neutropenia 5/49, thrombocytopenia 2/6, anemia 6/16 nausea/vomiting,peripheral neuropathy,Surgical and pathologic response,Pain decreased and physical functioning,duration of response,Toxicity,progression-free survival, proportions of responders, and safety,Interval to disease progression, objective response rates, and palliative effects (improved performance, body weight, or symptoms,partial response (PR,toxicities,response, toxicity and survival,Response rate of LV5-FU2-oxaliplatin,Grade 4 toxicities,hematological toxicity,alopecia,fatigue,myelosuppression and infectious complications,response rate,survival, response, and toxicity,anorexia,severe neutropenia, thrombocytopenia and stomatitis,WHO grade III/IV toxicity,leucopenia, neutropenia, anaemia, nausea, and anorexia,complete remission,global QL scores,Median survival,vomiting,median PFS with FLO versus FLP,diarrhea,survival, response, toxicity, and quality of life (QOL,superior response rates,Median duration of response,survival rates,number of items and domains except for cognitive functioning, and diarrhoea,CR plus partial response (PR) rate,median survival,Median overall survival,partial remissions,efficacy,performance score, weight gain, or patient survival,weight loss,thrombocytopenia,Survival,FLO,renal toxicity,grade) anemia,leukopenia,median TTP,median survival times and 1-year survival rates,serious adverse events,median duration of objective remission,Drug toxicities,Median overall survival times,Overall survival (OS,objective clinical response rates,efficacy and tolerability,median survival duration,Progression-free survival,Overall survival,grade 2 and 3 vomiting,emesis and alopecia,unadjusted hazard ratio (HR,LV5-FU2-CDDP,Overall response rate,complete tumor remission,median time to progression,nausea/vomiting 40%, diarrhoea,response, survival, and QOL benefits of ECF,Overall response rates,incidence of toxicities (leukopenia in particular) exceeding JCOG grade 3,median remission duration,prolonged survival,Global QOL scores,survival time,overall response rate,median time to tumor progression,TTF,complete alopecia,tolerated,Global health status/QOL,Hematologic and nonhematologic toxicity,median overall survival,Median progression-free survival and overall survival times,hematologic toxic effects,survival curves,noninferiority of XP versus FP for progression-free survival (PFS,Response rates,CR plus PR rate,objective response rates [CR plus partial response (PR) rates,PFS,EORCT QLQ-C30,lethargy,Grade 3 and 4 leukopenia,survival durations,diarrhea, stomatitis, and leukopenia in the DF arm and nausea, vomiting, and leukopenia,Complicated neutropenia,survival, tumor response, toxicity, and quality of life (QL,toxic death,survival rate,leukopenia plus thrombocytopenia,toxicity,Health related quality of life (HRQOL,thromboembolic events,survival,Median failure-free survival,Frequency and grade of the side effects,meaningful survival advantage,survival advantage,Grade 3 or 4 neutropenia,mild neurotoxicity,efficacy and safety,neutropenia,stomatitis and diarrhea,Stenocardia,partial remission,adverse events,FLO reduced toxicity,progression-free survival (PFS,HRQOL,longer progression-free survival,PAM combination complete response (CR) rate,thrombocytopenia and plantar-palmar erythema,median overall survival time,toxic deaths,complete response (CR) rates to PELF and FAMTX,improved OS,survival and response advantage, tolerable toxicity, better QL and cost-effectiveness,median duration of response,median failure-free survival duration,inferior survival,anorexia, nausea, vomiting, leukopenia, thrombocytopenia, and cumulative bone marrow suppression,Objective responses,overall response rate (ORR,activity and toxicity,median survival times|Significantly higher survival rates were demonstrated in those patients with recurrent cancers (p < 0.01) and those who responded to the FPEPIR regimen (p < 0.05).
164|survival (EFS) rates,number of bacterial and fungal infections and the number of days of hospitalization,thrombocytopenia,median hospital stays,3-year probability of event-free survival,area under the plasma G-CSF concentration-time curve,febrile neutropenia,likelihood of event-free survival,rate of hospitalization for febrile neutropenia, prolong survival,granulocyte counts,CDI,severe neutropenia,hematologic recovery,myelosuppression,hematological toxicity,neutropenia,Culture-confirmed infections,absolute neutrophil counts, number of days with neutropenia, number of days with fever, number of days spent in hospital, or number of days on antibiotics,platelet count,number of days with fever and intravenous antibiotics and duration of hospitalization,disease control,median total duration of febrile neutropenia,febrile neutropenia, culture-confirmed infections, and duration of intravenous antibiotic administration,rate of hospitalization for febrile neutropenia,Duration of granulocytopenia,number of severe infections,duration of neutropenia,median length of this phase,probability of subsequent hospitalization,number, type, or severity of infectious episodes,neutropenia (neutrophils < 1 x 10(9)/l) and severe neutropenia (neutrophils < 0.5 x 10(9)/l), days in hospital, days of fever, and days on antibiotics,toxicity, particularly myelosuppression,total duration of intravenous antibiotic use,number of platelet transfusions,median total costs of supportive care|Patients treated with G-CSF had shorter median hospital stays (6 days vs. 10 days, P=0.011) and fewer documented infections (12 vs. 27, P=0.009).
30|BCVA and lower CMT values,baseline BCVA letter score,central foveal thickness (CFT,new ocular or nonocular safety events,BCVA,mean change from baseline BCVA letter score,rapid reduction in CFT,BCVA and reduces CMT,logarithm of minimum angle of resolution (logMAR) best-corrected visual acuity (BCVA), central macular thickness (CMT,Baseline BCVA |The group receiving bevacizumab had better BCVA and lower CMT values at all time points (P < 0.05).
                
285|change in pulmonary function,height, weight, vital capacity, forced expiratory volume in 1 s, peak flow rate, erythrocyte sedimentation rate, and serum IgG,forced vital capacity,forced expiratory volume,height z scores,Lung function, clinical status, hospitalizations, growth, and steroid side effects,mild to moderate lung disease,serum IgG and cytokine concentrations,pulmonary function,morbidity and progression of lung disease,spirometry and serum concentrations of interleukin-1 alpha (IL-1 alpha), soluble interleukin-2 receptor (sIL-2R), and IgG,serum IgG concentrations,abnormalities in glucose metabolism,efficacy and safety,Interleukin-1 alpha, soluble interleukin-2 receptor, and IgG concentrations,height z scores fell|The prednisone-treated groups had a reduction in serum IgG concentrations (1 mg/kg vs placebo, p < 0.007; 2 mg/kg vs placebo, p < 0.003).
115|reduction of Positive and Negative Syndrome Scale total scores and of dyskinesia scores,PANSS rating scale,dyskinesia scores,sexual side effects,positive or negative symptoms, mood, cognition, or global impression ratings,residual symptoms and cognitive impairment,antipsychotic efficacy and tolerability,efficacy and tolerability,extrapyramidal side effects,side effects or adverse biochemical or haematological effects,constipation,E-EPA-augmented participants needed 20% less antipsychotic medication,response rate,symptoms of TD,Extrapyramidal Symptom Rating Scale dyskinesia scores,symptomatic remission,Response rates,rating scales and rise in red blood cell arachidonic acid concentration,symptom change scores and time to first response, while tolerability measures and cumulative antipsychotic dose,Positive and Negative Syndrome Scale (PANSS,EPA,PANSS and its sub-scales,tolerability of antipsychotic medications,triglyceride levels|In patients given 2 g/day E-E there were improvements on the PANSS and its sub-scales, but there was also a large placebo effect in patients on typical and new atypical antipsychotics and no difference between active treatment and placebo.
not found|Kristeller manoeuvre ,outcomes: caesarean section,operative delivery, spontaneous delivery, first- and second-stage augmentation, pharmacological pain relief, artificial rupture of membranes, vaginal examinations, episiotomy, labour length, neonatal wellbeing (Apgar scores) and transfer to neonatal intensive care unit (NICU,Pain perception,spontaneous vaginal delivery|There were no significant differences for the following outcomes: caesarean section (relative risk [RR] 0.99, 95% CI: 0.70-1.41), ventouse (RR 1.5, 95% CI: 0.31-7.62), Kristeller manoeuvre (
96|Rey's Verbal Memory (RVM) test for immediate and delayed recall,depressive symptoms and cognitive status,plasma homocysteine,plasma folate,clinical recovery,HDRS score,baseline Hamilton Rating Scale,Plasma homocysteine,mean Hamilton Rating Scale score,plasma folate and homocysteine,HDRS,depressive symptoms,clinical and social recovery|5 respectively was obtained at the end of the treatment period (p < 0.05 vs week 4) with 5'-MTHF and TRZ.(ABSTRACT TRUNCATED AT 250 WORDS)
not found|Pain evaluation,Pain scores,pain scores,Pain,troublesome bleeding,visual analogue and verbal rating scales,pain relief,intensity of pain,total treatment acceptability, helpfulness of the gas and willingness to undergo a similar procedure,Satisfaction,pain experienced with a visual analog scale (VAS,Pain or discomfort,median pain score,Patient satisfaction, pain and anxiety,mean pain score for cervical surgery,mean VAS score,total helpfulness,blood loss,bleeding,mean VAS value,pain or discomfort,Peri-operative blood loss and any side effects,Anticipated pain,anxiety levels,severity of pain,visual analogue scale,mild pain,mean pain scores,verbal rating scale,intensity of the pain experienced,anxious by Hospital Anxiety and Depression Scale (HADS) score,Visual linear analogue pain scores,moderate pain,pain,severe pain,side effects|Analysis of data from the 3 groups showed no statistically significant difference.
304|functional and pain outcomes,general health,trajectories of recovery,health, function, and return-home outcomes,Mean total SF-36 scores,length of stay, rate of readmission and rate of survival and improved activities of daily living,physical functioning, role-physical, and social functioning domains of the SF-36,gait performance,role-physical domain,functional recovery,efficacy and safety,Geriatric Depression Scale and Hospital Anxiety and Depression Scale for mood, functional tests for mobility and pain measures,ADL and IADL abilities,social activity levels, two timed mobility tasks, balance, or lower extremity strength,Postoperative mental impairment,time spent exercising,postoperative cognitive deterioration,quality of life,self-reported fear of pain and pain when performing ADL and IADL,mean total continuous hospitalization,upper extremity strength,Klein-Bell ADL scale and a modified version of the Disability Rating Index,length of hospitalized stay, rate of readmission, repeat falls and survival, and activities of daily living,hip fracture outcomes,depressive symptoms,incident depression,mental health,mental status,several activities and instrumental activities of daily living, and no differences in health, depression, or living situation,overall trajectory of time in exercise,physical outcomes and quality of life|Compared with participants who received usual care, those in the multicomponent rehabilitation program showed slightly greater upper extremity strength at 6 months (p = .04) and a marginally better gait performance (p = .08).
                
213|safety restraints,feasibility, acceptability, and effectiveness,probability of having a working detector,injury prevention knowledge or behavior|Among families without a working smoke detector at baseline, the intervention was associated with an increased probability of having a working detector at follow up (relative risk (RR) 3.3, 95% confidence interval (CI) 1.3 to 8.6).
not found|Hospitalization days,Arterial blood pH|Hospitalization days were statistically higher (p = 0.037) in the controls (5.59 +/-
160|mean number of days of detention (days spent,overall admission,readmitted compulsorily within 1 year of discharge,bed days (total number of days spent as an inpatient,Admission to hospital, bed days, and use of the Mental Health Act,Mental Health Act,rate of compulsory readmission,numbers of compulsory readmissions, numbers of patients readmitted voluntarily, days spent in hospital or satisfaction with psychiatric services|Use of the Mental Health Act was significantly reduced for the intervention group, 13% (10/80) of whom experienced compulsory admission or treatment compared with 27% (21/80) of the control group (risk ratio 0.48, 95% confidence interval 0.24 to 0.95, P = 0.028).
not found|overall morbidity,incidence of bronchopulmonary dysplasia, intraventricular hemorrhage, retinopathy of prematurity, or death,duration of oxygen therapy, and fewer days necessary to regain birth weight,duration of oxygen therapy,later development of large ductus shunts and decreases morbidity,dilator prostaglandin production,frequency of ductal closure,respiratory sequelae,incidence of major shunts, fewer surgical ligations,time required for mechanical ventilation, time receiving supplemental oxygen, or time in the hospital|No significant difference was observed in the time required for mechanical ventilation, time receiving supplemental oxygen, or time in the hospital, and there were no significant differences in the incidence of bronchopulmonary dysplasia, intraventricular hemorrhage, retinopathy of prematurity, or death between the two groups.
20|Mean morning PEF,Quality of life,efficacy, safety, and tolerability,medical withdrawals due to asthma,Asthma-specific quality of life,peak expiratory flow rate (PEFR,night-time asthma,asthma-specific quality of life, efficacy, and safety,reduced requirement of rescue albuterol,percentage of nights with no awakenings,mean morning PEF,duration of action,efficacy rating,quality of life domain ("Activity Limitation," "Asthma Symptoms," "Emotional Function," "Environmental Exposure") scores,asthma-specific quality of life, controlling asthma symptoms,T-lymphocyte activation,asthma symptom scores,peak expiratory flow rates (PEF), asthma symptoms,peak expiratory flow (PEF) measurements: the overall mean morning PEF,symptoms and lung function,rebound deterioration in asthma control, lung function, or bronchial hyper-responsiveness,asthma events including deaths,morning and evening asthma symptoms and sleep disturbances,Morning FEV1 30 min postdrug,Mean baseline FEV,lung function values before and after drug inhalation (specific airway resistance sRAW, forced expiration volume FEV1, vital capacity VC,number of rescue medication inhaled, side effects, heart rate, blood pressure, serum potassium dosage and electrocardiograms,Morning and evening peak expiratory flow rates,individual domains (activity limitation, symptoms, emotional function, and exposure to environmental stimuli,morning and evening PEFR,diurnal variation in PEF,rescue medication,bronchodilator response,Asthma Quality of Life Questionnaire (AQLQ,asthma quality of life,rate of occurrence of exacerbations,Diurnal variation in prebronchodilator peak flow rates,bronchodilatory effect,Serious adverse events,Peak expiratory flow rate (PEFR,acute reversibility and long-term efficacy,Symptom scores, morning and evening peak expiratory flow (PEF) rates, use of rescue medication, spirometric indices, and histamine challenge,adverse event profile,FEV1 or AR,Adverse effects and clinical laboratory parameters,concentrations of ECP and tryptase,beta-adrenoceptor density on MNL and no significant side effects,daily morning and evening peak expiratory flow (PEF,symptom-free nights,peak expiratory flow rate (PEFR) morning and evening before medication, asthma symptomscore, and use of additional doses of prn,percentage of symptom-free days and rescue-free days and nights with no sleep disturbance,number of asthma episodes,global AQLQ score,tachyphylaxis,Efficacy and safety,number of sleep disruptions,corresponding major exacerbation rates,Nocturnal awakenings,morning and evening peak expiratory flow, percentage of nights without awakening, and asthma symptoms,morning PEFR,morning PEF,Efficacy, safety,mean morning PEFR,efficacy,Asthma Quality of Life Questionnaire (AQLQ); 2) Living With Asthma Questionnaire (LWAQ); 3) Sickness Impact Profile (SIP); 4) Rating Scale (RS); and Standard Gamble (SG) utilities,safety and clinic lung function,bronchial hyperreactivity and beta-adrenoceptor density,percentage of predicted FEV1,FEV1 and AR,symptoms improvement rate,efficacy and tolerability,values of FEV1,morning PEFR and asthma symptoms scores,forced expiratory volume,minor exacerbation rates,morning PEF rate,adverse reactions,Asthma Quality of Life Questionnaire and spirometry at the end of each treatment period; and (2) daily asthma symptoms, morning and evening peak expiratory flow rates (PEFRs), and rescue salbutamol use,rescue-free" nights,lung function and reduces asthma symptoms,improvement rate of morning FEV1 and PEFR,mean diurnal variation in PEF,mean morning and evening peak expiratory flow rate (PEFR), a composite daily asthma score, and minor and major exacerbation rates,electrocardiographic activity,mean morning peak expiratory flow (PEF,quality of life,Lung function,asthma-specific quality of life,tolerated,FEV1,Pulmonary function and asthma symptoms,diurnal variation,number of days with symptoms and of nights with awakenings,lung function,Mortality and admissions to hospital,morning and evening peak expiratory flows (PEF), assessment of asthma symptoms, and use of rescue medication,asthma control, morning and evening PEF rates, and spirometric indices,Overall control of asthma,incidence of asthma exacerbations,rating scale utilities,tolerability profile,mean overall symptom score,better morning and mean peak expiratory flow,Mean PEFR,morning peak expiratory flow rate: salmeterol,mean evening,soluble interleukin 2R (sIL-2R), eosinophil cationic protein (ECP), and tryptase of salmeterol,lung function, asthma symptoms, and frequency of rescue albuterol use,daytime symptoms,Efficacy,worsening of control of asthma,efficacy and safety,PEF,nocturnal symptoms,bronchial hyperreactivity,Adverse events,asthma score,time spent in major exacerbation,Evening PEFR,daytime and night-time asthma scores, percentage of symptom-free days and nights, use of additional inhaled bronchodilator, and percentage of days and nights,airway responsiveness,pulmonary function,tolerability,daytime and nocturnal symptoms,diurnal variation in PEFR, nocturnal and daytime symptoms and use of additional salbutamol,Diurnal control of morning and evening peak flow,morning peak expiratory flow,AQLQ and RS utilities,serum concentration of sIL-2R,lung function and change in quality of life,side effects|Compared with albuterol, salmeterol treatment was associated with better morning and mean peak expiratory flow (p = 0.013 and 0.016, respectively), less daytime and nocturnal symptoms (p = 0.008 and 0.01, respectively), reduced requirement of rescue albuterol (p = 0.04), and better efficacy rating by patients (p = 0.04).
171|physical endurance or health-related quality of life (HRQOL,CD4+ T-lymphocyte counts,mean ,incidence and severity of diarrhea,Strength increased at the knee extensors, pectoralis, knee flexors, shoulder abductors, ankle plantar flexors, and elbow flexors,Service levels,Quality of life,SEM VO2max,Total muscle area,number of infections and aspects of health-related quality of life (i.e., perception of health, physical function, energy, health distress, and role function,feelings of stigma,adherence self-report score,Diarrhea,knowledge score,Medical Outcomes Study-HIV Health Survey Overall Health subscale,cardiorespiratory fitness, endurance, and body composition,medication adherence,Cardiorespiratory fitness,physical endurance levels,depressive symptoms, affective state, stigma, and worry about HIV,Infection line sepsis incidence,quality of Well-Being Index (QWB,quality of life and survival,HIV-RNA level or CD4 cell count,quality of life,diarrhea,days of work or school lost due to diarrhea,CD4+ T-cell counts or viral load,lipid levels, blood pressure, or abdominal visceral fat,maximum oxygen consumption (VO2max) and strength by 1-repetition maximum,Cardiorespiratory fitness (VO2max,energy and appearance,physical function scores,body cell mass,negative affective state (depression/dejection and tension/anxiety) and stigma as well as infections,diarrhea frequency and severity,medication refill history,Nutritional subjective global assessment, subjective self-reported health feeling and Karnofsky index,Lean body mass,diarrhea episodes,labor delivery costs,adherence greater,Cross-sectional muscle area and muscle attenuation,physical and role function,physical fitness,visible blood or mucus in stools,survival rate,Emotional distress,Medication adherence|A larger proportion of subjects in the intervention group demonstrated adherence greater than 90% compared with the control group at each time point after baseline.
not found|repetitive behavior (P<.001), aggression (P<.001), anxiety or nervousness (P<.02), depression (P<.03), irritability (P<.01), and the overall behavioral symptoms of autism (P<.02,Irritability score,CGI-I scale,extrapyramidal effects, cardiac events, or seizures,rate of a positive response,average weight gain,Increased appetite, fatigue, drowsiness, dizziness, and drooling,effective and well tolerated,social behavior and language,safety and efficacy,score on the Irritability subscale of the Aberrant Behavior Checklist and the rating on the Clinical Global Impressions - Improvement (CGI-I) scale|Other than mild, transient sedation, risperidone was well tolerated, with no evidence of extrapyramidal effects, cardiac events, or seizures.
                
37|Survival,progression-free and overall survival,progression-free survival or overall survival,median survival,progression-free survival and overall survival,Progression-free and overall survival,relative risk of death,death or severe morbidity,likelihood of progression-free survival,survival,risk of death,lengthened progression-free and overall survival,survival rate|The median survival for the intervention debulking surgery group was 15 months (95% CI 10-20 mo) and that of those randomised to chemotherapy alone, which was 12 months (95% CI 8-16 mo), were not significantly different (hazard ratio = 0.71; 95% CI 0.44-1.13).
                
67|knee pain,greatest muscular strength gains,visual analog scale scores and scores on the Lequesne index,disability,muscle peak torques,total WOMAC scores,Pain reduction,visual analog scale pain and rates of attrition,Pain and disability index scores,ROM and ambulation speed,VAS score,periarticular soft tissue disorders,exercise performance, reduced pain, and improved function,active ROM, pain, and gait velocity,pain and disability,ambulation speed and the Lequesne index,knee range of motion (ROM), visual analog scale for pain, and muscle peak torques,Lequesne's index, knee range of motion, peak muscle torques of knee flexion and extension, and ambulation speed,muscular strength,knee active range of motion (ROM) (goniometry) or pain (visual analogue scale,walking speed,Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) scores and 50 meters walking time,isokinetic strength, pain, and functional status,angular velocity peak torques,range of motion and ambulation speed,pain on movement assessed by visual analog scale (VAS|In the treatment group, the improvement in VAS score was statistically and significantly higher (p < 0.001) and more pronounced than in the placebo group.
399|exhaled nitric oxide (FENO), pulmonary function,forced expiratory volume in 1s (FEV(1,body height and suppression of 24-h urinary cortisol excretion,quality of life (QOL,plasma cortisol levels,prevalences of AEs,airway outcomes,standardized version of the Asthma Quality of Life Questionnaire (AQLQ[S,morning and evening peak expiratory flow,Efficacy and tolerability assessments,asthma symptoms, use of rescue medication, and asthma symptom-free days,spirometric forced expiratory volume in 1 second (FEV(1) in liters,pulmonary function, asthma symptom scores, and rescue medication use,Asthma exacerbation rates,lung function, asthma exacerbations, asthma symptoms and rescue medication use,Oral candidiasis rates,Tolerability,FVC and PEF,hypothalamic-pituitary-adrenal axis function,urinary cortisol levels,urinary cortisol suppression,asthma symptom score,forced expiratory volume in 1s, forced vital capacity, and morning peak expiratory flow,clinical improvement (asthmatic symptoms and consumption of rescue medication,serum cortisol levels,Week-12 mean urinary cortisol excretion,Adverse events (AEs), including local oropharyngeal AEs,asthma symptom score and rescue medication use in diaries,OUC levels,forced expiratory volume in 1 s (FEV1,forced expiratory volume in 1 second (FEV1,Frequency of adverse events,body height,voice alteration,Efficacy and safety,24-hour urinary free cortisol levels,Creatinine-adjusted 24-hr urine cortisol levels,Rescue medication use,morning PEF,exhaled nitric oxide levels,FEV1, morning PEF and PAQLQ(S) and PACQLQ scores, and improved asthma symptom score sums and the need for rescue medication,hypothalamic-pituitary-adrenal axis,exhaled nitric oxide, lung function, diary cards and quality of life,plasma cortisol response,standard laboratory variables (hematology and biochemistry); physical examination, including vital signs; reporting of adverse events (AEs); and 24-hour urinary cortisol as a measure of hypothalamic-pituitary-adrenal-axis function,Median creatinine-adjusted urine cortisol,efficacy and tolerability,adverse events (AEs) and 24-h urine cortisol,lung function and asthma symptoms,FEV1 and forced vital capacity (FVC,candidiasis and dysphonia with FP,Week-12 daily, daytime, and nighttime asthma symptom scores and rescue medication use,incidence of adverse events,tolerated,dynamic cortisol response,FEV1,Forced expiratory volume in 1s (FEV(1,mean low- and high-dose peak serum cortisol levels,daily peak expiratory flow (PEF), change in asthma symptom score sum, change in use of rescue medication, paediatric and caregiver asthma QOL questionnaire [PAQLQ(S) and PACQLQ, respectively] scores, change in body height assessed by stadiometry, change in 24-h urinary cortisol adjusted for creatinine and adverse events,urine cortisol levels,safety and tolerability profile,spirometric indices,forced vital capacity (FVC), peak expiratory flow (PEF), asthma symptoms, use of rescue medication and time to onset of effect,FEV(1,oral candidiasis,forced expiratory volume in 1 second, asthma symptom scores and rescue medication use,overnight 10-h urinary cortisol (OUC) levels, exhaled nitric oxide levels, lung function, symptoms, and quality of life,Median percentage of days without asthma symptoms,asthma symptoms and rescue medication use,change in lung function,FEV(1), FVC and PEF,asthma symptoms, morning PEF, use of rescue medication and QOL,hypothalamic-pituitary-adrenal axis outcomes, with OUC levels,Efficacy,Asthma symptom scores,efficacy and safety,morning peak expiratory flow (PEF), asthma symptom scores, and rescue medication use,FENO levels,forced vital capacity, peak expiratory flow by spirometry, and diary assessments of peak expiratory flow, asthma symptoms, and rescue medication use,Adverse events,methacholine hyper-responsiveness,reversibility of Delta FEV,pulmonary function, controlling asthma symptoms,overall AQLQ(S) score,exhaled nitric oxide,good safety and tolerability profiles,equally safe and well tolerated|The increase in FEV(1) was significantly greater in ciclesonide-treated patients (95% confidence interval: 0.016-0.174; p=0.019 versus budesonide).
621|Yield of bone scintigraphy,Low back pain (LBP,Musculoskeletal pain,neurologic deficit,radiation burden,back pain,Neoplastic involvement,Neurologic deficit,yield of explanatory x-ray findings,Back pain,actual roentgenogram use: older age, longer duration of symptoms, reflex asymmetry, and point vertebral tenderness,erythrocyte sedimentation rate (ESR), and anemia|The yield of explanatory x-ray findings was over three times greater among patients with indications for radiography than among those without.
57|rate of erythrocyte transfusion,efficacy and safety,erythrocyte transfusion,probability of vascular events|The rate of erythrocyte transfusion was 42% with tranexamic acid and 60% with placebo (P=0.06).
580|disability and falls,composite score of 25 item version of the National Eye Institute visual function questionnaire,Visual acuity testing and referral to eye services,quality of life,relative risk of having visual acuity,Fracture rate,mean composite score of the visual function questionnaire,incidence of declining functional status,Self rated health, functional state, well being, loneliness, aspects of the mental state (depressive complaints, memory disturbances), and mortality,long term institutional care, and overall expenditure per person,activities of daily living, social functioning, sensory functions, mental and emotional problems, current medical problems, blood pressure, urinalysis, haemoglobin level and compliance with medication,incidence of fractures,visual outcomes,incidence of falls,risk of admission|No differences were found in long term institutional care, and overall expenditure per person in the intervention group exceeded that in the control group by 4%.
200|prevalence of contraceptive use,probability of adherence,contraceptive uptake,contraceptive uptake, patterns of contraceptive usage, and pregnancy rates,contraceptive usage,pregnancy rate,level of contraceptive knowledge,contraceptive continuation rates,contraceptive acceptability,undergo sterilization,started contraceptive use|Counselling sessions improved the couples' knowledge and practice in the study group.
||
38|Seizure frequency,overall understanding of epilepsy,Patient compliance and clinical control,blood levels of antiepileptic drugs (AEDs,50-item true-false test specifically designed to evaluate the SEE program, the Washington Psychosocial Seizure Inventory, the Beck Depression Inventory, Lubin's Depression Adjective Checklist, the State-Trait Anxiety Inventory, the Acceptance of Disability Scale, and Sherer's Self-Efficacy Scale,medication compliance,fear of seizures,plasma anticonvulsant levels and prescription refill frequencies), and seizure frequency,serum levels,adherence relative,hazardous medical self-management practices,Compliance and seizure frequency|Significant differences between the two groups were found on the three major subscales of the 50-item true-false test.
299|virologic failure,depressive and psychiatric symptoms, perceptions of loneliness, and social support,adherence,antiretroviral medication adherence,emotional distress,virologic outcome,ACTG adherence questionnaire,depressive and psychological symptoms,psychiatric distress,self-efficacy,mean BDI scores,likelihood of virologic failure,call completion rates,time to virologic failure,depressive and psychiatric symptoms,BDI scores and depression remission,depressive symptoms,barriers to health care and social services,overall levels of psychiatric distress,HIV risky behaviors and health practices,Virologic failure,depression, suicidal ideation, and anxiety,ART adherence,time to regimen failure, the Kaplan-Meier survival curve,risky sexual behavior,overall treatment effect|ANCOVA revealed that no treatment condition produced reductions in the main outcome measures of depressive and psychological symptoms; however, Information Support participants received significantly more support from friends at 4- and 8-month follow-ups and reported fewer barriers to health care and social services at 4-month follow-up compared to participants in the other two conditions.
46|pain, analgesia, insomnia, aspect of the epithelial border, intensity and duration of stromal edema, Descemet folds, anterior uveitis, and filaments,interference with activities of daily living (ADL,visual analog pain score,difficulty walking score,linear speed of reepithelialization,symptoms of initial discomfort,healing rate and level of discomfort,level of discomfort,degree of discomfort,healing,size of the corneal lesions, delay from trauma to first ED visit, presence of foreign body or siderosis, initial degree of discomfort, and presence of specific symptoms (irritation, foreign body sensation, photophobia, redness, and pain,cumulative incidences of healing,percent healing,discomfort and interference with ADL,incidence and severity of inflammation nor relieve pain,corneal abrasion,healing rate of traumatic CEDs,healing rate,healing, comfort, and complications,Discomfort,mean size of the initial erosion,rate of healing,visual analog scale and the number of pain medication doses taken since presentation,Abrasion size,initial abrasion size,pain of corneal abrasion,pain of simple corneal abrasions,rates of healing for patched and non-patched traumatic corneal epithelial defects (CEDs,surface speed of reepithelialization,abrasion size,Percentage of healing and healing rates,pain scores|There were no significant differences between the 2 groups for pain, analgesia, insomnia, aspect of the epithelial border, intensity and duration of stromal edema, Descemet folds, anterior uveitis, and filaments.
                
429|low number of deaths,cerebral infarction,incidence of vascular death, cerebral ischemic infarction, nonfatal myocardial infarction, or major hemorrhage,incidence of major hemorrhages,nonfatal myocardial infarction and cardiac or vascular death (principal end-points,efficacy and tolerability,hemorrhagic complications,cerebral infarcts, ischemic cardiopathy and vascular death,need for revascularization,mean time of follow,survival analysis,death, non-fatal myocardial reinfarction or a non-fatal cerebrovascular event,nonfatal ischemic stroke, nonfatal acute myocardial infarction, or vascular death,nonfatal acute myocardial infarction,total walking distance and in pain-free walking distance,non-fatal reinfarction,fatal cerebrovascular events,incidence of nonfatal acute myocardial infarction,vascular death,death,peak-flow,overall incidence of hemorrhage,overall incidence of major and minor hemorrhagic events,cardiovascular events,vascular events,central nervous system bleeding episodes,total walking distance,myocardial infarction,incidence of nonfatal stroke,incidence of non-fatal cerebrovascular events,bleeding episodes|This pilot trial has not found differences between triflusal and aspirin in the prevention of vascular complications after TIA or ischemic stroke, although given the wide CI, potentially important group differences could not be ruled out.
1387|DUI rate,alcohol traffic violation rate,overall effectiveness|The alcohol traffic violation rate during the first year was significantly less for participants in the interlock program (2.4%) than for those in the control group (6.7%).
not found|Appearance of healthy granulation tissue and cessation of ulcer discharge,healing ulcers,acute trophic ulcers,wound healing,effectiveness (degree of wound healing,ulcer area reduction,average wound healing,ulcer volume reduction,surface area of the ulcer, bacterial culture of the ulcer swab, appearance of healthy granulation tissue, cessation of ulcer discharge and overall gradation of clinical healing and safety,plantar ulcers,wound healing effects,ulcer sizes,side effects|Using the t-test, there was no statistically significant difference in wound healing between the two therapies (p = 1.7).
1999|plasma levels of KDGPF2a,pain and distress of primary dysmenorrhea,pre- to post-treatment scores,Moos' Menstrual Distress Questionnaire (MDQ,Perceived abdominal and back pain,VAS, KDPGF2alpha or MDQ,pre- to post-treatment KDPGF2alpha levels,plasma KDPGF2a,Menstrual Distress Questionnaire,Visual Analog Scale (VAS) and plasma concentration of the prostaglandin F2alpha metabolite, 15-keto-13,14-dihydro-prostaglandin F2alpha (KDPGF2alpha,prostaglandin F2a metabolite, 15-keto-13,14-dihydroprostaglandin (KDPGF2a), b) perceived abdominal and back pain and c) perceived menstrual distress,pain and prostaglandin levels,MDQ,visual analog scale, and menstrual distress,VAS scores,perception of pain and the level of menstrual distress|The changes in pre- to post-treatment KDPGF2alpha levels were not statistically different between the SMT and LFM groups (P = 0.15).
77|Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS)-Total score,severity, disability, and pain,pain, disability, and severity of CD,efficacy were TWSTRS-Severity, -Disability, and -Pain subscale scores, and Analog Pain Assessment, Investigator Global Assessment, Patient Global Assessment, and Sickness Impact Profile scores,Clinical assessments and adverse events,clinical parameters, laboratory tests, and adverse events,TWSTRS-Total, three visual analog scales (Patient Global Assessment of Change, Principal Investigator Global Assessment of Change, Patient Analog Pain Assessment), and adverse events,efficacy was the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS)-Total score,safety and efficacy,Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS,TWSTRS-Total scores|All three visual analog scales demonstrated improvements at week 4 (p < 0.0001, 0.0001, and 0.001).
27|recurrent urinary-tract infections,time to onset of first UTI,odds of bacteriuria,number of urine specimens with bacterial counts of at least 10(4) colonies per milliliter, types and numbers of different bacterial species, numbers of urinary leukocytes, urinary pH, or episodes of symptomatic urinary tract infection,presence of urinary symptoms,glomerular filtration rate (GFR,absolute risk,Total antibiotic consumption,frequency of bacteriuria with pyuria,rates of bacteriuria and symptomatic urinary tract infection,number of patients experiencing at least 1 symptomatic UTI/year,Cost savings,symptomatic UTI,IL-6,median time to recurrence of UTI,likelihood of UTI and symptoms,recurrent urinary tract infection,Cost effectiveness,Signs and symptoms of urinary tract infection,frequency of bacteriuria,infections with Escherichia coli,urinary symptoms and urinary tract infections,urinary tract infections,relative risk (RR) 0.51,urinary tract infections and urinary symptoms,incidence of UTI,relative risk of withdrawal,antibiotic-treated UTI,time to first recurrence of UTI,Urinary pH,recurrence of urinary tract infection,urinary tract infections (UTI,recurrence of symptomatic UTIs,cumulative rate of first recurrence of urinary tract infection,rate of recurrence of urinary-tract infections and the development of antibiotic resistance,WBC) counts and the combination of bacterial and WBC counts,bacteriuria and pyuria,actual infection rate,symptomatic UTI's, First recurrence of symptomatic urinary tract infection, defined as bacterial growth >/=10(5 )colony forming units/ml in a clean voided midstream urine specimen,urinary tract infection (UTI,urinary tract infection,bacterial counts, urinary WBC counts, or UTIs,time to occurrence of a symptomatic UTI,annual antibiotic consumption,bacteriuria,bacterial count, WBC count, or WBC and bacterial counts,urinary bacterial counts and white blood cell,mean annual cost of prophylaxis,urinary symptoms, such as urinary frequency and cystitis,recurrence rate,urinary cytokine excretion,Urinary cytokines,urinary symptoms or urinary tract infections,acidification of urine,frequency of UTI,distribution of the recurrences,6-month incidence of a second UTI,interleukin (IL)-6 of the urinary cytokines,adherence to beverage drinking, courses of antibiotics prescribed, and organisms responsible for UTIs|There was a statistically significant difference in interleukin (IL)-6 of the urinary cytokines between the multiple daily cranberry dosing group (group A [C, C]): median, 3.16 (range, 0.01 to 7.34) and the placebo group (group C [P, P]): 9.32 (0.53 to 29.61 pg/mL; p = 0.038, Kruskal-Wallis test).
118|progression of disability,T1-Gd lesion volume,T1-Gd lesion burden,Diarrhea, nausea, and hair thinning,Serious infections,relapse rates, disability progression,MRI evidence of disease activity,disease activity assessed by MRI and relapse rate,proportion of patients with confirmed disability progression,acceptable safety and tolerability and reduced MRI disease activity,annualized relapse rate,elevated alanine aminotransferase levels,number of gadolinium-enhancing T1 (T1-Gd) lesions|Teriflunomide as add-on therapy to IFN had acceptable safety and tolerability and reduced MRI disease activity compared with IFN alone.
268|Mortality,need for institutional care and (2) mortality,mean duration of these complications,mortality and outcome at discharge, medical and neurological complications, and length of hospitalization,feasibility and safety,modified Rankin scale (mRS) and Barthel Index (BI,Rankin score|CU: 2.4 days; P<0.02), and the outcome in patients experiencing complications covered by the monitoring protocol was significantly better in the SU (66%) than in the CU (35%) group (P<0.0001).
                
210|nausea,point-prevalence tobacco abstinence rate,sleep disorder,mean (+/-S.D.) weight change,short-term abstinence,ST abstinence,proportion of patients who quit,6-month weight change,7-day point-prevalence abstinence,continuous abstinence rate,nicotine withdrawal symptoms and tobacco craving,abstinence rates,serious adverse events,frequency of nicotine toxicity symptoms,cessation rate,craving and withdrawal symptoms,weight gain,tobacco withdrawal and nicotine toxicity,headache,chewers' chances of abstinence,level of smokeless tobacco use,composite withdrawal symptoms and adverse events,prevalence of ST initiation,efficacy and safety,withdrawal symptoms,cessation of ST use,Enhanced Condition quit,fatigue,response rate,Tobacco craving,tobacco abstinence rates,cessation rates for active and placebo patch,arousal,relapse,prolonged and continuous tobacco abstinence rates, craving and nicotine withdrawal, and weight gain,prolonged and continuous tobacco abstinence rates,spit tobacco cessation rate,Withdrawal symptoms,7-day point-prevalence tobacco abstinence rate,Prevalence of cessation,safe and well tolerated,craving and weight gain,Continuous abstinence rate,Safety and tolerability,tobacco abstinence,mean cessation rates,craving and withdrawal signs and symptoms,smokeless tobacco cessation,7-day point-prevalence tobacco abstinence rates,mean weight change,craving, withdrawal symptoms,Prolonged abstinence,cessation rates,tobacco craving and nicotine withdrawal symptoms,likely to stop using ST,restlessness,Nicotine withdrawal symptoms and weight change,Self-reported rates of sustained abstinence,Cessation prevalences,quit rates,prevalence tobacco abstinence rate,prevalence abstinence rate,tobacco withdrawal symptoms|Survival curve analysis showed that any of the 3 treatment groups involving group behavioral therapy or placebo gum were equally effective and superior to the minimal contact plus 2 mg of nicotine gum treatment in terms of abstinence.
4|angiographic evidence of stenotic disease,cardiac death, myocardial infarction (MI), or coronary revascularization,luminal stenosis,prevalence of CAD,48-month MACE,died of cardiac causes,circumflex artery disease,risk of coronary artery disease,sensitivity,sensitivity, specificity, positive and negative predictive values,peak systolic velocity (PSV,early diastolic annular velocity (E'), and prolongation of the time to E,E, A, E/A, DT or IVRT,highest probability of coronary stenosis,rate of MACE,Significant coronary disease,prevalence of coronary artery disease,Risk stratification,degree of vessel stenosis and calcification score,crude probability of surviving free of cardiac events,coronary artery disease at cardiac catheterization,positive for inducible ischemia,Sensitivity,renal transplantation (RT,cardiac events,Event rates,Coronary artery calcification,filling pressures,ischemic response,multifocal atherosclerotic coronary disease,normal thallium imaging,Obstructive CAD,Sensitivity for single-vessel CAD,zero calcium score,annular systolic velocity (S,left ventricular (LV) diastolic function,aortic valve sclerosis,48-month MACE (cardiac death, nonfatal acute myocardial infarction, and coronary revascularization after RT,pharmacologic stress thallium scintigraphy,positive thallium scan,lower S' and E' velocities,progressive disease of the coronary circulation,cardiac death or MI,probability of event-free survival,triple vessel disease,coronary artery disease,Agatston mean score,left atrial enlargement,normal renal allograft function and serum lipid levels,Regional left ventricular wall motion abnormality (WMA,adverse cardiac outcomes,cardiovascular events,sensitivity and specificity of DSE for CAD diagnosis,time to E' at peak stress,Abnormal tissue Doppler (TD)-derived indices,sensitivity and specificity,Specificity,calcification score,inducible ischemia in 4, and catheterization before death revealed multivessel CAD,Mean CIMT,conventional (peak early (E) and late (A) transmitral, E/A ratio, E-wave deceleration time (DT), and isovolumic relaxation time (IVRT)) and TD-derived indices (lateral annular systolic (S'), early diastolic (E'), and late atrial velocities (A'), time to E' and E/E,Cardiac events, including cardiac death, nonfatal myocardial infarction, unstable angina, pulmonary edema, and need for coronary revascularization, occurring between the time of the dobutamine stress echocardiogram and the last patient follow-up contact,positive-stress electrocardiograms,sensitivity and specificity in identifying CAD,angiographic coronary artery disease,DSE,cardiovascular outcome,mortality|The sensitivity and specificity in identifying CAD was 47.3 and 95.2%, respectively, while positive predictive value and negative predictive value was 90% and 66%.
186|systolic arterial blood pressure (Pasys,perioperative neurological deficits,blood pressure (BPs and BPm) and RPP index,systolic blood pressure values,number of postoperatively hypotensive episodes (systolic blood pressure values,proportion of patients with stroke (including retinal infarction), myocardial infarction, or death,systemic vascular resistance,percentage reduction in MCAV(mean,anxiety,rate of myocardial ischemia,cardiac morbidity and mortality,mean arterial blood pressure,Episodes of myocardial ischemia,prevalence of myocardial ischemia,hypertensive events,ischemic episodes,stroke-related deaths,Per- or postoperative hypertension,mean arterial pressure,arterial blood pressure,Pulmonary artery occlusion pressure,blood pressure,blood pressure profiles,Mean arterial pressure,postoperative hypotension,Intraoperative fluid requirements,Neurological complication rates,Per- or postoperative hypotension,quality of life, length of hospital stay, or the primary outcome in the prespecified subgroups of age, contralateral carotid occlusion, and baseline surgical risk,frequent episodes of peroperative hypertension,clamp MAP,anxiety, satisfaction or overall experience,systolic pressure,Hemodynamic status,Overall experience and satisfaction with CEA,Complication rate, combined death/stroke rates,blood pressures,fallow blood pressure: systolic (BPs), mean (BPm), diastolic (BPd), heart rate (HR), and RPP index,combined stroke/cardiopulmonary related death,cerebral blood flow,Blood pressure,specific carotid endarterectomy experience questionnaire (CEA-EQ,suffered myocardial ischemia,perioperative neurological and cardiopulmonary complication rates,Mean middle cerebral artery velocity (MCAV(mean,Cardiopulmonary complication rates,myocardial ischemia,Transcranial Doppler (TCD) and mean arterial pressure (MAP) assessed by continuous intra-arterial blood pressure transducer|There were no differences in the number of postoperatively hypotensive episodes (systolic blood pressure values < 100 mmHg) between the two groups.
                
30|radiographic alignment,rearfoot pressure,serious adverse events,Foot Health Status Questionnaire,plantar pressure loading and comfort,plantar pressures,safe and well-tolerated,peak pressure and pressure-time integrals,quadriceps and gluteus medius electromyographic activity,Surface electromyographic activity,Plantar pressures,Foot pain scores,Greater vastus medialis and gluteus medius activity,foot pain, function, quality of life, and plantar pressure loading,Less vastus lateralis activity,progression of pes cavus in CMT1A,Contact time and area increased in both neutral-cushioned running shoes,foot posture, ankle flexibility, and strength, assessed every 6 months,physical functioning,Plantar pressure,Function scores|Less vastus lateralis activity was found with the vertical jump with all orthotic conditions, again regardless of foot type.
                
107|disability,perceived disability,low back pain,Self-appraised pain scores,pain, depression, anxiety and improved sleep,disability scale,pain and functioning,intense pain,quality of pain,mean pain intensity on VAS,walking time,general health status, pain, functioning, coping strategies and mood,trunk and pain flexion performance, and their serotonin and dopamine levels,Baseline mean FFbH score,pain and disability,baseline VAS scores,lumbar motility,Lower back pain,VAS pain intensity,pain, depression, anxiety and stress hormones, and sleeplessness and for improving trunk range of motion associated with chronic low back pain,mean of posttreatment pain score,pain, depression, anxiety and their sleep,functional ability/disability (Functional Questionnaire Hanover, FFbH) and pain intensity (10 cm visual analogue scale, VAS,adverse effects,disability and pain,mean of pain score,pain intensity (by Visual Analogue Scale) and duration; lateral fingertip-to-ground distance in centimetres; walking time and interference on daily activities,pain relief and enhancing the physical functional activities,Roland Disability Questionnaire (RDQ), the McGill Pain Questionnaire (PPI and PRI), the State Anxiety Index and the Modified Schober test (lumbar range of motion,lateral spine flexion range,pain,pain reduction|Clinical significance was evident for the comprehensive massage therapy group and the soft-tissue manipulation group on the measure of function.
40|dental and skeletal vertical relationships,spontaneous downward and backward growth direction|The results indicate that a spontaneous downward and backward growth direction of the mandible observed in the control group could be changed to a upward and forward direction by FR-4 therapy.
43|knowledge between groups, and incidence of predefined adverse neonatal outcomes,hazard ratio (HR) for repeat birth,risk behavior or contraceptive use,baseline contraceptive use or other measures of risk or family formation,infant feeding, infant care, or immunisation,sexual relationships and contraception-use intentions and behaviors, and readiness to engage in pregnancy prevention,Questionnaire data,dropout rate,breastfeeding or infant vaccination knowledge or compliance,repeat pregnancy rate,Patient satisfaction,knowledge with respect to breastfeeding or infant vaccination schedules,risk of repeat birth,started contraceptive use,high self-esteem, positive life events, and romantic involvement and residence with the first infant's father,birth rates,contraception knowledge,subsequent pregnancy,subsequent pregnancy with increased levels of intervention exposure,satisfaction rate,knowledge of OCs,marital rates,percentage returning to school,risk practices, or contraceptive use,adverse neonatal outcomes,patient satisfaction with the contraceptive teaching method,contraceptive uptake,repeat pregnancy|More women in the intervention group were not pregnant and still using contraception, and were able to successfully switch contraceptive methods compared to women in the control group.
37|regained birth weight earlier,coagulase-negative staphylococcal bacteraemia,CONS infections,incidence of catheter-related coagulase-negative staphylococcal sepsis,CVC reinsertion,CONS infection,episodes of CONS bacteraemia,catheter-related sepsis,episode of CONS bacteraemia,Adverse effects,duration of catheterization,CONS bacteraemia,colonization of catheters by coagulase-negative staphylococci,number of thrombotic,Bacterial contamination of the catheter tip at removal,septicemia|Two babies in the treatment group had more than one episode of CONS bacteraemia, compared with nine in the control group (P = 0.02).
20|hematologic or biochemical test results,Seizure control,plasma concentration of concomitant AEDs,gingival index scores, red blood cell folic acid levels, free phenytoin blood levels, photographs, and impressions,poststudy serum folate levels,Serum folate and phenytoin levels,seizure frequency,Iatrogenic osteomalacia,adverse side effects,plaque and gingival index scores or free phenytoin blood levels,Their plasma and red cell folic acid levels,neuropsychological functions, such as visuo-spatial analysis, visuo-motor speed and verbal abstracting ability,phenytoin hyperplasia,recurrence of gingival overgrowth,neuropsychological functions,overgrowth,subnormal blood thiamine levels,recurrence of phenytoin-induced gingival overgrowth,gingival hyperplasia,red blood cell folic acid levels,hypocalcaemia and elevated serum alkaline phosphatase,plasma and red cell folate levels,Vitamin E levels,incidence of hypocalcaemia and raised serum alkaline phosphatase,gingival overgrowth,bone mineral content,size of the gingival hyperplasias,Phenytoin blood levels,frequency of epileptic attacks,frequency of seizures, behaviour, and personality, or in a number of cognitive functions,serum DPH-levels|The poststudy serum folate levels were three times baseline levels for the active drug group (p less than 0.001) but unchanged in the placebo group.
31|High rates of participant retention,weight loss included more computer log-ons, achieving computer-selected goals, more self-monitoring, increased walking, and decreased energy and fat intake,weight loss and blood chemistry,Retention,waist circumference, BMI, blood pressure, resting heart rate, self-reported physical activity and dietary variables, and physical activity and dietary cognitions,weight loss, dietary behavior, physical activity, and engagement,mean (SD) weight,waist circumference,weight parameters, lipid profile, plasma glucose, blood pressure, intervention costs, dietary intake, and physical activity,Daily self-weighing,weight losses,Weight loss for InPerson,relative to usual care,smaller weight loss,mean weight loss,mean BMIs,Mean entry weight,SD) weight gain,moderate weight loss,BMI,physical activity-related cognitions,weight loss and improved health-related outcomes and behaviours,Measured weight and waist circumference,fasting glucose and blood pressure,initial weight loss and changes in waist circumference,Weight loss,weight and body composition, and diet intake,Body weight and waist circumference,body mass index,weight from randomization,website utilization,weight loss, prevent weight gain,systolic blood pressure,Change in body weight, BMI, percent body fat, and waist circumference,weight loss goal,dietary fibre or alcohol,percentage of initial body weight,energy and fat intake,average PSF,saturated fat,mean daily energy intake,below entry weight,weight at baseline and 6 months and percent of subjects achieving a 5 and 7% weight loss,resting heart rate,Changes in waist circumference,physical activity,weight,mean 12-month weight losses,weight regain,weight gain over a period of 18 months,weight loss,Assessments of weight, nutritional knowledge, eating behavior, and related cognitive variables,percentage of energy from fat,sustaining weight loss|Both groups reduced percentage of energy from fat (P < 0.05), saturated fat (P < 0.001) and energy-dense/nutrient-poor items (P < 0.05), with no change in dietary fibre or alcohol (P > 0.05).
                
not found|GFR,urinary protein level,proteinuria, blood pressure and renal function,hyperkalemia,fractional albumin clearance,albuminuria and GFR,serum potassium levels,orthostatic dizziness,night blood pressure,BP,Urinary albumin to creatinine ratio, BP and biochemical parameters,albuminuria, 24-h ambulatory blood pressure (ABP), and glomerular filtration rate (GFR,urinary type IV collagen level,24-h ABP,24-h blood pressure,Mean serum creatinine, potassium and blood pressure,albuminuria (geometric mean [range,estimated glomerular filtration rate,systolic 24-h ABP,proteinuria,fractional clearance of albumin,nephrotic range albuminuria and blood pressure,proteinuria and kidney function,blood pressure,adverse events,potassium concentrations,Baseline aldosterone levels,tolerated,nephrotic range albuminuria,change in albuminuria,albuminuria from [geometric mean,proteinuria, blood pressure (BP) and renal function,renal and cardiovascular outcome,Median (range) number of antihypertensive drugs,albuminuria, 24-h ambulatory blood pressure, and glomerular filtration rate (GFR,albuminuria and blood pressure,glomerular filtration rate,Estimated glomerular filtration rate (eGFR,urinary protein and urinary type IV collagen,Albuminuria,proteinuria and retard renal progression,albuminuria,diastolic 24-h ABP,albuminuria, 24-hour blood pressure, and glomerular filtration rate (GFR|Albuminuria decreased by 40.6% [95% confidence interval (CI) 23.4-57.8%] and BP by 7 mmHg (2-12 mmHg)/3 mmHg (1-6 mmHg) with spironolactone, but did not change with placebo.
not found|mean five-day cumulative fluid input,fluid intake,acute adverse effects,infusion quantity,osmolal clearance,duration of respiratory support required, in time to regain BW, or in time to discharge,murmurs consistent with patent ductus arteriosus,mortality and morbidity,Episodes of jaundice, hypoglycaemia and hypotension requiring treatment,alive and had no signs of bronchopulmonary dysplasia,occurrence of episodes of jaundice, hypotension, hypoglycaemia, hypernatraemia or hyponatraemia,Serum electrolytes, bilirubin, creatinine and urine osmolalities,endogenous creatinine clearance,incidence of clinically significant patent ductus arteriosus, intracranial hemorrhage, bronchopulmonary dysplasia, necrotizing enterocolitis, dehydration, acute renal failure, or metabolic disturbances,neonatal mortality rate,median creatinine and arginine vasopressin levels,fluid balance, electrolyte and metabolic disturbances,risk of patent ductus arteriosus with congestive heart failure,excretion of all other electrolytes, acids, and nitrogenous metabolites,urine osmolalities and lower urine output,weight,necrotizing enterocolitis,Mean weight loss,Arginine vasopressin levels,congestive heart failure|On each of the three days an increase of the infusion quantity resulted in a 2--3 times larger urine flow, the osmolal clearance increasing significantly at the same time.
200|Respiratory distress syndrome,maternal or fetal complications,mean diastolic pressure,eventual fetal outcome,average days of pregnancy prolongation,Neonatal blood pressure, heart rate and axillary temperature,mean gestation,higher birth weights,Respiratory rate,incidences of either superimposed preeclampsia,perinatal mortality,mean blood pressure,Birth weight,Fetal outcome,Satisfactory blood pressure control (diastolic pressure less,mean peak levels of propranolol, propranolol glucuronide, 4-hydroxypropranolol, and 4-hydroxypropranolol glucuronide,systolic,severe hypertension and/or fetal distress,Proteinuria,maternal blood pressure (BP), laboratory indices, umbilical Doppler velocimetry, and neonatal outcome,blood-pressure, prevented proteinuria, and reduced the number of hospital admissions,Intrauterine growth retardation and neonatal hypoglycaemia,Plasma uric acid and creatinine concentrations,systolic and diastolic blood pressures,maternal side-effects,birth weight, placental weight, head circumference, and Apgar score,proteinuria, creatinine, and uric acid,proteinuria,Neonatal bradycardia,Mean blood glucose,mean birth weight of the babies,Diastolic blood pressure,palpitations,maternal BP; neonatal outcome,control blood pressure,diastolic,albuminuria,mean systolic or diastolic pressures, mean gestational age, or initial laboratory findings at time of entry,CCT and serum creatinine,maternal mean arterial pressure,gestational age at birth or birthweight,number of infants with a cord pH,birthweights of the babies,average time of delivery,Intrauterine death,preterm delivery,neonatal outcome,Heart rate, blood pressure, blood glucose, respiratory rate, and Silverman score of the babies,birth weight, head circumference and Apgar score and in the frequencies of respiratory distress, bradycardia and hypoglycemia,perinatal deaths,birth weight,blood pressure,preterm delivery, neonatal respiratory distress syndrome and jaundice,number of caesarean sections,gestational age at delivery, birth weight, number of infants admitted to the special care unit, or cord blood gas measurements,Intrauterine growth retardation, neonatal hypoglycaemia, and hyperbilirubinaemia,adverse effects,Heart rate,incidence of cesarean delivery for fetal distress,Peripheral blood flow,abruptio placentae,maternal systolic and diastolic BP,neonatal death,intrauterine growth retardation,frequency of fetal growth retardation,uricemia level, platelet counts, foetal cardiac rythm, and occurrence of pre-eclampsia,average birthweight and the proportion of preterm or small-for-gestational-age babies,mean peak plasma level of naphthoxylactic acid,Loss of blood-pressure control leading to withdrawal,mean systolic or diastolic blood pressures, mean gestational age, or initial laboratory findings at time of entry,Side-effects,diastolic blood pressure,blood pressure control,Median cord pH,maternal blood pressure,systolic blood-pressure,diastolic blood pressure (DBP,weight of the newborn,Hypertension,symptomatic hypoglycaemia,Blood pressure and birth weight,Umbilical artery resistance,Blood glucose levels,systolic blood pressure,systolic pressure,renal function,Arterial blood gas analysis,gestational age at delivery, birth weight, incidence of fetal growth retardation, or neonatal head circumference,hypertensive complications,maternal hypertension,side effects|There were no differences between the two groups in mean systolic or diastolic pressures, mean gestational age, or initial laboratory findings at time of entry.
not found|remission (UCSS < or =2) rates,Tumour necrosis factor production,colectomy or death,Remission,median improvement in UCSS,clinical remission,Disease activity and quality of life,Therapy success,clinical and endoscopic remission,Clinical remission,physical examination, clinical chemistry and hematology laboratory tests, and occurrence of adverse experiences,Mayo score,median baseline activity scores,acute moderate or severe ulcerative colitis,erythrocyte sedimentation rates and serum concentrations of C-reactive protein and interleukin-6,IBDQ and EuroQol,remission,clinical response,subscore for rectal bleeding,modified Truelove and Witts severity score, 2) increase in corticosteroid dosage, 3) addition of immunosuppressants, 4) colectomy, or 5) death,ulcerative colitis symptom score (UCSS,operation for septic complications,therapy success,colectomy|The antibody to tumor necrosis factor alpha, infliximab, has shown to be effective in the treatment of steroid-refractory ulcerative colitis in pilot studies.
not found|influenza-like illness,influenza infection,influenza-like illness and health service use in residents,staff vaccination coverage and all-cause mortality,Staff influenza vaccination rates,Influenza vaccination levels and influenza-like illness,cause mortality of residents,death, morbidity, and health service,National influenza rates,total patient mortality,non-fatal influenza infection,uncorrected rate of mortality,rates of hospitalization and influenza-like illness (ILI) in residents and sick leave from work in staff,total mortality rate,sick leave from work in staff,resident hospitalization rates,mortality|Outbreaks and number of cases were significantly reduced by vaccination, which should be strongly recommended for institutionalized elderly people.
250|report abstinence,prenatal alcohol consumption,antepartum alcohol consumption,Risk of antepartum drinking,alcohol quit rate,rates of abstinence,Demographic background and obstetric history of subjects, current and lifetime use of alcohol and substances, composite Addiction Severity Index scores, and antepartum alcohol use,alcohol consumption and peak intoxication levels,highest blood alcohol concentration (BAC) levels,birthweights and birth lengths, and fetal mortality rates,alcohol consumption,Newborn outcomes of gestation, birth-weight, birth length, and viability|Both the AO and BI groups had reductions in antepartum alcohol consumption, but differences in reductions by group were not statistically significant (p > 0.05).
91|beta-galactosidase activity,total colonic transit time,defecation and encopresis frequency/week and successful treatment,taking PEG + E,serious adverse events,laboratory tests and physical examinations,Overall improvement,stool consistency,loosest (diarrheal) stool,defecation frequency,Abdominal pain,nonhard" stools,number of stools and a lower median daily score,chronic constipation,abdominal pain, straining, and pain at defecation,laboratory tests,Clinical efficacy and tolerance,efficacious and well tolerated,encopresis frequency,Lactobacillus, clostridial spores, Bacteroides and enterobacteria, pH, biliary acids and neutral sterol concentrations,Bristol score of stool consistency,clinical complete remission rate of constipation,loss of efficacy and no serious toxicity,tolerated,Clinical tolerance,opiate induced constipation,paediatric constipation and evaluate clinical efficacy/side effects,mean number of liquid stools,PEG + E,reducing hard stool formation,faecal bifidobacteria counts,bowel movement frequency, stool consistency, clinical complete remission rate of constipation and abdominal symptoms, and the safety of forlax and lactulose,faecal bacterial mass,self-reported frequencies, consistency, and ease of defecation,median weekly frequency of bowel movement,total incidence rate of adverse events seen,loosest stool,total short-chain fatty acids,side effects|However, success was significantly higher in the PEG group (56%) compared with the lactulose group (29%).
924|psychosocial mediators of safer sex,refusal, condom decision-making, and ability to change work contract, but not ability to take leave; 4) built social support by increasing social interactions outside work, social function participation, and helping other sex workers; and 5) addressed environmental barriers of economic vulnerabilities by increasing savings and alternative income,HIV-1 seroincidence rate,Overall condom use,weighted geometric mean incidence rate of STDs,knowledge of STDs and condom protection,cumulative sexually transmitted illness incidence,reduced STI prevalence,proportion of unprotected sexual acts,estimated odds ratios (ORs) for chlamydia, gonorrhoea, trichomoniasis, and aggregate STI,number of paying clients,Male condom use,gynecologic examination, HIV serology and laboratory tests for STD,Baseline STI prevalences,levels of reported protection,rates of sexual risk and violence,number of sex partners,HIV risk behaviors,proportion of consistent condom users,number and percentage of protected sex acts,sexual risk behaviors,aggregate prevalence,incidence rate of STDs (gonorrhoea, chlamydial infection, trichomoniasis and genital ulcer disease,HIV/STD related knowledge and perceptions, condom use, and history of STDs,Incidence density,number of unprotected sex acts,infection rate of STDs,aggregate STI prevalence,higher HIV/AIDS knowledge, lower probability of contracting HIV and increased condom use|We observed a 40% decline in cumulative sexually transmitted illness incidence (P = .049) in the intervention group.
not found|post-operative blood transfusion,length of hospital stay,intraoperative fracture of the femoral shaft,time to mobilising with a frame, wound infection, time to discharge, time to fracture union, and mortality,shorter convalescence and earlier full weight-bearing,operative time needed to insert the intramedullary hip-screw,mean radiation time,mortality, length of hospital stay, transfusion rate, change in mobility and residence, and quality of life as measured with the EuroQol 5D outcome score,intraoperative and postoperative complications or rate of fixation failure,Implant failure and/or nonunion,femoral shaft fracture,reoperation rate,mean Harris hip score,difficulty of the operation, intraoperative complications, and blood loss,pain, mobility status, and range of movement,Mean hospital stay,Operative and fluoroscopy times, blood loss, functional outcome, complication rate, and failure of fixation,patient status (ASA classification), operative data (type of implant, duration), postoperative data (blood loss, radiographic findings, early complications), and outcome (Harris score, time to walking, mortality,walking ability, rising from a chair, curb test, and additional assessments of abductor strength, pain, living conditions, and complications,technical complications,operation time,Femoral shaft fractures,functional outcome,surgical time,rate of wound complications,Intraoperative complications,early or long-term functional status,walking ability,ADL, hip function or the HRQOL,serious general complications and wound infections,Major fracture complications,reoperation within the first postoperative year,intraoperative blood loss, of perioperative lethality and in duration of hospital care,postoperative complications,operative complications,revision rate,University Level,number of patients transfused and the mean of units of blood transfused,longer operative time,anaesthetic time, operating time, radiation time and blood loss,blood loss,time necessary to support full weight bearing,mental state (MMSE), their nutritional and immune state and their pulmonary function,mechanical complications, such as fracture of the femoral shaft or failure of fixation,time to union and the length of sliding of the lag screw,hospital stay, surgical time, blood loss, functional outcome at 1-year follow-up, neck-shaft angle, fracture collapse, and mortality,level of mobility,Clinical: pain, social functioning score, and mobility score,fixation failure and reoperation,prevalence of perioperative complications, such as bronchopneumonia, cardiac failure, and urinary tract infection,Screw migration,rates of functional recovery,fluoroscopy time,Radiologic: fracture healing and failure of fixation,mean time to mobilisation with a frame,1-year mortality rate,mean anaesthetic and operation times,Length of time of operative procedure, hemoglobin levels at 6 and 48 h after surgery, packed cells units administered, and hospital stay,intra-operative femoral fractures,mortality rate,rates of cutting,reoperation rates,operation time for gamma-nailing,wound infections,general complications, technical failures, revision surgery, activities of daily living (ADL), hip function (Charnley score) and the health-related quality of life (HRQOL, EQ-5D,revision surgery,mortality within six months, postoperative mobility, or hip function,trochanteric wound hematoma,Major complications included missed distal locking screws (one patient), cutting out of the lag screw superiorly,operating time, blood loss, wound complications, stay in hospital, place of eventual discharge, or the patients' mobility,unstable fractures,Operating time,Mortality,time to surgery, operating time, receipt of blood transfusions, duration of hospital stay, or fracture classification,quality of life,mean blood loss,Urine retention,intra-operative complications,Mean blood loss,stability, complications and cost effectiveness,postoperative blood loss,intraoperative blood loss, medical complications, mortality or length of hospital stay,Cortical hypertrophy,rate of technical failure,intraoperative bleeding,operating time,Limb shortening,Mean operative time,pre-operative walking ability,fracture healing,EuroQol 5D outcome scores, the mortality rates,Decreased bleeding and post-operative pain, reduced post-operative morbidity and faster recovery of function,sliding of the lag-screw and subsequent shortening of the limb,severe general complications,intraoperative blood loss,pain without cortical hypertrophy,neck shaft angle,functional outcome or major complications,re-operation rate,surgical procedure (time, duration of x-ray irradiation, and total blood loss); the initial postoperative period (complications, duration of hospital stay, and the time before returning home); the time before full weight bearing became effective; the functional and social recovery; mortality; and the quality of immediate and final anatomic restitution and healing,Tip-apex distance,HRQOL (EQ-5D(index) score,failure of proximal fixation: cut-out,mean duration of operation and fluoroscopy screening time,operative morbidity,major complication rate,walking ability and autonomy recovery, but hip function,blood loss and the length of operative time,image intensifier screening time,Lag-screw cut-out,fluoroscopic time,subcapital femoral fracture,postoperative walking ability,radiological or functional outcome,Postoperative pain,pain,operative times, fewer blood transfusions, and shorter hospital stays,overall complication rate|There was no difference in the rates of cutting-out of the two implants but use of the Kntscher-Y nail was associated with a greater incidence of shortening.
69|relapse prevention,number and length of hospitalizations per patient,relapse rates,recurrence rates of major mood episodes,time to first relapse or number of relapses with depression,relapse status, symptom severity, and medication compliance,relapse reduction,bipolar episodes,Kaplan-Meier survival analyses,mood ratings, social functioning, coping with bipolar prodromes, and dysfunctional goal attainment cognition,time to relapse,feasibility and efficacy,relapses and longer delays before relapses,depressive,number of recurrences,overall social functioning,Time to first manic or depressive relapse, number of manic or depressive relapses, and social functioning,survival time,number of manic relapses,number of total recurrences and the number of depressive episodes,relapse and hospitalization rates,Event curves of time to first manic relapse,number of prior episodes, the number of therapy sessions and the type of BD predicted survival time,knowledge of the disease, medication and social strategies,Beck Depression Inventory, the Internal State Scale, and the Global Assessment of Functioning,time to depressive, manic, hypomanic, and mixed recurrences,number of relapsed patients and the number of recurrences,25th centile time to first manic relapse|Event curves of time to first manic relapse significantly differed between experimental and control groups (log rank 7.04, df=1, P=0.008), with significant reductions in the number of manic relapses over 18 months (median difference 30% (95% confidence interval 8% to 52%), P=0.013).
not found|caries increment,mean DeltaDMFSa value,caries incidence,dropout rate,numerical anti-caries effect,size of a substantive scheme,DMFT or DMFS,approximal caries development,approximal caries incidence,mean DMFT,DMF index,early childhood caries,DMFT increment,Costs|No statistically significant difference in caries increment during the two experimental years was found between the groups.
not found|toxicity,clinical efficacy and safety,Blood and bone marrow cultures and cytokine profiles,median time to fever clearance,Late relapses,nalidixic acid resistant,Salmonella typhi,mean duration of fever,clinical cure and bacterial eradication rates,fever clearance time,clinical cure and time to defervescence,overall treatment failure (acute treatment failure and relapse,culture-positive relapses,fever and symptoms,treatment failure, which consisted of at least one of the following: persistent fever at day 10, need for rescue treatment, microbiological failure, relapse until day 31, and enteric-fever-related complications,efficacy and safety,cytokine production capacity,excellent efficacy and safety profile,clinical failure,clinical cure rate,growth of S. typhi in stool culture,negative stool cultures,nalidixic acid-resistant (Na(R,median FCT,duration of hospitalisation,standard deviation fever clearance times,Median (range) fever clearance times,adverse events,Mean ,stool-culture positive,positive stool culture,positive stool cultures,serious side effects,Relapse,overall clinical cure rate,Positive fecal carriage immediately posttreatment,acute treatment failures and one relapse,tolerated,fever clearance times,complete cure,Blood cultures,Apyrexia and resolution of digestive and neurological symptoms,adverse effects,Defervescence (maximum daily temperatures,positive fecal cultures,six "clinical" failures,overall treatment failure (clinical or microbiological failure, development of typhoid fever-related complications, relapse or faecal carriage of S. typhi,acute clinical failure,SD time required for defervescence,ileal perforation,therapeutic responses,treatment failure,Overall treatment failure,fever clearance time, late relapse, and faecal carriage|Short-course treatment with oral ofloxacin (5 days) is significantly better than that with ceftriaxone (3 days) and will be of particular benefit in areas where multiresistant strains of S. typhi are encountered.
107|forced expiratory volume at 1 s (FEV1), peak expiratory flow rate (PEFR), and responses on the Asthma Quality of Life Questionnaire, a validated disease specific measure of functional status,daytime asthma outcome,decline in [corrected] FEV(1) values,higher FEV1,peak expiratory flow rate (PEFR), asthma symptoms and histamine bronchial responsiveness,Gastroesophageal reflux,respiratory function,Reflux,acid reflux and improvement of reflux symptoms scores,peak expiratory flow rate readings,evening PEFR,pathological GOR,PEFR and quality of life,asthma symptoms,oesophageal symptoms,pulmonary function (FEV1,asthma symptoms, inhaled beta 2-agonist use and histamine bronchial responsiveness,mean morning and evening PEFR,chest symptoms,Pathologic GER,peak expiratory flow variability; reversibility to inhaled ipratropium bromide as a parameter of vagal activity; asthma symptoms scores; and medication used,nighttime asthma symptoms,gastroesophageal reflux (GER,Upper gastrointestinal endoscopy, 24 hour oesophageal pH measurements, spirometry and histamine bronchoprovocation test (HIT,Gastroesophageal reflux (GER,Lung function tests,consumption of beta-adrenergic stimulating drugs,Day and night heartburn symptoms,pulmonary function,gastro-oesophageal reflux (GOR,Peak expiratory values, use of sympathomimetics, and pulmonary and gastric symptoms,asthma symptoms and the degree of acid reflux,day time wheeze, cough, breathlessness, beta 2-agonist use or night time wheeze and breathlessness,asthma symptoms or peak expiratory flow rate,intake of pulmonary medication,typical reflux symptoms,pulmonary function and quality of life,reflux and night time asthmatic symptoms,Daytime pulmonary symptoms,FEV1, FVC, histamine bronchial responsiveness and diurnal variation of PEFR,asthma control assessed by symptoms, peak expiratory flow rate and bronchodilator usage,signs of OD,nocturnal asthma symptoms,airway hyperresponsiveness, as determined by the provocative concentration of methacholine producing a 20% fall in forced expiratory volume in one second (PC20); and airway obstruction,Spirometry, and diary cards,peak expiratory flow rate and quality of life,alleviation of their oesophageal and bronchial symptoms,pulmonary medication intake,Asthma Quality of Life Questionnaire, and on the subdomains of activity limitation, symptoms, and emotions,severity of their reflux|Daytime pulmonary symptoms did not improve significantly (p = 0.14), but a reduction in nighttime asthma symptoms (p = 0.04) was found during omeprazole treatment.
not found|intestinal perfusion,pressure response,Mean blood flow velocity,Mean arterial pressure (MAP,Vascular resistance of SMA,LVO,mean arterial pressure (MAP,mean arterial blood pressure,intestinal perfusion and blood pressure,infusion rate,Mean (SE) MAP,percentage LVO increase,Success,Left ventricular output (LVO,blood pressure and intestinal perfusion,haemodynamic response,gestational or postnatal age or baseline BP,systolic BP,treatment failure,MAP values,rate of inotrope infusion|Dobutamine failed to increase MAP above 30 mm Hg in six infants out of 10, whereas dopamine succeeded in all 10 infants.
79|relapse rates,Plasmodium falciparum malaria,protective against further episodes of P. vivax,recurrence of infection,polymerase chain reaction-single strand conformational polymorphism,Radical curative efficacy,P. vivax malaria,true relapse rate,recurrence,CQ resistance,blood stage antimalarial activity,rate of protective efficacy,Parasite clearance times,Recurrences,blood stage antimalarial efficacy,Blood stage antimalarial efficacy,relapse of Plasmodium vivax malaria,prevalence of recurrence of parasitaemia with fever,Plasmodium vivax malaria relapse|PCR-based comparison of parasitic DNA collected pre- and post-treatment was successful for eight of the 10 cases of apparent relapse and indicated that two such cases, both given the short regimen of treatment, were, in fact, probable cases of re-infection rather than of relapse.
32|leukotriene B5 levels,eicosapentaenoic acid (EPA, 20:5) and docosahexaenoic acid (DHA, 22:6) levels,platelet fatty acid composition,cholesterol and lipoprotein concentrations; haemostatic and rheological variables; the ankle brachial pressure index; walking distance; and cardiovascular events and death,endothelial function,Neutrophil PAF production and plasma lyso-PAF,small reduction in non-fatal coronary events,Blood extractions and clinical explorations,Endothelial function,LDL-C levels,coronary events,Urinary excretion of TXB2 and 6-keto-PGF1 alpha,HDL3-C levels,whole blood viscosity,lipid pattern, disease severity, inflammation profile, and endothelial function,neutrophil leukotriene B4 (LTB4) generation,sTM levels,blood lipids,Plasma concentrations of EPA, DHA, oleic acid, folic acid, and vitamins B-6 and E,levels of inflammatory markers,Plasma lipid levels and platelet and neutrophil function,Peripheral arterial disease (PAD,cholesterol and high density lipoprotein cholesterol,red cell deformability,blood pressure, red cell deformability, fibrinogen, and lipid levels,FMD,blood viscosity,Platelet aggregation,low-density lipoprotein cholesterol (LDL-C) and high-density lipoprotein-2 cholesterol (HDL2-C,Plasma total cholesterol and ApoB concentrations,endothelial function and inflammatory status,Lipid concentrations,inflammatory status,systolic blood pressure,plasma triglyceride concentration,total homocysteine,serum triglyceride levels,Fibrinogen levels,plasma viscosity, haemoglobin concentration, packed cell volume, or platelet count,walking distance,Walking distance before the onset of claudication,total cholesterol levels,Mean arterial blood pressure,walking distances and pressure indices,haematocrit,arachidonic acid content of platelet phospholipids,viscosity,Serum thromboxane B2 (TXB2) levels,ankle-brachial pressure index values,blood pressure, blood lipids, and platelet responsiveness,plasma soluble thrombomodulin (sTM) and brachial artery flow-mediated dilation (FMD), and the inflammatory status by measuring high-sensitivity C-reactive protein and myeloperoxidase|Fish oil decreased neutrophil leukotriene B4 (LTB4) generation following calcium ionophore stimulation by 33%, while leukotriene B5 levels increased significantly.
not found|abdominal pain,relief of postpartum episiotomy pain,visual analogic scale, a verbal scale and pain relief scores,relief of post-episiotomy pain,analgesic activity,SPID, TOTAL, and global ratings,pain score,relative analgesic efficacy,adverse reactions,Pain intensity,lower pain score,Analgesia,pain relief,pain intensity difference, total pain relief, and reduction of pain,pain severity and relief on categorical scales,quality of pain relief,adverse effects|Ibuprofen was more effective after one hour than either of the other two drugs, whatever the scale or parameter used.
1200|Morbidity,Injurious falls,risk of severe or fatal,functional balance and gait,hospital admission rates,injurious falls, balance, gait, and fear of falling,fall-fracture rates,fear of falling,Tinetti Balance Scale,Tinetti Gait Scale,total morbidity rates,total morbidity rate,balance, gait, and fear of falling,injurious falls,Falls,Rates of fracture from falls|No significant changes in the fear of falling were detected among the tai chi practitioners, tai chi villagers, and control villagers.
                
25|signs and symptoms of mandibular dysfunction,mean maximum opening,patients' pain, tenderness, or limited opening,Helkimo dysfunction index,painful movement of the mandible except in retrusive movement,pain on palpation, self-reported pain and functional outcome,intensity and unpleasantness of myofascial pain,Observable pain scores, maximum comfortable interincisal distance, and maximum interincisal distances,pain,quality of life,temporomandibular disorders (TMD), intraoral appliances (IAs) and biofeedback (BF,mean maximum comfortable opening,subjective symptoms,self-reported pain and functional outcome,pain and depression,total mean observable pain scores,All pain ratings,subjective symptoms and clinical signs,mobility,signs and symptoms of TMD,EMG activity,pain reduction|No significant differences could be detected in painful movement of the mandible except in retrusive movement, wherein stomatognathic treatment was clearly superior immediately afterward.
161|Overall survival,Mortality,early relapse, multiple relapse, anemia, or B symptoms,risk of recurrence,Remission rates, overall survival (OS), and toxicity,freedom from treatment failure,OS,FFTF,survival and progression-free survival,toxicity and protocol violations,adverse effects|Freedom from treatment failure at 3 years was significantly better for patients given BEAM-HSCT (55%) than for those on Dexa-BEAM (34%; difference -21%,
60|toxicity,Survival,baseline weight loss,superior appetite stimulation,weight gain,symptomatic or nutritional parameters,lipolysis or lipid oxidation,percentage of patients with appetite improvement,ratio of T-helper cells to T-suppressor cells,weight and LBM gain,Appetite, tiredness, nausea, well-being, caloric intake, nutritional status, and function,loss of weight and lean tissue,cytokine production,plasma EPA levels,quality of life,appetite, tiredness, nausea, well-being, caloric intake, nutritional status, or function,tumor necrosis factor production,LBM,weight, lean body mass (LBM), dietary intake, and quality of life,Global quality of life,mean survival,net gain of weight, lean tissue, and improved quality of life,Palmitate oxidation,Weight gain,baseline appetite,plasma-free fatty acid and triacylglycerol concentrations,whole-body lipolysis, palmitic acid release, or palmitate oxidation,Karnofsky performance status, nutritional state, and survival,weight or appetite better,weight loss,total T cells, T-helper cells, T-suppressor cells, natural killer cells, and the synthesis of interleukin-1, interleukin-6, and tumor necrosis factor by peripheral blood mononuclear cells|There were no significant differences in cytokine production among the various groups, except for a decrease in tumor necrosis factor production in malnourished cancer patients, which was restored by omega-3 fatty acids.
not found|pregnancy rate per cycle,implantation rate,implantation rate (number of gestation sacs per embryo replaced expressed as a percentage,pregnancy and fertilisation rates,Mean associated laboratory time|The implantation rate was higher in the IVF group than in the ICSI group (95/318 [30%] vs 72/325 [22%]; relative risk 1.35 [95% CI 1.04-1.76]).
not found|psychological (hopefulness, hopelessness, self-esteem, self-efficacy and symptom distress) and clinical outcomes (treatment toxicity,feelings of control over their health,internalizing and externalizing behavior problems,psychologic distress,school competence,classmate and teacher social support|A strong relationship was found between the patients' and parents' amount of psychologic distress.
not found|recurrence patterns,OCR,time-to-recurrence of tumor,Probability of cancer-related survival,survival,local recurrence,quality of life, and survival,postoperative recovery,hospital stay, faster recovery of gastrointestinal function, and less use of intravenous analgesia,Quality of life,morbidity, hospital stay, tumour recurrence, and cancer-related survival,social functioning,port site recurrences,hospitalization time,wound recurrence,Conversion of LAC,Preoperative workup, intraoperative results, complications, length of stay, pathologic findings, and long-term outcomes,Flatus,shorter hospital stays,DFS,converted to OC (COC,Overall recovery,Wound complications,operative time,blood loss,safety and efficacy,oral-intake times,long-term complications, quality of life, and survival rate,cumulative recurrence rate,quality of life,incidence of port-site recurrence,incisional hernias,LCR extraction site,forced expiratory volume in 1 second and forced vital capacity,Incision length,anastomotic type, perioperative complication, recurrence, and survival rates,death,perioperative mortality,operative time, blood loss, complications, pathologic findings and lymph node yield, length of postoperative hospital stay, gastrointestinal function, use of analgesic drugs, recurrence, and survival rates,overall morbidity and operative mortality,Survival and disease-free interval,reduced risk of tumour relapse,anastomotic height,probabilities of survival,survival rates,No port-site or abdominal wall recurrences,operation time, administration of parenteral analgesics, start of food intake, and mortality rate,Morbidity,Mean anesthesia duration,Overall quality of life,overall and disease-free survival rates,QoL,probabilities of being disease free,blood transfusion, hospital stay after surgery, length of resected segment and pathological staging,cancer-related survival,number of dissected lymph node,Overall long-term morbidity rate,Mean operation time,Wound infections,Long-term outcomes (3-year overall survival [OS], disease-free survival [DFS], local recurrence, and quality of life [QoL,perioperative morbidity|Morbidity was lower in the LAC group (p=0.001), although LAC did not influence perioperative mortality.
73|incidence of BPD,mean birth weight and gestational age,pulmonary morbidity,BPD,mortality rates, air leaks, bronchopulmonary dysplasia, intraventricular hemorrhage,adverse outcomes,poor outcome (grade IV hemorrhage, cystic periventricular leukomalacia, or death,H2O. Severe neuroimaging abnormalities (PVL and/or grade III-IV IVH,PaCO2,severe IVH/PVL,pulmonary outcomes (occurrence of air leaks, need for oxygen or ventilation,survival, gas exchange, airway pressures, airleak, intraventricular hemorrhage (IVH), periventricular leukomalacia (PVL), and other nonpulmonary complications,mean number of days oxygen was required, number of days ventilated, or length of hospital stay,PaCO2 between CV and HFJV,neonatal mortality or pulmonary morbidity rates,Oxygenation,mortality or morbidity rates,bronchopulmonary dysplasia,peak inspiratory pressure-PEEP,incidence of air leaks,risk of grade III-IV IVH and/or PVL,peak inspiratory pressure and DeltaP,Survival, incidence of BPD at 28 days, retinopathy of prematurity, airleak, pulmonary hemorrhage, grade I-II IVH, and other complications,develop cystic periventricular leukomalacia,Mortality rates,arterial blood gases,positive end-expiratory pressure (PEEP,intraventricular hemorrhage|There were no differences in pulmonary outcomes (occurrence of air leaks, need for oxygen or ventilation at 36 weeks postconception), and there were no differences in the mean number of days oxygen was required, number of days ventilated, or length of hospital stay.
150|Motor function, balance, and ADL (Barthel's Index,functional outcome and quality of life,daily life activities and quality of life,neurologic outcome,neurological score and the Barthel and Sunnaas activities of daily living index scores,functional outcome or life satisfaction,stroke patients' ability to perform daily life activities, their health-related quality of life, and their use of health care and social services,mobility problems,health care and social services,Fugl-Meyer assessment, Barthel Index, and Functional Independence Measure, respectively, at weeks 0, 5, and 10, performed by blinded assessors,motor function, activities of daily living function, walking ability, social activities, and life satisfaction at 3-month and 1-year follow-up,neurologic status,dizziness,balance, mobility, ADL, QL, and days spent at hospitals/nursing homes,quality of life (QL|At 3-month and 1-year follow-ups, no clinically important or statistically significant differences were observed between groups for any of the outcome variables.
95|actuarial TRM,median PRED dose required to achieve complete resolution of acute GVHD,CMV infections,response to treatment and evolution of aGvHD to grade III-IV,response rate,cytomegalovirus (CMV) infections, transplant-related mortality (TRM), and relapse,median interval,chronic GVHD and survival,actuarial survival,CMV infections, TRM, and survival,resolution of acute GVHD,active GVHD,3-year actuarial TRM|The actuarial survival at 3 years was 63% versus 62% (P = .9) with a median follow up of 580 and 778 days.
not found|Plasma sodium level and plasma osmolarity,intraoperative fluid retention,hemodynamic changes and serum electrolyte concentrations,concentrations of sodium, potassium, magnesium, calcium, chloride, lactate, albumin, and phosphate,Magnitude of hypotension,acid-base balance,serum potassium level,plasma sodium, chloride, and osmolality,Systolic and diastolic blood pressure, heart rate, and cardiac index,systolic blood pressure, heart rate, central venous pressure, or arterial blood oxygenation,Arterial pressure (AP) and heart rate (HR,incidence of hypotension,arterial blood pressure and heart rate,pH, Paco2, and serum,serum electrolyte concentrations,occurrence of hypotension,serum sodium,serum osmolality,volume and duration of fluid preload,CO, urine output, or creatinine clearance,number of blocked segments and the total amount of ephedrine,volume of HS,volume of fluid loading,persistent elevation in serum osmolarity,postoperative cellular immune response,osmolar gap exceeded 10mOsmkg(-1), plasma sodium,Blood loss,extracellular volume,perioperative weight gain,metabolic acidosis,serum sodium values,time and the volume of the first micturition,mean arterial pressure,plasma sodium concentrations,mean infused volumes of Ringer lactate solution,number of blocked segments,Serum sodium and osmolality,serum sodium concentration,hyponatremia and hypoosmolarity,Adverse clinical effects,physiologic endpoints: heart rate, blood pressure, and pulmonary capillary wedge pressure,plasma sodium,positive fluid balance,Systemic and pulmonary hemodynamic measurements, oxygen delivery, oxygen consumption, and shunt fraction,systolic arterial pressure,Serum sodium and osmolarity,Phytohemagglutinin-induced lymphocyte proliferation, plasma elastase, and neutrophil chemotaxis,level of anesthesia or maximal heart rate, and electrolyte imbalance,renal free water clearance,body weight,Pulmonary, cardiac, and renal functions,metabolic acidosis of equal extent,systemic hypotension,chest tube drainage,duration of operation, operative blood loss or transfusion requirement,postoperative cellular immune function,arterial hypotension,Heart rate,maintain arterial pressure,leukocyte and differential counts, flow cytometric phenotyping of mononuclear cells, and natural killer cell activity against K 562 tumor cells,Hypotension,stroke index,negative fluid balance,heart rate,thoracic losses,reduction of bicarbonate,serum ADH level,Weight gain until the first postoperative morning,cumulative sodium balance,organ perfusion and patient survival|Serum sodium and osmolarity were significantly greater in the HSL group (P less than 0.001), reaching a maximum of 151 +/-
80|median nerve distal motor latencies and sensory nerve conduction velocity,symptom relief in terms of the Global Symptom Score (GSS), which rates symptoms on a scale of 0 (no symptoms) to 50 (most severe,mean improvement in GSS,Mean grip strength,symptomatic and neurophysiologic outcome,percentage of wrists,severity of CTS,nocturnal paresthesias,visual analog scale score for nocturnal paresthesias,symptomatic improvement|At 6 and 12 months, the percentages of responders were 85.5% versus 76.3% (P = 0.163) and 69.9% versus 75.0% (P = 0.488), for local steroid injection and surgical decompression, respectively.
                
not found|growth of uterine leiomyomas,uterine and leiomyoma size or in Delta size,uterine and non-leiomyoma sizes,length and severity of uterine bleedings,myoma volume,uterine and leiomyoma volumes (Delta size,progression of uterine leiomyomas,leiomyoma-related symptoms,uterine and leiomyoma size,uterine, leiomyoma, and non-leiomyoma sizes,tolerated,severity of the uterine bleedings,uterine and leiomyoma sizes,uterine, leiomyoma and non-leiomyoma sizes, and leiomyoma-related symptoms,uterine leiomyoma size,leiomyoma sizes,leiomyoma volume,Leiomyoma sizes|No significant differences were detected in symptoms related to leiomyomas and hormonal status.
                
28|clinical efficacy and safety,local or systemic toxicity,myasthenia gravis-like syndrome,parasite clearance time (PCT), fever subsidence time (FST) and coma resolution time (CRT,immediate efficacy,motor disabilities, cortical blindness, and afebrile seizures,patient died with complications,Mild, transient pain,times to parasite clearance,time to recovery from coma,parasite and fever clearance times, and the time taken to gain consciousness,median values of parasite and fever clearance times (PCT and FCT,residual neurologic sequelae,body weight, admission parasitemia, hemoglobin and white blood cell count,Hypoglycaemia,cure rates,Mortality rates,Overall, cerebral malaria,peripheral asexual parasitaemia,fever clearance time, coma recovery, or length of hospital stay,parasite or fever clearance time (PCT or FCT,pre-treatment spontaneous hypoglycaemia,Plasmodium vivax parasitaemias,transient pain,adverse effect or toxicity,median time of defervescence,safety and efficacy,Complications,serious side effects,QTc wave prolongation,Adverse effects,tolerated and rapidly effective,rate of parasite reduction,mortality and residual neurologic sequelae,survival rates,tolerated and effective,Parasite and fever clearance times,Mean [SD] fever clearance times,median times for recovery of consciousness,died with pulmonary complications,efficacy,respective median parasite clearance times,risk of death,time taken to clear 50% of parasites,initial parasite density and PCT or FST,mortality rate,left facial palsy,mean parasite clearance times,clinical, haematological, biochemical, or parasitological measures of therapeutic response,adverse reactions,peripheral reticulocyte counts,local reactions,survival rate and side effects,cure rate,parasitological cure rates,curative efficacy,tenesmus,adverse effects,biochemical or ECG changes,serious adverse effects,odds ratio for death,neurologic disease, residual neurologic sequelae,Overall mortality rates and coma resolution times,dizziness and vertigo,mean [SD] parasite clearance time,neurological sequelae,vomiting, dizziness, hypoglycaemia and tinnitus,duration of coma or mortality,survival rate,toxicity,survival advantage,body weight, admission parasitemia, hematocrit and white cell count,Fever clearance times,Temperature defervescence,parasite clearance time,efficacy, tolerability, and delayed neuropsychiatric effects,hospitalization,parasite clearance times,higher risk of hypoglycemia,severe hearing impairment,admission (median Glasgow Coma Score = 9) regained consciousness,time to recovery of consciousness,mortality rates,major adverse drug effects|Clinical and parasitological measures of recovery in survivors were similar in the 2 groups with mean fever clearance times of 37.3 h (standard deviation [SD] = 26.1 h) and 31.5 h (SD = 24.2 h) and mean parasite clearance times of 33.4 h (SD = 13.9 h) and 29.4 h (SD = 12.7 h) in the intravenous and intramuscular groups respectively.
103|Hamilton anxiety scale total score, psychic factor, and somatic factor and the Clinical Global Impression severity and improvement scales,relapse rates,social skills, decreasing anxiety in specific social interactions, and enhancing ratings of social competence,efficacy, safety, and tolerability,Yale-Brown Obsessive Compulsive Scale score,Safety,Psychiatric comorbidity,Children's Yale-Brown Obsessive-Compulsive Scale (CY-BOCS) total score,incidence of insomnia, nausea, agitation, and tremor,Hamilton anxiety scale and the Clinical Global Impression scale,Clinical Global Impressions-Improvement (CGI-I) score,CY-BOCS total score,asthenia, anorexia, pain, and somnolence,vital sign determinations, laboratory findings, or electrocardiographic measurements,response rates,Clinical Global Impression-Improvement Scale and the Children's Yale-Brown Obsessive Compulsive Scale,tolerated, and adverse effects,CGI,NIMH GOCS ,insomnia, fatigue, sedation, and restlessness,Adverse events, including suicidal and homicidal ideation,rate of discontinuation for adverse events,adverse medication effects,response rate,effective and well tolerated,clinical, laboratory, cognitive, and qualitative EEG measurements,tolerated and efficacious,safety and efficacy,composite score for nine delineated items from the generalized anxiety disorder section of a modified version of the Schedule for Affective Disorders and Schizophrenia for School-Age Children,vomiting,insomnia and asthenia,Efficacy and safety,Pediatric Anxiety Rating Scale,depressive symptoms,adverse medical events,tolerated and effective,tolerated except for mild and transient headaches and gastrointestinal side effects,obsessive-compulsive disorder,CGI-I scale,observed and self-reported obsessions and compulsions,self-reports, parent ratings, independent evaluator ratings, and behavioral assessment,efficacy,Children's Yale-Brown Obsessive Compulsive Scale (CY-BOCS) and the Clinical Global Impression-Improvement (CGI-I) scale,Change in CY-BOCS score,height, weight, blood pressure, pulse, and cholesterol levels,Obsessive-compulsive symptom severity,efficacy and tolerability,lower CY-BOCS scores,CGI-OCD,OCD,overall score on the nine delineated items, Pediatric Anxiety Rating Scale, Hamilton Anxiety Rating Scale, Screen for Child Anxiety Related Emotional Disorders, and the severity of illness and improvement scores from the Clinical Global Impression scale (CGI,remission rate,severity of anxiety,CY-BOCS scores,Social Anxiety Scale, child or adolescent version (SAS-CA) and for responder analysis, a (dichotomized,rate of relapse,anxiety symptoms and improving functioning,anxiety disorders,child version of the Yale-Brown Obsessive Compulsive Scale and the National Institute of Mental Health Global rating scale,oppositional defiant disorder,Children's Yale-Brown Obsessive Compulsive Scale (CY-BOCS) and the Clinician's Global Impression-Obsessive Compulsive Disorder scale (CGI-OCD,tolerated,Anxiety disorders,insomnia,acceptable and well tolerated,decreased appetite,Children's Yale-Brown Obsessive Compulsive Scale (CY-BOCS), the National Institute of Mental Health Global Obsessive Compulsive Scale (NIMH GOCS,ratings of elective mutism, anxiety, and social anxiety, rated by clinician, parents, and teachers,Clinician Global Impression-Improvement scale,Clinician and teacher ratings,social distress and behavioral avoidance and increasing general functioning,risk of relapse,OCD response (phase I) and relapse,CGI improvement score <3,treatment-emergent suicidality,anxiety,OCD symptoms,efficacy and safety,Adverse events,adverse events,drowsiness, irritability, and/or oppositional behavior,obsessive-compulsive symptoms,Mean Children's Yale-Brown Obsessive Compulsive Scale (CY-BOCS) scores,generalized anxiety disorder,Children's Yale-Brown Obsessive Compulsive Scale (CY-BOCS,Social anxiety disorder,rate of clinical remission|Fluoxetine was associated with significantly greater improvement in OCD as assessed by the CY-BOCS (p = .026) and other measures than was placebo.
109|bacteriuria infections,urinary tract infections (UTI,occurrence of bacteriuria,postoperative bacteriuria and urinary tract infection,Urinary tract infection,urinary tract infections,infectious rate,Postoperative asymptomatic bacteriuria,Asymptomatic bacteriuria,chronic pyelonephritis,infectious complications,recurrent urinary tract infections,bacteriuria,number of patients developing clinical pyelonephritis, fetal maturity at delivery and birth weight,incidence of postoperative bacteriuria and urinary tract infection,time to occurrence of a symptomatic UTI|Significantly less bacteriuria occurred in the MH-treated patient group.
1000|stress scores,Intimate partner violence (IPV,behavioral adaptation,hide money,symptoms of PTSD and depression,number of subsequent pregnancies, women's educational achievement, use of substances, use of welfare, or children's externalizing behavior problems,sense of mastery and better mental health,superior executive functioning,sensitivity and responsiveness,subsequent pregnancies, participation in education and work, use of welfare, marriage, cohabitation, experience of domestic violence, mental health, substance use, and sense of mastery; observations of mother-child interaction and the home environment; tests of children's language and executive functioning; and mothers' reports of children's externalizing behavior problems,likelihood of a major depressive episode, PTSD, or IPV,Violence scores,mean gestational age,severity of abuse,low birth weight newborns,intimate partner violence recurrence,intimate partner violence and pregnancy outcomes,Severe psychological abuse,episodes postpartum,birth outcomes,health-related quality of life, adoption of safety behaviors, and use of community resources,Provider cueing,initial feasibility, acceptability, and efficacy,domestic violence,advanced language,preterm neonates,IPV discussions,subsequent miscarriages,intimate partner violence,available bank account numbers,neighbors to call police if violence began,recurrent episodes of intimate partner violence victimization|Compared to the control group, the differences were in the predicted direction, but not statistically different.
not found|Wound aetiology,Local reactions,Pain,median VAS pain scores,pain relief,4-point scale and pain from ulcer cleansing on a visual analogue scale,efficacy and safety,Plasma concentrations,pain relief and pain intensity daily,analgesic effect,PIDD5>50 and initial pain intensity,maximum individual concentrations,leg ulcers,pain of debridement,Plasma levels,pain associated with debridement on a 100 mm visual analogue scale (VAS,median patient VAS scores,local reactions,total maximum pain relief score,local reactions or adverse effects on granulation tissue, ulcer area or bacterial flora,pain from cleansing of the leg ulcers and the frequency of post-cleansing pain,wound pain,pain intensity evaluations,Pain control,Analgesic efficacy,severe adverse reactions,verbal rating scale,summed pain relief score ,median number of debridements required for a clean ulcer,pain intensity,pain|No statistically significant differences in local reactions or adverse effects on granulation tissue, ulcer area or bacterial flora were observed in the EMLA-treated patients compared with the control patients.
not found|frequency of thrombosis,risk of thrombosis,sensitivity,deep vein thrombosis,risk for seroconversion,PF4/heparin seroconversion,frequency of HIT|The risk for seroconversion was higher than major versus minor surgery odds ratio, 7.98 [95% confidence interval, 2.06-31.00], P = .003, controlled for potential confounders, as was the risk for HIT (2.2% [95% confidence interval, 0.3%-4.1%] vs 0.0%, P = .010).
50|length of hospitalization,clinical course of TTN,duration of oxygen requirements, the period of tachypnoea and the time to hospital discharge,weight,duration of supplemental oxygen requirement, the period of tachypnoea, time to discharge from hospital and weight loss in the first 24 h of life and before discharge,duration of tachypnea|There were no significant differences between the two groups in the duration of oxygen requirements, the period of tachypnoea and the time to hospital discharge.
                
not found|muscle insulin responsiveness,Mean changes in HbA(1c) values,LDL particle concentration,metabolic variables and adiponectin levels,hemoglobin A1c concentrations,levels of fasting plasma glucose and glycated hemoglobin, insulin sensitivity, and beta-cell function,glycemic control,hepatotoxicity,Glycemic control,fasting plasma glucose,mean BMI,fasting plasma glucose levels,LV end-diastolic volume,body mass index,homeostasis model assessment index improvement,mean fasting plasma glucose and postprandial plasma glucose levels,Individual weight gains,lipid profiles,Hypoglycaemic events,high-density lipoprotein cholesterol levels,Significant TC, LDL-C and Apo B improvement,lower risk of cardiovascular events,Frequency of adverse gastrointestinal events,gastrointestinal events,insulin responsiveness,cholesterolaemia,skeletal muscle glucose uptake,lipid risk factors for cardiovascular disease,plasma adiponectin levels,Homeostasis model assessment index,proinsulin-to-insulin ratio,adverse event,High-sensitivity C-reactive protein levels,high-density lipoprotein cholesterol concentrations,transient side-effects,HbA(1c) response,HDL cholesterol,acute insulin response to glucose,HbA1C,inflammation and subclinical atherosclerosis,plasma resistin levels,plasma aminotransferase activities,mean glycosylated hemoglobin,side-effects,plasma adiponectin concentrations,glycaemic reductions,time to monotherapy failure,disposition index,body mass index (BMI), glycaemic control, lipid profile [total cholesterol (TC), low-density lipoprotein-cholesterol (LDL-C), high-density lipoprotein-cholesterol and triglycerides] and lipoprotein parameters [apolipoprotein A-I and apolipoprotein B (Apo B,Skeletal muscle glucose uptake,LDL particle size,mean CIMT,plasma concentrations of resistin,fasting insulin and proinsulin,cumulative incidence of monotherapy failure,weight gain and edema,glycated haemoglobin decrease,Significant total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglycerides, apolipoprotein A-I, and apolipoprotein B improvement,anthropometric parameters, fasting plasma glucose, HbA1c, total cholesterol, triglyceride, high-density lipoprotein cholesterol, free fatty acids, and adiponectin concentrations,Glycemic durability,synergic action of insulin and exercise,adverse effects (5, early morning hypoglycemia, and 1, anxiety,cardiovascular function and glycemic control,triglycerides, HDL cholesterol, LDL particle concentration, and LDL particle size,LV mass index,ambulatory blood pressure,efficacy and tolerability,plasma glucose levels,regression of maximal CIMT,fasting glucose,fasting plasma glucose (FPG) and HbA(1c,Treatment tolerability,fasting plasma glucose (FPG), haemoglobin A1c (HbA1c), fasting insulin and its precursor peptides, and lipids,HbA1c concentration,fasting plasma glucose values,body mass index, glycated haemoglobin, fasting plasma glucose, postprandial plasma glucose, fasting plasma insulin, postprandial plasma insulin, homeostasis model assessment index, total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglycerides, apolipoprotein A-I, and apolipoprotein B.
                Significant decreases in glycated haemoglobin, fasting plasma glucose, postprandial plasma glucose, fasting plasma insulin, and postprandial plasma insulin,changes in HbA(1c) values (primary) or fasting plasma glucose values (secondary,Triglyceride levels,Maximal CIMT progressed,tolerated,Glycemic index, other clinical profiles, and tolerability,whole-body glucose uptake,change in HbA1C,LDL cholesterol,fasting plasma glucose, HbA(1c), insulin resistance index, and BMI,high-density lipoprotein cholesterol ratios,plasma lipids,cardiac structure or function,exercise-induced increment during insulin stimulation,plasma adiponectin level,HbA1c levels,insulin resistance,Baseline HbA(1c) values,plasma adiponectin,adverse effects (2, ankle edema, and 2, gastrointestinal disturbance,Minor hypoglycaemic events,hsCRP,insulin resistance and proinsulin levels,Significant BMI decrease,hyperglycemia,recovery of pancreatic beta-cell function,beta-cell function,weight and serum lipids,efficacy and safety,Metabolic effects,plasma levels of adiponectin,Ejection fraction,glucose and lipid variables and tolerability,ambulatory diastolic blood pressure,Left ventricular (LV) mass index, ejection fraction, and left ventricular end-diastolic volume,change in hsCRP and maximal CIMT,symptomatic hypoglycaemia,plasma insulin, proinsulin, split proinsulin and free fatty acid levels,Mean FPG levels,peripheral insulin sensitivity,change in hsCRP,skeletal muscle or whole-body insulin sensitivity,fasting plasma insulin and postprandial plasma insulin,lipid and lipoprotein variables,mean values for plasma HbA(1c) concentration,lipid metabolism,fasting plasma glucose, fasting proinsulin, and insulin levels; frequently sampled intravenous glucose tolerance test; and glucagon stimulation test for C-peptide,hypoglycemia,glucose and lipid parameters,durability of the treatment effect,transaminases,body mass index (BMI), glycemic control (glycosylated hemoglobin [HbA(1c)], fasting and postprandial plasma glucose and insulin levels [FPG, PPG, FPI, and PPI, respectively], and homeostasis model assessment index), lipid profile (total cholesterol [TC], low-density lipoprotein cholesterol [LDL-C], high-density lipoprotein cholesterol [HDL-C], and triglycerides [TG]), and lipoprotein variables (apolipoprotein [apo,mean plasma adiponectin level,HbA(1c) and FPG,HbA1C and fasting plasma glucose,hsCRP levels,glycaemic control|After 6 months of treatment, the reduction in plasma glucose levels was similar between the 2 groups.
not found|global impression of improvement,rate of decline of vital capacity,adverse events, including dysphagia|There were no significant adverse events, including dysphagia, in the BTxb group, and there was no significant increase in the rate of decline of vital capacity.
41|Skin temperature,Digital Skin Temperature (DST), Digital systolic Blood Pressure (DBP) and Doppler Spectral Analysis (DOSA) of the radial and ulnar arteries,number and severity of Raynaud's attacks,cutaneous blood flow,mean daily frequency and severity of winter ischemic attacks,frequency and duration of the attacks (both per se and combined to a severity score), cold sensation, numbness, paresthesia, pain, cold water and cold weather provocation and the appearance of spontaneous attacks,hypertension both systolic and diastolic blood pressure normalized,blood chemistry nor systemic blood pressure,frequency or severity of attacks of Raynaud's phenomenon,mean two-week episode rate,diastolic blood flow velocity of DOSA,severity score, the occurrence of numbness and paresthesia and cold weather provocation,efficacy and acceptability,side effects,visual analogue scales, 5 point rating scales, and skin temperature response|The severity score, the occurrence of numbness and paresthesia and cold weather provocation improved significantly on ketanserin treatment.
49|Modest mean weight loss,relapse rate,Relapse assessed monthly and defined as re-emergence of psychotic symptoms (delusions, conceptual disorganisation, hallucinations, suspiciousness, and unusual thought content,time to recurrence,efficacy, safety, and tolerability,Positive and Negative Syndrome Scale (PANSS) efficacy variables,extrapyramidal symptoms,second psychotic relapse,Extrapyramidal symptoms and insomnia,safe and well tolerated,haloperidol plasma concentration,Steady state,brief psychiatric rating scale (BPRS), the scale for the assessment of negative symptoms (SANS), the clinical global impression (CGI) severity and improvement scales, and the Simpson and Angus scale for extrapyramidal symptoms (EPS,incidence of clinically significant weight gain,Extrapyramidal symptoms,Mean fluphenazine levels,relative risk of relapse,relapse risk,longer time to relapse,incidence of treatment-related adverse events (AEs,plasma concentrations of haloperidol,probability of relapse (Kaplan-Meier,Incidence of relapse/impending relapse,rate of discontinuation due to adverse or serious adverse events,relapse,recurrence,notable plasma fluphenazine levels,Prolactin levels,Relapse,dyskinesia scores and dysphoria,hazard ratio (placebo/paliperidone palmitate,LEDS scale,delayed time-to-relapse,relapse of schizophrenia,Injection site tolerability,mean rate of life events,dyskinesia and symptom measures,mean Clinical Global Impressions-Global Improvement scale scores,Time to relapse/impending relapse,time to relapse following randomization,mean steady-state level,efficacy and tolerability,hyperprolactinemia or prolonged heart rate-corrected QT interval (QTc,sedation, EKG and liver function abnormalities,rate of relapse,6-month cumulative estimated relapse rate (Kaplan-Meier,dyskinesia and dysphoric mood,Serum prolactin levels,insomnia,dyskinesia ratings and symptom measures,Estimated risk of relapse,relapse and readmission to hospital,PANSS total, PANSS positive, PANSS-derived Brief Psychiatric Rating Scale, and Clinical Global Impressions-Severity of Illness scale (CGI-S) scores,plasma fluphenazine levels,Time to relapse,Headache and restlessness,remission state,weight decrease,frequency of relapse,level of EPS,risk of relapse,schizophrenia relapse,psychosocial distress,cumulative relapse-free survival,Positive and Negative Syndrome Scale and the Clinical Global Impressions-Severity of Illness Scale) and discontinuation for any reason,anxiety,time to relapse,increased weight,time to first schizophrenia relapse,psychotic relapse,extrapyramidal symptom-related AEs,Brief Psychiatric Rating Scale (BPRS) positive item cluster or rehospitalization due to positive symptoms,sedatives,risk of relapse at six months,Time-to-relapse,number of days of remission,Times to relapse/impending relapse and discontinuation,incidence of glucose-related adverse events,mean haloperidol plasma concentration,delaying time-to-relapse,PANSS negative symptom subscale,weight gain or cardiovascular abnormalities,schizophrenic symptoms,mean weight,number of symptom-free days dose,estimated 26-week risk of recurrence,Brief Psychiatric Rating Scale,Social adjustment ratings|A poor outcome at 2 years was associated with male sex, poor outcome after the first 5 weeks of the first admission, negative schizophrenic symptoms on first admission, and a diagnosis of definite or probable schizophrenia using the Feighner criteria.
not found|FVC,clinical status and PFT,sputum production or change in lung function,Clinical score (CS,spirometric measures, numbers of hospitalizations, use of oral or IV antibiotics, or anthropometric measurements,severity of illness (mean National Institutes of Health score,Coughing,forced expiratory volume,efficacy and safety,admission, clinical status and pulmonary function tests (PFT,forced expiratory volume at 1 second, forced vital capacity, and forced expiratory flow,sputum production, symptom score or peak expiratory flow rate,Pulmonary function and exercise response,forced expiratory flow,complications, including hemoptysis, hypoxemia, and pneumothorax,mean annual rates of decline,mean annual rate of decline for forced expiratory flow,mechanical percussion,pulmonary function,heart rate and arterial oxygen saturation response,Shwachman clinical score,hospital admission to discharge,Complete pulmonary function tests (PFTs,symptom scores, sputum production, or simple lung function tests,pulmonary function and exercise response,FEV(1,vital capacity,lung function and anthropometric measures,Clinical status and pulmonary function (forced vital capacity [FVC], FEV1, and FEF25-75|No difference was shown in symptom scores, sputum production, or simple lung function tests.
not found|turbidity, thereby improving water aesthetics,diarrheal morbidity,incidence rate of diarrhoea,incidence and severity of diarrhea,Mothers' personal and domestic hygiene and diarrhoea incidence,geometric mean of faecal coliform levels,severe nutritional deficit,Diarrhoea rates,Feasibility and efficacy,diarrhoeal incidence,incidence of diarrhoea,Monthly water quality testing and weekly diarrhoea surveillance,episodes of severe diarrhoea,episodes of diarrhoea,Campylobacter,lowest diarrheal rate,diarrheal rates,Diarrhea,mortality rate to diarrhoea,incidence rate ratio of disease,diarrhoeal morbidity,performance of duties,occurrence of diarrhoea,incidence of diarrhea diseases,E. coli contamination of stored water and less diarrhoea,Compliance,diarrhoea,percentage of intervention households storing water safely,prevalence of diarrhoea,rates of diarrhoea,free of thermotolerant coliforms,Occurrence and severity of diarrhoea,diarrhoea episodes,Diarrheal disease risk,diarrhea,diarrhoeal diseases,water quality,childhood diarrhoea,baseline diarrhoea, prevalence of diarrhoea,days of work or school lost due to diarrhea,highly credible gastrointestinal illness" (HCGI,incidence of diarrhea,risk of severe diarrhoeal disease,risk of diarrhea,yearly diarrhoea incidence,diarrhoea rates,water pressure,diarrhea frequency and severity,risk of diarrhoea,diarrhoea, including dysentery and persistent diarrhoea,diarrhea episodes,diarrheal illness,feasibility, acceptability and effect,diarrhoeal disease,Annual incidence of diarrhoea,water quality and childhood diarrhoea,ratios of cost to benefit,mean faecal coliform level,visible blood or mucus in stools,diarrhoea incidence|Water filters eliminated thermotolerant (faecal) coliforms from almost all intervention households and significantly reduced turbidity, thereby improving water aesthetics.
not found|IOP,Glaucoma control,Mean number of ocular hypotensive medications,mean IOP,visual acuity,corneal endothelial cell count,final visual acuity,subsequent cataract surgery,visual field examination, diurnal intraocular pressure (IOP) curves, gonioscopic appearance, and number of antiglaucoma medications,Mean postoperative IOP,Mean preoperative IOP|The visual acuity was not worsened in any eyes and became better than 2 Snellen lines in 14 eyes.
448|changes in different dimensions of psychopathology, side effects, compliance, social needs, quality of life, substance abuse and cognitive functions,Response rate,cognitive impairment,executive skills and visuomotor tracking and on the average of the 6 cognitive domains,prolactin secretion,control prolactin (PRL) levels,Side effect occurrence,weight or glucose metabolism,elevated serum prolactin concentrations,total BPRS score,total Brief Psychiatric Rating Scale (BPRS) or Clinical Global Impression scores,BPRS ratings,motor skill, attention span, verbal reasoning and fluency, visuospatial construction and fluency, executive skills and visuomotor tracking, and immediate recall of verbal and nonverbal materials,mean serum prolactin concentration,general clinical status,PANSS total score,ESRS dyskinesia,EPS ratings on the Simpson Angus Scale,galactorrhea,retention in treatment, defined as time to discontinuation of study drug,benztropine use, medication side effects, or changes in symptomatology,PRL levels,Brief Psychiatric Rating Scale (BPRS), Clinical Global Impression (CGI), and Modified Scale for the Assessment of Negative Symptoms (SANS) summary scores,Positive and Negative Syndrome Scale (PANSS) scores and Clinical Global Impression (CGI,negative symptoms,serum prolactin,Dyskinesia,executive function, memory and attention,clinical signs,severity of tardive dyskinesia,Brief Psychiatric Rating Scale (BPRS) scores,adverse events,Neuropsychological change,positive syndrome, the negative syndrome, depression ratings or cognitive skills,Serum prolactin levels,CGI dyskinesia,BPRS total, BPRS positive-symptom cluster, and CGI Severity of Illness item scores,Extrapyramidal Symptom Rating Scale (ESRS) dyskinesia subscale scores and the Clinical Global Impression (CGI) dyskinesia scores,overall cognitive function,cognitive skills, particularly verbal reasoning and fluency skills and immediate recall,Severity of Illness and Global Improvement scores,serum prolactin (PRL) levels,Simpson Scale and Abnormal Involuntary Movement Scale scores,EPS, weight, serum prolactin level, and glycosylated hemoglobin level,PRL secretion,executive function (Verbal Fluency Test, p<0.04), attention (Stroop Color Word Test, p<.03) and verbal memory (Paragraph Recall Test, p<0.02,positive symptoms,PRL level,psychosis and mood without inducing extrapyramidal symptoms,Brief psychiatric rating scale (BPRS), Positive and negative syndrome scale (PANSS), and Extrapyramidal symptoms rating scale (ESRS|Both quetiapine and haloperidol produced a clear reduction in the Positive and Negative Syndrome Scale (PANSS) scores and Clinical Global Impression (CGI)
12|shunt surgery,endoventricular fibrinolysis,rebleeding, ventriculitis or meningitis|Our results show that the percentage of shunted babies was identical in treated and control patients despite the enhancement of endoventricular fibrinolysis obtained in all treated patients.
not found|patient mortality,mean age+/-SD,respiratory failure and reducing mortality,mortality rate|The mortality rate (85.7%, six of seven) of the control group was higher than that of the study group (31.3%, five of 16; p = .0272).
                
not found|schizophrenic relapse,Response rate,greatest deterioration,total AIMS score,weight or glucose metabolism,relapse rates,cumulative relapse rates,Severity of relapse and total cumulative dosage,ESRS dyskinesia,tardive dyskinesia,deterioration of schizophrenic and depressive features and cis(z)-flupenthixol plasma levels,morbidity,Dyskinesia,Prolactin levels,severity of tardive dyskinesia,Serum prolactin levels,CGI dyskinesia,Extrapyramidal Symptom Rating Scale (ESRS) dyskinesia subscale scores and the Clinical Global Impression (CGI) dyskinesia scores,EPS, weight, serum prolactin level, and glycosylated hemoglobin level|An experimental method was utilized to compare the masking effects of two neuroleptic agents--molindone and haloperidol--on 18 neuroleptic-treated schizophrenic patients exhibiting operationally defined withdrawal-exacerbated tardive dyskinesia.
not found|total score,Brief Psychiatric Rating Scale assessments|Schizophrenia is often characterized by compromised neuropsychological functioning, especially on tasks sensitive to frontal and temporohippocampal functions but the extent to which cognitive dysfunction can be modified in schizophrenics remains unclear.
96|active quality of living subscale of the Childhood Asthma Questionnaire,active quality of life score,subscales of the same questionnaire, peak flow rates, use of medication, symptom scores, days off school, asthma events, global assessment of change, and adverse reactions|There were no clinically relevant or statistically significant changes in the active quality of life score.
not found|thyroid-stimulating hormone serum levels, iodine excretion, and thyroid volume,Salt iodine content,Neck circumference,thyroid size,iodine excretion,urinary iodine excretions,thyroid volume,Thyroid gland size,mean iodine concentration,Goiter prevalences,Iodine excretion,goitre prevalence and iodine excretion,iodine deficiency,mean iodine concentrations,median urinary iodine excretions,median urinary iodine|During the same period, goitre prevalence remained unchanged in the control zone, which received plain, unfortified salt.
not found|nasal polyp size,improvement of all SF-36 domains,symptoms and objective clinical and biological parameters,physical component summary,quality of life,levels of myeloperoxidase, ECP, and matrix metalloproteinase 9 in nasal secretions,Markers of inflammation such as eosinophilic cationic protein (ECP), IL-5, myeloperoxidase, matrix metalloproteinase 9, and IgE,size of nasal polyps, nasal symptoms, and mucosal and systemic markers of inflammation,polyp size,modified 31-item Rhinosinusitis Outcome Measure questionnaire, physician's assessment, nasendoscopy with photography, and MRI,MRI,nasal peak inspiratory flow and symptoms and by nasal endoscopy,Nasal obstruction, sense of smell, and polyp size,Severe nasal polyposis,nasal symptoms,Concentrations of eosinophils, ECP, and soluble IL-5 receptor alpha,levels of ECP, IL-5, and IgE in nasal secretions|Patients with nasal polyps showed worse scores on all SF-36 domains, except for physical functioning, compared to the Spanish general population.
38|hematologic and neurologic improvement and changes in serum levels of cobalamin,hemoglobin levels,sensitive peripheral neuropathy,Therapeutic effectiveness,Tolerability,presence of reticulocytosis,tolerated,alteration of cognitive function (loss of memory, impaired concentration,mean serum vitamin B12 concentration,mean white blood cell count,mean pretreatment values for serum cobalamin, methylmalonic acid, and homocysteine,Neurologic sensory assessment, including soft-touch and pinprick examinations,loss of sense of vibration,mean platelet count,Neurologic improvement,higher serum cobalamin and lower serum methylmalonic acid levels,Reticulocytosis,Correction of hematologic and neurologic abnormalities|The higher serum cobalamin and lower serum methylmalonic acid levels at 4 months posttreatment in the oral group versus the parenteral group were significant, with P < .0005 and P < .05, respectively.
183|nausea,relapse rate,Craving (Visual Analogue Scale; Obsessive and Compulsive Drinking Scale) and withdrawal (Clinical Institute Withdrawal Assessment) rating scales,relapse rates,consecutive weeks of abstinence and less craving,efficacy, safety, and tolerability,Overall, rate and time to treatment discontinuation,percentage of days on which drinking occurred and the number of drinks per drinking day,time to first heavy drinking day,time to first relapse,time to first drinking day, time to first day of heavy drinking,safe and well tolerated,high retention and adherence to therapy and medication,Obsessive Compulsive Drinking Scale,self- and objective reports of substance use, treatment retention, medication compliance, and adverse effects,Medication compliance,cumulative abstinence duration and weeks of heavy drinking,alcohol craving and consumption,alcohol drinking and eating disorder features,Alcoholics Anonymous attendance,alcohol craving (OCDS total score: P: < 0.05; Obsessive subscale score,drinking activity and trough plasma concentrations of naltrexone and its primary metabolite, 6-beta-naltrexol,Alcohol Dependence Scale (ADS) and Depression Anxiety and Stress Scale (DASS,levels of liver enzyme activities,alcohol craving,cognitive resistance,percent days drinking, average drinks per drinking day, average drinks per day, heavy drinking days (four or more for women and six or more for men), and time to first heavy drinking day,relapse into heavy drinking,Relapse rate; time to first relapse; side effects,medication dosage, length of treatment, sample size and attrition rate,cumulative abstinence duration,alcohol drinking,abstinence rates,alcohol use, medication adherence, and adverse events,medication compliance,alcohol consumption,treatment exposure or medication compliance,total abstinence,alcohol-drinking indices,drinking outcomes,safety and tolerability,compliance and adverse clinical events--with the exception of the gamma-GT,somatization,dropout rate,serum GGT activity,Compliance,drinking relapses,tolerated and efficacious,changes in serum biological markers (alkaline phosphatase, alanine transaminase, aspartate transaminase, and gamma-glutamyltransferase), craving, and psychosocial functioning,craving score,frequency of heavy drinking days,safety and efficacy,drinking days, heavy drinking days,abstinence rate,drinking measured by the time line follow-back method, craving using the Tiffany Craving Questionnaire, psychotic symptoms using the Positive and Negative Symptoms Scale (PANSS), side effects and a measures of abnormal involuntary movements,rates of cocaine and alcohol use and drug severity,drinking behavior,Alcohol consumption, craving, carbohydrate-deficient transferrin, medication compliance by tablet count, and adverse clinical events,insomnia, dizziness, and confusion,psychiatric symptoms, alcohol craving, g-GGT levels and adverse events,Adverse effects,relapses to heavy drinking,drinking and alcohol-related problems, including abstention rates, number of drinking days, relapse, and severity of alcohol-related problems,lower weekly urge ratings,Efficacy and tolerability,craving symptoms,time to first drink, amount of alcohol consumption, intensity of craving, severity of alcoholism problems, and liver enzymes,median time to relapse,adverse events (nausea and headache,Drinking days and heavy drinking days, alcohol craving, liver enzymes, and manic and depressed mood symptoms,alcohol use and gamma-glutamyl transpeptidase level,percent days drinking, average drinks per drinking day, average drinks per day, heavy drinking days, and time to first heavy drinking day,alcohol consumption and depression,drinking-related outcomes,craving scores,alcohol consumption, craving, and biologic markers of drinking (carbohydrate-deficient transferrin and gamma-glutamyltransferase,cocaine and alcohol use and drug severity,Time to first drink, time to relapse, and the cumulative abstinence time,survival function,symptoms of eating pathology,adverse neuropsychiatric and gastrointestinal effects, poorer compliance,medication adherence,bioavailability, tolerability, and potential efficacy,Significant side effects (nausea,cocaine (urine screens) and alcohol use (timeline followback,frequency of any self-reported adverse effects or in liver enzyme values,NTX plasma concentrations,efficacy and tolerability,outcome regarding time to first drink and time to relapse,Zung Depression, Zung Anxiety, MMSE, OCD Screener, Craving, and Somatization,Levels of blood markers of alcohol abuse,Discontinuation due to adverse events,number of days to relapse,Craving and psychiatric symptom improvements,odds ratio of relapsing to heavy drinking,rate of relapse,aspartate aminotransferase, alanine aminotransferase, and gamma-glutamyltransferase,urge, self-efficacy (confidence about staying abstinent in risky situations), and self-reported coping skills,quality of life,time to first episode of heavy drinking; secondary efficacy assessments included time to first drink, alcohol consumption, craving, and changes in the serum biological markers gamma-glutamyl transferase (GGT), and aspartate and alanine aminotransferases,tolerated,episode of heavy drinking,nonrelapse rates,Alcohol consumption, craving, adverse events, and urinary riboflavin levels,craving,risk of a heavy drinking day,relapse prevention of alcoholism,number of subjects relapsed,alcohol relapse,family loading of alcohol problems,mood symptoms,drinking outcomes of EOA,subsequent relapses,medication compliance rates,heavy drinking days, craving, gamma-glutamyl transferase, and carbohydrate-deficient transferrin concentrations,cumulative rate of abstinence,heavy-drinking days,drinking days,Side effects,dizziness,potential value and acceptable tolerability,rate of adverse events,heavy drinking,Time to the first drink, time to first relapse, drinks per drinking day and cumulative abstinence,pain from arthritis,time to first heavy drinking as derived from self-reports of drinking (timeline-follow-back method,risk of relapse,cocaine use and alcohol use,headache,maintenance of abstinence and relapse to drinking,mean time period,efficacy and safety,number of adverse events,biochemical markers of heavy drinking or alter liver function markers,heavy drinking days,rate of treatment attrition,self-efficacy,adverse events,abdominal pain,drinking days (binary outcome), alcohol craving, and some liver enzyme levels,coping skills, lower urge, and higher self-efficacy,number of drinks/drinking day,Drinking outcomes,alcohol craving (Obsessive and Compulsive Drinking Scale: OCDS,percentage of cocaine-positive urine screens,Drinking reductions,consumption of alcohol,beta-endorphin levels,Alcohol consumption, craving, adverse events, and changes in the biochemical markers of heavy drinking and possible toxicity,Time to First Heavy Drinking Day and Total Abstinence,drinking, craving or biochemical markers,event rate of heavy drinking days,side effects,number of drinking days, heavy drinking, and time to relapse to alcohol use|Naltrexone treatment was associated with significantly more adverse neuropsychiatric and gastrointestinal effects, poorer compliance, and a greater rate of treatment attrition.
101|lower urinary tract disease symptom score (LUTDSS), the International Prostate Symptom Score (IPSS), the Quality of life assessment index, the maximum flow rate (Q(max,international prostate symptom score (IPSS) and urodynamic parameters,voiding symptoms and LUTDSS,IPSS, QoL, uroflowmetry values or PFS values,Q(max,maximum urinary flow,score of the daytime frequency,average flow rate, changes in the IPSS storage score, IPSS voiding score, and quality-of-life (QoL,mean total IPSS, the total storage and voiding symptom scores,Index score,detrusor overactivity,uroflowmetry values and changes in other PFS values,storage symptom score of the frequency to the combined score of daytime frequencies and the score of nocturia,cystometric capacity,International Prostate Symptom Score,daytime frequency and nocturia,Baseline symptom scores,intermittency, nocturia and quality of life scores,score of nocturia,disappearance of involuntary contraction,volume at first desire and maximum desire to void,systolic and diastolic blood pressure,efficacy and safety,average and maximum flow rate and bladder capacity,quality of life score,residual urine volume,International Continence Society nomogram grade,blood pressure,therapeutic effects,total International Prostate Symptom Score (IPSS), maximum flow rate on free uroflowmetry, and residual urine volume,LUTDSS and the IPSS,RUV,symptomatic and urodynamic parameters,clinical efficacy or adverse effects,IPSS and QoL,nocturia,score of daytime frequency,voiding symptoms,Maximum flow rate (Qmax) and residual urine volume (RUV,adverse effects,lower urinary tract symptoms,relieving nocturia,Involuntary contractions,International prostate symptom score (IPSS) and quality of life (QOL) index,LUTS (IPSS), quality of life (QoL), uroflowmetry, and pressure-flow study (PFS) values,frequency of adverse reactions,storage and voiding symptoms,median post-therapeutic RUV,bladder outlet obstruction,overall efficacy,storage symptoms|Maximum flow rate (Qmax) and residual urine volume (RUV) tended to improve in both groups, again with no marked differences between groups.
279|adverse events, changes in visual acuity, and biomicroscopy and ophthalmoscopy findings,clinical resolution and microbial eradication at Visit 3 (Day 8 or 9), individual clinical outcomes at follow-up visits, and safety,conjunctivitis episodes,clinical resolution of the baseline infection,pinhole visual acuity testing, biomicroscopy, and culture of the infected eye(s,Antibacterial effectiveness,microbiological success rate,various bacterial pathogens,incidence of ocular AEs,rates of bacterial eradication,recovery rates,clinical resolution and bacterial eradication of the baseline bacterial infection,efficacy and tolerability,microbial eradication rates,clinical cure,eye irritation,Conjunctival cultures,recovery rates in culture-positive and culture-negative patients,Ocular AEs,Streptococcus pneumoniae,bacterial pathogen,Clinical resolution and microbial eradication,prevalence of a positive bacterial culture,Survival statistics,effective and well tolerated,bacterial eradication rates, a survival time analysis of the duration of symptoms,clinical resolution and bacterial eradication rates,Adverse events,clinical resolution and bacterial eradication of the baseline bacterial infection at visit 3, individual clinical outcomes (ocular conjunctival discharge and bulbar conjunctival injection) at the follow-up visits, and microbial and clinical outcomes for overall bacterial species and individual gram-positive and gram-negative bacterial species,safety and efficacy,clinical resolution and eradication of the baseline bacterial infection on day 8 in culture-confirmed patients,efficacious and well tolerated,adverse events, slit-lamp findings, and ophthalmoscopy,eye pain,adverse events,Bacterial eradication rates,bacterial eradication rate,allergic conjunctivitis,conjunctivitis,Adverse experiences,Efficacy and tolerability,blurred vision,antibacterial efficacy,Tolerability assessments included ocular adverse events (AEs), changes in visual acuity, biomicroscopy and ophthalmoscopy findings, and nonocular AEs,clinical and microbiologic efficacy,clinical resolution of signs and symptoms (rating of zero on ocular discharge, bulbar and palpebral injection,cure rates,clinical resolution and bacterial eradication,adverse event rates,cumulative frequency of adverse events,bacterial conjunctivitis,clinical resolution and microbial eradication of baseline bacterial infection,Microbiological efficacy,Clinical cure,rates of clinical resolution,visual acuity,times of medication instillation,median duration of symptoms,visual acuity and biomicroscopy and ophthalmoscopy findings,Rates of bacterial eradication,Staphylococcus aureus|Clinical resolution with azithromycin ophthalmic solution was statistically significant compared with that of vehicle (P = .030) at visit 3.
57|strength, gait, balance and quality of life,body composition,VO(2)max, body weight, and height,S- and SE-induced muscle hypertrophy,strength and function,extension and flexion strength of the right and left legs, the 50-foot walk time, range of motion at the knee joint, the Osteoarthritis Screening Index (OASI), and the Arthritis Impact Measurement Scale (AIMS,right quadriceps strength,bone mineral density (BMD,dynamic leg strength and the BMD of the femoral neck, Ward's triangle, and the lumbar spine,muscle strength and endurance time,lean tissue mass,IGFBP-1/IGF-1 and IGFBP-3/IGF-1 ratios,functional fitness,KE maximal strength, KE endurance, and functional performance as assessed by 6-minute walking, chair-rising, and stair-climbing tests, and by self-reported disability,Isokinetic strength measurements,handgrip strength,body composition and metabolism,strength increased for EX,right sided quadriceps strength,Mean FRT results,strength changes,high-density lipoprotein (HDL) cholesterol and low levels of low-density lipoprotein (LDL) cholesterol,function and disability,immune function,lower extremity strength, function, and disability,VO2peak, muscle strength, LV morphology, and diastolic filling,bone mineral density,LDL cholesterol and total cholesterol,Compliance rates,proportion of type IIB/AB fibers,peak power per kg body weight,Relative VO2peak,Peak power,HI maintained BMD,nonparetic ankle PF,Maximal strength,body weight,strength and functional mobility,Cross-sectional area of type II muscle fibers,physical health or falls,Muscle hypertrophy response,steadiness (isometric, shortening or lengthening contractions) changes,1-RM,Absolute counts of lymphocyte subsets (CD20+, CD3+, CD3+CD4+, CD3+CD8+, CD3-CD56+CD16, Cross-sectional area (CSA) of quadriceps assessed by MRI, isometric and isokinetic knee extension strength, isometric trunk strength, leg extension power, normal and maximal gait-speed on a 30 m track, stair climbing time, number of chair stands in 30 s, lung function (FEV1) and self-reported health,muscle size, knee extension strength, leg extension power, functional performance and self-reported health,LP and KE 1RM muscle strength,6-minute walk, stair-climb time, repeated chair-rise time, and habitual and maximal gait velocities,self-reported function and disability,physical health status,IL-6 levels,knee joint pain,repetition maximum leg press strength,quality of life (assessed by the short form-36 questionnaire) and body composition (measured by dual x-ray absorptiometry scan,baseline strength or mobility values,strength, whole muscle size, and specific force,dorsiflexion,perceived anger, tension, and overall social functioning,Changes in strength,VO2max,functional reach,stair ascent and descent performance,muscular strength, body composition (percent fat and lean tissue mass), and program adherence,skeletal muscle strength and endurance, VO(2peak), FBF, and HRV,safety and efficacy,MHCIIx,postural control,Weight change, quadriceps strength, gait speed, quality of life and health care utilization,health-related quality of life,transcript levels of isoforms of MHC (MHCI, MHCIIa, and MHCIIx,muscular strength, anaerobic power, and mobility,physical and cognitive function,SF-36 Health Survey questionnaire and self-reported physical activity,Strength and mobility,muscle strength, self-reported function, and disability,Strength gain,Average peak power,physical activity,dyspnoea and mastery of daily living activities,higher quality of life,lean body mass,muscle endurance,number of capillaries per fiber perimeter length,muscle function, functional limitations, and self-reported disability,dynamic muscle strength, muscle size, and functional capacity,peak concentric work and concentric power,peak aerobic power (VO2peak), muscle strength, left ventricular (LV) morphology, and diastolic filling,interference from fatigue on activities of daily living,Adherence,dynamic steadiness,body fat content,isometric muscle strength and walking speed,left ventricular morphology and systolic function,PER,insulin-like growth factor-1 (IGF-1) bioavailabilty,BMD,VO2peak,Mean protein intake,plasma lipoprotein levels,perceived vigor,bilateral leg press,Dynamic strength,Total body potassium and type,resting metabolism or fat oxidation (resting or postprandial,Maximal walking speed,10 repetition maximum leg press and calf press strengths,unilateral biceps curl,strength, anaerobic power, and mobility,PF and dorsiflexion (DF) isometric MVC torques,physical function,transcript levels of MHCI,KE strength and endurance and the 6-minute walking test,Dynamic muscle strength,Muscle mass, muscle strength, and dynamic balance,muscle size and strength and type I single-fiber size and contractility,Isotonic muscle strength,Walk training,fractional synthesis rate (FSR) of MHC,thigh muscle strength, fiber cross-sectional area (CSA), and tissue composition,Muscle strength,peak oxygen consumption (VO2) and the onset of claudication pain,isokinetic and concentric strength,resting lymphocyte subsets and stress hormone concentrations,strength, morale, and quality of life,Maximal gait velocity and chair rise time,maximal gait speed: 14%, stair climbing time: 17%, isometric trunk flexion: 5% and self-reported health,IGFBP-1 and IGFBP-3 levels,mean (+/-SE) time to climb and descend stairs,control lipoproteins,KE,health-related quality of life and changes in the domains of pain and physical function,nonparetic KE,exercise capacity and quality of life and reduces catecholamine levels,knee extensor position fluctuations,chair stand time,maximum oxygen uptake,Peripheral blood mononuclear cell (PBMC) subpopulations, cytokine and prostaglandin (PG) E2 production, proliferative response, and delayed type hypersensitivity (DTH) skin response,left quadriceps strength,strength tests and HRQOL,balance, endurance, or disability measures,rhGH and muscle strength,peak isometric and isokinetic (concentric and eccentric) knee extensor strength, concentric work, concentric power, stair ascent and descent, and gait speed,6-min walk distance,health outcomes,Resistance exercise and bone turnover,Bone mineral density (BMD) of the femoral neck,sit-and-reach performance, elbow flexion, knee flexion, shoulder flexion and extension and hip flexion and extension,maximum knee torque,strength took place,muscle strength, psychological well-being, and health status,Functional performance,Single-repetition maximum strength,Percent body fat of weight trainers,knee extension and flexion, hip abduction and extension, and plantar and dorsiflexion,total body, femoral neck, and lumbar spine,Leucine oxidation and serum prealbumin levels,ankle joint stability,isometric knee extensor strength (IKES), isometric elbow flexor strength (IEFS), handgrip strength (HGS), leg extensor power (LEP), and anthropometric indices (Body impedance analysis, arm muscle circumference, and body weight,SF-36 physical functioning score,skeletal muscle strength and endurance, aerobic power (VO(2peak)), heart rate variability (HRV), and forearm blood flow (FBF,knee extensor steadiness adaptations,arthritis activity,Electromyographic (EMG) activity,strength and health-related quality of life (HRQOL,resting metabolism or fat oxidation rates,dynamic strength, exercise capacity, muscle, and bone,measures for domains of upper body strength,outpatient clinic visits,resting cardiac indexes,elbow flexion and knee extension dynamic strength,LV morphology and diastolic filling,overall measured physical function score,elbow flexion and knee extension dynamic and isokinetic strength,higher levels of upper body,contractile RFD,Summed peak moment,neuromuscular performance,gait speed and chair stand,performance of functional activities,depression scores,Significant weight loss,walk speed and self efficacy satisfaction,depressive status,MMSE,gait velocity and chair rise time,knee extensor strength,mental or physical health functioning,muscle strength,lower extremity strength, physical performance, and disability,time to descend and ascend stairs,cycle ergometer peak power,Resting IGF-1 levels,Serum CRP levels,nadir serum testosterone concentration,Muscle strength, plasma levels of TNF-alpha, soluble TNF receptor (sTNFR)-1, and interleukin (IL)-6,strength and health-related quality of life,disability, physical performance, and pain,KE torque and KE torque/body mass,eight repetition maximum of all RT exercises,muscle strength, 24-hour urinary creatinine for muscle mass, and backward tandem walk for dynamic balance,bone turnover,leg press and bench press maximal strength,self-reported physical functioning score,older adults' health-related quality of life (HRQOL) and habitual physical activity,back pain and its related disability and health-related quality of life,strength and exhibited less frequent progressive JSN,isokinetic knee extension strength,Weight and diet,peak walking time,Maximal isometric knee extension torque,GDS scores,CD3+, CD3+CD4+, or CD3+CD8+ cells,leg press peak power and leg extensor strength,faster times on the lifting and carrying task,resting adrenaline, noradrenaline and cortisol concentrations or distributions of lymphocyte subsets,fat-free body mass,Stair-climbing power,midthigh cross-sectional muscle area,mixed muscle protein,strength and functional performance,muscle endurance gains,Physical performance included timed chair rise, usual and fast,strength, pain, physical function and quality of life,LP and KE relative training force and total work,one-repetition (1-RM) load,peak aerobic power, left ventricular morphology, and muscle strength,Serum levels of bone-specific alkaline phosphatase (BAP), osteocalcin (OC), and pyridinoline cross-links (PYD,Sleep quality,depressive symptoms,Knee pain,muscular strength and bone density,skeletal muscle peak power,total cholesterol, HDL cholesterol, and LDL cholesterol,body weight, grip strength, flexibility, waist to hip ratio, or the sum of eight skinfolds,functional health status,exercise time, or training effects,chest press and leg extension strength,Total energy intake,health-related quality of life and physical activity,gait tests, balance tests, physical health status measures, self-reported falls (up to 25 months of follow-up), and inpatient and outpatient use and costs,Total body potassium, mid-thigh muscle area, type I and II muscle-fiber cross-sectional area, and protein turnover,LV cavity size, wall thickness, mass, or systolic function,knee extensors,bone mineral density (BMD) and biochemical markers of bone turnover,muscle power, balance, and mobility,leg power,lower body strength,HGS,extremity strength improvements,muscle weakness or physical frailty,oxidative capacity,gait, balance, physical health status, fall risk, and health services,health-related quality of life (P<0.001) and plasma norepinephrine levels,Total body bone mineral content,chair rise performance, gait speed, and in mobility tasks such as gait, transfers, stooping, and stair climbing,quality of life,LEP,Six-minute walking distance,Summed isokinetic moments (N m) of 8 leg movements: hip, knee and ankle flexion/extension, and hip abduction/adduction,ischemic symptoms nor electrocardiographic changes,leg strength and change in walking endurance,muscular strength, peak oxygen consumption (peak VO2), and myocardial oxygen demand (mVO2,health benefits,FR,fat-free mass of the leg,gait, balance, or physical health status,maximal isometric muscle strength,personality type, self-efficacy, and locus of control,Vitality quality-of-life scale,muscular fitness,muscle mass, maximal isometric strength, RFD, and muscle activation,isometric knee extension (KE) and flexion (KF) strength and walking speed,body composition and quality of life,plantar flexion or postural control,contractile impulse,peak aerobic capacity,Mononuclear cell (CD3+, CD3+CD4+, CD3+CD8+, CD19+, and CD3-CD16+CD56+) number, lymphocyte proliferative (LP) response to mitogen, natural cell-mediated cytotoxicity (NCMC), and serum cortisol levels,stair climbing test,isometric steadiness,bilateral leg extension,maximal electromyogram signal of quadriceps femoris,maximal voluntary contraction force,knee pain score (range, 1-6), performance measures of physical function, x-ray score, aerobic capacity, and knee muscle strength,type I fiber area,citrate synthase activity,strength, muscle mass, and function,peak VO2 nor reduce mVO2 during isometric, isodynamic, and dynamic exercise,LP peak power,quality of life, sleep quality, and self-efficacy,physical disability questionnaire,SF36 quality of life measures,skeletal muscle,submaximal walking endurance,leg press maximal strength,adverse events,protein utilization and muscle mass,time to perform all 4 functional tasks,strength gains,Rate pressure product,paretic ankle PF,adverse health effects,physical and overall disability,HRV measures,time effect for mobility as performance,total body strength,strength gain,strength gain on chair rise performance,Functional outcomes,skeletal muscle characteristics and overall exercise performance,isokinetic lower-extremity strength and highly standardized knee radiographs,ankle dorsiflexion, training resistances, and gait velocity,pain,overall muscle strength,depressive status, physical and psychological health, functional and quality of life status,CD20+ cell count,NCMC,self-reported disability score (range, 1-5,LP response,rate of loss,level of spontaneous physical activity,high intensity training elicited greater (p<0.05) gains,Isometric lower-extremity force, 6-minute-walk distance, free gait speed, mental status, and physical function,Overall program adherence,Hip flexion, extension, abduction, and adduction, shoulder extension, flexion, and adduction, knee flexion, elbow flexion and sit-and-reach score,plasma levels of sTNFR-I,gait velocity,leg strength and walking endurance,Mean electromyogram signal amplitude of vastus lateralis,gait, balance, fall risk, and health services,Isokinetic dynamometry strength tests,strength gain on mobility skills,Strength,knee pain questionnaire,Femoral neck bone mineral density and lumbar spine bone mineral density,total strength,isokinetic and isometric quadriceps strength, pain and function determined by categorical and visual analog scales, and overall status using physician and patient global evaluations by the Arthritis Impact Scale, version 2, Western Ontario McMaster's Arthritis Index, and Medical Outcome Study Short Form 36,peak VO2 or claudication onset time,cardiovascular fitness and 5RM performance,resting heart rate and rate-pressure product; lower exercise diastolic blood pressure and rating of perceived exertion; increased GXT duration; increased leg, back, and shoulder 5RM scores; and improved AAHPERD flexibility, coordination, and cardiovascular endurance scores,physical health according to the short-form health survey,Isokinetic ankle strength, training intensity, postural stability, and gait velocity,physical performance, quality of life, and self-efficacy,LP power,CD4+ cell count,Muscular strength,Dynamic muscle strength (1-RM,Hamilton Rating Scale of Depression,heart rate,1RM lower-body strength, chair-rising time, walking velocity, stair-climbing time, and flexibility,pain scores,knee extension power output,Continuous-Scale Physical Functional Performance Test,left sided quadriceps strength,CT,body weight, body composition, and energy metabolism,chair stand and SPPB score,clinical knee examination, muscle strength, physical performance measures, and questionnaires to measure quality of life variables,muscle size,HDL cholesterol and decreased triglycerides,muscle CSA, muscle strength, EMG, and rate of force development,Body fatness and lean tissue mass, excluding skeletal mass,vertical obstacle heel clearance, limb flexion at obstacle crossing, horizontal foot placement and vertical landing velocity,muscle strength and neuromuscular performance,KE torque, KE torque/body mass and walking speed,performance-based measure of function,extremity strength (hip abduction, ankle dorsiflexion, knee flexion, ankle plantarflexion, and knee extension,timed get-up-and-go test (TUG), Berg balance scale, physical performance test (PPT), and mini-mental status exam (MMSE,ST and SA,muscle power, balance, and physical performance,Isometric force,maximal muscle strength, rapid muscle force [rate of force development (RFD)], muscle activation, and muscle size,body composition and muscle function,distance walked in a 6-min walking test,clinical signs and symptoms of osteoarthritis (OA,Peak oxygen uptake,fatigue and disease-specific quality of life as assessed by self-reported questionnaires,gain in gait speed,risk of falls and fracture,1 RM strength,Late Life Function and Disability Instrument (LLFDI,aggregate functional performance score,frequency of knee OA progression in JSN consensus ratings,total of 1RM,6-minute-walk distance and gait speed,myosin adenosine triphosphatase histochemistry,weight loss,overall status,cardiovascular fitness,MHCI mRNA levels,Rate pressure product during isometric and isodynamic exercise,Blood samples,1-mile walk times and heart rate,low intensity training improved (p<0.05) strength,peak oxygen uptake (P<0.02) and quality of life scores,force, power, and functional abilities (maximal treadmill walking speed, vertical jumping, and box stepping,ankle strength, training intensity, postural control, and gait velocity,maximum strength,thigh muscle strength, fiber area, and tissue composition,Serum testosterone,FSR of MHC,maximal gait velocity or chair rise time,most time domain and all frequency domain measures of HRV,aerobic capacity and myocardial oxygen demand,knee extension strength,muscle strength of the weight trainers,One-repetition maximum (1 RM) and peak power for KE and LP,Western Ontario and McMaster Universities Osteoarthritis (WOMAC) index pain and physical function subscales,strength-gain response,Quality of life subscales of bodily pain,Baseline physical activity level and class attendance,Depressive symptoms,back pain and health-related quality of life,incidence of falls, and the change in strength,Hamilton Rating Scale of Depression score,body weight, body mass index, waist circumference, or subcutaneous skinfolds,muscle function and physical performance,mobility and strength,KE strength and endurance, stair-climbing power, and chair-rising time,muscle volume,distance walked, force produced, gait speed, and physical function,AAHPERD strength and agility scores,physical function measures,mobility,strength in PF,stride length,left ventricular (LV) morphology and systolic function,extremity strength,vastus lateralis muscle fascicle force,exhaustive submaximal walking time measured at an intensity of 80% of baseline peak aerobic capacity,Individual changes in KE torque/body mass,IEFS,6-m walk, 6-m backwards walk, 400-m walk, floor rise to standing, and stair climbing ability,aerobic and functional working capacity,dynamic balance control and coordination while performing daily life tasks,functional fitness included upper and lower body strength, hip and shoulder flexibility, agility and balance, coordination, blood pressure, and resting heart rate,Change in back pain,all strength measures,gait speed,mean (+/-SE) time to get in and out of a car,strength, postural control, and gait velocity,functional performance,deficit in plantarflexion (PF) maximal voluntary contraction (MVC) torque,self-reported physical function,depression measures (Beck Depression Inventory,slower gait velocity, enhanced balance,strength, power, and selected functional abilities,exercise performance,type II fiber area,ability to walk backward,peak exercise performance and community-based functional status,anaerobic power,HR,Maximum strength,falls efficacy,aerobic working capacity and quality of life and decreases neurohormonal activation,vitality,positive functional outcomes,nutritional status,obstacle-crossing stride velocity,outcome assessments (muscle strength dynamometry, six minute walk test, WOMAC OA Index, total drugs, SF-12 quality of life, Adelaide Activities Profile, and the Arthritis Self-Efficacy Scale,car task,area of both type 1 and type 2 fibers in the biceps brachii muscle,strength and physical function,peak cycling power output,capillary supply and VO2peak,general health,quality of life and muscular fitness,pain and function,High rates of exercise adherence,capillary density,Functional Reach Test (FRT) and the Timed Get-Up-and-Go Test (TUG,isokinetic upper and lower extremity muscle strength, psychologic well-being, and health status,strength, gait and balance improvements,Leg-extension and leg-press exercises,mitochondrial volume density,voluntary strength (isometric, concentric, and eccentric) and functional mobility,OC,Overall compliance,proportion of type 2 fibers,strength,incidence and progression of knee osteoarthritis,repetition maximums,role physical,timed up and go, 50-foot walk, and walking up and down 8 stairs,muscle strength and endurance gains,overall leg strength,weight,Physical performance and self-rated function,maximal strength,specific force,knee pain,strength and mobility gains,average strength,Gait velocity,pain score,contractile ATP demand,Ergometrical fitness,body strength, shoulder flexibility, and agility and balance exercise,surface electromyographic activity of the triceps surae and tibialis anterior muscles,PPT scores,body composition, aerobic capacity, or self-reported physical function,social functioning,mean rate of joint space narrowing (JSN,repetition maximum scores,1-RM, thigh lean tissue mass (LTM), fat mass, and bone mineral density (BMD, g/cm2,6-minute walk distance, Short Physical Performance Battery, Physical Performance Test, and Medical Outcomes Study Short-Form Health Survey,left sided biceps strength,Continuous Scale Physical Functional Performance test, maximal strength, and anaerobic power,LV morphology and systolic function,Baseline cortisol concentration,Functional gains,IGF-1 bioavailability,limb ischemia,functional test: the 8-foot up-and-go, chair stand, and walk time,physical performance,balance and coordination,Average muscle endurance,transcript levels and synthesis rate of muscle MHC and response to resistance exercise,total cholesterol to HDL ratio,Serum insulin-like growth factor-I,Median compliance,plasma levels of TNF-alpha and sTNFR-I or IL-6,incidence and progression of knee OA,body fat mass,thigh muscle strength,Paretic ankle DF,quality of life alone, nor in body composition parameters,sustain hospital costs,isokinetic and isometric knee extensor strength,strength, endurance, heart rate variability, and forearm blood flow,shortening fluctuations,FBF,PBMC subsets, interleukin (IL)-1 beta, tumor necrosis factor-alpha (TNF), IL-6, IL-2, or PGE2 production, lymphocyte proliferation, or DTH response,plasma lipoprotein response,time to lift,IGF-1 levels,peak vertical and anterior-posterior ground reaction forces,1RM strength,pain and stiffness,muscle strength and alters skeletal muscle composition,peak isometric and isokinetic concentric and eccentric strength,isotonic muscle strength (1-RM) of the seven exercises, isokinetic and isometric knee extensor strength, and muscle endurance for the chest press and leg press exercises,glycolytic ATP supply,circulating IGF-I levels,right leg flexion and left leg extension,size or systolic function of the senescent left ventricle,leg power, balance, and mobility,Upper and lower body strength, anaerobic power (Wingate testing), and mobility (timed up and go, walking, climbing stairs,Leg extensor power at resistance,percentage of myosin heavy chain type IIB,inflammatory mediators (serum C-reactive protein [CRP] and interleukin-6 [IL-6,risk of falling,risk of weight loss,Cross-sectional thigh-muscle area,strength, anaerobic power, and whole body physical function,plasma lipoprotein profiles,x-ray scores,physical performance and body composition,energetic pathways: oxidative capacity,isokinetic strength,Average strength,muscle strength gains,Continuous Scale Physical Functional Performance test total score,functional task performance,physiologic capacity, quality of life, morale, function and self-efficacy without adverse events,size and contractility,mean change in HRQOL and physical activity scores,CD3+ cell count,physical performance and disability,quadriceps strength,pain and functioning,walking endurance,lean mass,Body weight and height, physical activity level and maximal oxygen uptake,role emotional,maximum cycle ergometer exercise capacity or distance walked,BAP,back pain and its related disabilities,peak exercise performance,concentric strength (1-RM in bench and leg press,isokinetic knee extension muscular performance,muscle size, strength and physical function,knee extension dynamic muscle strength,symptom limited treadmill walking endurance,One repetition maximum (1-RM) strength testing,type I and type II fiber areas, and capillary density,muscular fitness and body composition,Peak VO2,Step time,obstructed gait function,normal pace kneel rise time,Upper and lower extremity strength,stride duration,peak anaerobic power,risk of musculoskeletal injury,incidence of injury and program adherence,quality of life and body composition,muscle oxidative properties, glycolytic ATP synthesis, and contractile ATP demand,coefficient of variation (CV,gait velocity and balance,transcript levels of MHCIIa and MHCIIx,lengthening fluctuations,functional ability,tandem gait,endurance, balance, or disability,arm strength in S,paretic KE,Functional ability tests were chair rise, kneel rise, rise from lying on the floor, 118-m self-paced corridor walk, stair climbing, functional reach, stepping up, stepping down, and lifting weights onto a shelf,thigh tissue composition,peak VO2|STREN improved significantly in chest press and leg extension strength (P less than or equal to 0.05) while W/J and CONT showed no change.
not found|Thromboembolic complications,rates of thromboembolic adverse events,baseline adverse event (AE) profile,serious adverse events,incidences of ventilator-free days, intensive care unit-free days, and thromboembolic, serious, and adverse events,tICH volume,risk of mortality or with thromboembolic or adverse events,24-h CT scans,rates of mortality,CT scans|The earlier after injury that the initial CT scan is obtained, the greater is the likelihood that the hematoma will expand on subsequent scans.
not found|Subjective symptom scores for nasal congestion, nasal drainage, and sneezing and objective measures of nasal resistance,temperature of active vapor,Viral shedding,Mean viral titers,nasal patency and nasal symptoms,Mean titers,RV shedding,nasal resistances,subjective response,alleviation of cold symptoms,nasal patency,severity of disease,Nasal patency,daily symptom scores,symptoms (general practice study) and observers recorded symptoms and signs, weight of nasal secretions, isolation of virus, and antibody responses,viral shedding,Viral titers,nasal resistance,subjective symptom scores for nasal congestion, nasal drainage, and sneezing on isolated days,peak nasal expiratory and inspiratory air flow,nasal patency and on nasal symptoms|Significant improvements in the placebo-treated group were obtained on subjective symptom scores for nasal congestion, nasal drainage, and sneezing on isolated days during the treatment period (40%, vs 25% on day 3, 71% vs 60% on day 6, and 100% vs 67% on day 7).
not found|purchase cost of FS,Cumulative incidence of peritonitis,peritonitis rates,Exit site infection rates,median survival time to first peritonitis episode,episodes of peritonitis,total cost of infection,total cost of CAPD,gram-negative infections,peritonitis incidence and associated hospitalizations,peritonitis rate, exit site infection, clinical outcome, and patients' acceptance to the procedure,number of peritonitis episodes,cost-effective,Length of hospitalization for peritonitis or exit-site infection,1-yr infection-free survival rates,efficiency and total cost of Freeline Solo (FS, twin-bag) and Basic Y (BY, single-bag) systems,technique survival,cost per bag,Exit-site infections,incidence of catheter exit wound infections,Peritonitis-related hospitalization,gram-positive infections,episode of peritonitis,Training time, details of peritonitis and exit-site infection (ESI) including the costs of antibiotic treatment, outpatient visits, hospital stays, technique, and patient survival,corresponding ESI rates,Peritonitis,cost of the twin bag,peritonitis rate,total costs,rate of episodes caused by Staphylococcus aureus, streptococci, enterococci, corynebacteria, enterobacteria or pseudomonads,average peritonitis-free interval,incidence of peritonitis,Peritonitis rates|Patients on the B system had a better acceptance of the procedure than patients on the Y system, as assessed by a six-item, 10-point questionnaire (total score, 43.1 +/-
20|asthma attack,peak flow rate,acute asthma attack,Clinical scores,Improvement in flow at mid and low lung volumes,therapeutic failures,pulmonary function,PEF,FEV1,Pulmonary index scores,Tal score,lung function parameters,clinical score, oxygen saturation, and pulmonary function tests,pulse rate and respiratory rate and assessment of the severity of symptoms,Peak expiratory flow rate and pulmonary index,heart rate or systolic or diastolic blood pressures occurred.(ABSTRACT TRUNCATED AT 250 WORDS|Both drugs induced a comparable degree of bronchodilatation and no significant differences were found between the OB group and the F group, suggesting equipotency for both drugs after a 20 min interval, at the 200 micrograms dose level.
102|body composition, protein biochemistry, muscle power, respiratory muscle strength, and use of dietary supplements,body mass index centile,nutritional status,Skeletal muscle strength and power,skeletal muscle strength and energy intake|Long term use of oral protein energy supplements did not result in an improvement in nutritional status or other clinical outcomes in children with cystic fibrosis who were moderately malnourished.
60|pain,depression scores|Highly susceptible, hypnotically treated women had lower depression scores after birth than women in the other 3 groups.
125|mortality, number of operations, and length of stay for the survivors|There were no statistically significant differences between the two groups for the outcome measures of mortality, number of operations, and length of stay for the survivors.
not found|premature luteinization,Serum P and sonography confirmed ovulation,Serum concentrations of E(2), LH, and FSH,ovulation and pregnancy rates,serum LH concentration,ovarian sonography and serum concentrations of E(2), LH, and FSH,serum concentrations of E(2), LH, and FSH,spontaneous abortion,Ovulation rates,LH|: In ovulatory cycles, no statistically significant differences were observed during the follicular phase comparing serum concentrations of E(2), LH, and FSH between the treatments.
not found|asymptomatic bacteriuria,Pyelonephritis,Urine cultures (UC,Readmission for pyelonephritis,rate of resistance of isolated uropathogens,risk of recurrent pyelonephritis,average birth weight,acute pyelonephritis,Urinary tract infection (UTI,positive UC,incidence of cystourethritis,faster clinical recovery,Antibiotic suppression,positive urine cultures,rate of failure,birth outcomes,clinical responses or birth outcomes,hospital length of stay,Therapeutic success (clinical cure and bacteriological eradication of uropathogens,Escherichia coli,rate of bacteriological cure,Blood cultures,febrile days,recurrent pyelonephritis,efficacy, safety and cost,Overall cure,length of hospitalization, hours until becoming afebrile, days until resolution of costovertebral angle tenderness, or infecting organism|There were no significant differences in clinical responses or birth outcomes of inpatients or outpatients treated for acute pyelonephritis after 24 weeks' gestation if they completed their assigned protocols.
65|likelihood of clinical response, hyperprolactinemia, and extrapyramidal side effects,therapeutic efficacy,Haloperidol plasma level,clinical improvement,extrapyramidal effects,HL steady-state plasma levels and clinical improvement,Extrapyramidal side effects,extrapyramidal symptoms,HL steady-state levels and clinical improvement,serious adverse reactions,plasma levels,wide range of D(2) occupancy,hostility,degree or rapidity of symptom alleviation,D(2) receptor occupancy was determined with [(11)C]raclopride and positron emission tomography, and clinical response, extrapyramidal side effects, and prolactin levels,hyperprolactinemia, and extrapyramidal side effects,HL plasma level,antipsychotic efficacy,Plasma haloperidol levels,Brief Psychiatric Rating Scale,acute psychotic symptoms,distressing extrapyramidal side effects,Side effects,D(2) occupancy,side effects|For most patients, plasma levels not exceeding 12 ng/mL yield the best results in the first 3 weeks of treatment.
not found|future intentions to use family planning,acceptability and feasibility,reduced incidence of self-reported STI symptoms or high-risk sexual behaviour,proportion of new STI patients tested for HIV,incident pregnancy, largely due to high levels of contraceptive discontinuation and user failure,cessation of symptoms,family planning (knowledge, use, and intentions to use), family size preferences, fertility, and mortality (child and infant,knowledge of family planning,lower HIV-1 incidence,intention-to-treat basis,incidence rate ratio of HIV-1,contraceptive initiation rate,pregnancy rates,fertility reduction|These positive results indicate that the use of referral can have a significant and dramatic impact on family planning services in a relatively short time.
not found|toxicity,efficacy and tolerance,mild neutropenia,diarrhea,efficacy and safety,Clinical success rates,tolerated,Chronic osteomyelitis,Efficacy and safety,Treatment failure or relapse,serum glutamic oxalacetic transaminase and serum glutamic pyruvic transaminase,Gram-positive bacteria,average duration of antibiotic therapy,favorable clinical response,Adverse reactions,persistent Klebsiella pneumoniae infection|Our trial suggests that oral ofloxacin is as effective as parenteral therapy with betalactam antibiotics in the treatment of osteomyelitis, which could allow a reduction of the period of hospitalization and economic costs.
not found|patient outcomes (length of initial hospital stay, length of time between initial hospital discharge and readmission, and rehospitalization rates) and charges for care (charges for initial hospitalization, rehospitalizations, health services after discharge, and nurse specialist services,quality-of-life scores,Hospital length of stay,length of hospital stay,emergency department visits and hospitalizations within 30 days of discharge,Barthel Activities of Daily Living Index,Length of hospital stay,Quality of life,quality of life and reduce hospital use and medical costs,readmitted to hospital,repetitive hospitalizations,Length of the index hospital stay,rate of rehospitalization,hospital utilization,total cost,higher Quality of Life scores,rehospitalizations and ED visits,Extent and speed of hospital-general practitioner communication,Length of stay,90-day readmission rates,rate of falls, hospitalization for falls, institutionalization, and death,average stay in hospital,rate of hospital utilization,overall cost of care,cost per patient for laboratory (including cardiology graphics) services,hospital costs,percentage of medications with a discrepancy or prescription error,quality of life, involvement, and satisfaction with discharge care, and hospital-general practitioner integration,frequency of prescription errors in the discharge medication and medication discrepancies after discharge combined,readmissions, fewer total days rehospitalized, lower readmission charges, and lower charges for health care services,90-day readmission rate,delaying or preventing rehospitalization,Length of stay, total cost of acute hospital care, cost of laboratory, pharmacy, and rehabilitation services,number of deaths, attendance at hospital outpatient clinics and general practice and proportion of days in hospital over the follow-up period, together with patients' general well-being, satisfaction with the service and knowledge of and adherence to prescribed medication,health-related quality of life (HRQL,mortality or discharge disposition,undesirable outcomes,Mean length of stay,rehospitalization,Survival,satisfied with their medical care,self-reported preparedness for discharge and frequency of primary care providers' follow-up within 30 days of discharge,perceptions of mental quality of life,self-care knowledge,institutionalization,Event-free survival,generic quality life,feasibility and efficacy,length of stay, functional status, self-care knowledge and quality of life (QOL,mean length of stay,number of readmissions for heart failure,hospital readmissions,Total inpatient and outpatient median costs and readmission median cost,rehospitalization within the 90-day interval and the cumulative number of days hospitalized during follow-up,readmissions,rates of readmission,quality of life, discharge satisfaction, and hospital length of stay,days of hospitalization,health-related quality of life (disease-specific and generic measures), rates of readmission, and emergency room use,shorter length of stay,discrepancy or prescription error,functional status,SF-36 Physical component, Mental Component, and General Health subscales,emergency rehospitalizations or emergency department (ED) visits,falls, autonomy, hospitalization for falling, institutionalization, and death,or length of hospital stay,discharge planning involvement, health service access, confidence with discharge procedures, and opinion of discharge based on previous experience,pharmacy costs,days of rehospitalization,CHF readmissions,rates of readmission within 90 days of hospital discharge, quality of life, and costs of care,Adverse events,number of diagnostic procedures during hospitalization, the number of deaths, the diagnoses on discharge and the functional capacity,prolonged hospital stay,MLHFQ's Physical Dimension and Emotional Dimension subscales,total number of bed-days,re-admission to hospital within 6 months,overall Minnesota Living with Heart Failure Questionnaire (MLHFQ) score,proportion of patients re-admitted to hospital,mean number of days hospitalized,unscheduled readmission,cost of hospitalization,mean duration of physiotherapy,length of stay,number of readmissions,mortality rates,taking CHF medication,satisfied with their care|A low-cost discharge-transfer intervention may improve the rates of outpatient follow-up and of completed workups after hospital discharge.
2382| weight,weight changes,blood pressure and hypertension incidence,life-style change groups (weight reduction, sodium reduction, and stress management,Age, weight, height and 24-hour urinary excretion of sodium, potassium and creatinine,potassium change,intralymphocytic sodium concentration and blood pressure,Systolic and diastolic blood pressure,return of hypertension,BP,natriuresis whereas intralymphocytic sodium,BP decreases,systolic and diastolic BP,mean body weight,mean systolic and diastolic blood pressures,diastolic blood pressure,systolic blood pressure change,hypertension incidence,high blood pressure (BP,hypertensive events,Blood pressure, heart the rate and body weight,systolic and diastolic blood pressure fell,blood pressure,diastolic pressure,average BP,systolic blood pressure and intervention compliance measures,Salt restriction and physical activity,BP levels,lowering systolic and diastolic BP,systolic blood pressure,Sodium excretion,mean blood pressures,reduced sodium intake,diastolic blood pressure change,urinary sodium excretion,frequency of cardiovascular events,intralymphocytic sodium,mean urinary sodium excretion,blood pressure and intralymphocytic sodium concentration,lowering diastolic BP, systolic BP, and the incidence of hypertension,diastolic blood pressure or systolic blood pressure,24-hour sodium excretion,incidence of hypertension,sodium and weight reductions,weight loss,systolic BP|Differences were statistically significant for systolic and diastolic BP in the weight loss group and for systolic BP in the sodium reduction group.
8|PIP syndrome,suppression of polydipsia,maximum weight gain,body weights,weight gain,duration and intensity of excessive drinking|Naloxone decreased the maximum weight gain per day significantly in five cases.
67|pregnancy rate per patient,mean embryo quality score,Clinical pregnancy rates,number of preclinical pregnancies,vitro fertilization-embryo transfer,preclinical pregnancy rate,oocyte classification and embryo quality score,dose or duration of gonadotropin stimulation, number of oocytes retrieved, fertilization rate, or number of embryos transferred,pregnancy rate of ART,pregnancy rates,implantation rates,ongoing pregnancy rates,pregnancy rates per cycle, group implantation rates, and implantation rate per embryo transfer procedure,clinical pregnancy rate per cycle and per transfer,ovarian response|A significantly higher number of preclinical pregnancies (P less than 0.0001) occurred in patients treated by protocol A.
573|median time to loss of response,Infliximab safety,clinical remission,adverse event,intention to treat,frequency of severe or serious adverse events,efficacy and tolerability,clinical response (a decrease in the Crohn's disease activity index (CDAI) to > or =100 points or remission (CDAI score,efficacy, safety, pharmacokinetics, and immunogenicity,Antinuclear antibodies,efficacy and safety,clinical remission (Crohn's Disease Activity Index score,time to the loss of response,remission,Adverse events,clinical response,maintenance of remission,tolerated,Efficacy and safety,Steroid sparing,time to loss of response,clinical response rates,incidence of serious infections,sustain clinical remission,Clinical response,Median values for Crohn's Disease Activity Index, inflammatory bowel disease questionnaire (a quality of life measurement), and serum C-reactive protein concentration,percentage of patients with steroid sparing, defined as discontinuation of steroid therapy without a disease flare (Crohn's Disease Activity Index score,efficacy,complete absence of draining fistulas,Crohn's Disease Activity Index score|At week 30, 23 of 110 (21%) group I patients were in remission, compared with 44 of 113 (39%) group II (p=0.003) and 50 of 112 (45%) group III (p=0.0002) patients.
63|parental health, intelligence and literacy,effective regardless of parental health, literacy skills, and IQ,number of safety precautions parents,parental health and safety behaviours|The intervention improved parents' ability to recognize home dangers, to identify precautions to deal with these dangers and resulted in a significant increase in the number of safety precautions parents implemented in their homes with all gains being maintained at 3 months post-intervention.
not found|overall cesarean delivery rate,Frequencies of delivery,mean birth weight or the frequency of macrosomia,hospital stay,reduced oxytocin infusion duration,hyperactivity,Bishop score,safety and effectiveness,mean number of applications,cervical state,incidence of cesarean delivery,complications,cumulative rate of deliveries,relation to cesarean delivery rate, Apgar scores at 5 minutes, and arterial umbilical cord pH,average costs,Myometrial activity,Apgar scores and umbilical artery pH,Cervical ripening,uterine hyperactivity,Gastrointestinal side effects,cervical length, fetal fibronectin status, or Bishop scores,safety, efficacy and cost,vaginal delivery,intervals to delivery and shortened labor,cervical inducibility,myometrial activity,mean time to delivery,fetal or maternal morbidity,obstetric outcome,efficacy, safety and cost,cervical ripening and/or induction of labour,Bishop scores,labor induction,cervical ripening success rate,PGFM serum levels,interval to delivery and duration of labor,induction rate,incidence of cesarean sections,cesarean rate,Overall success,ruptured membranes,Student t test, Fisher exact test, Wilcoxon test, Mann-Whitney U test,cesarean section rate,emergency Caesarean section,time to achieve active labor,side-effects,severe fetal heart rate decelerations,surgical deliveries,serious adverse reactions,route of delivery or fetal outcome,maternal age, race, parity, maternal height or weight, or indication for induction,cervical Bishop scores, shorter induction-to-delivery intervals, lower maximum doses of oxytocin, and fewer days of induction,mean cervical score,maternal or neonatal morbidity,uterine hypertonus associated with fetal bradycardia,uterine contractions lasting,safety, efficacy,effective inducing regular contractions,mean duration of labour,fetal distress,induction-active labor intervals,uterine hyperstimulation,analgesia,instrumental vaginal deliveries and cesarean sections,incidence of patients going into labor,hyperkinetic labor,number of patients managed with artificial rupture of membranes,methods of delivery, neonatal parameters (Apgar scores, umbilical artery blood pH and standard base excess,efficacy,cervical scores,cesarean delivery rate, infectious morbidity, or other complications of labor,induction of labor with oxytocin,induction-delivery interval,stimulate regular contractions,gastro-intestinal discomfort,effective inducing vaginal delivery,cesareans for fetal distress,cervical priming and labor induction,mode of delivery and Apgar score,effectiveness and safety,Successful initial induction,proportion of women who reached complete dilation,median interval to delivery,Age, duration of pregnancy and percentage share of primiparae,Mean change in Bishop score, success of softening, time to labor, and time to delivery,median interval to delivery of 2 days,shorter induction-to-delivery time,Rates of cesarean section,Mean Bishop score change (+/-SD,adverse perinatal outcome (neonatal seizures, intracranial hemorrhage, the need for mechanical ventilation, or nerve injury,cesarean section,induction-to-delivery interval or in cesarean section rate,oxytocin-induced labor,change in Bishop score, interval to complete dilation, maximal oxytocin dose required to establish labor, and route of delivery,duration of labour,labor characteristics such as ripening time and cesarean section rate,spontaneous delivery,levels of maternal serum 13,14-dihydro-15-keto-PGF2 alpha and progesterone,rate of hyperstimulation,length of time to delivery,cervical ripening and induction of labor,cesarean sections,rate of spontaneous birth,Uterine hyperstimulation and perinatal outcome,spontaneous labor,Cesarean sections,Safety and efficacy,mean change in cervical score, mean application-to-delivery interval, incidence of uncomplicated spontaneous labor, incidence of cesarean delivery,fetal heart rate abnormalities,cesarean delivery rate, antepartum fever, hyperstimulation, Apgar scores, birth weight, or umbilical artery pH,overall cesarean section rate,untoward reaction,successful cervical ripening,acute fetal distress,rates of clinical amniotits,parity, gestational length, maternal characteristics, indications for induction or preinduction cervical scores,Side effects,time to achieve cervical ripening,Overall mean cost per patient that was incurred by labor induction,maximum oxytocin dose required to establish progressive labor,cesarean delivery rate,Transvaginal cervical length, fetal fibronectin, and Bishop score,collateral effects,delivery rates,median induction-to-vaginal delivery time,Systemic side effects,umbilical artery pH,oxytocin for labor induction,Mean change in Bishop score,vaginal delivery rate,reduced time to delivery with intracervical,failures of induction of labor,number of antepartum tests, labor inductions, or cesarean sections, the maximum oxytocin dosage, or the interval from admission to delivery,efficacy and safety,cervical ripeness,spontaneous labor rate,length of labour,Efficacy and cost,incidence of spontaneous versus induced labor, need for oxytocin augmentation, gel-to-induction interval, Bishop score change, maximum oxytocin dose, maximum dilatation rate, length of labor, cesarean section rate, fetal Apgar scores, fetal umbilical vein pH, or fetal umbilical artery,myometrial hypercontractility,failure rate (labor,Vaginal prostaglandins,Uterine tachysystole,Active phases of labor,cervical ripening and labor induction,shorter induction-delivery interval,Cervical state,success rate,fetal deaths,instrumental vaginal delivery,Uterine hyperstimulation,reduced induction to delivery intervals,mode of delivery or to the adverse maternal/neonatal outcome,serum PGFM and progesterone levels,reduced time to active labor,myometrial hyperstimulation,incidence of abnormal cardiotocography during labor,request for initial pain medications,frequency of fetal distress, outcome of labor, assisted delivery rates or maternal side effects,Apgar score or umbilical artery pH,Bishop score, lag time from dosage to delivery, spontaneous versus induced labor, cesarean section rate, length of labor and neonatal outcome|Compared with intracervical therapy prostaglandin E2 given intravaginally was more likely to significantly change the Bishop score (60.4% vs 40.4%, p = 0.04) and stimulate regular contractions (72.9% vs 48.1%, p = 0.01).
480|median symptom score,cough,severity of fever,temperature and symptoms on diary cards,severity of illness,adverse event profiles|The influenza-confirmed patients reported reductions in the severity of fever (P = 0.002), cough (P = 0.023) and expectoration (P = 0.004) after one-day of treatment with Antiwei, compared to placebo.
178|sexual life,postoperative ejaculation problems,religious worship (praying and fasting,quality of life (QOL,global QOL,Cancer core and colorectal cancer-specific quality-of-life questionnaires,sexual dysfunction score,EORTC QLQ-C30 and EORTC QLQ-CR38,Quality of life,postoperative quality of life (QOL) and sexual function,general health status,SF-36 Health Survey HRQoL domain,mean scores for constipation,median time since surgery,Anorectal dysfunction,Quality of life measures,sexual dysfunction,Performance Status Rating, Neuroticism Scale in the Eysenck Personality Questionnaire, and Functional Living Index-Cancer,overall QOL,QOL outcome,embarrassment scale,worse rectal function,mental functioning,urinary dysfunction,Short Form-36 (SF-36) health survey questionnaire and the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Colorectal 38 (EORTC QLQ-CR38) questionnaire,poorer quality of life,constipation and gastrointestinal symptoms,adverse colorectal concerns,impairment in social functioning,lower physical and emotional well-being scores and colorectal concerns scores,rectal function,Sexual functioning scores,HRQOL functional aspects,total cumulative scores,scales QLQ-C30 module,Sexual life,Mean QoL scores for body image and male sexual problems,total QoL, role function, social function, body image, and future perspective, and more gastrointestinal and defecation-related symptoms,incontinence for gas and solid stools,patient's quality of life,perception of body image,presence of stoma,health-related quality of life (HRQoL) and religious practices,3-year actuarial overall survival and locoregional control rates,pelvic dysfunction,quality of life (HRQL,Urinary complaints,subsequent health-related quality of life,sexual problems,Overall, quality of life,social functioning,colorectal cancer specific questionnaire on quality of life (CRC_QoL,Sexuality,Cancer QLQ-C30 and CR-38 questionnaires,global quality of life score,Male sexual function,QLQ-CR38 questionnaire,fatigue,response rate,cumulative gender specific indicators,rate of rehospitalisation and rate of non-reversed temporary stomas ("failure" stoma,Major bowel dysfunction,quality of life (QOL) outcomes,GI symptoms,anal incontinence,overall quality of life,general health perception,sphincter-saving resection,smaller mean (0) better quality of life,quality of life (QoL) and functional outcome,poorer social functioning,Severe postoperative complications,lower body image score,physical function and overall quality of life and higher values for fatigue,quality of life scores,quality of life questionnaires,Quality of life and functional outcome,global QoL,QoL,sexual function and body image,survival, tumour recurrence and complication rates,cumulative gastrointestinal problem score,morbidity and quality of life,Response rate,levels of depression,readmitted, stenosis and anastomotic leakage,global health status/HRQOL and the pain scales, constipation,scales of function and symptoms,financial worries,RAND-36 questionnaire and questionnaires assessing urinary, sexual, and bowel dysfunction,Generic and cancer-specific quality of life questionnaires,Bowel dysfunction (diarrhea and faecal incontinence,tumour recurrence,median time of completion,cumulative score,inferiority feelings, depression and disorders of sexual activity,Ankara University Life Standard Questionnaire,disturbed micturition and sexual problems,SF-36 questionnaire and religious practices,quality of life,QOL,poorer body image and more problems with gastrointestinal function, male sexual dysfunction, and defecation,Health-related quality of life,HRQoL,work responsibilities, sexual life, and religious worship,quality of life on the following dimensions: physical well-being, psychological well-being, dietary habits, surgical response, social concerns, body image, stress and marital adjustment,modified version of the American Society of Colorectal Surgeons (ASCRS) Fecal Incontinence questionnaire,EORTC QLQ-C30 physical scores,Health-related quality of life data,quality of life (QoL,global health-related quality of life,problems with social functioning,HRQOL levels,problems with constipation,modified City of Hope Quality of Life-Ostomy (mCOH-QOL-Ostomy) and Medical Outcomes Study 36-Item Short-Form Health Survey, version 2 (SF-36v2,Quality of life scores,anal dysfunction after AR,higher self-esteem,gastrointestinal concerns,RAND 36-item health survey QOL questionnaire; and (b) self-administered disease-related questionnaire with special reference to anorectal and urogenital function,male or female sexual function,health-related quality of life (HRQOL,symptoms of Defaecation and Embarrassment with Bowel Movement,faecal incontinence and diarrhea,fatigue, pain, financial difficulties, weight loss and chemotherapy side effects,anxiety,short-term and the long-term complication rates,ASCRS Fecal Incontinence questionnaire scales of lifestyle, coping/behaviour and depression/self-perception,symptom scores for fatigue, pain, GI problems, and sleep disturbance,severe impairment of sexuality,failure rate,HRQL,quality of life and sexuality,urinary incontinence,psychological well being, social concerns and marital adjustment,body image, finance, and gastrointestinal symptoms,severe postoperative complications,generic quality of life instrument SF-36 together with a new symptom-specific Fecal Incontinence Quality of Life Scale,Physical function,SF-36 and EORTC QLQ-CR38 (sexuality subscale) scores,median scores,favorable QoL scores,emotional state,total score of the symptom-specific scale,Physical function and overall quality of life,global health status,time (role function, emotional function, body image, future perspective, and micturition-related problems) and group in favor of APE (sleeping problems, constipation, diarrhea,postoperative general QOL,EORTC questionnaires QLQ-C30 and QLQ-CR38, and rectal function,dietary habits (p.003) and tolerance to stress,occurrence of late major complications,Better global quality of life (p.001), physical well being (p.001) and less surgical sequela,severe emotional symptoms,symptom and function scales,quality of their life,physical functioning,social life and work responsibilities,Lower physical well-being and greater adverse colorectal concerns,sexuality,gastrointestinal problems,sexuality and quality of life,pain,incidence of dysuria,side effects,generic (EQ-5D) and two disease-specific questionnaires (EORTC QLQ-C30 and EORTC QLQ-CR38|A significantly ( P< 0.001) greater number of patients in the abdominoperineal resection group stopped praying daily (either alone or in a mosque) and fasting during Ramadan.
                
not found|toxicity,Clinical cures,safety and tolerance profile,success rate of MBT Loramyc,efficacy and safety,resolution of symptoms and signs of oral candidiasis,clinical cure rate,Oropharyngeal candidiasis,clinical success at Day 7, clinical cure, improvement in clinical symptoms, mycologic cure, recurrence rate, and safety,Gastrointestinal conditions,resolution of lesions plus eradication of Candida albicans,tolerated,Clinical relapse rates,rates of relapse,Eradication of pathogenic yeasts,cure rate,nausea and abdominal pain,median duration of oropharyngeal candidiasis,success rate,local effectiveness and safety,mycological cure rate,Regression of visible lesions,Laboratory abnormalities,eradication of the organism cultured at entry,clinical success,Clinical cure,eradication of culturable organisms,efficacy, safety, and tolerance,efficacy, safety and tolerance,oropharyngeal candidiasis,Mycological cure|No toxicity was observed that could be attributed to clotrimazole.
48|trigeminal neuralgia symptoms,efficacy and tolerability,pain relief,effect and plasma concentration,analgesic effect,incidence and duration of post-herpetic neuralgia,Comprehensive Psychopathological Rating Scale (CPRS,HbA1, fasting serum glucose, and safety tests,tolerated,relieved of their pain,daily ratings of pain intensity on a 10-step verbal scale,global rating of the analgesic effect on a 5-step verbal scale,efficacy and tolerance,adverse effects,post-herpetic neuralgia lasting,pain and paresthesia,pain or paresthesia,median total ami- and nortriptyline concentrations,visual analog scale (VAS) and the overall efficacy,pain,Side effects,side effects|Pimozide was compared with carbamazepine in a double-blind crossover trial in 48 patients with trigeminal neuralgia who were refractory to medical therapy.
1115|subarachnoid blood,severity of ischaemic deficits secondary to vasospasm,neurologic outcome,Symptomatic vasospasm,platelet aggregability,cerebral infarction,platelet function,serious adverse events,mean cerebral blood flow,severe deficit or died,delayed cerebral vasospasm,cerebral arterial spasm,Mean middle cerebral artery velocities,thromboxane release,impaired CO2 response,severity of ischemic neurologic deficits,Incidence of cerebral infarction and ischaemic neurological deficits,platelet count,cerebral vasospasm,vasospasm (moderate disability or worse on the Glasgow Outcome Scale,Mean hemispheric cerebral blood flow (CBF,Serum Mg++ levels,low-density regions on computerized tomography associated with vasospasm,severe or caused death,cerebral infarction and poor outcomes (death and severe disability,angiographically demonstrable vasospasm,GOS scores,inhibitory effect,Cerebral arterial spasm,electrocardiographic changes,risk of DCI,poor outcome" (Rankin >3) and "excellent outcome" (Rankin 0), we used the "intention-to-treat" principle,Mean GOS scores,Angiographic vasospasm,extensive and diffuse vasospasm,Daily transcranial Doppler (TCD) ultrasonographic recordings,symptomatic vasospasm,delayed ischemic deterioration,frequency of delayed cerebral ischemia (DCI,cerebral blood flow,cerebral vascular reactivity,adenosine diphosphate-induced platelet thromboxane B2 release,Glasgow coma scale,Glasgow Outcome Scale (GOS,occurrence of a new hypodense lesion on computed tomography compatible with clinical features of DCI,neurological complications,tolerated and reduces cerebral infarction|Poor outcomes were also significantly reduced by 40% (95% confidence interval 20 to 55%) with nimodipine (20% (55/278) in patients given nimodipine v 33% (91/278) in those given placebo).
                
10|subepidermal lymphocytic infiltration,apoptotic bodies,clinical remission,toxic effects,Serum aspartate aminotransferase, alanine aminotransferase, cholesterol and triglycerides,oral lesions,histological assessment of the leukoplakia,oral lesion,loss of polarity of basal cells,Cheilitis, facial erythema, and dryness and peeling of the skin were common; conjunctivitis and hypertriglyceridemia,clinical size of the lesion,size of the lesions,Major response rate (complete response and partial response,micronuclei and chromosome aberration rate,cell proliferation,size and clinical appearance of the lesions,histologic response,concentrations of acitretin in plasma, saliva and tissue,percentage of bcl-2-positive cells,dysplasia,remission of oral leukoplakia,area of oral leukoplakia,mean response,count of the apoptotic bodies,complete remission,acitretin concentration in plasma and tissue,adverse events,Relapse,major toxicities,change in histology,bcl-2 positivity,incidence of micronucleated exfoliated oral mucosa cells,Blood, saliva and urine samples,histological reduction in dysplasia,visually obtaining bidimensional measurement of the size of leukoplakia lesion(s,Serum beta carotene concentration,serum alpha tocopherol,serum retinol levels,number of layers of spinous cells,laboratory values,size of oral lesion,complete regression rates,number and total volume of the silver-stained Nucleolar Organizer Regions (AgNOR) and the proliferating index of Proliferation Cell Nuclear Antigen (PCNA) in oral mucosa cell nuclei|Immunohistochemical analysis for bcl-2 protein showed that before treatment a weak positivity of the basal layers, with a focal positivity of some parabasal cells, was present: five out of nine specimens were positive.
||
223|intervention activity,depressive symptoms (CES-D mean scores,global anxiety symptoms,mental health and substance abuse services,adherence to antidepressant medication, satisfaction with care of depression and with antidepressant treatment, and reduction of depressive symptoms over time,patient-rated improvement,mental health specialist,primary outcome (depression severity according to the Symptom Checklist scale) and satisfaction with care, a secondary outcome,depression, functional outcomes, and receipt of depression treatment,HAMD or SF-36 scores,Client satisfaction,general health status,depression (20-item Hopkins Symptom Checklist [HSCL-20]) and pain (BPI) severity,mean number of IADL dependencies,adherence to adequate dosage of medication,PHQ-9 score,mean PCS,glycemic control,Edinburgh postnatal depression scale (EPDS) score,favour of TM,symptoms of depression and quality of life,treatment satisfaction,depression care and depression and diabetes outcomes,crude mean EPDS score,modified Beck Depression Inventory (mBDI) outcomes,treatment participation rates, Hopkins Symptom Checklist depression scale scores, major depression (Structured Clinical Interview for DSM-IV), Patient-Rated Global Improvement ratings, treatment satisfaction, and adequacy of medication,drug adherence rate,Short Form-12 Mental Component Scale,favorable depression outcomes,Patient satisfaction,depressive symptoms, physical activity levels, and diabetes-related outcomes,PTSD and depressive symptoms, episodic alcohol intoxication, or functional limitations,reduced anxiety,mean score on the self-reported Symptom Checklist-20 depression scale,diastolic blood pressure ,Epidemiologic Studies Depression Scale (CES-D) to assess depression, an electronic monitor to measure blood pressure, and the Medication Event Monitoring System to assess adherence,Hamilton depression rating scale (HDRS,HSCL-20 depression severity,HbA1c outcomes,PTSD symptoms,Depression symptoms,functioning and quality of life,Hopkins Symptom Checklist, Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, criteria for major depression, health-related quality of life, medication adherence, patient satisfaction, and use of depression-related health care services,suicidal ideation and depression severity,mean Hopkins Symptom Checklist Depression Scale depression scores,response and remission rates (CALM vs UC,emotional functioning,depression severity measured using the 20-item Hopkins Symptom Checklist (SCL-20) and reported as treatment response,rates of watchful waiting,Medication adherence, treatment response, remission, health status, health-related quality of life, and treatment satisfaction,quality-of-life outcomes,mental functioning,depression scores,mental health status,mean EPDS,Average HSCL depression scores,depression symptom severity, using the Hopkins Symptom Checklist (SCL) depression items and the Patient Health Questionnaire-9, and patient satisfaction,quality of care and clinical and functional outcomes,depression (Hopkins Symptom Checklist 90), global improvement, and satisfaction with care,levels of glycosylated hemoglobin,EPDS score,adequacy of dosage of antidepressant medication treatment,pain and depression,Personal Health Questionnaire,functional impairment,chronic illness care, adherence to medication, and quality of life,SCL depression score,Depression and anxiety disorders,Hamilton Depression Rating Scale (Ham-D) and functional status using the Medical Outcomes Study 20-item short form (SF-20) subscales,depression and HIV symptom outcomes,rates of AD use,probability of having any medical visit,CES-D scores,women's knowledge of their postpartum depression diagnosis,Symptom Checklist-20 depression score,depression, depression treatments, satisfaction with care, functional impairment, and quality of life,clinician adherence,greater chart documentation of depression,recovery from common mental disorders as defined by the International Statistical Classification of Diseases and Related Health Problems-10th revision (ICD-10,counseling or used antidepressant medication,depression symptoms, quality of life, medication adherence, provider visits, or patient satisfaction,change in Beck Depression Inventory (BDI) scores and in the proportion of patients fulfilling DSM-III criteria for major depression,anxiety symptoms, depression symptoms, functional disability, and quality of care,Posttraumatic behavioral and emotional disturbances,Clinical improvement,depression and pain,refill medication prescriptions,Serious adverse events,health-related quality of life, health status, HIV symptom severity, and antidepressant or HIV medication regimen adherence,rates of depression treatment,Patient Health Questionnaire-9 (PHQ-9) depression scale,depression,physical function, pain, general health, energy, emotional role, mental health and standardized physical and psychic scales of SF-36,coping and health-related quality of life,HRS-D score,rate of alcohol abuse/dependence,mental health-related quality of life,Quality-of-life scores,adherence to an antidepressant medication,antidepressant adherence and depressive symptom outcomes,patient treatment satisfaction on day 112, measured by the 10- point Satisfaction with Depression Care Scale (SDCS,satisfaction with depression treatment,Recovery rate,complete remission from depression,mean depression scores,standard laboratory tests to measure glycemic control and the Center for Epidemiologic Studies Depression Scale (CES-D) to assess depression,episodes of relapse/recurrence,remission,adherence to an oral hypoglycemic,HRQL, physical functioning, and mood symptoms,mean Hopkins Symptom Checklist (HSCL) Depression Scale scores (L. Derogatis, K. Rickels, E. Uhlenhuth, & L. Covi, 1974,Hamilton Depression Rating Scale (HAMD), the Medical Outcomes 36-item Short Form (SF-36), the DIS, the Mini-Mental State Examination (MMSE), the Older Americans Resources and Services (OARS) questionnaire to assess basic and instrumental activities of daily living (OARS-ADL and OARS-IADL) and the Rating Scale for Side Effects,depression outcome,reductions in TAU outpatient visits,medical visit for mental health problems,quality of care, mental health outcomes, and retention of employment,SCL-20 item score), remission (mean SCL-20 item score, <0.5), and depression-free days,raw rates of suicidal ideation,intensity and frequency of visits,posttraumatic stress disorder (PTSD) and depressive symptoms, episodic alcohol intoxication, and functional limitations,depression severity,depression response, defined as a Hamilton Depression Inventory score <8 (remission,Hopkins Symptom Checklist; social functioning,rate of new prescriptions,mothers' awareness of their depression diagnosis,adequate dosage of antidepressant medication,pedometer readings; depression, coping, and health-related quality of life,suicidal ideation and depression,depressive symptoms,MH problems,moderate depression severity,hemoglobin A1c levels,anxiety and depressive symptoms, mental health-related quality of life, and employment status,depression-free days,proportion of patients fulfilling criteria for DSM-III major depression,treatment adherence, report of remission and functioning,physical activity,Telephone assessments of panic, anxiety sensitivity, depression, and disability variables,clinical outcomes,Blood pressure,patient adherence,depression outcomes,health functioning,depression severity (Hopkins Symptom Checklist Depression Scale and the Patient Health Questionnaire), patient-rated improvement, and satisfaction with treatment,incremental cost of feedback plus care management,suicidal ideation, resolution of ideation,mean duration of the index episode,symptoms of depression (PHQ-9,treatment engagement rate, and the secondary outcome was treatment response,depression care,higher mental health-related quality of life,mental health, social functioning, and general health perceptions scales of the SF-20,Prescription rates of antidepressant medication,lower depression severity,assessment of mood symptoms (Hamilton Rating Scale for Depression [HRS-D]), physical HRQL (SF-36 PCS), and functional status (Duke Activity Status Index [DASI]); and hospital readmissions,mean HRQL and physical functioning,Beck Depression Inventory,probability of both receiving at least moderate doses of antidepressants,antihypertensive medications,BPI pain severity,Pain and depression,quality of mental health care,satisfaction and clinical outcomes,depression and quality of life,psychiatric diagnoses,recurrent depressive episodes,structured assessment (severity of depression, medication adherence, side effects), algorithm-based feedback to the patient and treating physician, and as-needed facilitation of follow-up care,Adherence,6-month Patient Health Questionnaire (PHQ9) scores; baseline and 6-month Short Form (SF) 12 scores; Medicaid claims data; questionnaire on patients' perceptions of treatment; GCM case notes; physician and office staff time study; and physician and office staff focus group discussions,Outpatient visit and hospitalization rates,LDL cholesterol levels,satisfaction with care for diabetes, coronary heart disease, or both (P<0.001) and with care for depression,relapse or recurrence, the median time to recurrence,patients diagnosed with major depression,favorable course of depression in both degree and speed of symptom reduction,anxiety, depression, and disability measures,Depressive symptoms assessed by Center for Epidemiological Studies-Depression Scale (CES-D) score,adherence,overall physical health (SF-12 PCS scores,suicidal ideation,glycated hemoglobin levels,Severity of depression,Symptomatic outcomes,recovery from depression,Additional secondary outcomes (antidepressant adherence and use of health services,rates of mental health care,Hamilton Depression Rating Scale,adherence to antidepressants, satisfaction with care, and depressive outcomes,Overall response rates,feasibility, acceptability, and effectiveness,major depressive disorder,mean HDRS score,minimal anticipatory anxiety, and agoraphobia subscale score <10 on Fear Questionnaire) and responding (Anxiety Sensitivity Index score <20) and change over time in World Health Organization Disability Scale,satisfaction,mental health-related quality of life assessed by Mental Health Summary Score (MCS-12) and satisfaction with mental health care assessed using a 5-point scale,depressive disorder-free and symptom-free times,quality of life,simultaneous modeling of glycated hemoglobin, low-density lipoprotein (LDL) cholesterol, and systolic blood-pressure levels and Symptom Checklist-20 (SCL-20) depression outcomes,referral rate to mental health services,hemoglobin A1c (HbA1c) levels,substantial contamination,Depressive symptoms,greater adherence,larger gains in mental health status and health-related quality of life,control of medical disease and depression,favorable depressive outcomes,Functional Assessment of Cancer Therapy Scale,mean Patient Health Questionnaire-9,depressive symptoms or satisfaction,improving AD use rates,emotional,Response rates,lowering HIV symptom severity,BPI,Subjects' depressive symptoms, health status, and satisfaction with care,patients' blood pressure, increased physical activity, and decreased depressive symptoms,treatment rate,depressive symptoms and acute care visits, worse general and mental health,categorical depression responder,mood symptoms,Hamilton depression rating score (HDRS) and the SF-36 to assess depressive symptoms and quality of life, respectively,patients' functioning and quality of life,health outcomes (probable depression and health-related quality of life [HRQOL]), and employment,A1C, diabetes complications, self-care management, or BMI,symptoms of depression as assessed by the PHQ-9,rates of antidepressant adherence,depressive symptoms and improved social functioning,proportion of responders (> or = 50% reduction from pretreatment BSI-12 score) and remitters (total BSI-12 score < 6,severity of illness, length of hospital stay, health services and medication use, mortality and process of care,CBT effect,Hamilton Depression Rating Scale and the Beck Depression Inventory,Primary outcomes (depressive symptoms, patient satisfaction with health care,emotional well-being,clinical symptoms and functional status,rate of antidepressant prescription,mean PHQ-9 values in depression symptoms,mental health and substance abuse visits,Suicide rates,symptom improvement,severity of depressive symptoms,depressive symptomatology,quality of care, health outcomes, and employment,Visits, antidepressant prescriptions, and overall use of health care,Baseline A1c levels,mean Symptom Checklist-20 depression score,suicidal ideation and depressive symptoms,depression response,GCMs,major depressive disorder episodes,physical functioning (DASI,energy, mental health and the standardized psychic scale,adherence to antidepressant regimens and satisfaction with care,World Health Organization Disability Scale,mean Beck Depression Inventory (BDI) score,SF-36 Mental Component Score,number of women taking antidepressants,Satisfaction and retention,Symptom Checklist-90 Depressive Symptom Scale,BDI severity,BDI mean scores,resource utilization,clinical and functional outcomes,time in depression severity,remission rates and improved indicators of emotional and physical functioning,short-term (30-day) and long-term (90-day) use of antidepressant medication at guideline dosage levels, satisfaction with overall care for depression and antidepressant medication, and reduction in depressive symptoms,quality of life, and lower pain levels,medication adherence, glycemic control, and depression outcomes,higher rating of patient-rated global improvement,rate of improvement,report treatment response,Mental health-related quality of life (HRQL,categorical pain responder,Depression severity,mental HRQL,Form Health Survey (SF-12) emotional, physical, and pain-related functioning; Sheehan disability; financial situation; and number of social stressors,adherence to adequate dosage of antidepressant medication,satisfaction with mental health care,feasibility, acceptability, and efficacy,PHQ-9 effect size,systolic blood pressure,step counts,Twelve-item Brief Symptom Inventory (BSI-12) anxiety and somatic symptoms score,instrumental activities of daily living (IADLs,HSCL,depressive symptoms and improved health status,depression improvement,probability of major depression,anxiety and fatigue but not pain or physical functioning,rate their health as fair or poor,17-item Hamilton Rating Scale for Depression (HAM-D17) total score, response (50% decrease from baseline HAM-D17 score), and remission (HAM-D17  7,lower Symptom Checklist depression scores,SCL-20 depression scores,satisfaction with depression care,antihypertensive medication,depression symptomatology,proportion of patients receiving prescriptions and cognitive behavioral therapy,physical functioning,Ham-D scores,Epidemiology Depression Scale,Depression (CES-D) scale,Rates of suicidal ideation,Hopkins Symptom Checklist (SCL-20), Short Form (SF)-36, Sheehan Disability Scale,pain and depression outcomes|Those randomized to CM exhibited less MH problems at the conclusion of the trial, indicating that the close monitoring program is effective, feasible and valuable.
not found|Mean weekly seizure frequency (complex partial and tonic-clonic,partial seizures and cognitive function,antiepileptic efficacy,total number of seizures,Serum VGB concentrations,drowsiness, confusion, nausea, irritability, and constipation,Minor neurological side effects,Loss of efficacy,median complex partial seizure frequency,frequency of complex partial seizures and partial seizures secondarily generalized,efficacy and tolerability,seizure frequency,vigabatrin serum levels,motor speed and overall score,Global efficacy ratings,laboratory parameters, brain magnetic resonance imaging, evoked potentials, cognitive function, or psychosocial tests,efficacy and safety,Serum levels,Fatigue, drowsiness, and dizziness,electrocardiogram (ECG), electroencephalogram (EEG), and visual-, auditory-, and somatosensory-evoked potentials,seizures,drowsiness and visual disturbances (diplopia, ataxia, visual abnormalities,Plasma concentrations,appearance of vertigo, headache, dysarthria, and ataxia,multifocal electroencephalographic abnormalities,complex partial seizures, "temporal" electroencephalographic abnormalities,complex partial seizure frequency,adverse events,efficacy and good tolerability,VGB,severe adverse effects,serious systemic toxicity,Serum concentrations of phenytoin,seizure control,mild drowsiness,Adverse effects,overall incidence of adverse events,median monthly frequency of seizures,psychological effects,partial seizures,Seizure frequency,Tolerability,Adverse effects, particularly drowsiness and mood changes,cognitive abilities and quality of life,therapeutic successes,weekly seizure occurrence,total number of seizures and the number of partial seizures,plasma concentrations,response to vigabatrin,Cognitive function, including measures of memory and concentration, mood, and behaviour|Vigabatrin was found to be an effective and well-tolerated antiepileptic drug when used as adjunctive therapy in patients with difficult to control complex partial seizures and for partial seizures secondarily generalized.
50|Pain scores,Pain scores, progress of labour and fetal outcome,degree of analgesia,Relief of low back labor pain,Pain score,Mean pain reduction,relief scores,pain relief,progress of labour and fetal outcome,median reductions in visual analogue scores,labour pain,visual analogue scores,median pain score,analgesic efficacy,mean VAS score,analgesic effect,analgesic effect or pain,low back labor pain,back pain,maternal age and weight, gestational age, parity and gravidity and degree of effacement,Reduction of labour pain,Pain perception,patient acceptability,adverse effects,median visual analogue scale pain score for labour pain,Mean pain scores,Pain intensity,initial pain score,Pain severity,time to delivery and rate of instrumental and cesarean delivery,pain scores,numerical rating scale,relief of pain|Mean pain reduction were significantly greater in the treatment group compared to the placebo group at 30 minutes,
23|motor performance,MDI and PDI,Development Scale,abnormal motor development,developmental benefit from long term family support after preterm birth,infant development (cognitive, motor and language), behavioral regulation, caregiver-child interactions and caregiver mental health,cognitive, motor or behavioral outcomes,motor and mental performance,periventricular leukomalacia,Bayley mental and motor scores,perinatal hypoxia or abnormal neurosonography,mental development index (MDI,age of loss or acquisition of reflexes and general abilities,height, weight and head circumference,Psychomotor Developmental Index,weight gain,Intelligence tests,corrected age and include cognitive, motor and language development assessed with the Bayley Scales of Infant and Toddler Development (Bayley-III,Infant Behavioral Assessment (IBA,cognitive, motor and behavioral problems and parenting stress,realistic developmental milestones and child-rearing attitudes,parental stress,IBAIP improved the mental, motor, and behavioral outcomes,Psychomotor Development Index,mental development and on the quality of caregiver-infant interactions,Mental Development Index,Mean birthweight and gestational age,neurological development,Maternal anxiety status (STAI) and maternal feelings of confidence in dealing with her baby (LCC,average mental development index (MDI,optimal growth, Denver scores, and face-to-face interactions,risk of cognitive, motor and behavioral problems,favorable perception of infant temperament,self-confidence and satisfaction,Mental Development Index or Psychomotor Development Index scores,Mental Developmental Index,cognitive scores,psychomotor development index (PDI,disabling cerebral palsy (CP,infant cognitive development and maternal coping,prevalence of CP,parenting stress,Neurobehavioral functioning,Behavioral Rating Scale of the BSID-II,personal-social subscales,practical reasoning,CBCL syndrome scales,Orientation and State Regulation of infant behavioural profiles, the STAI and LCC scores,cerebral palsy diagnoses,Bayley mental scores and the Home Observation for Measurement of the Environment (HOME) inventory,caregiver-child interaction measured using an observational task, and infant behavior, parenting, caregiver mental health and social support measured via standardized parental questionnaires,mental development scores,social development,T group's motor performance,IBA,Bayley mental developmental index (MDI) score,Bayley Scales of Infant Development and the Child Behavior Checklist/2-3 (CBCL) and the Parenting Stress Index,biological factors,motor development assessed using the Alberta Infant Motor Scale and the Neurological Sensory Motor Developmental Assessment,mean neurodevelopmental scores,Mean (SEM) Griffiths quotients (GQ,Parental compliance,cognitive or motor outcomes,cognitive, motor and behavioral outcomes,neonatal neurobehavioural development and maternal mental health,mental development,Motor performance,eye-hand coordination,Developmental and behavioral outcomes,cognitive, motor and behavioral outcomes and parenting stress|Orientation and State Regulation of infant behavioural profiles, the STAI and LCC scores significantly improved in the EIP group (mean difference (95% CI):
20|pain and discomfort,pain score,Good quality impressions,Severe crowding,dental crowding and pain,level of discomfort,Good quality alginate impressions,degree of tooth alignment,crowding alleviation,Demographic and clinical characteristics,coefficient of reliability,VAS scores,score tooth pain,visual analog scale (VAS,frequency of analgesic consumption,Anterior irregularity,Initial orthodontic pain,pain experience,nature, prevalence, intensity, and duration of pain,Pain perception,prevalence, intensity, and duration of pain,pain perception,rate of alignment,pain/discomfort,pain response,Pain and discomfort,Effective tooth movement,probability of crowding alleviation duration,pain,aligning capability|When tooth movement was analysed the mean movement per contact point for Titanol was 1.7 mm and for Nitinol 1.42 mm.
not found|pain relief and sufficient paraesthesia coverage,Limb survival, patient survival, quality of life and cost-effectiveness,frequency of minor and major amputations,prior vascular leg surgeries,sex distribution, ischemic skin lesions, risk factors and several key group mean physiological values including ankle systolic pressure, ankle/brachial ratio (ABI) and foot TcPO2,Quality of life,Long-term pain relief,pain relief,limb salvage,mean ABI,TcpO2,limb salvage rates,cumulative limb survival,TcPO2,amputation rate,limb survival rate,Limb salvage and amount of tissue loss,regional perfusion index,probability of limb survival,heal ulcers or toe amputation wounds,amputation levels,Tissue loss,Foot TcPO2,limb survival,SCS provided long-term pain relief but limb salvage,pain relief and ulcer healing quality of life,total healing of foot ulcers,Fontaine stage II (claudication pain, no rest pain or lesions,temporary TcPO2 elevations|In the SCS-Match group a significant improvement in pain relief (p < 0.005) and TcpO2 (p < 0.001) was seen.
42|rectal temperature,modified Rankin Scale,mean duration of hypothermia,Mean diffusion-weighted imaging (DWI) lesion growth,Fever,Body temperature,Final neurological impairment (Scandinavian Stroke Scale score,mean time from symptom onset to thrombolysis,change in NIHSS,CBT,lower body temperatures,mean modified Rankin Scale score,Mean DWI lesion growth,Mortality,Body temperatures,Feasibility and safety,Elevated core body temperature (CBT,NIHSS scores,Target temperature,hypothermia,body temperatures,mean CBT,body temperature,myocardial infarctions without sequelae,Blood cytology, biochemistry, ECGs, and body temperature,rapid ventricular rate|Fever of greater than 37.5 degrees C occurred in 36.4% of patients in the placebo group, compared with 5.0% in the acetaminophen group (Fisher's exact test, p = 0.014).
||
32|MADRS total scores,17-item Hamilton Rating Scale for Depression,HARS scores,pure dysthymia and in double-depression,Anticholinergic symptoms and sleepiness,efficacy variables (i.e. Hamilton Rating Scale for Depression, final overall efficacy assessment, Clinical Global Impression and symptom check list self-rating,somatic anxiety,global clinical rating and patients' self-rating (HSCL,Hamilton Rating Scale for Depression,Montgomery-Asberg Depression Rating Scale,initial MADRS total score,Hamilton Depression Rating Scale,safety and efficacy,adverse events,safety and antidepressant efficacy,Hopkins Symptom Checklist,DSM-III-R symptom criteria,self-rated version of the Inventory of Depressive Symptoms,Montgomery and Asberg Depression Rating Scale (MADRS), the Hamilton Anxiety Rating Scale (HARS), and the Check-List for the Evaluation of Somatic Symptoms of J.D. Guelfi and C.B. Pull (CHESS 82,response rates,clinical rating-scale scores,anxious-depressive symptomatology,Hamilton Depression Scale, the Widlocher Psychomotor Retardation Scale, and the Andreasen Negative Symptoms Scale,side effects|In 32 Dysthymic patients, phenelzine in high doses was found to be superior to imipramine.
24|nausea,Exhaled carbon monoxide and cotinine-confirmed continuous abstinence rates,efficacy, safety, and tolerability,Smoking-cessation rates,continuous abstinence rate (CAR), defined as no reported smoking (not even a puff) or other nicotine use and confirmed by end-expiratory carbon monoxide level,cardiovascular events or mortality,cigarette smoking abstinence rates,continuous quit rates,smoking abstinence rates,prevalence abstinence rates,Nausea,tolerated, with nausea,Nausea, headache, and insomnia,CARs,efficacy, safety and withdrawal symptoms,Overall abstinence,abstinence outcomes,abstinence rates,Craving, withdrawal, and smoking satisfaction,Continuous abstinence,Serious adverse events,7-day PP,constipation,cardiovascular mortality,Rates of smoking,Efficacy and safety,Efficacy and tolerability,smoking cessation,continuous abstinence rates,effective smoking cessation,exhaled carbon monoxide-confirmed 4-week rate of continuous abstinence from smoking,gastrointestinal disorder,medication adherence,increased appetite,craving and nicotine withdrawal symptoms,serious adverse events,continuous abstinence,nasopharyngitis,motivation to stop smoking or withdrawal symptoms,efficacy and tolerability,Gastrointestinal adverse events,Adverse events (AEs,Nicotine withdrawal symptoms,insomnia,CAR,tolerability assessment,Overall adverse events,percentage of abstinence,cardiovascular events,efficacy, tolerability, and safety,CAR from weeks 9 to 24 and 7-day point prevalence (PP) of abstinence,rate of sustained 12-month abstinence,withdrawal symptoms, motivation, utilization of treatment, and medical events,depression-related adverse events,Superior CARs,continuous abstinence rate,carbon monoxide-confirmed continuous abstinence rate,CAR from Weeks 9 through 24, 7-day point prevalence of abstinence, safety assessments, and measures of craving, withdrawal, and smoking reward,psychiatric SAEs,headache,anxiety,carbon monoxide-confirmed continuous quit rates,Hughes and Hatsukami Minnesota Withdrawal Scale,efficacy and safety,Minnesota Nicotine Withdrawal Scale, the Brief Questionnaire of Smoking Urges, and the modified Cigarette Evaluation Questionnaire,Craving,Minnesota Nicotine Withdrawal Scale, the Brief Questionnaire on Smoking Urges, and the modified Cigarette Evaluation Questionnaire,Adverse events,Nausea, abnormal dreams, upper-respiratory tract infection, and insomnia,carbon monoxide-confirmed continuous abstinence rate (CAR,adverse events,carbon monoxide-confirmed 4-week continuous quit rates,continuous abstinence rate (CAR,Overall, medication compliance,vital signs, adverse events (AEs), and smoking status,7-day point prevalence for abstinence,skin allergy,12- and 24-week smoking-abstinence rates, safety and withdrawal symptoms including stress,carbon monoxide-confirmed continuous abstinence,bupropion rate,abstinence relapse,cause mortality,abnormal dreams,smoking abstinence|Smoking-cessation rates at the end of treatment were 59.5% with varenicline versus 32.3% with placebo (P < 0.001).
60|number of circulating PMNLs, (2) their intrahepatic sequestration, (3) their systemic activation,peak concentration of alanine transferase and glutathione-S-transferase,Mean,Morbidity and mortality,postoperative liver function,postoperative outcome,morbidity or mortality rates,liver tolerance to ischemia-reperfusion,serum alanine aminotransferase levels,blood loss,resected liver tissue,Peak postoperative concentrations of aspartate transferase,Pringle maneuver, activation of PMNLs and cytokine plasma levels,degree of their postischemic activation and the postoperative rise in liver enzyme serum levels,Morbidity and mortality rates and lengths of ICU and hospitalization stays,Complications, including death, severe liver dysfunction and biliary leakage,Intraoperative blood loss,SD time,attenuation of superoxide anion production, beta(2)-integrin up-regulation, and interleukin 8 serum concentrations,Serum concentrations of aspartate transferase, alanine transferase, glutathione-S-transferase, and bilirubin and prothrombin time|Morbidity and mortality rates and lengths of ICU and hospitalization stays were similar in both groups.
                
14|total lung capacity,mean (SEM) functional residual capacity,Wet and dry weight of sputum,removal of lung radioactivity,clearance of lung radioactivity,removal of mucus: cough,Mucus transport,Wet and dry weights of sputum,whole lung or regional TBC,Shwachman-Kulczycki clinical score,postural drainage,Functional residual capacity and total lung capacity,positive expiratory pressure breathing,whole lung and regional tracheobronchial clearance (TBC,Lung function,PEP-induced lung function improvement per milliliter of sputum,Lung volumes,physiotherapy maneuvers,number of spontaneous coughs,radioactivity content,whole lung TBC,postural drainage plus percussion|Lung function improved significantly after PEP, AD, and PEP-AD, but PEP-induced changes did not exceed those after AD.
100|pain,range of motion, swelling about the knee, and pain,passive range of motion after total knee arthroplasty,pain at rest, stiffness, 50 foot walking time, quadriceps muscle strength, and knee flexion degree|The results showed (a) that all three methods could be effective in decreasing not only pain but also the objective parameters in a short period of time; and (b) that the treatment results in TENS, EA and ice massage were superior to placebo.
300|frequency of postinterventional pancreatitis and hemorrhage,Success rate of SBDC,shorten cannulation and fluoroscopy times,likelihood of post-ERCP pancreatitis,success rate of cannulation,serum amylase,success rate of selective CBD cannulation,PEP,procedure-related mortality,serum amylase and lipase tests,acute pancreatitis,SBDC success rate or incidence of PEP,incidence of acute pancreatitis,post-ERCP pancreatitis,number of insertions of the guide wire into the pancreatic duct,Rates of accidental pancreatic duct cannulation,SBDC time, fluoroscopy time, and incidence of complications,ease of cannulation of common bile duct (assessed by attempts required for common bile duct cannulation & rates of precut sphincterotomy) and overall complication rates,Selective cannulation rate,overall selective cannulation, time to cholangiography, number of pancreatic opacifications and guide-wire pancreatic duct insertions, and complication rates,incidence of PEP,Rates of overall complication,success rate of selective cannulation,risk of PEP,Overall rate of PEP,suspected sphincter of Oddi dysfunction,overall cannulation success rate,successful cannulation of the common bile duct,Pancreatitis,complete filling of the pancreatic duct,SBDC success rate,Pancreatic opacifications,overall cannulation rate|Rates of accidental pancreatic duct cannulation were 21 in group I and 27 in group II, P= 0.34.
not found|nausea,abdominal pain,proportion of patients entering first remission,Remission,prednisone for relapse,severe adverse event,mean Harvey-Bradshaw index,CD activity index,side effects|Fewer patients in the methotrexate group than in the placebo group required prednisone for relapse (11 of 40 [28 percent] vs. 21 of 36 [58 percent], P=0.01).
400|vital status, venous thromboembolism, and postthrombotic syndrome,Postthrombotic syndrome,Deep-vein thrombosis,Symptomatic pulmonary embolism,risk of pulmonary embolism,survival,pulmonary embolism|At 8 years, vena cava filters reduced the risk of pulmonary embolism but increased that of deep-vein thrombosis and had no effect on survival.
not found|children's perceived athletic competence, physical appearance, social acceptance, behavioral conduct, and global self-worth; increased their figural creativity; and improved aerobic power,self-concept scores,psychological status and physical fitness,five activities (aerobic dance, jogging for fitness, swimming for fitness, life saving, and weight training,total positive self,agility and self-esteem,self-concept, depression level, and physical fitness of juvenile delinquents,academic achievement or motor proficiency,children's creativity, self-perception, and aerobic power,self-concept, mood, and fitness,cardiovascular fitness, agility, and self-esteem,Self-esteem,Running performance,50-m dash performance or perceptual skill,heart rate,physical fitness,self-concept and physical fitness,Total Positive Self-concept scores and increase in sports skills,self-concept, academic achievement, motor proficiency, and cardiovascular fitness|The article examines whether participation in an aerobic exercise program (AE), as compared with a traditional physical education class (PE), significantly increased children's perceived athletic competence, physical appearance, social acceptance, behavioral conduct, and global self-worth; increased their figural creativity; and improved aerobic power as measured by an 800-meter run around a track.
not found|exertion changes,exercise capacity and health-related quality of life,body composition,General Health scale,quality of life (QOL,SPPB,6-minute walk, symptoms questionnaire, or SF-36,included affective (Beck Depression Inventory), health-related quality of life (Quality of Life Index, Living Questionnaire of Minnesota, Life Satisfaction Index and Short Form-36 questionnaire) and personality (Eysenck Personality Questionnaire) parameters,Prealbumin and postalbumin concentrations,VO2AT,maximum workloads,HRV index,VO2 kinetics,lower body strength, body composition and quality of life,SVI,Functional capacity,Minute ventilation (VE), carbon dioxide output (VCO2) and oxygen uptake (VO2,exercise capacity and self-reported physical functioning,serum urea clearance (Kt/V) and dialysate urea clearance (DUC,serum urea clearance,aerobic capacity, 'squat test' and Physical Function and Physical Component Scale (SF36,Serum albumin levels, creatinine generation rate (CGR,Mental Component Scale,maximal exercise testing and evaluation of CHD risk factors and risk-factor categories,Cardiovascular (CV) disease,C. Symptom scores,cardiovascular risk profile,variables: pain -37,sleep disturbance -25%, grip strength,change in proteinuria,patients' quality of life,pain, fatigue, sleep disturbance, and biochemical markers,physical work capacity,nutritional status and quality of life,total cholesterol (TC) level, high-density lipoprotein fraction of cholesterol (HDL-C), and body mass index over time,SF-36 questionnaire, and WLmax,cardiorespiratory fitness, measured by time and METs (measure of energy expenditure as ml of oxygen per kg of weight and per minute; 1 MET is equal to 3.5 ml O(2)/kg/min) achieved on a graded exercise test, and quality of life, measured by the SF-36 questionnaire,degree of anemia,heart rate variability (HRV,BDI depression and changes in VO2max,behavioural change, reaction time, lower extremity muscle strength, Kt/V and three components of quality of life,Sickness impact profile scores,muscle strength,overall increase in Kt/V. DUC,lipid and glucose metabolism, hematologic function, blood pressure and work capacity,peak exercise capacity,aerobic capacity,Physical Function subscale,physical performance assessed by the Short Physical Performance Battery score (SPPB,VO2max and VO2AT,CHD risk and maximal exercise capacity,Baseline median (IQR) SPPB score,PWV,pain intensity (measured by the visual analogue scale, VAS), fatigue (VAS), sleep disturbance (VAS), and grip strength (mmHg); biochemical variables-- urea, creatinine, calcium, alkaline phosphatase, phosphorus, cholesterol, HDL-cholesterol, triglyceride, erythrocyte, hematocrit--were evaluated,self-reported depression (Beck Depression Index,vulnerability to arrhythmias,Dialysis efficacy,level of anemia and the HD prescription,CHD risk,physical function and vascular parameters,peak oxygen uptake,peak oxygen uptake measurements,VO2 at anaerobic threshold,included affective (Beck Depression Inventory, BDI), quality of life (Quality of Life Index, QLI) and personality (Eysenck Personality Questionnaire, EPQ) parameters,cardiovascular complications and suffer from impaired exercise capacity,behavioural change, physical fitness, physiological condition and health-related quality of life,dropout rate,quality of life and physical strength,work performance and perception of quality of life, and/or alterations in cardiovascular status,physical performance tests, evaluated by the "sit-to-stand-to-sit tests" and the 6 minutes walking test, and knee extensor muscles strength, evaluated by isometric dynamometry,visceral proteins,serum albumin levels and CGR,QOL scores,favor of exercise,ejection fraction (EF), stroke volume index (SVI) and cardiac output index (COI,fatigue -55,lipid profile, normalized insulin sensitivity and glucose metabolism,anaerobic threshold (VO2AT,Caloric intake and body weight and composition,mean protein intake,HRV index, mean NN interval, and standard deviation NN (SDNN,Maximum lactate values,exercise capacity,DUC,physical function and quality of life,renal functions, cardiovascular fitness, inflammation, and oxidative stress,Oxygen uptake efficiency slope,Parasympathetic activity,behavioural change, physical fitness, physiological conditions and health-related quality of life,physical function and aerobic capacity,diet or body weight,weight, blood pressure, haemoglobin and haematocrit values, cholesterol and Kt/V,physical impairment measures,GFR, hemoglobin, glycated hemoglobin, serum lipids, or C-reactive protein (CRP,heart rate change and perceived exertion,submaximal exercise test, muscle strength, and 6-minute walk test at baseline,resting blood pressure,physician-rated affect or physician-rated Karnofsky index of disability,self-rated Karnofsky index of disability,CV risk,EF,arterial compliance,health-related quality of life indices,depressed HRV index,QLI,participation in pleasant, socially oriented activities,Total body potassium, mid-thigh muscle area, type I and II muscle-fiber cross-sectional area, and protein turnover,level of depression,exercise time,mood, level of depression, and psychosocial functioning,Resting blood pressure,distance traveled during a 6-minute walk test and aortic pulse wave velocity,aerobic capacity, '2-min stair climbing', 'squat test', self-rated health (SF36), blood pressure and lipids,Adequacy of dialysis (Kt/V) and initial levels of each serum protein,performance of pleasant activities,chronic renal failure,maximal heart rate (HR,functional capacity,submaximal exercise test,arrhythmias,Exercise adherence,feelings of improved health, better exercise tolerance, and improved appetite and viewed exercise as enjoyable,exercise capacity, muscle strength, physical functioning and health-related quality of life,resting systolic blood pressure and 24-hour proteinuria,mean BNP levels,24-hour vagal cardiac activity,cardiac vagal activity,LVIDd,Hemoglobin (Hb) values,Physical Component Scale of the SF-36,LVM,Mean protein intake,exercising heart rate,patient's physical functioning,vascular risk profile,Visceral protein status and caloric intake,BDI score value,quality of life,Total body potassium and type,Attendance,Left ventricular volumes (EDV, ESV) and mass (LVM,Life Satisfaction Index,aerobic and fuctional capacity,peak Vo2,maximum O2 uptake (VO2max, At baseline HRV index, mean RR, SDNN, and aerobic capacity,Peak oxygen consumption (VO2 peak,maximal aerobic capacity (VO2max,Transferrin levels,Quality of Life Index,physical capacity (VO2max,augmentation index (augmentation pressure as a percentage of central pulse pressure), peripheral (brachial) and central blood pressures (measured noninvasively using radial tonometry), physical activity, and self-reported physical functioning,change-over-time in right knee extensor muscles dynamometry,self-report of depression,Exercise,dysphoric mood,coronary heart disease risk factors,physical function and arterial stiffness,physical functioning and psychological status,VO2 peak (ET,progression of renal disease,HRV index and maximal oxygen consumption,median maximal work capacity,physical function and greater risk of increased arterial stiffness because of hypertension, metabolic disturbances, and vascular calcification,calcium, phosphorus, HDL-cholesterol and triglyceride levels,STS-60 measurements,Mean intakes,arterial compliance and B-type natriuretic peptide levels,RAND-36 scores, symptoms and depression,percent fat, muscle strength, hematocrit, and self-reported physical functioning,aerobic capacity, physical function and self-rated health,Kilocalorie and protein intakes,prealbumin levels,Overall 10-year CHD risk score,pulse pressure,aerobic and functional capacity,change-over-time,C. Supine bicycle exercise,HDL cholesterol levels,pleasant activities,medical complications,heart rate variability,mean PWV,Adverse events,peak oxygen uptake (peak Vo2); isokinetic muscle testing for muscle strength; and dual-energy X-ray absorptiometry scans for body composition,maximal oxygen consumption,exercise duration,exercise testing duration,protein utilization and muscle mass,level of anemia, the medications and the HD prescription,VO2 peak and VO2 at ventilatory threshold (VT; V-slope,symptoms or health-related quality of life,work capacity, greater strength and energy,incidence of arrhythmias,Eysenck Personality Questionnaire,aerobic exercise capacity and reduced muscle strength,dialysis efficacy, blood pressure and quality of life,resting EF,6-minute walk test distance (intradialytic exercise, +14%; home-based exercise, +11%; usual care, +5%), pulse wave velocity (intradialytic exercise, -4%; home-based exercise,SF-36 Health Status Questionnaire assessed self-reported functioning,aerobic exercise capacity,physical performance, nutritional status and quality of life,knee extensor strength, leisure-time physical activity and self-reported physical function and activities of daily living (ADL) disability,Leucine oxidation and serum prealbumin levels,surrogate markers of CV risk-arterial compliance and BNP levels,behavioural change and physical fitness components such as reaction time, manual dexterity, lower extremity muscle strength and VO2 peak,physical functioning,LV systolic function,Hematocrit,Serum levels of prealbumin, transferrin, and predialysis and postdialysis albumin,capacity,blood pressure and lipids,fitness level|Exercise training was associated with an improvement in the mood, level of depression, and psychosocial functioning of these patients; the sedentary controls either became more depressed or reduced their participation in pleasant, socially oriented activities.
130|loss of lung tissue,change in CT lung density,exacerbation severity,exacerbations, health status and physiological indices,SEM,changes in CT and forced expiratory volume,decline of FEV(1,Exacerbation frequency,degree of emphysema|Self-administered spirometry performed every morning and evening at home showed no significant difference in decline of FEV(1) between treatment and placebo.
127|pulpal health and restoration longevity,Hall PMCs,normal clinical and radiographic conditions,pulp vitality without apical radiolucency,level of colonization,unacceptable discomfort,Retention rate, marginal integrity, and pulpal symptoms,preoperative signs and symptoms of irreversible pulpitis,risk of pulp exposure,deep carious lesions|The teeth with no pulp exposure after direct or stepwise excavation showed normal clinical and radiographic conditions at the last check-up (mean = 43 months).
20|verbal numerical pain scale,PI and PT,pain (visual analogue scale,subjective pain intensity [(PI) with a visual analog scale], pressure pain threshold [(PT) with algometry], and range of motion [(ROM) with a goniometer] of upper trapezius muscle (lateral bending of cervical spine to the opposite side,ROM, EMS,Pain,NPDVAS, algometry, in myofascial trigger point characteristics, and in the ROM (homolateral rotation, controlateral rotation, bending and extension,IThC, IToC, IVC, and IRC,pain relief, ENS,NPDVAS, algometry, TP characteristics, and cervical contralateral rotation,VAS, NPDVAS, algometry,neck muscle strength,pain, pain on motion, and both the patient overall assessment and the physician global assessment,quick symptom reduction,IThC, ItoC, and IVC,Northwick Park Neck Pain Questionnaire score,B4 (B1 plus stretch with spray), B5 (B4 plus TENS), and B6 (B1 plus interferential current and myofascial release,pain, pain on motion, and tenderness,myofascial trigger points,average time until pain relief and painless walking,pain and disability,Pain levels,Neck pain,pain levels (VAS, NPDVAS and algometry), the myofascial TP characteristics and the range of cervical movement (ROM,2 treatment pressures (P1, pain threshold; P2, averaged pain threshold and tolerance,pain threshold (IThC), pain tolerance (IToC), visual analog scale (IVC), and ROM (IRC,IRC,neck pain and disability visual analogue scale" (NPDVAS), an algometric evaluation of pain, an evaluation of the TP characteristics, and the range of cervical bending and rotation contralateral to the affected trapezius muscle,cervical myofascial pain and trigger-point sensitivity,Back pain and the whiplash syndrome,proximal conduction time of the ulnar nerve,algometry and cervical extension,ROM,pain and range of movement,myofascial pain,values of verbal numeric pain scale, Northwick Park Neck Pain Questionnaire, and isometric neck muscle strength,cervical mobility,pain levels using the neck pain and disability visual analogue scale (NPDVAS) and algometry, evaluation of myofascial trigger point characteristics and measurement of the range of cervical movement (range of motion, ROM,active ROM, paravertebral muscle spasm and neck pain and disability scale (NPDS) scores,pain, range of motion (ROM) and functional status,chronic neck and shoulder pain,knee and cervical spine studies,intensity or frequency of pain,pain,excitation threshold of the suprascapular nerve,disability, isometric neck muscle strength, and pain|After 3 weeks, both pain (visual analogue scale (P less than .023) and range of movement (P less than .002) had improved in the group on active treatment compared to the controls.
36|safety and tolerability,Plasma Abeta42 levels,Safety, efficacy,plasma biomarkers of AD or serum Zn(2+) and Cu(2+) concentrations,plasma and CSF biomarkers and cognition,tolerated,category fluency test,adverse event,safety, efficacy, and biomarkers of AD,serious adverse events,CSF Abeta(42) concentration,ADAS-cog, MMSE, and a neuropsychological test battery (NTB,Cognitive efficacy,Plasma zinc levels,early AD (mini-mental state examination [MMSE] score between 20 and 26 points or Alzheimer's disease assessment scale-cognitive subscale (ADAS-cog) score|The effect of treatment was significant in the more severely affected group (baseline cognitive subscale score of the Alzheimer's Disease Assessment Scale, >/=25), due to a substantial worsening of scores in those taking placebo compared with minimal deterioration for the clioquinol group.
996|death of the baby or chronic lung disease,pulmonary morbidity,neonatal mortality,mean (+/-SD) birth weight,CLD,adverse outcomes,Air leaks,chronic lung disease or death of the infant on or before the 28th day after delivery, and secondary outcomes were respiratory distress syndrome and chronic lung disease or death,severity of lung disease,neonatal respiratory morbidity, respiratory distress syndrome and chronic lung disease (CLD) develop,death or chronic lung disease,total incidence of respiratory distress syndrome,Respiratory disease,incidence of respiratory distress syndrome,adverse outcome (chronic lung disease or death,neonatal complications,Fetal lung maturation,number of deaths fell,incidence of other complications of prematurity,chronic lung disease or death,intraventricular haemorrhage and necrotising enterocolitis,bronchopulmonary dysplasia,death,frequency of respiratory distress syndrome,death or continuing oxygen requirement,incidence of chronic lung disease,severe respiratory distress syndrome,respiratory morbidity, in particular respiratory distress syndrome,fetal lung maturation,maternal side effects,risk of death and severe morbidity,frequencies of respiratory distress syndrome,chronic lung disease|Similarly, there were no differences in outcome between the treatment and placebo groups for the infants born at >32 weeks' gestation.
                
not found|pain with heavy work,Thumb pinch strength and range of motion,remaining trapezial space and key pinch force,pinch strength,Two- and three-point pinch strength,range of motion of the thumb, grip strength, lateral pinch strength, the ability to perform activities of daily living, or subjective satisfaction,pain relief, patient satisfaction, mobility, DASH-score, key pinch force and gripping force,Pain, strength, stability, and range of motion,No infection or clinical silicone synovitis,median values for both key pinch and tripod pinch,signs of foreign-body reaction,pain relief,major radiographic cyst formation,Radiographic examination,trapezial height,pain free|Thumb pinch strength and range of motion were not significantly different in the two groups.
10|probability of not needing transfusion, determined by Kaplan-Meier analysis, and the total number of RBC transfusions,polycythemia,initial mean blood pressures,late-onset sepsis (LOS) and intraventricular hemorrhage (IVH,haemoglobin levels,higher blood pressure (BP) and hematocrit (Hct,mean minimum arterial-alveolar oxygen tension ratio,Apgar scores after birth and daily SNAP scores,initial diastolic BP and higher Hct,Mean (SD) blood pressure at admission,median duration of dependence on supplemental oxygen,RBC volume/mass, per biotin labeling, after delayed clamping,multiple clinical and laboratory comparisons over the first 28 days including Score for Neonatal Acute Physiology (SNAP,Circulating RBC volume/mass,bilirubin levels,gestational age and birth weight,haematocrit levels,initial glucose levels,incidence of our primary outcomes (BPD and suspected NEC,median red cell transfusion requirements,RBC volume/mass and Hct, clinical benefits,Apgar scores, temperature on admission, heart rate, blood pressure and requirements for artificial ventilation,initial mean (SD) haemoglobin value,delayed clamping of the umbilical cord and pathological jaundice or polycythaemia,red blood cell (RBC) transfusion and morbidity,initial hematocrit,postpartal adaptation and anaemia of prematurity,weekly hematocrit (Hct) values,neonatal adaptation,Ultrasonographic evidence of periventricular/intraventricular haemorrhage (PVH/IVH,arterial-alveolar oxygen tension ratio and also packed cell volume,blood pressure,RBC transfusions,needed red cell transfusion,Initial packed cell volume, peak serum bilirubin concentrations, red cell transfusion requirements, and respiratory impairment (assessed by ventilatory requirements, arterial-alveolar oxygen tension ratio over the first day in ventilated infants, and duration of dependence on supplemental oxygen,red blood cell (RBC) transfusions,umbilical cord,Higher Hct values,duration of supplemental oxygen dependence and red cell transfusion requirements,mean haematocrits,sepsis,shorter duration of ventilation or supplemental oxygen,neonatal period blood glucose and haemoglobin levels,maternal and infant demographic, clinical, and safety variables,intraventricular hemorrhage and late-onset sepsis,initial bilirubin levels,haemoglobin value and blood pressure at admission,number (mean (SD)) of RBC transfusions,adverse effects,venous haematocrit,Periventricular/intraventricular haemorrhage and umbilical cord clamping,mean initial packed cell volume,mean BP,haemoglobin and ferritin levels,rates of IVH and LOS,mortality|There were no significant differences in Apgar scores, temperature on admission, heart rate, blood pressure and requirements for artificial ventilation.
                
100|voiding problems,Delayed voiding,length of hospital stay,time under vesical drainage presented a minor frequency of urinary retention,postoperative urinary retention,duration of suprapubic vesical drainage with suprapubic catheter,mechanical complications,shorter post-operative hospital stay,rate postoperative urinary retention, urinary tract infection, and stay postoperative,cost-effective, safe and comfortable,Asymptomatic bacteriuria at catheter removal,Postoperative urinary tract infection,infection rate and post-operative morbidity,bacteriuria (10(5) organisms/mL) and positive blood cultures, and duration of hospital stay (days,Voiding discomfort,Residual volumes exceeding 200 mL and need for recatheterisation,recatheterisation, urinary tract infection, mean duration of catheterisation and hospital stay,incidences of preoperative asymptomatic bacteriuria,immediate voiding difficulties,Infection,rate of mechanical complications,success rates,perception of pain,sequence of vaginal cleansing and urethral catheterization,Postoperative normal bladder function,urinary retention after operation, requiring bladder emptying,voiding interview, uroflowmetry and retrograde urethrography,time to first void, volume of first void, time between catheter removal and discharge from hospital, weight of prostatic resection, and tissue pathology,Postoperative urinary tract infection (UTI,incidence of UTI,Mean duration of catheterisation,Mean duration of hospitalisation,median catheterization time,urinary tract bacteriuria,pathology, weight of prostatic resection, mean volume of first void, or time to first void after catheter removal,incidence of complications and the duration of post-operative hospital stay,recatheterization,severe infectious complications,prevalence of significant bacteriuria,Positive urine cultures,length of hospitalization,onset of bacteriuria,duration of continuous catheter drainage,Recatheterization,time to first void or the volume of the first void,rates of both clinical cystitis and asymptomatic significant bacteriuria,rate of recatheterization, febrile morbidity, symptomatic urinary tract infections, or subjective pain assessments,cure rate,urinary tract infection,Bacteriuria,Sponatneous micturition and urinary retention,postoperative bacteriuria at catheter removal,postoperative urinary tract infection rates,febrile morbidity,mean postoperative stay,retention of urine, urinary symptoms and infection,time between catheter removal and discharge from hospital,volume of urine,rate of febrile events, urinary tract infections, or need for recatheterization,length of catheterization,recurrence rate,Postoperative normal bladder functions,mean duration of catheterization,rate of postoperatively impaired bladder emptying,fever,Urinary retention,postoperative bacteriuria,catheter efficacy and morbidity,symptomatic urinary tract infections,urinary tract infection and asymptomatic bacteriuria,bacteriuria,pain,subjective pain assessment,Postoperative acute urinary retention,rate of readiness for discharge,urinary symptoms and fever|Residual volumes exceeding 200 mL and need for recatheterisation occurred in 9% in the standard prolonged catheterisation group versus 40% of patients in the not prolonged catheterisation group (OR 0.15, 95% CI 0.045-0.47).
179|area under the symptom score-hour curve, the proportion of patients with asthma exacerbations and changes in forced expiratory volume,incidence of acute otitis media,median time to resolution of illness,efficacy, safety and tolerability,symptomatic influenza A and B viral infections,safe and well-tolerated,forced expiratory volume,time to freedom from illness,median time to symptom alleviation,time to alleviation of influenza illness,median time to illness alleviation,parental work absenteeism,normal activities,pulmonary function,tolerated,influenza-positive by culture, serology or polymerase chain reaction,exacerbation frequency,Protective efficacy,protective efficacy,Influenza infection rates,asthma exacerbations,relief medications|Oseltamivir-treated patients also experienced fewer asthma exacerbations up to day 7 (68% versus 51%; P = 0.031).
40|head circumference and weight,Mean energy and protein intakes,feeding, weight, and length,higher suck-swallow ratios,proportion of intraoral positive pressure generation,Anthropometric measures-nude weight, crown-heel length (CHL), and occipito-frontal circumference ,faster rate of sucking,weight,Weight-for-age, length-for-age, and weight-for-length (z scores,Mean energy intake,head circumference,Neonatal Oral Motor Assessment Scale,weight gain,CHL,Feeding velocity|It has been a tradition for plastic surgeons to withhold breast feeding from babies after cleft lip repair to prevent wound disruption.
92|toxicity,recurrence pattern,disease-specific overall five-year survival,survival,hazard ratio for progression adjusted for stage,risk of bowel complications,Grade 3/4 nausea,5-year PFS rates,rate of Grade 3/4 leucopenia,small bowel obstruction,grade 3 or 4 cardiac toxicity,overall survival,cancer-specific survival (CSS,progression-free survival (PFS) and overall survival (OS,intestinal complications demanding surgery,progression-free survival (PFS,hazard ratio (HR) for death,stage-adjusted death hazard ratio,PFS rate,tolerated,Adverse effects,median time to recurrence,OS rate,5-year survival rates,5-year OS rates,survival or progression-free interval,risk for relapse or death,progression-free and overall survival,Radiotherapy delayed local relapses and CT delayed metastases,pelvic or aortic node metastasis, cervical involvement, or adnexal metastases,overall and progression-free survival,7-year progression-free survivals,acute toxicity,median disease-free survival,alive and disease free,overall survival (OS,7-year overall survivals,overall and disease-free survival,progression-free survival,acceptable rate of acute toxicity|There was no statistically significant difference in survival or progression-free interval of the two arms.
28|speed of ambulation,pain and function,mean function score,Number of painful days, cosmetic disturbance, and footwear problems were least and functional status and satisfaction,pain, speed of ambulation, and self-rated activity and functional ability levels,level of disability,Foot Health Status Questionnaire,synovitis or function,Foot pain scores,Pain, functional limitations, and quality of life,Foot pain and functional limitations,visual analog scale (0-100), patient assessment of global improvement, number of painful days, cosmetic disturbance, footwear problems, functional status, and treatment satisfaction,pain and improving function,pain and disability,foot pain, function, quality of life, and plantar pressure loading,pain for supportive athletic shoes,first-step pain or pain felt,Pediatric Pain Questionnaire-visual analog scale (VAS), Timed Walking, Foot Function Index (FFI), and the Physical Functioning Subscale of the Pediatric Quality of Life Inventory (PedsQL,foot disability,metatarsal phalangeal (MTP) joint pain,mean pain score,minor adverse reactions, such as tender spots, blisters, and callus,function, foot-related quality of life,FFI total score,pain and functional status,Foot pain and disability, using the Foot Function Index (FFI), along with disease activity, tolerance, and adverse reactions,pain relief for metatarsalgia,disability and pain measures,FFI scores for total score,mean pain scores,activity limitations,physical functioning,Pain intensity,foot pain,Plantar pressure,overall pain,MTP joint synovitis, and lower extremity function,pain intensity,Function scores,child health-related quality of life,pain,side effects,pain reduction|A reduction in mean pain scores from baseline to final visits showed that semi-rigid orthoses had a highly significant effect on pain.
25|Better uncorrected and spectacle-corrected visual acuity and contrast sensitivity,severe night glare,spherical equivalent refraction,Mean spherical equivalent refraction,Mean best spectacle-corrected visual acuity (BSCVA), change in BSCVA, proportion of cases with improvement of 1 or more lines of BSCVA, proportion of cases with BSCVA and uncorrected visual acuity (UCVA,change of two or more lines and safety index (ratio postoperative to preoperative best-corrected visual acuity,predictability +/-0.50 D and stability of manifest refraction,quality of vision,Mean astigmatism correction,mean spherical equivalent refraction,uncorrected visual acuity,safety (BSCVA), efficacy (UCVA), predictability, and stability,Slit-lamp microscopy, manifest refraction, uncorrected and spectacle-corrected visual acuity, contrast sensitivity, and specular microscopy,best-corrected visual acuity and subjective evaluation of quality of vision,Mean endothelial cell loss,safety index,Contrast sensitivity curve|The safety index was significantly better for Artisan (1.12 +/- 0.21) than for LASIK (0.99 +/-
not found|self-reported sleep, but objective sleep,Therapeutic gains,sleep efficiency,sleep disruption,sleep latency, wake after sleep onset, and early morning awakening,sleep complaint,Time awake after sleep onset and sleep efficiency,polysomnographic measures,Sleep improvements|Countercontrol therapy reduced the sleep complaint for the total group by about 30% at the end of treatment, with gradual improvement continuing through a 4-week follow-up.
60|skin complications|Both splints were equally effective in correcting the deformity but the aluminium alloy splint was able to be fitted to a wider variety of finger shapes and sizes and caused significantly fewer skin complications.
not found|duration of induction,Uterine activity,risk for duration of induction to vaginal delivery,Cervical dilatation,mean induction-delivery interval,augmentation of labor with oxytocin,risk for duration >24 h,mean duration of induction,fetal outcome,uterine activity,cervical status,incidence of Caesarean section|Surgical inductions was avoided in 52 per cent of the vaginal group and 40 per cent of the extra-amniotic group.
31|lactic dehydrogenase and alanine aminotransferase,blood pressure, urinary output, lactic dehydrogenase, aspartato aminotransferase and alanine aminotransferase values,systolic blood pressure values,Serious maternal morbidity,laboratory values (platelet count, lactate dehydrogenase activity, aspartate aminotransferase activity) and clinical parameters (mean arterial pressure, urinary output,lactic dehydrogenase and aspartate aminotransferase,platelet counts, alanine aminotransferase, aspartate aminotransferase and lactate dehydrogenase levels,overall maternal morbidity and mortality,maternal platelet count, urinary output, lactic dehydrogenase, alanine aminotransferase, and postponement of delivery,risk of a recurrent HELLP exacerbation,Hematological and metabolic complications,time to recovery of platelet counts,consequence of liver rupture,need for readmission to the obstetrical recovery room,diastolic blood pressure values,mean arterial blood pressure,duration of hospitalization,entry-to-delivery interval and the number of recurrent HELLP exacerbations in the antepartum period,syndrome of hemolysis, elevated liver enzymes, and low platelets (HELLP,liver enzymes and blood pressure,aspartate aminotransferase activity,platelet count,maternal platelet count,mean arterial pressure,mean duration of hospitalization,maternal morbidity,mean arterial pressure, urinary output, platelet count, lactic dehydrogenase and aspartate aminotransferase,Platelet count,HELLP syndrome,antepartum HELLP (hemolysis, elevated liver enzymes, and low platelet count) syndrome,lactate dehydrogenase,antihypertensive treatment,Length of hospitalization,mean entry-delivery interval,course of postpartum hemolysis, elevated liver enzymes, low platelets (HELLP) syndrome,urinary output,mean arterial blood pressure, mean serum aspartate aminotransferase level, mean urine volume per hour and mean platelet count,Arterial blood pressure, urine output, hematocrit ratio, platelet count, serum alanine and aspartate aminotransferases and uric acid levels,time in platelet count,aspartate aminotransferase,Maternal urinary output,percentage of women who received platelet transfusion,urinary output, mean arterial pressure, platelet count, lactic dehydrogenase, and aspartate aminotransferase,mean arterial pressure and urinary output every 2 hours, hematocrit and platelet count every 6 hours and lactic dehydrogenase, aspartate aminotransferase, and alanine aminotransferase,early onset HELLP (hemolysis, elevated liver enzymes, and low platelets) syndrome,maternal mortality|Platelet count recovered faster in the prednisolone group as compared to the placebo group (mean 1.7 days versus 6.2 days, P<0.01).
                
not found|percentage rehospitalized,total number of days hospitalized,hospital readmissions,rehospitalization, arrest, quality of life, symptomatology, treatment noncompliance, and perceived level of coercion,quality of life and level of coercion,total length of court-ordered outpatient commitments,hospital outcomes|Outpatient commitment can work to reduce hospital readmissions and total hospital days when court orders are sustained and combined with intensive treatment, particularly for individuals with psychotic disorders.
4| weight,blood pressure and hypertension incidence,life-style change groups (weight reduction, sodium reduction, and stress management,potassium change,BP,death, health insurance claims,BP decreases,systolic and diastolic BP,mean body weight,cardiovascular mortality,diastolic blood pressure,systolic blood pressure change,hypertension incidence,high blood pressure (BP,hypertensive events,cardiovascular mortality and medical expenses,blood pressure,diastolic pressure,cardiovascular disease (CVD) mortality and medical expenditures,average BP,systolic blood pressure and intervention compliance measures,BP levels,lowering systolic and diastolic BP,Sodium excretion,systolic blood pressure,incidence of CVD-related deaths,mean blood pressures,CVD mortality and medical expenditure,reduced sodium intake,frequency of cardiovascular events,diastolic blood pressure change,urinary sodium excretion,lowering diastolic BP, systolic BP, and the incidence of hypertension,CVD mortality,diastolic blood pressure or systolic blood pressure,CVD survivorship,incidence of hypertension,sodium and weight reductions,systolic BP,weight loss,weight changes|Sodium reduction interventions lowered urinary sodium excretion by 44 mmol/24 h (P less than .01), diastolic blood pressure by 0.9 mm Hg (P less than .05), and systolic blood pressure by 1.7 mm Hg (P less than .01).
72|greatest temperature reduction,discomfort (convulsions, crying, irritability, vomiting and shivering,production of TNF and oxygen radicals,production of oxygen radicals,clinical or laboratory abnormalities,alertness,Rectal temperatures,mean duration of subsequent fever,efficacy, tolerability, safety,mean fever clearance time,Plasma concentrations and inducible concentrations of tumour necrosis factor (TNF) and interleukin-6,temperature decrement and longer duration of antipyresis,Itching, appetite, activity, and overall condition,Activity,antipyretic response,smallest temperature reduction,duration or severity of childhood varicella,time to total scabbing,time to last vesicle formation, time to total scabbing, and time to total healing,induced concentrations of TNF, and the production of oxygen radicals,rapid reduction of fever,parasite clearance time,activity,mood, comfort, appetite, or fluid intake,tolerated,Blood samples, oral temperatures, pulse, blood pressure, and respiration,percentage of fever reduction,Parasite clearance time,Oral temperature,adverse effects,Antipyretic efficacy,antipyretic efficacy,reduction of fever,body temperature,efficacy,Plasma concentrations of TNF and interleukin-6,Rectal body temperature and parasitaemia|The following results were better in the placebo group (p less than .05): time to total scabbing 5.6 days (SD 2.5) versus 6.7 days (SD 2.3) in the acetaminophen group, and itching on day 4 in the placebo group (symptom score 2.9 (SD 0.20) vs 2.2 (SD 0.26].
916|combined incidence of nonfatal stroke (including intracerebral bleeding), pulmonary or systemic embolism, nonfatal myocardial infarction, and vascular death,frequency of noncerebral major bleeding complications,gastrointestinal bleeding|The frequency of noncerebral major bleeding complications was low: only four cases (0.9%) of gastrointestinal bleeding were observed, all of them in the warfarin group.
                
307|determination of drug toxicity using blood tests and ECG and determination of MS-related disease activity, either clinical relapses or new or contrast-enhancing lesions on MRI,relapse rate,serum creatine phosphokinase,number of relapses, EDSS variation and safety laboratory data,final Expanded Disability Status Scale scores,annual rate of documented relapses,blood tests,risk for a 1-point EDSS increase,safety, tolerability and efficacy,SD of gadolinium-enhanced and new T2 lesions,relapse with active lesions on MRI,Mean number of new or enlarging T2 lesions,Annual rate of documented relapses,total relapse rate, Expanded Disability Status Scale score, and the number of gadolinium-enhanced (Gd+) and new T2 lesions in magnetic resonance imaging,Blinded neurologic examinations and brain MRI readings,clinical or MRI disease activity,MRI and clinical disease activity,safety and efficacy,safe and well tolerated,total attack number,adverse events,contrast-enhanced lesion number,Disability Status Scale score,infections or musculoskeletal disorders, including myalgia,cholesterol levels,disease activity|Mean number of new or enlarging T2 lesions was 296 in the simvastatin group and 252 in the placebo group (ratio of new lesions, 117, 95% CI 889 to 155; p=025).
27|survival or immediate neurological outcome,Encephalopathy, multi-organ dysfunction, intraventricular haemorrhage (IVH) and arterial pH at 6h,survival and neurological outcome,death or abnormal neurological examination at discharge,intraventricular haemorrhage (IVH) and the mean arterial pH,Death or abnormal neurological examination at discharge,neurologically abnormal at discharge,incidence of encephalopathy,cerebral oedema,need for inotropic support|The incidence of encephalopathy (74% versus 63%), cerebral oedema (52% versus 30%), need for inotropic support (44% versus 29%), intraventricular haemorrhage (IVH) and the mean arterial pH at 6hrs were similar between the two groups.
                
300|pain and distress of venepuncture,Anticipatory anxiety,Pain,local skin blanching,untoward effects, and AMLI,venipuncture-induced pain,localized erythema,mild local erythema,frequency of untoward effects,analgesic effect,relieving venous puncture pain,adequate pain relief,pain, movement, and verbalization,100-point Visual Analogue Scale (VAS,pain, movement, and verbalization to puncture,adequate analgesia,adverse effects,pain of venous cannulation,shorter application time, vasodilation and lower cost,clinically acceptable anaesthesia,pain,pain scores|Group I (EMLA), subgroup A (< or = 30 minutes), experienced significantly more pain, movement, and verbalization than groups II and III.
100|time spent sleeping,sleeping,crying,parental attention,crying time,daily crying diary,time spent crying, sleeping and being held/rocked on a 24-hour diary,hours of crying,crying behavior,chiropractic spinal manipulation,Overall decline in crying|Thirty two of 46 infants in the treatment group (69.9%), and 24 of 40 in the control group (60.0%), showed some degree of improvement.
                
2|acute postoperative complications,survival,rate of severe stenosis,angina pectoris status and need for anti-anginal medication,lower major adverse events (death, myocardial infarction, repeat revascularization procedures and stroke,cardiac outcome, quality of life, and cost-effectiveness,survival free from stroke, myocardial infarction, and repeat revascularization,maximal pressure for stent deployment,Q myocardial infarction (MI,number of perioperative adverse events,death and myocardial infarction,Survival rates without stroke or myocardial infarction,survival and freedom from MI,cost-effective,learning curve,4-year clinical outcome,patency rate,morbidity, hospital stay, and costs,Freedom from angina pectoris,freedom from major adverse cardiac and cerebrovascular events (MACCEs), including cardiac death, myocardial infarction, stroke and repeat target vessel revascularization,MACCEs,Hospital stay,30-day mortality,overall costs,Restenosis and a positive stress test,functional class, antianginal treatment, and quality of life,incidence of death and myocardial infarction,event-free survival, including death, myocardial infarction, and the need for additional revascularization,Repeat revascularization procedures,Perioperative adverse events,cardiac outcome and quality of life,Reintervention,cardiac outcome,Death,conversion rate to sternotomy,respective repeat revascularization rates,Quality-adjusted lifetime,perioperative myocardial infarction rate,restenosis of the LAD,incremental cost of surgery|The functional class, need for antianginal drug, and quality-of-life assessment showed no significant differences.
                
not found|pregnancy outcomes and midluteal P levels, but luteal phase length,pregnancy outcomes and luteal function,ovulation and pregnancy rates|No statistically significant differences were observed between the two groups in terms of ovulation and pregnancy rates.
211|duration of diarrhoea,number of diarrhoeal episode,diarrhoea frequency,duration of hospital stay,hospital stay,severity of diarrhea and length of hospital stay,overall stools frequency,Acute diarrhoea,treatment failure rates,diarrhea resolve,frequency and duration of acute diarrhoea,duration and frequency of diarrhea and vomiting,ORS consumed, frequency of stools, duration of diarrhea, time for rehydration, hospital stay, weight gain and IVF needed,vomiting and diarrhea,duration of symptoms and of viral excretion,IL-10,Rotavirus,Small intestinal functional capacity,mean stool frequency and improved stool consistency,Median duration of diarrhoea,daily number of stools,daily frequency or duration of diarrhoea or vomiting,safe and well tolerated,Stool frequency,reduced length of hospital stay,duration and the severity of diarrhea,Duration of diarrhea and number of stools,efficacy and safety of Bifilac,duration of diarrhea and number of stools per day,diarrhea duration and stool output,duration of diarrhoea, total diarrhoea stools, or diarrhoea score,diarrhea and colonization of L. reuteri,time to recovery,Stool-reducing substances,7-day response,duration of diarrhea and assessment of stool consistency,average stool frequency,frequency of diarrhea stools,response rate (reduction of daily stool frequency to < or =3 watery or loose stools,weight gain,mean (SD) duration of watery diarrhea,colonization of the gastrointestinal tract,safe and well-tolerated,Intake-output,nonrotavirus diarrhea,Hospital stays,geometric mean,severe rotavirus diarrhea,duration of diarrhea,frequency and duration of diarrhoea and vomiting,diarrhea frequency,acute nonbloody diarrhea,stool frequency and duration of hospitalization,median percent weight gain,Hospital stay,duration of parenteral rehydration, adverse events, and gastrointestinal tract colonization by administered strains,clinical response,diarrhea,diarrheal phase,total stool weights,loose stools,Mean duration of diarrhea,duration of rotaviral diarrhoea,daily stool frequency, vomiting, and fever,patients'characteristics and baseline clinical symptoms,success rate (cessation of diarrhea and appropriate weight gain,good colonization of the GI tract,frequency of loose stools,frequency and duration of diarrhea,mean duration of diarrhoea,duration of diarrhea at home, serum sodium & potassium and dehydration degree,acute rotavirus diarrhea,acute watery diarrhoea,acute diarrhoea,lactose concentration,shorter duration of watery diarrhoea,Degree of dehydration, duration and volume of oral rehydration salt [ORS] therapy, duration and volume of Intra venous fluids and duration of rotaviral shedding,beta-glucuronidase, beta-glucosidase, and glycocholic acid hydrolase levels,tumor necrosis factor-alpha values,duration of diarrhoea and daily number and consistency of stools,serum immunoglobulin A and decreases in C-reactive protein levels,Duration of diarrhea,Gut colonization,duration of the diarrhoea,Anthropometric parameters, duration of the diarrhoea and rotavirus shedding,efficacy and tolerability,time of intravenous rehydration,number of stools,daily frequency and total duration of diarrhoea and vomiting and the length of hospital stay,shorter duration of diarrhoea,duration of diarrhea and of hospitalization,adverse reactions,median onset of treatment response (reduction of daily stool frequency,overall ORS requirement,rotavirus infection,duration of vomiting and fever and rate of admission to hospital,length of hospitalization,rate of success,Frequency and consistency of stools,rotavirus antigen,incidence of antibiotic-associated diarrhoea,Mean duration of hospitalization (days), weight gain, and reduction in diarrhea frequency,number of rotavirus-positive children with watery stools,frequency and duration of diarrhea, requirement for intravenous therapy, and hospital stay,acute diarrhea,cumulative stool output,watery diarrhea,overall recovery rates,Counts of Bifidobacteria and Lactobacillus species,daily stool frequency,Weight gains, period of hospitalization, and reduction in diarrhea frequency,frequency of episodes of diarrhoea,resolution of bowel abnormalities,percentage of children with persistent watery diarrhea,duration of watery diarrhea,Stool output and frequency, oral rehydration solution intake, and excretion of rotavirus,duration of diarrhea during hospitalization,Safety and tolerance,Number of episodes (frequency) of diarrhea,rotavirus shedding,median (range) duration of diarrhea,period of rotavirus excretion,median duration of diarrhea,duration of diarrhea and normalizes stool consistency and frequency,stool frequency,Kaplan-Meier survival analysis,Clinical failure,risk of having diarrhoea lasting,frequency and duration of diarrhea and reduction in hospital stay,Diarrhea,proportion of patients with continuing diarrhea,percentage of CD8 lymphocytes,watery diarrhoea,diarrhoea,duration of rotavirus excretion,mean loose stool frequency and frequency of ORS use and frequency of intravenous fluid use,shortening of the duration of diarrhea,adverse events,mean (+/-SD) duration of watery diarrhea,acute watery diarrhea,mean duration of diarrhea (in days) degree of dehydration, duration and volume of oral rehydration salt [ORS] therapy, duration and volume of intravenous fluid [IVF] therapy, duration of rotaviral shedding (P<0.01,median duration of hospitalization,sucrose breath test,mean (+/-SD) duration of diarrhea,mean duration of diarrhea,duration of acute diarrhoea and the duration of hospital stay,stool frequency and duration of diarrhea,bacterial enzyme profile: urease activity during diarrhea,frequency of vomiting, mean loose stool frequency, stool consistency, and mean frequency of oral rehydration salts (ORS) and intravenous fluids administered,Interferon- gamma and IL-12,frequency of diarrhea,duration of rotavirus diarrhoea,mean hospitalization days,Output of urine, stool, and vomitus,diarrhea duration,duration of diarrhea or numbers of stool,side effects,persisting diarrhoea|Patients receiving SF 68 had a reduced duration of diarrhea compared with placebo, with a highly statistically significant difference between treatments.
not found|Survival,weight gain and head growth,mean daily weight gain,Level III NICU,stable milk production,duration of hospital stay,hypothermia, hypoglycemia, and sepsis,severe morbidity,Infant physiological data, ie, oxygen saturation, heart rate, respiratory rate, and axillary temperature; maternal milk production; and duration of breast-feeding,Oxygen saturation,weight gain,Nosocomial infections,number of mothers exclusively breastfeeding their babies,average weight gain per day (KMC,infant temperature, heart rate, or respiratory rate,duration of KMC,breast feeding rates, weight gain and length of hospitalization,low-birth-weight infants' physiological profile, maternal milk production, and duration of breast-feeding,number of years of maternal education,Body weight loss,coregulation behavior,Adverse events and duration of hospitalization,mortality, infectious episodes, hospital stay after eligibility, and growth and feeding patterns,cost of care,time to discharge,Parental Stress Scale (NICU,head growth,unscheduled clinic visits,incidence of hyperthermia, sepsis, apnea, onset of breastfeeding and hospital stay,serious illness (lower-respiratory-tract disorders, apnoea, aspiration, pneumonia, septicaemia, general infections,Hospital stay,coregulation of the dyad's responses during the play episodes of the Still-Face Paradigm and vitality in infant efforts to reengage the mother during the neutral face portion of the Still-Face Procedure,Mortality,respiratory rates,deaths,mean birthweight,average daily weight gain,CMC babies died,equal weight gain, equal length of stay in the hospital, and equal duration of breastfeeding,weight accretion or linear growth,Mean birth weight,total attachment score,growth indices,head circumference,weight gain, earlier hospital discharge,care taking activities like bathing, diapering, sleeping with their babies and spent more time beyond usual care taking,mean duration of maternal education,Hypothermia,infant weight gain, temperature maintenance during KMC and CCC, and length of hospital stay,incidence of severe disease,effectiveness, feasibility, acceptability and cost of kangaroo mother care (KMC,majority of deaths,incidence of morbidities,earlier hospital discharge,breastfeeding rate at discharge,growth and reduces morbidities,risk of dying,higher oxygen saturations,mortality|Exclusive breastfeeding at discharge was more common in KMC infants in Merida (80% vs 16%) and overall (88% vs 70%).
20|suicidal behaviour,single-item Clinical Global Impressions scale,state-anger, trait-anger, and anger,interpersonal sensitivity, anger/hostility, and depression scales of the Symptom Checklist 90 (SCL-90) as well as the total score of the modified Overt Aggression Scale (MOAS,impulsive aggression and severity of depression,CGI,global measures (CGI-I and GAS,somatization, interpersonal sensitivity, anxiety, hostility, phobic anxiety, and Global Severity Index scales of the Symptom Checklist,interpersonal sensitivity and anger/hostility,obsessive-compulsive, depression, paranoid ideation, and psychoticism scales,self-reported changes on the anger subscales of the State-Trait Anger Expression Inventory (STAXI,efficacy and tolerability,Self-injury,Body weight and additional side effects,ZAN-BPD impulsivity item,Affective Lability Scale total score; and (ii) the Affective Instability Item of the Zanarini Rating Scale for Borderline Personality Disorder (ZAN-BPD,global symptomatology, level of functioning, aggression, and depression,Efficacy,self-reported changes on anxiety, depression, paranoia, anger/hostility, and interpersonal sensitivity scales of the Symptom Checklist-90,efficacy and safety,acute state symptoms,rapid mood shift, impulsivity, and aggression subscales from the Borderline Personality Disorder Severity Index,borderline psychopathology, health-related quality of life, and interpersonal problems,depressive, anxiety, psychotic, or impulsive symptoms,total score for the 9 BPD criteria on a 1-to-7 Likert scale, the Clinical Global Impressions scale modified for borderline personality disorder (CGI-BPD,Weight loss,Scores for impulsivity, aggression and hostility,depression, anxiety, and impulsivity/aggressive behavior,four STAXI scales (State Anger,Additional weight loss,global depression, hostile depression, and schizotypal symptom pattern,State-Trait Anger Expression Inventory,Adverse effects,depression, borderline psychopathologic symptoms, and anxiety,global mood and functioning, anger, and depression,headache, insomnia, nausea, numbness, constipation, and anxiety,severity of schizotypal symptoms, hostility, and suspiciousness,body weight,rapid mood shifts,total Affective Lability Scale scores,Mild weight loss,chronic dysphoria and impulsive aggression,changes in scores on the symptom checklist (SCL-90-R), the Hamilton Depression Rating Scale (HAM-D), the Hamilton Anxiety Rating Scale (HAM-A), and the State-Trait Anger Expression Inventory,scales and self-reports related to affect, behavior, psychosis, general psychopathology domains, and clinical safety,changes on the Symptom-Checklist, on the SF-36 Health Survey, and on the Inventory of Interpersonal Problems,global functioning, depression, hostility, schizotypal symptoms, and impulsive behavior,regardless of diagnosis, on "illusions," "ideas of reference," "psychoticism," "obsessive-compulsive symptoms," and "phobic anxiety," but not on "depression,four STAXI scales (State-Anger, Trait-Anger, Anger-Out, Anger-Control,self-reported changes on the anger scales of the Trait Anger Expression Inventory (STAXI,global symptom severity (Clinical Global Impressions-Improvement Scale [CGI-I]) and functioning (Global Assessment Scale [GAS]) as well as in specific core symptoms (depression, aggression, irritability, and suicidality,Weight gain,depression (Hamilton Rating Scale, Beck Depression Inventory), global severity (Global Assessment Scale, Symptom Checklist-90 items [SCL-90]), anxiety, anger-hostility (SCL-90, Inpatient Multidimensional Psychiatric Scale [IMPS], Buss-Durkee Hostility Inventory), psychoticism (Schizotypal Symptom Inventory, SCL-90, IMPS), impulsivity (Ward Scale, Barratt Impulsiveness Scale, Self-Report Test of Impulse Control), and borderline psychotherapy (Borderline Syndrome Index,scores for depression, suicidality and daily stresses,Anger and aggression,impulsivity and aggression scores,4 subscales of the STAXI (state-anger, trait-anger, anger-out, anger-control,clinician-rated scales measuring depression (the Montgomery-Asberg Depression Rating Scale) and impulsive aggression (the Modified Overt Aggression Scale,weight loss,depression, anxiety, anger expression, dissociation, and global functioning|No significant positive effects of the drug were found.
33|mean duration of hospitalization,Subjective improvement in symptoms after aspiration,haematological and biochemical variables,Shorter duration of amoebic liver abscess resolution time,pain intensity and abdominal tenderness,Clinical parameters, viz, fever, pain and abdominal tenderness,clinical symptoms fever, pain in right upper abdomen and liver tenderness, and the laboratory parameters erythrocyte sedimentation rate, white blood cells, haemoglobin and C-reactive protein and the abscess size,length of hospitalization and duration of time to becoming afebrile,Improvement of liver tenderness|Shorter duration of amoebic liver abscess resolution time in the group of patients treated with the combined therapy was observed particularly in the first four weeks of the treatment.
not found|cancellation rate,Ovarian arrest,abortion rate,Ovarian quiescence,oocytes fertilization rate and embryo quality,Response to COH, pregnancy rate (PR), tolerance,serum luteinizing hormone, progesterone, and testosterone levels,Ovarian response and outcome of in-vitro fertilization,premature luteinization or luteolysis,peak estradiol level and the hMG requirement,follicular recruitment and subsequent IVF,time to down-regulation and pregnancy and live birth rates,number of oocytes retrieved and fertilized, the number of embryos transferred, and the pregnancy rate per initiated cycle,quality of ovarian stimulation,fertilization rate,oestradiol concentrations and in follicle number, in the quantity of oocytes collected and fertilized, or in the number of embryos obtained or transferred,number of follicles greater,plasma LH,Stimulation response and occurrence of luteinizing hormone (LH) surges,pregnancy rate per transfer,pregnancy rates per initiated cycle and per embryo transfer,fertilized oocytes,number of retrieved oocytes,basal FSH level,live birth rate/retrieval,peak estradiol level,stimulation characteristics and clinical pregnancy rates,ovarian response,cleaved embryos,median total amount of hMG,implantation rate,mature oocytes and more embryos with good morphology,Luteolysis,LH serum concentrations,number of mature oocytes,cleavage rate,cleavage rate of mature oocytes,Fertilization and cleavage rates,pregnancy rate,number and size of follicles,vitro fertilization,Serum gonadotropin and ovarian steroid hormone levels, as well as fertilization, spontaneous abortion, and live birth rates,cancellation rate, mean number of oocytes collected or fertilized, and number of cases of failed fertilization,IVF cycle outcome,fertilization, biochemical, and clinical pregnancy rates,Agonist-induced luteinizing hormone (LH) and follicle-stimulating hormone (FSH,amount of hMG required,cancellation rates, more oocytes per pickup (OPU), more embryos transferred per patient, and a higher pregnancy rate,progesterone values,number and quality of embryos available for transfer,ovulation), pregnancy rate,Ovarian response, cancellation, fertilization, and pregnancy rates,pregnancy rate per cycle,stimulation requirements, response to stimulation, number of follicles aspirated, or the number of oocytes obtained,hormone serum levels,fertilization rates per oocyte,spontaneous abortion rate,ongoing pregnancy rate per treatment cycle,pregnancy/embryo transfer,Clinical pregnancy and live birth rates,Ovarian suppression,number of oocytes,number of retrieved oocytes and the fertilization rate,follicular recruitment, oocyte recovery and fertilization rates,pregnancy and live birth rates per cycle commenced or per embryo transfer,pregnancy rates per first treatment cycle, treatment cycle, oocyte retrieval, and ET,gonadotrophin secretion,peak serum estradiol level, number of oocytes retrieved and fertilized, fertilization rate per oocyte, number of embryos transferred, and pregnancy rate per initiated cycle,Cancellation rate,Duration of down-regulation; clinical pregnancy and live birth rates,fertilization rates, number of embryos transferred, and pregnancy rates,number of embryos cleaved and transferred,higher fertilization rate,Ovarian stimulation patterns and IVF outcome,Mean follicular phase serum luteinizing hormone (LH) and progesterone (P) levels,gonadotrophin secretion and ovarian parameters of IVF cycles,plasma free alpha subunit and dimeric LH concentrations while plasma oestradiol response,number of FSH ampoules,plasma luteinizing hormone,IVF,number of ampoules of gonadotrophins required,live birth rates|Ovarian suppression was significantly more prompt in group B. Follicle cysts were diagnosed in 19% and 16% of groups A and B, respectively; their appearance and regression were significantly more rapid in group B cycles.
84|toxicity,average cost for all medical care,median survival time,symptom-free survival and survival without reduced 'quality of life,prolonged high quality of life,survival,normal-quality (ie, normal symptom scores) survival for physical symptoms,Toxicity,quality of life and prolong survival,mean and median survival,survival benefit,anxiety,overall survival,symptom-free survival, progression-free survival and survival,Cost-effectiveness,serum carcinoembryonic antigen concentration,quality of life and survival,serum aspartate aminotransferase and bilirubin measurements,incremental costs per gained year of life,Since symptom-free survival, progression-free survival and survival,adverse effects,Overall survival and quality-adjusted survival,Quality of life and survival|This study identified a treatment modality that prolongs survival in patients with nonresectable liver metastases and no extrahepatic metastases from colorectal cancer, suggesting that control subjects receiving no therapy may not be necessary in future randomized trials.
670|extensive stage IIIC or IV disease,hazard ratio for progressive disease,Complete resection of all macroscopic disease,hazard ratio for death (intention-to-treat analysis,Postoperative rates of adverse effects and mortality|The hazard ratio for death (intention-to-treat analysis) in the group assigned to neoadjuvant chemotherapy followed by interval debulking, as compared with the group assigned to primary debulking surgery followed by chemotherapy, was 0.98 (90% confidence interval [CI], 0.84 to 1.13; P=0.01 for noninferiority), and the hazard ratio for progressive disease was 1.01 (90% CI, 0.89 to 1.15).
64|anxiety,women's physiologic measures, level of anxiety, and satisfaction during cesarean delivery,women's physiologic measures, anxiety, and satisfaction during cesarean delivery|Our results indicated that compared to the control group the experimental group had significantly lower anxiety and a higher level of satisfaction regarding the cesarean experience.
212|HC2,specificity for HC2,HPV infection,Histologic outcomes of cervical intraepithelial neoplasia grade 2 (CIN2) or worse (CIN2+) and CIN3,specificity of p16 cytology for HGCIN detection,Nuclear staining of cytologically atypical squamous cells,PCR,Sensitivity, specificity and positive predictive value (PPV,specificity,ability of p16(INK4a) and HR HPV detection,HPV Effectiveness,detection of CIN 2,3 and cervical cancer,sensitivity, specificity, and positive and negative predictive values,highest sensitivity,sensitivity values for Pap tests,area under the receiver operating characteristic (ROC) curve,sensitivity and specificity,sensitivity for HSIL,high/intermediate-risk human papillomavirus,DNA chip and LA tests,cervical intraepithelial neoplasia II and more severe lesions,equivocal cervical cytologic diagnosis,sensitivities of HC2 and FISH for CIN 2,High-risk HPV types,atypical glandular and/or squamous cells,sensitivity and specificity of the Pap test, HPV test,incremental cost of HPV testing,sensitivities of ProEx C and hr-HPV testing in detecting high-grade cervical intraepithelial neoplasia 2+ disease,High-grade squamous intraepithelial lesions (HSIL), atypical squamous cells,specificity of HC II in detection of > or = CIN 2,microinvasive cervical carcinoma,prevalence of a high-risk HPV infection,HR HPV,overall specificity,Cervical cancer,accuracy for detection of high-risk HPV,cervical intraepithelial neoplasia including LSIL,Histological diagnosis of >/= cervical intraepithelial neoplasia,relative accuracy for detection of high-risk HPV,Cervical histology, HPV test results, and repeat Pap smear results, and sensitivity of HPV testing,high-grade cervical intraepithelial neoplasia (CIN,Sensitivity, specificity, PPV, and negative predictive value (NPV,High-risk HPV DNA,PPV relative to ASC-US cytology,HR-HPV,repeat Pap smear showing high-grade intraepithelial neoplasia (HSIL,sensitivity values of HCT II tests,sensitivity,negative predictive value,High-grade cervical lesions,histologic HSIL or cancer,Pap smears,Sensitivities of Hybrid Capture II for detecting CIN and high-grade CIN,performance of 4 HPV DNA tests, namely, HC II, Linear Array (LA), DNA chip, and cycle sequencing,repeat Pap smear showing ASCUS, LSIL or HSIL,Cervical intraepithelial neoplasia,Performance of HCII and LA,squamous metaplasia,CIN biopsy results,sensitivity of high-risk HPV,sensitivity for diagnosing cervical intraepithelial neoplasia,LSIL,rates of detection of HPV DNA and of E6 and E7 transcripts,Sensitivity to detect CIN3 or above by testing for cancer-associated HPV DNA,sensitivity for detecting CIN,High viral load,Sensitivity rates,specificity and positive predictive value,cervical intraepithelial neoplasia grade 2 (CIN2,prevalence of HSILs and the prevalence of high-risk HPV detection,Sensitivity values,detection rate of grade 2,3 cervical intraepithelial neoplasia (CIN 2,3) or cervical cancer,ProEx C sensitivity,cost of reflex HPV testing,HPV-positive rates,HPV DNA and mRNA transcripts,proportion of women referred for colposcopy,overall sensitivity of HPV testing,viral clearance,rate of referral for colposcopy,sensitivity of the second Pap smear and HPV-DNA test,cost-effectiveness,HR-HPV viral load,Hybrid Capture II positive rates,repeat Pap smear result,Sensitivity and specificity,sensitivity of the Pap smear,sensitivities of combined triage and cytology for detecting CIN,specificity of HC2,referral rate of women for colposcopy,Specificity,cervical intraepithelial neoplasia,specificity of combined triage,sensitivity of a positive high-risk HPV test,HCII and linear array (LA,Sensitivity, specificity, and positive predictive value (PPV|Compared with HPV DNA testing, which detected 87.5% (7/8) of the cases of CIN 2 or 3, repeat Pap smear showing high-grade intraepithelial neoplasia (HSIL) detected 11.1% (1/9) of cases (p = 0.004), and repeat Pap smear showing ASCUS, LSIL or HSIL detected 55.6% (5/9) (p = 0.16).
not found|rMSSD,health-related quality of life and perceived social support,Abdominal motion during voluntary diaphragmatic breathing,dyspnea intensity (DI) and dyspnea-related distress (DD,dyspnea-related distress,standard deviation) years, forced expiratory volume 1 second/forced vital capacity % = 46 ,heart rate, oxygen saturation, dyspnea, and pain,highest tolerated resistance,Inspiratory muscle endurance,6 MWD,diaphragmatic mobility,RC/ABD ratio,Pulmonary function (FEV1), exercise capacity (6-min walking distance, 6 MWD), health-related quality of life (chronic respiratory questionnaire, CRQ) and cardiac autonomic function (rMSSD,dyspnea and functional performance,exercise tolerance,CRQ,22 cm H2O, and expiratory muscle strength (PEmax) ,perceived social support,amplitude of the rib cage to abdominal motion ratio (RC/ABD ratio) (primary outcome) and diaphragmatic mobility (secondary outcome,exertional dyspnea relief,functional performance,physical performance, psychologic well-being, and health-related quality of life (HRQoL,exercise capacity, pulmonary function, quality of life or cardiac autonomic function,exercise performance,Exercise performance,Exercise duration,exercise duration,MIP, MEP, Pdi, and Pdimax,expiratory volume,maximum respiratory pressure (320 cases) and transdiaphragmatic pressure,Diaphragmatic mobility,6-minute walk test and in health-related quality of life,pulmonary function,FEV1,abdominal motion,activity domains,incremental cycle ergometry and a 6-minute walk (6MW) test,physical function,lung function or exercise performance,6MW distance,health-related quality of life using St. George Respiratory Questionnaire-Hong Kong Chinese version and perceived social support using the Multidimensional Scale of Perceived Social Support-Chinese version,6-minute walk test and health-related quality of life,exertional dyspnea and physical function,diaphragm participation,thoracoabdominal motion and functional capacity,expiratory time,Changes over time in dyspnea [modified Borg after 6-minute walk distance (6MWD) and Shortness of Breath Questionnaire] and functional performance (Human Activity Profile and physical function scale of Short Form 36-item Health Survey|An improvement in the 6-minute walk test and in health-related quality of life was also observed in the TG.
                
784|Sample regurgitation,similar pregnancy,pregnancy and cumulative pregnancy rates,Pregnancy rate per cycle,frequency of bleeding,ease of introduction of the catheter, the presence of bleeding, and semen regurgitation after removal of the catheter,cumulative pregnancy rates,pregnancy rates,length of infertility, day-3 FSH level, number of prior IUI cycles, total motile sperm count, days of abstinence, infertility diagnoses, insemination ratings, and stimulation protocols|However, there was no significant difference in pregnancy rates with use of either the Gynetics catheter or the Makler cannula.
not found|equal response in motor and phonic tic symptoms,YGTSS total score,ADHD Rating Scale total score,MPH-IR effectively suppressed ADHD, oppositional defiant disorder, and peer aggression behaviors,vital sign, adverse event, or electrocardiographic or laboratory measures,exacerbate tic symptoms,linear analogue rating, parent CBCL "hyperactivity" subscale, and teacher CBCL subscales "nervous/overactive," "anxious," and "unpopular,ADHD response rate,tic response rate,tic and ADHD symptoms,ADHD and tic severity were total scores on the DuPaul Attention Deficit Hyperactivity Scale (DADHS) and the Yale Global Tic Severity Scale (YGTSS,total score on the teacher-rated ADHD Rating Scale,Clinical Global Improvement scale,tic frequency and severity,Yale Global Tic Severity Scale total score,efficacy and safety,ADHD (Conners Abbreviated Symptom Questionnaire--Teacher,inattentive symptoms and hyperactive/impulsive symptoms,moderate or severe sedation,reduction of tic severity,overall severity of tic disorder or obsessive-compulsive disorder behaviors,safety and efficacy,Discontinuation rates,tolerated without meaningful adverse effects,safe and well tolerated,body weight, and rates of treatment-emergent decreased appetite and nausea,tic symptoms (Yale Global Tic Severity Scale,extensive battery of parent-, teacher-, child-, and physician-completed rating scales and laboratory tasks,mean score on the parent-rated hyperactivity index,Tic Symptom Self-Report total score,Continuous Performance Test, commission errors,adverse effect,Clinical Global Impressions (CGI) tic/neurologic severity scale score,ADHD included Parent and Teacher Child Behavior Checklists (CBCL), continuous performance tests, and neuropsychologic tests of executive function,core symptoms of ADHD (ADHD Rating Scale,rated ADHD and tic symptoms weekly and monitored adverse effects, laboratory findings, and cardiovascular parameters,tolerability and efficacy,CGI severity of ADHD/psychiatric symptoms scale score,global linear analogue scale,Tic severity,tic severity,blood pressure and pulse,heart rate,Hopkins Motor/Vocal Tic Severity Scale, the Tourette Syndrome Severity Scale, or the Yale Global Tic Severity Scale,drug blood levels,heart rate and blood pressure|The primary analysis revealed no statistically significant beneficial effect of deprenyl on the DADHS
595|alloimmunization,immune anti-D|Nine (1.5%) out of 595 control patients had immune anti-D at follow-up at 6 months and later; 4 (0.78%) of 513 treated women were immunized.
61933|Survival,colorectal cancer mortality,complications of DCBE,survival,incidence of Dukes' stage D cancers,mortality reductions,Death rates,numbers of deaths,Reduced mortality,colorectal cancer mortality rate,mortality reduction,RR,13-year cumulative mortality,risk,risk of death from CRC,Cumulative 18-year colorectal cancer mortality,Positivity rates,cumulative ratio of a positive test,Mortality from CRC,colonoscopy related deaths,Mortality rates,mortality from CRC,Incidence of CRC,death from CRC,mortality|Death rates from causes other than CRC among participants never became higher than among controls.
                
not found|reading rates in AMD,distance logMAR VA, reading speed, critical print size, visual functioning questionnaires, and observed visual task performance,Reading speed and acuity tests,initial reading performance,subject reading speed, duration, and preference,task performance,distance, intermediate and near acuities, and contrast sensitivity,reading speed and duration of comfortable reading speed,distance and intermediate acuity,25-item National Eye Institute Visual Functioning Questionnaire and the Melbourne Low-Vision ADL (Activities of Daily Living,highest visual acuity,reading rates,Reading speed and duration with CCTV, illuminated stand magnifier, and spectacle lenses|Forty-six percent of subjects had highest visual acuity while viewing the VRD; 30% of subjects had highest acuity viewing the CRT; and 24% of subjects had equal acuity across the two displays.
76|Median seizure reduction,FAST-KD median percentage seizure reduction rate,mean weight loss,frequency of the seizures,cholesterol,asymptomatic hypoglycaemia,dehydration (IV fluids,seizure frequency, side effects, urine and blood ketone levels,Seizure frequency,Tolerability,weight,cholesterol levels,constant ketonuria and increased fat utilization,antiepileptic drug number, seizure frequency, electroencephalogram background/paroxysmal activity, and adverse effects at 6 months and 1 year on the ketogenic diet,free of seizures,Body-mass index (BMI,pancreatitis,resting energy expenditure (REE), substrate utilization; body composition and quality of life (QOL,seizure frequency, electroencephalography (EEG), adverse reactions, and antiepileptic drug (AED) number,constipation,antiepileptic efficacy and diet tolerability,hypercalcuria,epilepsy etiology,mean percentage of baseline seizures,Antiepileptic efficacy and diet tolerability,LDL levels,vomiting,Efficacy and safety,Adverse effects,Efficacy and tolerability,Frequency of seizures,average length of KD treatment,constipation, vomiting, lack of energy, and hunger,lipid ratios,reduction of seizure frequency,weight loss,Hyperuricemia,questionnaire, and blood ketone levels,reduction in seizures,Antiepileptic efficacy,antiepileptic efficacy,acidosis (citric acid and sodium citrates,efficacy and tolerability,median time to improvement,Mean antiepileptic drugs,Median duration,seizures,Effectiveness,diarrhea and weight loss,tolerated,bone density,diet efficacy and seizure or epilepsy type, age at diet onset, sex and etiology of epilepsy,Headaches, abdominal pains, and hyperkinetic behavior,Seizure reduction,seizure reduction,overall tolerance and compliance,Blood glucose,hyperlipidaemia,blood urea nitrogen,seizure free outcome,seizure frequency,seizure-free,efficacy and safety,urine calcium to creatinine ratio,weights, electrolytes, hydration status, vomiting, acid balance, need for interventions (citric acid and sodium citrates (Bicitra) and IV fluids,partial epilepsies,Mean seizure frequency,quality of life and cognition,2) Dietary tolerability,generalized and focal discharges,tolerability,tolerability and efficacy,frequency of seizures,Baseline seizure activity,severe episodes of hypoglycemia,Gastrointestinal symptoms,Serum acetoacetate and beta-hydroxybutyrate levels,number of antiepileptic drugs,seizure reduction and tolerability,Dietary tolerability,paroxysmal features|Antiepileptic efficacy was higher for the 4:1 than the 3:1 diet (p < 0.05).
not found|RHL awareness,pain level,overall rate of decline,routine episiotomy policy,change in the sum of evidence-informed healthy body weight promotion policies or programs being delivered at health departments,Rates of ventouse delivery,antibiotics in caesarean section and use of polyglycolic acid sutures,antibiotics at caesarean section in Mexico,Pain ratings,movement since surgery and worst pain on movement,Pain,postoperative pain outcomes,correct comprehension and time spent finding key results,pain,rate of decline|Rates of ventouse delivery increased significantly in intervention units but not in control units; there was no difference between the two types of units in uptake of other practices.
not found|number of drinking days, abstinence rates, average blood alcohol concentration and standard ethanol content per drinking day,proportion of patients who attended their first outpatient appointment,positive symptoms and in symptom exacerbations,abstinence rates,depression,important community-functioning variables, including hospitalization; money available for living expenses; and quality of life,psychosocial functioning and symptomatology,psychopathology and functional ratings,number of days of substance use,psychiatric symptoms and substance use,substance use and improving symptomatology and general functioning,urinalysis results from twice-weekly treatment sessions,Differential effectiveness,rate of institutionalization,client psychosocial outcomes, and psychiatric and substance abuse symptomatology,substance abuse and quality of life,substance use, mental health, and housing outcomes,number of weeks ill with a mood episode,patients' general functioning,stable community days, hospital days, psychiatric symptoms, and remission of substance use disorder,arrests and total convictions,depressive and manic symptoms,drinking days,aggregate index of alcohol and other drug use (polydrug use on the OTI,cannabis use,psychosocial functioning,average total costs|The integrated treatment program resulted in significantly greater improvement in patients' general functioning than routine care alone at the end of treatment and 12 months after the beginning of the study.
not found|CD4+ T cell count,mean absolute CD4 T-cell counts,proportion of subjects maintaining CD4 cell count,CD8+CD28+ lymphocytes,baseline viral load, CD4 count, and length of treatment,antiviral CD8,Plasma, cerebrospinal fluid (CSF), and lymphatic tissue viral loads,virological failure,serum levels of the CD8+ T-cell-derived inhibitory molecules interleukin-16 (IL-16), monocyte inhibitory protein-1beta (MIP-1beta) and RANTES ('regulated upon activation, normal T-cell expressed and presumably secreted'), and the enhancer of HIV replication, monocyte chemotactic protein-1 (MCP-1,CD4+ T-cell percentage,Changes in CD4+ T-cell differentiation phenotype,CD4 cell counts,Plasma and peripheral blood lymphocyte (PBL) samples,viral load,CTL count and either viral rebound rates or clearance rates,T cell responses,Viral load,plasma viral load (pVL,good virological response,p24-specific T helper response,Drug susceptibility and their corresponding replication capacities,average frequency of HIV-specific CD8 T cells,low CD8+CD38+ T lymphocyte count,T lymphocyte responses,viral growth and clearance rates,breadth of the HIV-specific CD8(+) T lymphocyte response,undetectable plasma HIV RNA and their mean CD4 cell count,T cell count from pre-STI level, and VL rebound to pre-HAART baseline,Plasma viral load (VL), peripheral blood mononuclear cell (PBMC) lymphoproliferative (LPR) response to HIV p24 protein, and HIV-1 epitope-specific interferon-gammarelease from CD8 T cells,viral load (VL) and HIV-specific CD8+ T-cell (cytotoxic T-lymphocyte [CTL]) responses,triglycerides,median CD4+ cell count,time to viral rebound,CD4(+) or CD8(+) T cells expressing activation markers or producing IFN-gamma in response to HIV, no increase in CD4,HIV genotypic drug resistance,effector/memory CD8 T cell dynamics,level of expression of T-cell activation antigen CD38 on CD8 T cells,CD4+ or CD8+ T-cell counts/microL, HIV loads and serum concentrations of each cytokine,successive HIV RNA concentrations,number of spot-forming cells,Vgamma9Vdelta2 T cell effectors,NA titers,mean time before plasma viral load,Mean stimulation indices of lymphocytes treated with phytohemagglutinin (PHA) and CD3,immunological parameters,plateau VLs,VL,median nadir CD4+ cell count,plasma HIV-1 RNA rebound,HIV-specific CD8+ T cells,T cells, VL, HIV-1-specific neutralizing antibodies, and IFN-gamma-producing HIV-1-specific CD8(+) and CD4,percentage of CD4 and CD8 lymphocytes,safety, retention of immune reconstitution, and clinical therapy failure,stronger HIV-1 specific cellular immune responses,toxicity and cost,lipid, hepatic transaminase, and C-reactive protein levels,morbidity and mortality,augmented CD8(+) T cell responses,HIV-specific CD8 T cell frequencies,effective virologic response,cost and toxicity,Serum lipids, glucose and insulin levels during an oral glucose tolerance test, 24-h urinary free cortisol and 17-hydroxycorticosteroids, and anthropometric parameters,drug resistance mutations,24-hour urinary free cortisol,serum levels of IL-16,Likewise, CD4 count prior to treatment interruption,serum cholesterol and triglyceride levels,plasma viral load (VL) set-point, and on HIV-1-specific responses,CD4+ cells and achieved viral suppression,frequencies of CD8 T cells releasing IFN-gamma after mitogen-induced or Gag-specific stimulation,insulin resistance profiles or anthropometric measurements,certain toxicity, immunologic, or virologic parameters,HIV proviral DNA or replication-competent HIV in peripheral CD4,CD4 T cells,higher CTL and LPR levels,HIV-specific CD8(+) T lymphocyte frequencies,Median (IQR) time off therapy,HIV dynamics and T-cell immunity,plasma viral HIV-RNA value,overall CD4+ T-cell percentage,Genotypic resistance,Levels of MIP-1beta,antiviral immunity,frequency of detectable HIV RNA,T cell counts,glucose or insulin levels,median CD4 cell count,HIV-specific cytotoxic T-cell responses,viral recrudescence,viral rebound,CD4 lymphocytes,24-hour urinary 17-hydroxycorticosteroids,peripheral CD4+ T cells,HIV-related diseases and CD4 cell counts,length of time without antiretroviral treatment,clearance rates,plasma HIV RNA,total cholesterol,Kinetics of plasma viral rebound,peak plasma viral load,nadir CD4+ cell count,plasma viral load,drug resistance necessitating salvage treatment,viral basic reproductive rate,virologic, immunologic, and toxicity parameters,virological control,frequency of reverse-transcriptase gene mutations,resistance to reverse transcriptase or protease inhibitors,CD4(+) or CD8(+) T cell counts or the percentage of cells that were CD4(+)CD25(+), CD8(+)CD25(+), or CD4(+)DR,viral resistance or therapy failure, retention of CD4 T cell numbers on ART, or retention of lymphoproliferative recall antigen responses,HAART resumption and consequent inhibition of HIV replication, Vgamma9Vdelta2 T cell reactivity,low density lipoprotein (LDL) cholesterol,T cells or HIV RNA in peripheral blood or lymph node mononuclear cells,Flow cytometry and cell proliferation assays,Plasma virus doubling time,mean CD4 cell count,mutations suggestive of drug resistance, and plasma saquinavir levels,glucose metabolism and fat redistribution,plasma viremia,quantity and quality of the post-STI response,sustained viral rebound,control of HIV-1 replication,CD4 T lymphocytes,serum concentrations of IL-16,total cytotoxic T lymphocyte (CTL) response and in lymphoproliferative response (LPR,CD8(+)CD38(+) and CD8(+)DR(+) cells,study-defined safety criteria, viral resistance, therapy failure, and retention of immune reconstitution,dynamic and predictive variables of CD4 cell loss,CD4 LPRs,efficacy and safety,HIV-1-specific CD4 and CD8 T-cell responses,plasma VL,CD8+CD38+ lymphocytes,vigorous HIV-specific T cell immune response,magnitude and breadth of HIV-1-specific CD8 T-cell responses,overall reduction of time on therapy,adverse events,median duration of the first interruption,rebound of HIV-1 RNA,CD4,gammadelta T cells,total cholesterol, LDL cholesterol, and triglyceride levels,neutralizing activity (NA,CD8 T lymphocytes,CD4 nadir,final STI, HIV-1-specific CD8 T-cell responses,T cells,antigen-driven interferon-gamma production|Four out of 7 patients in the HAART group failed to control HIV by week 6 and had to restart therapy due to either viremia rebound or CD4 decrease.
600|major laryngotracheal pathology as identified by endoscopy, and respiratory infections,complication incidence,pneumonia,cumulative frequency of pneumonia, mortality, and accidental extubation,incidence of pneumonia and increasing the number of ventilator-free and intensive care unit (ICU)-free days,complications,length of ventilator support, pneumonia rate, or death,length of ventilator dependence,accidental extubations,number of days of mechanical ventilation, frequency of pneumonia or ICU length of stay,Ventilator-associated pneumonia,incidence of ventilator-associated pneumonia,number of ventilator-free days, number of ICU-free days, and number of patients in each group who were still alive,damage to mouth and larynx,laryngotracheal pathology and respiratory infections; length of intubation and type of patient injury,number of days of mechanical ventilation, frequency of pneumonia and length of intensive care unit (ICU) stay,hazard ratio of developing ventilator-associated pneumonia,mechanical ventilation,mortality|Among mechanically ventilated adult ICU patients, early tracheotomy compared with late tracheotomy did not result in statistically significant improvement in incidence of ventilator-associated pneumonia.
                
141|average length of stay,incidence of hospital-acquired pressure ulcers,heel ulcers|There were three main findings: for non-heel ulcers and overall improvement, there was no statistically significant difference between the two products tested; for heel ulcers there was a significant difference (P = 0.019) with more patients healing in Group A than in Group B.
130|weight gain and feeding tolerance,caloric intakes, length gain, head circumference gain, feeding intolerance, and incidence of necrotizing enterocolitis,gains in length and head circumference, biochemical indexes of nutritional status, feeding intolerance, and incidence of necrotizing enterocolitis,Weight gain,Enhanced weight gain,serum albumin level,weight gain|SEM) of the treatment group was significantly greater (P <.05) than that of the control group (20.4 +/-
50|relapse rate,relative risk of sustained disability progression,relapse rate and progression of disability,anxiety, pharyngitis, sinus congestion, and peripheral edema,relapse rates,annual exacerbation rate,efficacy, safety, and tolerability,delay progression of disease,Median MSFC Z-score change,interferon beta-1a and glatiramer acetate,relapse frequency,MRI-measured disease activity and burden,rate of progression,Kurtzke Expanded Disability Scale (EDSS,accumulation of new or enlarging hyperintense lesions,mean number of exacerbations,disease activity,Expanded Disability Status Scale,severe flulike reactions and raised liver enzymes,worsening of disability as defined by the time to first confirmed progression on the expanded disability status scale (EDSS,Disability,time to first relapse,rate of clinical relapse at one year and the rate of sustained progression of disability, as measured by the Expanded Disability Status Scale,relapse risk, defined as new or recurrent neurological symptoms,cumulative probability of progression,number and volume of gadolinium-enhanced brain lesions on magnetic resonance images,safe and well tolerated,severe exacerbation,Time to neurological deterioration,EDSS score,first time in a large-scale MS trial,sensitive disability measure and relapse rate,upper-extremity function,enhancing lesions,EDSS scale,relapse rate and disability,cumulative numbers of Gd-enhancing lesions and new T2WI lesions,accumulation of burden of disease and number of active lesions on MRI,timed 10-meter walk, nine-hole peg test, and on MRI, T2 and T1 brain lesion loads and brain and spinal cord atrophy,injection-site reactions,Disability Status Scale scores,Neurological disability measured with EDSS,New or enlarging T2-hyperintense brain MRI lesions and gadolinium-enhancing lesions,proportion of patients with sustained progression, the relapse rate, the assessment of fine motor skills, visual evoked potentials, contrast sensitivity, depression and quality of life,For MRI activity total lesion volume on T2-weighted image (T2WI), new lesions and gadolinium (Gd)-enhanced lesions,proportion of patients free from relapses and that of patients free from new proton density/T2 lesions at MRI assessment,gadolinium-enhanced MRI,clinical relapses, newly active MRI lesions, and accumulated burden of disease on T2-weighted MRI,number of new lesions seen on T2-weighted images,mean time to sustained progression,volume of gadolinium-enhancing lesions,adjusted total number of treated relapses,MS activity,allergic reaction,total number of enhancing lesions,exacerbations,adverse event,rate of accumulation of T2 lesion load,mean change in EDSS score from baseline, relapse-related measures, MRI activity, and a standardized neuropsychological function test,prolonged time to first relapse,time to sustained progression in disability,Flu-like symptoms,change in ambulation index,Level of disability, impairment of functional systems, and performance of social roles,rate of clinical relapse at 1 year and the cumulative probability of disability progression sustained for 12 weeks, as measured by the Expanded Disability Status Scale,overall tolerability,safety and tolerability,time to sustained disability,progression on the expanded disability status scale (EDSS) and change in T1-hypointense lesion volume,overall survival curves,Safety and tolerability profiles,fatigue,mean level of disability,Injection-site reactions,EDSS (hazard ratio (HR) ,Progression rates,safety and efficacy,Adverse reactions,Hematologic and hepatic abnormalities,Mickey's Illness Severity Scores or Kurtzke's Disability Status Scale,time to sustained progression,time to first treated relapse,relapse risk, EDSS progression, T1-hypointense lesion volume, or normalised brain volume,Neutralizing antibody,Neutralizing antibody formation,Hypersensitivity reactions,exacerbation frequency and side-effect profile,standardised neurological status,number and change in volume of T2 active lesions,Patient attrition rates,Relapse rates,deep venous thrombosis, pulmonary embolism,relapsing-remitting MS (RR-MS,Multiple Sclerosis Functional Composite score at several timepoints, T1 and T2 lesion volume changes,mean (SD) of relapse rate,disability measures,MRI measures of disease activity,efficacy,Neurological examinations,Neutralizing antibodies,proportion of relapse-free patients,sustained progression,number of patients free of exacerbation,time to sustained EDSS progression,Annual relapse rate,lesion activity assessed by 6-weekly MRI,time to confirmed EDSS progression,Expanded Disability Status Scale (EDSS,cumulative number of unique newly active MRI lesions,neopterin levels,Time to first relapse,annual relapse rate,Disability Status Scale,tolerated and reduced progression of disability and clinical exacerbations,Annual relapse rate (ARR) and change of the mean Expanded Disability Status Scale (EDSS) and Neurological Rating Scale Score (NRSS,Disability Status Scale, (2) ambulation index, (3) Box and Block Test, and (4) 9-Hole,disabled on entry (Kurtzke disability score,relapse rate and EDSS score,total lesion volume on T2WI,rate of ventricular enlargement,overall number and severity of adverse events,Kurtzke Expanded Disability Status Scale (EDSS,number of new enhancing lesions,serious hypersensitivity reactions,Regional Functional Status Scale,unconfirmed progression, and progression of 0.5 EDSS units,neurologic impairment,rates of progression,Expanded Disability Status Scale progression,annualized relapse rate, the time to first relapse, and neutralizing antibody formation,tolerated,neurological functions,survival curves,EDSS scores,proportion of patients with enhancing lesions, the number of new enhancing lesions and change in their volume; the number of new lesions detected on T2-weighted images and change in their volume, and the change in volume of hypointense lesions seen on unenhanced T1-weighted images,rate of clinical relapse,adverse effects,intention-to-treat analysis of time to 1,relapse rate and improves disability,MS Functional Composite (MSFC), comprising quantitative tests of ambulation (Timed 25-Foot Walk), arm function (Nine-Hole Peg Test [9HPT]), and cognition (Paced Auditory Serial Addition Test [PASAT,MS relapse rate,proportion of relapse,Side-effects,final 2-year relapse rate,expanded disability status scale,accumulation of permanent physical disability, exacerbation frequency, and disease activity,safety endpoints,relapse-free,rates of adverse events,ARR,annual relapse rates,efficacy and safety,T2 lesion volumes,annualized relapse rate and time to first relapse, re- spectively,clinical and MRI indices of disease activity,Adverse events,mean relapse rates,adverse events,PPMS,time to sustained disability progression,Kurtzke Expanded Disability Status Scale,time to progression by > or =1.0 EDSS point (0.5 point if EDSS score,delay of confirmed disease progression,mean EDSS progression,time to neurological deterioration (Expanded Disability Status Scale,disability status scale change (entry expanded disability status scale,change of T2-lesion load over time,time to sustained progression of disease identified as worsening of the expanded disability status scale (EDSS) sustained for 3 months, and 2) the improvement of neurological functions,clinical disability-measured by the absolute change in Kurtzke's expanded disability status scale (EDSS) score- and the proportion of patients with improved, stable, or worse clinical disability,annualized relapse rate,11 MS Quality of Life Inventory subscales,Neutralizing antibodies to IFNbeta-1b,MRI activity,gadolinium-enhancing lesions,total number of enhancing lesions on T1-weighted images,MSFC progression, relapses, quality of life, and MRI activity,Standard Neurological Examination scores,change in EDSS,number of relapses,numbers of patients with improved, stable, or worse clinical disability,annualized rate of relapse,side effects,risk of sustained progression of disability|More disabled patients worsened by 0.3 (Cop 1 group) and 0.4 (placebo group) unit.
24|nighttime symptoms score,daytime nasal symptoms score,number of eosinophils in both nasal smear and biopsy,total symptom score,subjective parameters (daytime nasal symptoms score, daytime eye symptoms score, and nighttime symptoms score) and objective parameters (nasal smear, nasal peak inspiratory flow [NPIF], and nasal biopsy,daytime eye symptoms score,Furthermore, NPIF and nasal biopsy findings,NPIF values|However, there was a significant improvement in nighttime symptoms score between groups I and II (p < 0.01 versus p > 0.05).
||
not found|body mass index or health-related quality of life over time,specific CF nutrition knowledge score, self-efficacy score, and reported fat intake,weight change over 6 and 12 months and changes in CF-specific nutrition knowledge score, self-efficacy score, reported dietary fat intake and health-related quality-of-life score|There were substantial improvements in the intervention group's specific CF nutrition knowledge score, self-efficacy score, and reported fat intake compared to control, but no substantial change in body mass index or health-related quality of life over time.
not found|Mean haemoglobin levels,hemoglobin levels,renal anaemia,hematocrit and Hb levels,Hb level,frequency of exogenous peritonitis,mean haemoglobin levels,injection frequency and skin-fold thickness,plasma hemoglobin levels,hemoglobin level higher,mean EPO dose,haemoglobin levels,renal anemia,reticulocyte count,Stable haemoglobin levels,time-adjusted area under the haematocrit (Hct) curve (AUC|The dose reduction correlated with skin-fold thickness; the reduction was seen only in the patients with skin-folds of less than 20 mm.
652|Neuropsychiatric Inventory and Clinical Global Impression-Severity of Psychosis scale,NPI/NH Psychosis Total scores (sum of Delusions, Hallucinations items-primary efficacy measure,aggressive behavior,Abnormally high prolactin levels,Somnolence and urinary tract infection,aggression, agitation, and psychosis,extrapyramidal symptoms, nor of total adverse events,neuropsychiatric functioning,Cohen-Mansfield Agitation Inventory (CMAI), the Behavioral Pathology in Alzheimer's Disease (BEHAVE-AD) rating scale, and the Clinical Global Impression of Severity (CGI-S) and of Change (CGI-C) scales,extrapyramidal symptoms,CMAI total non-aggression subscale,efficacy and safety,cognition or any other vital sign or laboratory measure, including glucose, triglyceride, and cholesterol,endpoint CGI-C scores,psychotic symptoms subscale,incidence of weight gain,CGI-S and the CGI-C scores,tolerated,Overall discontinuation,efficacy, safety, cost-effectiveness, and quality of life,incidence of discontinuation due to adverse events,CMAI total aggression score,aggression, agitation, and psychosis associated with dementia,behavioral disturbances,aggression, agitation, and psychosis of dementia,Psychotic symptoms and behavioral disturbances,vital sign, electrocardiographic measure, or laboratory hematology and chemistry, including glucose, except for cholesterol,weight, anorexia, and urinary incontinence,psychosis and overall behavioral disturbances (NPI/NH, BPRS|There were significant overall treatment-group differences in increased weight, anorexia, and urinary incontinence, with olanzapine showing numerically higher incidences.
66|recurrence of duodenal ulcers,relapse rate,urea breath test (UBT) and histology,ulcer healing rate,Reinfection rates,free of ulcer,overall healing rates,Low H. pylori reinfection rate,ulcer remission rate,cumulative relapse rates,cure rate for H. pylori infection,erosive oesophagitis,duodenal ulcer healing,healing and relapse of duodenal ulcers,active duodenal ulcer recurrence,Helicobacter pylori eradication,cure of H. pylori infection and for healing duodenal ulcers,gastric ulcers,recurrence rate of PU,grade of gastritis and the quality of the ulcer scar,recurrence of gastric and duodenal ulcer disease,gastric ulcer,Helicobacter pylori and the recurrence of duodenal ulcer,Eradication rates,DU relapse rates,eradication and relapse rates,cure H. pylori infection,Cure rates of H. pylori infection,Clearance of H pylori,safe and well tolerated,13C-urea breath test,severity of inflammation and intestinal metaplasia,persistence of H. pylori infection,gastric ulcer relapse,efficacy and side effects,healing of duodenal or gastric ulcer,Refractory duodenal ulcer healing and relapse,H. pylori infection,cure rates,higher H. pylori cure rates,HP eradication,Helicobacter pylori eradication rate,Ulcer healing,ulcers,recurrence rates of duodenal ulcers,intestinal metaplasia,ulcers healed,Duodenal ulcer healed,ulcer remission,eradication of H. pylori infection,Ulcer healing (intention-to-treat,Helicobacter pylori infection,H pylori eradication,eradication,curing Helicobacter pylori infection and peptic ulcer recurrence,ulcer recurrence, testing of H. pylori status,rate of H. pylori infection,No recurrence,eradication of H pylori and healing quality of ulcer,healing and recurrence of benign gastric ulcer,Ulcer prevalence,Helicobacter pylori (H. pylori) eradication and duodenal ulcer recurrence,pylori cure rate,Healing rates,endoscopic relapse,healing of duodenal ulcer, and clearance as well as eradication of H pylori,relapse and gastritis outcome,ulcerous healing,cumulative rate of recurrence,cure rate for H. pylori infection and the ulcer recurrence rate,duodenal ulcer healing and absence of ulcer recurrence,duodenal ulcer relapse,Gastric ulcers,relapse,Ulcer relapse,Eradication rate,remission,percentage of healing,overall failure rate (absence of healing, relapse,reinfection rate,gastric acid secretion,Eradication of H. pylori, duodenal ulcer healing and ulcer recurrence,recurrence rate of ulcer,Helicobacter pylori and reduction of duodenal ulcer relapse,healing quality of ulcer,pylori infection,ulcer scar changes and H. pylori status,Healing and long-term relapse rates,eradication rate,Eradication rates PP,ulcer healing and H. pylori eradication rates,cumulative 12-month relapse rates,Intention-to-treat eradication rates,Helicobacter pylori-negative,early reinfection and ulcer recurrence,prevalence of H. pylori,healed of their ulcers,Eradication of H pylori,Duodenal ulcers,ulcer prevalence,Histological gastritis,safe and effective for eradication, healing and the prevention of relapse,Endoscopic evaluation of ulcer status and bacteriologic identification of H. pylori,duodenal ulcer scar,ulcer healing and relapse rate,safe and effective for eradication of H. pylori,healed ulcers,ulcer recurrence,side effect,cure Helicobacter pylori infection,frequency of ulcer relapse,rate of their recurrence,eradication rate of H. pylori and safety,Duodenal ulcer,curative effects on H. pylori infection,mean (+/- SD) duration of pain,recurrent gastric ulcers,free of GUs,heal gastric ulcers,relapse with gastric ulcer,Helicobacter pylori (H. pylori), healing of ulcer and prevention of relapse,eradication rates of H. pylori,gastric ulcer relapse rates,Helicobacter pylori eradication and prevention of ulcer recurrence,gastric ulcer healing,H. pylori negative,gastric ulcer disease,ulcer healing,cumulative percentages of patients with healed ulcers,Mild dizziness,incidence of side-effects,12-month recurrence,Gastric ulcer relapse,ulcer relapse rates,subsequent relapse rates,Active duodenal ulcer recurrence,H. pylori eradication rates,healing rates,transient worsening of corpus gastritis,Gastric ulcer relapses,eradication rates of Helicobacter pylori, gastric ulcer healing and prevention of relapse,H pylori clearance and eradication identified H pylori clearance,recurrence of ulcers,ulcer healing rates,recurrence rates,cure of H. pylori infection,healing of duodenal ulcer,good eradication rates,White scarring,Eradication of H. pylori infection,Side effects, mainly diarrhea,tolerated,ulcer recurrence and H. pylori infection,success rate of pain control,Cure of H. pylori infection,eradication rates,number of duodenal ulcers,Eradication of H. pylori,adverse effects,H pylori eradication rates,relapse rate of peptic ulcer,healing ulcers,eradication of H. pylori, healing of GU and prevention of relapse,bacterial colonization and inflammatory scores,duodenal ulcers,recurrence rate,Successful eradication,healing rate to H2-blocker therapy,rate of ulcer relapse,Helicobacter pylori infection and the recurrence of duodenal ulcers,ulcer recurrence rate,Clarithromycin resistance,H. pylori positive,gastric ulcer relapse and Helicobacter pylori reinfection,Helicobacter pylori, ulcer healing and ulcer relapse,duodenal ulcer recurrence,Videoendoscopic assessment of ulcer status,eradication of HP and prevention of duodenal ulcer (DU) recurrence,ulcer healed,H. pylori eradication,Presence or absence of H pylori (by urease testing, microscopy, and culture of antral biopsy specimens), duodenal ulcer, and side effects,Ulcer recurrence,recurrence of duodenal ulcer,Helicobacter pylori and ulcer healing,HP eradication and prevention of duodenal ulcer recurrence,pylori eradication (assessed by antral and corpus urease tests and histology and by 13C urea breath test,percentage of eradication,relapse rate of peptic ulcers,cumulative DU relapse rates,H. pylori status,Complete healing rates,efficacy and safety,probability of recurrence,duodenal ulcer healing and ulcer relapse,healing rate of PU and H pylori eradication rate,Amoxicillin resistance,tolerated and compliance,ulcer relapse rate,H pylori eradication and ulcer healing quality,Cumulative relapse rates,healing rate,eradication of H. pylori and ulcer recurrence,Ulcers,ulcer relapse,rates of H. pylori eradication,H. pylori status (culture, histology, and CLOtest) and ulcer relapse,H pylori eradication, and healing of gastric ulcers,long-term DU recurrence rate,Helicobacter pylori and for ulcer healing,Healing,eradication rate of H. pylori,Duodenal ulcer healing rates,cumulative relapse rate,Helicobacter pylori and healing and prevention of gastric ulcer recurrence,pylori eradication rate,H. pylori reinfection and ulcer relapse,Healing rate,Rates of ulcer healing,healing and relapse of gastric ulcer,idiopathic gastric ulcer,highest clearing index,Ulcer relapses,Trough plasma bismuth concentrations,long-term recurrence of gastric or duodenal ulcer,side effects,gastroduodenitis activity and gastric surface epithelium lesions|There was no duodenal ulcer recurrence in 43 H. pylori-negative/cured patients (0%), which was significantly different in terms of duodenal ulcer recurrence (P=0.001).
                
not found|eosinophilic airway inflammation,serum IgE concentration,sputum eosinophils,airway inflammation, serum total IgE and IgG levels to A fumigatu s, and blood eosinophil counts,exercise tolerance or pulmonary-function tests or resolution or absence of pulmonary infiltrates,rate of adverse events,systemic immune activation,relapse,exacerbations requiring oral cortico-steroids,serum IgE levels,concentrations of serum IgG specific for Aspergillus fumigatus fell,eosinophilic airway inflammation, systemic immune activation, and exacerbations,IgG levels to A fumigatu s,serum IgG concentration,Sputum eosinophil cationic protein levels,symptom scores,adverse effects|The rate of adverse events was similar in the two groups.
252|modified Rankin Scale,functional outcome,subarachnoid hemorrhage and disseminated intravascular coagulation|A significant improvement in functional outcome was observed in the edaravone group as evaluated by the modified Rankin Scale (p = 0.0382).
373|P53-specific immune responses,IFNgamma-expressing CA125-specific CD8+ T-cells,Quality of life,Cellular and humoral responses,safety (complete blood count, comprehensive panel, amylase, thyroid-stimulating hormone, and urinalysis) and antibody production (ELISA, fluorescence-activated cell sorting, and complement-dependent cytotoxicity,Increased pre-ASI CA-125 serum levels,complete clinical remission,longer survival,self-limited pain at injection site, myalgia, and fever,anti-KLH antibody titers with survival,anti-Le(y) antibodies,grade 3/grade 4 adverse events,elevated CA27.29 (MUC1 mucin) serum levels,safe and well tolerated,grade 1 fatigue, anemia, pruritus, myalgias, and hyperthyroidism and grade 2 hypothyroidism,longer survival and generated higher anti-OSM antibody titers,p53-specific T-cell responses,humoral immune responses,Induction of humoral and cellular anti-CA125 responses,grade 3 adverse effect (ie, rectal bleeding,Increased ADCC levels,median progression-free survival,T-cell responses,moderate to strong DTH reactions,AB3-induction and cellular cytotoxicity,CA-125 levels and CT-scans,IgM titer above pre-existing levels,Induction of CA125-specific B and T cell responses,production of anti-idiotypic antibodies, survival rate, and immunological effects,p53-specific response,Immune responses,grade > or =2 toxicity,Self-limited and mild fatigue,CD4+ T cells,No serious drug-associated adverse events,Antibody responses,Biologic activity,serious vaccine-related adverse events,tolerated and induced multiple antigen-specific immune responses,Long-lived and functional vaccine-elicited CD8+ and CD4+ T cells,Toxicity,safety and tolerability,toxicities,CD4+ and CD8+ fractions,specific anti-anti-idiotypic antibody (Ab3) response,Antibody responses, including human anti-mouse antibody (HAMA), anti-idiotypic antibody (Ab2) and anti-CA125,drop-out rate due to toxicity,Immunological reactivity,clinical response,Median survival,hematologic abnormalities,Median survival time,safety, tolerability, immunogenicity,anti-OSM immunoglobulin M (IgM) titer,Stabilization of disease and survival >2 years,Antibody titers,safety and immunogenicity,tolerated and no gastrointestinal, hematologic, renal, or hepatic toxicity,survival rates,mean survival,reactivity against MCF7 cells,peptide-specific cytotoxic T lymphocytes (CTLs,median survival,robust treatment-emergent humoral responses,cytotoxic antibodies against TF-expressing tumor cell targets,NY-ESO-1 specific humoral immunity (ELISA), T-cell immunity (tetramer and ELISPOT), and delayed-type hypersensitivity,P53-specific T-cells,Specific HLA-DP4-restricted CD4+ T cell responses,Shrinkage of marker lesions,low/high-avidity CD4+ T cells,CD4/CD8 ratio and the levels of CD25,serious adverse events,Immune responses, including antibodies and T cells to oregovomab and CA125,survival benefit,IFN-gamma producing p53-specific T-cell responses,median progression-free interval,tolerated without serious adverse events,Overall, toxicity,immunological response,median TTR,tolerated,peptide-specific cytotoxic T lymphocytes,Tumor burden,survival times,anti-OSM antibody titers,vigorous IgG response,time to relapse (TTR,grade 1 adverse effects,safety and immunogenicity primarily determined by Ab3 response,toxicity,Grade 3 to 4 toxicity,survival,Human anti-mouse antibody,CD4+ T-cells,ADCC activity of c-MOv18,ELISA; T-cell responses to CA125, autologous tumor and oregovomab by interferon (IFN)-gamma enzyme-linked immunoSPOT (ELISPOT,CD8 T-cell responses,headache,lytic activity of peripheral blood lymphocytes (PBLs,peripheral blood mononuclear cells (PBMC,generation of CA125-specific B and T cell responses,vaccine safety, with immunologic and clinical responses,CA125-specific antibodies (Ab1') and antibody-dependent cell-mediated cytotoxicity of CA125-positive tumor cells,Adverse events,IgG anti-STn titers,immunologic responses,CEA- and MAGE-3 peptide-specific T-cell responses,IL-2.
                Toxicity,Median TTR,TTR overall,hematologic or nonhematologic toxicity,Premature termination occurred due to patient withdrawal or disease progression,CA125 levels,fever, myalgia, and localized injection site reactions,IgM antibodies against the synthetic TF alpha hapten,anti-STn TH1 antigen-specific T-cell response,tumor reactive CD4+/CD8+ T-lymphocytes,Increased anti-OSM IgG titers,interval physical examinations and laboratory assessments with immune assessment, including HLA typing, human anti-mouse antibody, ELISA, and enzyme-linked immunospot,cellular immune response,Tumor expression,median IgM titers|Grade 3 to 4 toxicity was reported in 24.6% of patients in the placebo group and 20.1% of patients in the oregovomab group, respectively.
                
not found|allergic" airway inflammation,symptom scores, rescue albuterol use, and asthma control,Mean morning PEF,lung function and symptoms,mean morning peak expiratory flow rates (amPEF,FEV1, and PD20 methacholine,Quality of life,mean morning pre-medication peak expiratory flow (PEF,PEFR and symptom control,Growth,mast cells, lymphocytes, or macrophages in BAL or biopsies,Safety,lung function and symptom control, without altering BHR or increasing exacerbation rates,rate of treatment failure and decreased asthma control,BAL lymphocyte activation,percentage of symptom-free and rescue-free days and nights,airway inflammation and responsiveness,time to treatment failure,bronchial hyperresponsiveness (BHR) to histamine,severe exacerbations,percentage of symptom-free days,evening peak expiratory flow (PEF), daytime and night-time symptom scores and daytime and night-time use of rescue salbutamol,overall number of puffs of rescue medication and asthma symptom scores,symptom control and increased pulmonary function,night-time awakenings,Bronchial biopsies and BAL,FEV1, PD20 methacholine, symptom scores, and exacerbation rates,hazard ratio,Bronchial mucosal biopsy specimens, bronchial washings (BW), and bronchoalveolar lavage,FEV1, peak expiratory flow (PEF), supplemental albuterol use, nighttime awakenings, asthma symptoms, and physician global assessment,sputum eosinophil count,Patient-rated data (peak expiratory flow, asthma symptom scores, percent of days with no asthma symptoms,frequency of adverse events,time to the first severe asthma exacerbation and poorly controlled asthma days,Clinical asthma control,daily records of peak expiratory flow (PEF), symptom scores, and clinic lung function,FEV1, symptom scores, nighttime awakenings, and supplemental albuterol use,asthma exacerbation and adverse event frequency rates,Changes in airway responsiveness,adverse effects or exacerbations of asthma,deterioration of airway inflammation,rescue albuterol use, number of nighttime awakenings, and overall asthma symptom scores,Suppression of plasma and urinary cortisol and serum osteocalcin levels,forced expiratory volume in 1 second (FEV1), asthma symptom scores, and use of rescue medication,control of daytime symptoms,salmeterol/BDP in diurnal variation of PEF (all time points) and in use of rescue bronchodilator (salbutamol) and daytime and night-time symptoms,tolerance and a low incidence of exacerbations,morning PEFR,number of submucosal mast cells or eosinophils,morning PEF,evening peak expiratory flow, asthma symptom scores, symptom-free days, supplemental albuterol use, and days and nights not requiring albuterol,peak expiratory flow (PEF) and forced expiratory volume in 1 sec (FEV1), and in reducing symptoms of asthma, sleep loss, nighttime awakenings, and use of albuterol,hypothalamic-pituitary-adrenal axis,methacholine airway responsiveness,peak expiratory flow rates (PEFRs) and symptom scores,proportion of eosinophils, EG2(+) cells, other inflammatory cells, or ECP levels in sputum,Exacerbation rates,urinary cortisol/creatinine ratio,morning peak expiratory flow rate (PEFR,forced expiratory volume,clinical status,pulmonary function and asthma symptom control,lung function and symptom control,FEV1, morning peak expiratory flow, percent of symptom-free days, and daily albuterol use,Mean morning premedication peak expiratory flow rate (PEF,FEV,Safety and tolerability evaluations,free of asthma symptoms,relative risk of an asthma exacerbation,risk of an exacerbation,rates of treatment failure,tolerated,FEV1,submucosal mast cells,safety measurement,adverse effects,lung function,evening peak expiratory flow (PEF), nighttime and daytime symptom scores, and use of reliever medication,FEV(1,airway inflammation,lung function, reducing use of reliever medication and improving control of moderate persistent asthma,worsening asthma,adverse event profiles,pulmonary function and symptom control,number of severe exacerbations,eosinophilic airway inflammation,submucosal mast cell and eosinophil counts,adverse events and asthma exacerbations,FEV1, morning and evening PEF, and percent symptom-free days,EG1-positive eosinophils,Mean evening PEF,risk for severe exacerbations,efficacy and safety,PEF,mean increase in morning PEF,Adverse events,lung function, surrogate inflammatory markers, diary card responses, quality of life, and safety,HFA-BDP,mean morning peak expiratory flow,percentage of symptom-free days and asthma-control days,overall mean morning premedication PEF,FEV1, peak expiratory flow, and quality of life (symptoms and emotions,median sputum eosinophils,mean morning PEF-the primary efficacy measure,peak expiratory flow,sputum markers of airway inflammation,morning and evening PEF,morning peak expiratory flow,evening PEF,symptom scores, morning peak expiratory flow and forced expiratory volume|Salmeterol added to low-dose beclomethasone was superior (p < or = 0.05) to doubling the dose of beclomethasone in improving peak expiratory flow (PEF) and forced expiratory volume in 1 sec (FEV1), and in reducing symptoms of asthma, sleep loss, nighttime awakenings, and use of albuterol.
20|alveolar hemorrhage,relapse rate,incidence of acute GVHD grades I-IV, acute GVHD grades II-IV, chronic GVHD, interstitial pneumonitis, relapse, survival and disease-free survival,relapse-free survival,relapse rate or survival,risk of relapse,Overall survival,time spent at hospital,acute and also chronic GVHD,incidence of chronic GVHD,sustained engraftment,overall survival,GVHD incidence,early posttransplantation complications,leukemic relapse,risk of infections,acute GVHD grades II-IV,leukaemic relapse,chronic GVHD,probability of chronic GVHD,overall disease-free survival,incidence of de novo chronic GVHD,incidence rates of grades II-IV acute GVHD,transplant-related mortality,incidence of acute GVHD,actuarial incidence of acute GVHD grades II-IV,prevention of acute graft-versus-host disease (GVHD,total amount of MP,incidence of acute or chronic GVHD or event-free or overall survival|There was no significant differences between the two arms for the incidence of acute GVHD grades I-IV, acute GVHD grades II-IV, chronic GVHD, interstitial pneumonitis, relapse, survival and disease-free survival.
not found|analgesia,Plasma levels of immunoreactive beta-endorphin,peak analgesia, similar duration of action, and a low incidence of adverse effects,acute pain and plasma beta-endorphin levels|Both doses of S(+)-ibuprofen resulted in significantly greater analgesia over the first 60 minutes in comparison to racemic ibuprofen and placebo; the 400 mg dose of S(+)-ibuprofen also produced greater analgesia at 2 and 3 hours.
176|relapse rate,median survival time,nausea/vomiting,complete response rate,Quality of life,probability of survival free of disease,longer survival,overall survival,Median survival and time to progression,longest survival,local tumor control or overall survival,ORR,time to in-field progression,Survival without local recurrence,median survival time (MST,control of local disease,median 2 year survival,1- and 2-year survival rates,Toxicities,4-year survival rates,WHO grade 3 or 4 toxicity,Esophageal toxicity,incidence of acute and/or late high-grade toxicity,time to progression, response, and toxicity,Toxicity,response rate,progression-free interval,safety and efficacy,prolonged time to infield progression,Median survival times,deaths,Median survival,Median survivals,leucopenia,5-year survival rates,progression-free survival or overall survival,median survival,cough and dyspnea improved, pain became less, and slight paresthesia,median progression-free survival time,Response, time to progression, and survival,response rate, progression-free survival, or overall survival,Survival,oesophageal toxicity,intrathoracic relapses,survival impact,relapse-free survival rate,Overall survival,survival benefit,response or survival,Incidences of grade III-IV acute radiation esophagitis and leukopenia,loco-regional progression-free survival and overall survival,nausea and vomiting,overall response rate,response and survival,2-year survival,Median time to progression,death,incidence of acute and late high-grade toxicity,rates of survival and control of local disease,six toxic deaths,overall toxicity rates,complete response,survival rate,progression-free survival,frequency of loco-regional progression,toxicity,loco-regional progression-free interval and survival,survival,3-year survival rates,longer survival time,distant metastasis-free survival rate,1- and 2-year local control rates,survival advantage,higher toxicity,median time to local recurrence and 4-year local recurrence-free survival rate,pattern of relapse,Hematological toxicities,poorer survival,incidences of grade III-IV radiation esophagitis and leukopenia,failure-free survival,time to progression (TTP,incidence of oesophagitis,acute radiation pneumonitis rate,acute toxic effect,Haematological toxicity,Acute toxicity,overall response rate (ORR,Median follow-up time,response rate, overall survival,disease control or survival|Overall survival at 3 years was 10% among those given radiotherapy plus cisplatin and 2% among those who received radiotherapy alone (P = 0.00001).
39|Pain,Westergren erythrocyte sedimentation rate,efficacy and tolerability,nonspecific gastrointestinal complaints, including dyspepsia, nausea, vomiting, and diarrhea,efficacy and safety,cutaneous involvement,Adverse reactions,adverse events,joint scores, 50 ft walking time, and global patient assessment,ESR, haemoglobin, C-reactive protein, and histidine,pain, patient's overall assessment of joint and skin improvement, morning stiffness, Ritchie articular index, ESR and CRP,Adverse clinical effects,Ritchie articular index, visual analogue pain score and ESR,physician's global assessment and functional scores,visual analogue scale, duration of morning stiffness and ESR,SASP,Polyarthritis,articular index,Increased creatine kinase values,response rates,skin lesions,exacerbation or remission of psoriasis,serum total bilirubin,tolerated and potentially beneficial,joint pain/ tenderness and swelling scores and physician and patient global assessments,disease activity,Duration of morning stiffness|In addition to articular index the SASP group improved significantly in terms of visual analogue scale, duration of morning stiffness and ESR.
70|severity of complications, hospital stay, and compliance with the fast-track protocol,length of hospital stay, physical and mental function, and gut function,maintained grip strength, earlier mobilization,perioperative morbidity, hospital stay, and cost,Morbidity and mortality,number of complications,rate of postoperative complications and length of hospital stay,hospital stay and improved physical function,patients' physical and psychological function,readmission or complication rates, pain score, quality of life after surgery, or overall satisfaction with the hospital stay,pain and fatigue scores,postoperative complications, readmission rates, and mortality,shorter hospital stays,frequency of postoperative complications and reduced hospital stay,severe complications,cardiorespiratory and anastomotic complications,shorter median (interquartile range) hospital stay,postoperative morbidity,shorter hospital stay,Postoperative pain, rehabilitation, gastrointestinal functions, postoperative complications, and post-op length of stay,Hospital stay,time to achieve a predetermined mobilization target, time to resumption of normal diet, and length of stay,postoperative stay, and achievement of independence milestones,duration of intravenous infusion,30-day complication rate,Postoperative complications,postoperative pain and faster restoration of GI functions,postoperative stay,tolerated a regular hospital diet,hand grip strength, lung spirometry, and pain and fatigue scores,Discharge decision,median stay,median length of hospital stay,patient satisfaction, pain scores, or complication rates,morbidity or mortality,Grip strength,complications and length of hospital stay,Duration of catheterization,total time,Physiological and Operative Severity Score for the enUmeration of Mortality and morbidity (POSSUM) score,Time to discharge from hospital, complication and readmission rates, pain level, quality of life, and patient satisfaction scores,Food tolerance,quicker recovery of gut function,nonfunctioning epidural analgesia|The median stay was significantly reduced in the multimodal group (5 vs. 7 days; P < 0.001, Mann-Whitney U test).
52|mean Hb and Hct,bone marrow iron stores, reduced hemoglobin iron, and transferrin saturation,haemoglobin, reticulocyte count and packed cell volume,GFR,mean erythropoietin dose,Ferritin and TSat,Ferritin,Renal anemia,dose of r-HuEPO,Levels of SF and TSAT,changes in hemoglobin and ferritin, and clinical success,iron stores,serum ferritin values,transferrin saturation (TSAT,Hb, Hct, SF and TSAT levels,Hemoglobin (Hgb), ferritin and transferrin saturation (TSAT,Dietary protein and energy intake,change in hemoglobin,serious adverse drug events (ADE,hemoglobin concentration, reticulocyte count, serum ferritin, transferrin saturation, and EPO dose,ferritin,Levels of serum ferritin (SF), transferrin saturation (TSAT), hemoglobin (Hb) and hematocrit (Hct,serum ferritin,Safety,mean serum ferritin,mean Hb concentration and Hct,change in Hb concentration,blood hemoglobin values,response rate,CFB,hemoglobin values,Haemoglobin response and changes in red cell hypochromasia,Hb, Hct, SF, and TSAT levels,hemoglobin/ferritin/TSAT,final mean recombinant human erythropoietin dose,baseline hemoglobin (Hb), hematocrit (Hct), reticulocyte Hb content (CHr), serum ferritin (SF), TSAT, or r-HuEPO dose,safety and efficacy,change from baseline (CFB) to endpoint in Hgb values,anemia and iron status,CHr,adverse events,serum ferritin concentration,serious side effects,adverse gastrointestinal effects,ferritin/TSAT criteria,quality of life,Overall adverse event rates,ferritin levels,tolerated,mean EPO dose,Hemoglobin, hematocrit, serum ferritin (SF) level, and transferrin saturation (TSAT,hemoglobin/TSAT,TSAT,sex, age, duration of PD, mean dialysate dosage per day, erythropoietin dosage per week, or hematological parameters,total cost of i.v,visual analogue scales,Kidney Disease Quality of Life (KDQoL) questionnaire,transferrin saturation,duration of hemodialysis, dialysis frequency per week, EPO dosage per week, the level of intact parathyroid hormone, serum creatinine, blood urea nitrogen, or hematological parameters,Serum ferritin levels,erythropoiesis,hemoglobin levels,larger hemoglobin increase,serum iron parameters and Hb levels,haematocrit and serum iron concentration,therapeutic or unwanted effects,hemoglobin response,KDQoL scores,creatinine regression slope,hemoglobin and ferritin,hemoglobin/ferritin, hemoglobin/ferritin/TSAT, and hemoglobin/TSAT,mean hematocrit,serum iron, serum ferritin and transferrin saturation,hemoglobin,rHuEpo|At study completion (4 months), the mean hematocrit was significantly higher in the intravenous group than in the oral iron group (34.4% +/-
30|falls and improvements in gait and dynamic balance,timed functional lower-extremity tasks (walking at a corridor, U-turn, turning around a chair, stairs, standing on one foot, standing from a chair), and secondary outcome measures were exercise test and patient's global assessment,Tolerated maximum speed,Walking distance and speed on treadmill, UPDRS, Berg Balance Test, Dynamic Gait Index and Falls Efficacy Scale,gait parameters,Gait speed, cadence, and step length,gait and sit-to-stand measures,postural instability, dynamic balance and fear of falling,functional performance,postural instability and fear of falling,mean total UPDRS,balance, gait, fear of falling and walking distance and speed on treadmill,postural instability and fear of falling in Parkinson's disease,motor component of the Unified Parkinson's Disease Rating Scale (UPDRS,lower-extremity tasks,Gait parameters, 5-step test, report of falls,baseline UPDRS,double stance duration,Initial total walking distance,motor performance and corticomotor excitability,Berg Balance Test, Dynamic Gait Index and Falls Efficacy Scale,Basic gait parameters (overground walking speed and stride length at self-adapted speeds) and parameters of gait analysis based on vertical ground reaction forces,total and motor UPDRS,Unified Parkinson's Disease Rating Scales (UPDRS), biomechanic analysis of self-selected and fast walking and sit-to-stand tasks; corticomotor excitability,5-step test speed,Unified Parkinson's Disease Rating Scale (UPDRS), ambulation endurance and speed (sec/10 m), and number of steps for 10-meter walk,gait in PD, namely, speed and stride length,ambulation speed,activities of daily living, motor performance, and ambulation,Unified Parkinson's Disease Rating Scale (UPDRS), ambulation speed (s/10 m), and number of steps taken for a 10-m walk as a parameter for stride length,functional lower-extremity tests, exercise test parameters, and patients' global assessment,Stride lengths,Gait speed,gait speed, step and stride length, and hip and ankle joint excursion during self-selected and fast gait and improved weight distribution,Berg Balance Test, Dynamic Gait Index and Falls Efficacy Scale scores|High-intensity group subjects showed postexercise increases in gait speed, step and stride length, and hip and ankle joint excursion during self-selected and fast gait and improved weight distribution during sit-to-stand tasks.
12|grip and percussion myotonia,depressive symptomatology,subjective improvement,side effects,severity of myotonia,Initial grip strength and muscle fatiguability measured by grip strength ergometry|Both grip and percussion myotonia were significantly improved by imipramine treatment independent of change in depressive symptomatology.
29|inflammatory mediator release,myocardial mRNA expression for IL-6, MCP-1, and ICAM-1,C-reactive protein (CRP) levels and polymorphonuclear leukocyte counts, postoperative core temperature, duration of mechanical ventilation, period of stay in intensive care unit, oxygenation indices, and biochemical parameters,Myocardial inflammatory mediator mRNA expression,oxygenation, body temperature, fluid balance, leucocyte and platelet counts, days in the ICU or days on mechanical ventilation,indexes of O2 delivery,C-reactive protein concentration,clinical course, C-reactive protein, S100B protein and von Willebrand factor antigen,postoperative IL-6 and 8 levels,mean rectal temperature,oxygen delivery and reduces postbypass inflammatory mediator expression,Complement component C3a and absolute neutrophil count,safety and efficacy,clinical course, C-reactive protein, von Willebrand factor antigen (vWf,elevated liver enzymes, blood urea nitrogen, and creatinine,cardiopulmonary function,Systemic inflammatory response,reduced fluid requirements, lower body temperature, and lower DeltaA-VO2,interleukin-6 levels,serum IL-6 and IL-10,inflammatory response,serum interleukin (IL)-6 and 8 levels, acute phase reactants, and blood biochemistry,intubation time, CICU length of stay, fluid balance, arterio-venous O2 difference (DeltaA-VO2), and inotrope requirements,lower serum IL-6 and increased IL-10,temperature, supplemental fluids, alveolar-arterial oxygen gradient, and days of mechanical ventilation,postbypass inflammatory response,postoperative IL and CRP levels,plasma IL-6 and 8 levels,release of vWf,tumor necrosis factor-alpha levels,supplemental fluid,neutrophil count, CRP, and IL-6 and 8 levels,Serial blood analyses for interleukin-6, tumor necrosis factor-alpha, complement component C3a, and absolute neutrophil count,Oxygenation, body temperature, fluid balance, leucocyte and platelet counts, days in the intensive care unit (ICU) and days on mechanical ventilation,peak levels,alveolar-arterial oxygen gradients,mechanical ventilation|Compared with intraoperative MP alone, combined preoperative and intraoperative MP was associated with reduced myocardial mRNA expression for IL-6, MCP-1, and ICAM-1 both before and after bypass (P<0.05).
243|pain ratings,crying time and pain scores,pain responses,pain reduction,pain response,crying time and pain score by a pediatrician using the Neonatal Infant Pain Scale (NIPS,Children's Hospital of Eastern Ontario Pain Scale (CHEOPS,Affective state,pain,pain vocalizations,Ratings of pain intensity and affective state|No difference in outcome was seen between the sucrose and lidocaine-prilocaine treatment groups.
                
87|CEPD (creatinine and urea clearances,solute clearances,Solute clearances (Kt/V, normalized creatinine clearances,potassium and phosphate clearances,TPD and CEPD normalized creatinine clearances,protein loss,Potassium and phosphate clearances, dextrose absorption, protein losses and costs|TPD resulted in higher clearances of solutes than CEPD (creatinine and urea clearances in mL/min of 9.94 +/-
11|sustained attention,long-delay verbal memory performance,tests of attention, information processing and executive functions,memory performance,Beck Depression Inventory and several measures of cognitive functioning,Beck Depression Inventory (BDI,clinical and socio-demographic data and baseline intelligence level,levels of difficulty,fatigue symptoms as well as working memory -, and mental speed performances,social behavior,visuo-spatial memory,depression,cognitive impairment and personality/behavior disorder,Efficacy,new learning and memory performance,cognitive measures,executive functions (CKV) and spatial-constructional abilities (HAWIE-R,Cognitive disorders,verbal learning,neuropsychological test and scale scores,symptoms of fatigue,Neuropsychological improvement,verbal (VLT) and nonverbal learning and memory (NVLT,fatigue values (MFIS,Executive functioning and verbal learning,learning abilities,quality of life (QoL), depression and fatigue using self-rating scales,depression scores,memory,cognitive performance,Paced Auditory Serial Addition Test (PASAT) and executive functions,verbal learning, long-delay verbal memory performance, and working memory performance,depression ratings (BDI,neurological status and on QoL or fatigue,naming speed, speed of information recall, focused attention and visuo-motor vigilance,general health questionnaire (GHQ-28), extended activities of daily living scale, SF-36, everyday memory questionnaire, dysexecutive syndrome questionnaire, and memory aids questionnaire,memory-based cognitive abilities (general memory, visual working memory and verbal working memory,depression values (BDI,short term memory, quality of life or depression,cognitive skills,mood, quality of life, subjective cognitive impairment or independence|Baseline brain atrophy, quantified by the brain parenchymal fraction, was associated with treatment effects for one aspect of executive functioning.
not found|patient (Montgomery Asberg depression rating scale) and the physician (clinical global improvement and impression scales,MADRS and CGI,severity of depression, self reported measure of social outcome, and observer measure of psychological symptoms,rate of adverse events,mean mQoL ratings,standardised mental component scale,placebo-level adverse event withdrawal rates,nausea, dizziness and headache,Quality of life,Hamilton anxiety and clinical global impressions scales,relieving depression and anxiety,physical component scale,symptoms of depression and anxiety,Limbitrol,Hamilton rating scale for depression,SARS total score and the items 'social/leisure' and 'extended family,Montgomery-Asberg Depression Rating Scale total score,efficacy and safety,effective and well tolerated,safe and very well tolerated,Hamilton depression scale, the Hamilton anxiety scale, the clinical global impressions scale, Zung's self rating depression scale, and SF-36, and adverse events profile,MADRS total score,quality of daily life,several measures of depression and anxiety,frequency and severity of physical complaints,quality of life,recurrent depression,Troublesome side effects,Hamilton depression scale, the Beck depression inventory, and physician and patient global change measures,tolerated,Hamilton depression scores,overall incidence of side effects,Zung self rating depression scale,Hamilton scale,total MADRS and percentage of responders, the CGI improvement, the CGI severity of illness, the BSA psychic anxiety item and the HSCL,patient satisfaction,Nausea,somnolence and headache,MADRS, CGI, and Leeds Self-rating Scales,antidepressant effect,antidepressant efficacy and excellent tolerability|Nausea was the only adverse event reported significantly more in escitalopram-treated patients than in placebo-treated patients, although it was infrequent and transient.
353|hip BMD and biochemical markers of bone turnover,New vertebral fractures,femoral neck bone mineral density T score,risk reduction,vertebral BMD,incidence of serious adverse events,bone alkaline phosphatase,RR reduction for hip fracture,bone resorption,lumbar bone mineral density (BMD,Osteoporotic structural damage and bone fragility,efficacy and safety,serum levels of bone alkaline phosphatase,urinary excretion of cross-linked N-telopeptide, a marker of bone resorption,bone mineral density,risk of vertebral fracture,adjusted lumbar BMD,relative risk (RR,femoral BMD, incidence of new vertebral deformities, and biochemical markers of bone metabolism,lumbar bone mineral density (BMD), assessed by dual-energy x-ray absorptiometry,number of patients experiencing new vertebral deformities,tolerated,risk of nonvertebral fractures,bone loss,Incidence of adverse events (AEs,RR of vertebral fractures,Femoral neck and total hip BMD,Lumbar BMD, adjusted for bone strontium content,vertebral fractures,lumbar BMD,vertebral fracture risk,incidence of vertebral fractures|Lumbar BMD, adjusted for bone strontium content, increased in a dose-dependent manner in the intention-to-treat population: mean annual slope increased from 1.4% with 0.5 g/d SR to 3.0% with 2 g/d SR, which was significantly higher than placebo (P < 0.01).
23|delivery rate,embryo implantation rate,implantation rate (with fetal heart beat,implantation rate,delivery rates,average number of embryos transferred,ongoing IR,live born rate per embryo transferred,pregnancy, implantation, or live birth rates,live birth delivery rates,implantation rates,aneuploidy rate,embryonic morphology and chromosomal status, number of transferred embryos and clinical pregnancy rate,clinical pregnancy rate,pregnancy rate,live birth delivery rate,spontaneous abortion rate,number of embryos transferred,clinical IR,normal diploid status,Fertilization and blastocyst developmental rates,live birth rate,multiple birth rate,Pregnancy, implantation, multiple gestation, and live birth rates,reproductive outcome,Positive serum HCG rates per transfer and per cycle,vitro fertilization (IVF) cycle outcome,Implantation rates|In a "good prognosis" population of women, PGS does not appear to improve pregnancy, implantation, or live birth rates.
not found|postoperative bacteremia and T-tube bile infection,total cost of treatment,postoperative hospital stay,early morbidity rate,postoperative stay,recurrence of CBD stones,mortality rate,jaundice or pancreatitis, nor needed further biliary surgery,biliary peritonitis,CBD, bile leakage,bile leakage,postoperative bacteremia,Abdominal pains,duration of operation, incidence of wound infection, surgical or other complications,Postoperative jaundice|There was no significant difference in the duration of operation, incidence of wound infection, surgical or other complications following operation between the two groups.
48|Postcoital pain,pain score,pelvic veins,Pain,chronic abdominal pain,VAS,severe pelvic signs and symptom scores, lowest rates of sexual functioning,chronic pelvic pain,pelvic congestion with pain,pain relief,intensity of pain,evaluative pain intensity ratings,pain or functional disability,VAS score,psychological function, pain, and functional disability,stressful consequences of their pain (disclosure) or positive events (control,Health status,pelvic congestion,outcome variables (sensory or affective pain, disability, affect,quality of life,pelvic pain,visual analogue scale pain score,Pelvic pain assessed by the McGill pain score, subjective pain assessment and disturbance of daily activities,visual analogue score (VAS) score (scale 0-100), pain change score, use of analgesics, and quality of life score,diary VAS,substantial pain relief,pelvic congestion and pelvic pain,organic causes of pelvic pain,psychological status and sexual functioning,sexual functioning and reduction of anxiety and depressive states,pelvic venographic improvement,summary and daily diary visual analog scales for pain (VAS) and a 5 point self rating scale|After 9-12 months there were no significant differences between the two groups overall with regard to pelvic pain.
40|fasting blood glucose levels,nausea,accidental pregnancy rates,fibrinogen,subendothelial deposition of platelets and platelet thrombi,lipid and carbohydrate profiles,For fibrinogen and protein S activity,Withdrawal bleeding characteristics,Bleeding data,contraceptive reliability, cycle control, and tolerance,discontinuation rates,metrorrhagia,mean body weight,Hemostatic variables and lipids,intensity of bleeding,percentages of normal menstrual cycles and the percentages of cycles with intermenstrual and withdrawal bleeding,intermenstrual bleeding rates,fibrin-subendothelial interactions,efficacy, side effects, metabolic changes, and cycle control,safe and well tolerated,unscheduled bleeding and more scheduled bleeding,blood coagulation and thrombogenesis,metabolic effects,low-density lipoprotein cholesterol, very low-density lipoprotein cholesterol and total triglycerides,follicle size,antifibrinolytic variables, the global clotting tests and D-dimer,adequate contraceptive reliability,median values for the fasting levels of insulin, C-peptide and free fatty acids,blood pressure and body weight,overall change of all hemostatic variables,Withdrawal bleeding mean intensity,individual hemostatic parameters,latent period before withdrawal bleeding,fibrinolytic response,episodes of unscheduled bleeding,blood flow and wall shear rate,Compliance and safety data,cholesterol concentration,withdrawal bleeding episode,frequency of adverse events,glucose AUCs,plasma levels of HDL-cholesterol and its subfractions, LDL-cholesterol and apolipoproteins,HDL2 cholesterol,SBP and CBG,triglycerides, HDL-cholesterol and apoprotein A1,weight, blood pressure, Papanicolaou smears or laboratory data,Irregular bleeding between withdrawal bleeds,Bleeding,fibrinolytic capacity,hemostatic system,headache, nausea and metrorrhagia,intermenstrual bleeding (total bleeding and/or spotting,cumulative breakthrough bleeding rates,intermenstrual bleeding,Discontinuation and pregnancy rates,Hemostatic and metabolic effects,renin substrate and hemostatic parameters,glucose area under the curve (AUC,Bloating, breast tenderness, and nausea,dizziness and mood changes,incidence of treatment-emergent adverse events,tissue plasminogen activator (t-PA) and plasminogen activator inhibitor (PAI-1,escape ovulation,Mean blood pressure,fibrinolytic activity,Efficacy, cycle control, and side effects,lipid and carbohydrate variables,scheduled bleeding,incidence of missed pills,Irregular bleeding (break-through bleeding or spotting,percentage of cycles classified as normal,Fibrin deposition on vascular subendothelium,breakthrough bleeding and spotting rates,cycle control, efficacy, and side effects,fasting glucose levels,breakthrough bleeding and/or spotting,breakthrough bleeding rate,lowest rate of breakthrough bleeding (BTB,adverse reactions,ruptured follicles,cycle length or withdrawal bleeding episode length,body weight and blood pressure,threshold of fibrinolytic inhibition (ratio PAI-1,nausea and vomiting,occurrence of spotting and breakthrough bleeding,incidence of adverse events,tolerated,menstrual flow length,follicular ovarian activity,mean intensity,protein S concentration and protein S activity,Absence of all bleeding,metabolic and hemostatic effects,antithrombin III, total and free protein S and fibrinogen,Deposition of fibrin, platelets and platelet thrombi on vascular subendothelium,discontinuation rates for medical reasons,nausea, vomiting, dizziness, and chloasma,HDL-cholesterol,renin substrate,antithrombin III activity,plasma levels of ethinyl estradiol,Breakthrough bleeding and spotting,duration of bleeding,bleeding patterns,Reliability, cycle control, side effects, blood pressure, body weight and haemoglobin,breast pain,Contraceptive efficacy,Adverse events,levels of HDL-C,hemostatic variables, lipids, and carbohydrate metabolism,abdominal pain,overall and method failure probabilities of pregnancy,total triglycerides,blood-subendothelium interactions,bleeding disturbances,normal cycles,Haemoglobin,spotting rate,triglyceride and glucose concentrations,unscheduled bleeding days,Carbohydrate metabolism,AUCs for insulin and C-peptide,hemostasis variables,high-density lipoprotein cholesterol (HDL-C|There was also an increase in the threshold of fibrinolytic inhibition (ratio PAI-1) in both groups, which was less pronounced in the 20 micrograms EE group.
25|Urinalysis, cultures, and antimicrobial susceptibility tests,catheter life,resistance to oral antimicrobials,numbers and types of bacteria, urinary pH, urinary leukocytes, and generation of antimicrobial-resistant organisms,incidence of catheter obstructions and febrile episodes and the prevalence and species of bacteriuria,catheter encrustation,urinary bacterial load and inflammation,risk of UTI,symptomatic urinary tract infection (UTI) requiring antibiotics,struvite crystals,degree of bacteriuria or pyuria,polymicrobial bacteriuria, catheter obstruction, fever, bacteremia, urinary tract stones, and death,Urinary incontinence,Uric acid crystals,patency time,catheter changes or self-reported 'UTI,urinary pH|There was no significant difference in catheter encrustation between the various washouts.
not found|gastric volume and pH,visual analog scale scores,Intragastric volume and acidity,postoperative recovery,volume and pH of gastric fluid taken,Volume and pH of gastric contents,risk of aspiration syndrome,Residual gastric fluid volumes,mean pH,RGV measurements,thirst, hunger, anxiety, malaise, and unfitness,anxiety,gastric pH values,volume and pH of gastric fluid,unfitness and malaise,volume of gastric contents aspirated, the median pH of the gastric contents,Mean pH values,mean gastric volume,morbidity,mean (SD) residual gastric volume ,Gastric fluid volume (GV,residual gastric volume (RGV,gastric volume and acidity,intragastric pH and volume, median (range,volume and pH of gastric contents,mean gastric residue,postoperative morbidity,volume and pH,gastric fluid volumes or affect acidity,pain,Gastric pH,questionnaires about pain, nausea and headache scores,gastric pH,Discomfort,hungry and less anxious,Gastric fluid volume and pH,Mean volumes,Visual analog scales,preoperative discomfort,gastric volume,GV, GpH and subject hunger,preoperative discomfort, residual gastric fluid volumes, and gastric acidity,nausea, tiredness, and inability to concentrate,gastric emptying,gastric fluid volume and pH,Gastric pH and volume,pain, nausea and headache scores,mean values of gastric pH,gastric volume or pH, or on plasma osmolality,Gastric contents,mean values of gastric volume,Gastric fluid volume, pH, and emptying,Postoperative morbidity and serum osmolality,VAS of hungry and thirsty feeling,risk of aspiration,mean pain scores,immediate recovery time, or pain, nausea and headache scores,residual gastric volume,adverse intra-operative events,volume and median pH of gastric contents,hunger, thirst, tiredness, weakness, and inability to concentrate|There were no significant differences in immediate recovery time, or pain, nausea and headache scores at 30 or 120 minutes following recovery.
not found|anemia, thrombocytopenia, radiation skin reaction, diarrhea, or radiation-induced complications requiring surgical correction,anemia, thrombocytopenia, radiation skin reactions, diarrhea, or radiation induced complications requiring surgical correction,Leukopenia (WBC less,anemia, thrombocytopenia, radiation-induced skin reaction, and radiation-induced intestinal reaction,Life-table survival,estimated 5-year progression-free survival rate,Leukopenia (white blood cell count less,median dose of pelvic radiation,longer survival,survival,median pelvic cGy,5-year progression free survival rate|There was no statistically significant difference relative to anemia, thrombocytopenia, radiation skin reactions, diarrhea, or radiation induced complications requiring surgical correction.
41|evolution of the Raynaud's phenomenon or skin changes,Digital Skin Temperature (DST), Digital systolic Blood Pressure (DBP) and Doppler Spectral Analysis (DOSA) of the radial and ulnar arteries,haemorrheological parameters (total blood viscosity, plasma viscosity and thixotropism,hypertension both systolic and diastolic blood pressure normalized,frequency and duration of the attacks (both per se and combined to a severity score), cold sensation, numbness, paresthesia, pain, cold water and cold weather provocation and the appearance of spontaneous attacks,blood chemistry nor systemic blood pressure,diastolic blood flow velocity of DOSA,Raynaud's phenomenon,K infinity coefficient of Quemada's law,Dysphagia,frequency or severity of side-effects,severity score, the occurrence of numbness and paresthesia and cold weather provocation|The severity score, the occurrence of numbness and paresthesia and cold weather provocation improved significantly on ketanserin treatment.
102|postoperative deaths,severe pain,worst hip-rating-questionnaire and EuroQol scores,hip-rating questionnaire and the EuroQol health status measure,shorter length of anaesthesia,dislocation rate,pain and mobility,survival,mortality rate,postoperative mortality rate,hospital stay,Merete, Berlin, Germany], total arthroplasty ,General complications and the rate of mortality,mean survival time,marked osteopenia,Mean Eq-5d index score,number of revision procedures,complications, revision surgery, the status of activities of daily living (ADL), hip function according to the Charnley score and the health-related quality of life (HRQOL) according to the Euroqol (EQ-5D) (proxy report,hip complications,local complications,direct health service costs,hospitalization time,EQ-5D(index) score,mortality rates, fracture- or operation-related complications,duration of the operation and the perioperative blood loss,failure of internal fixation,total number of surgical procedures,severe cognitive dysfunction,bone mass and muscle volume of the middle femur,Bone and muscle mass,rate of hip complications,revision rate,Limb shortening,functional outcome scores,failure rate,Barthel index,Hip function (Harris hip score), health related quality of life (Eq-5d), activities of daily living (Barthel index,loss of blood and more wound complications,rate of secondary surgery,rate of failure,Average Harris hip scores,reduction in HRQoL (EQ-5D index score,Hip function,hip complications, revision surgery, hip function according to Charnley and the health-related quality of life (HRQoL) according to EuroQol (EQ-5D,Complications,range of passive hip motion,mortality and complications,cortical bone mineral density (BMD), bone volume, bone mass and muscle volume of the thigh, and the BMD of the distal femur and proximal tibia,Social function,blood transfusion,severe cognitive impairment,least pain,earlier postoperative mobilization,lower operative blood loss,Mean Harris hip score,Harris Hip Scores,mean patient survival,healing complications and 2 dislocations,mobility,Clinical morbidity,mortality rates,morbidity rate,lower transfusion requirements,Postoperative mortality,Barthel Index and Harris Hip Score,Barthel Index scores,Eq-5d visual analogue scale,mortality|Hip function was significantly better in the THR group at all follow-up reviews regarding pain (p < 0.005), movement (p < 0.05 except at 4 months) and walking (p < 0.05).
122|quality of life scores, performance status, toxicities, local response to treatment, and systemic disease progression,Side-effects,Complete-response rates,survival,extent and duration of local control, measures of toxicity or quality of life scores,5-year survival rate,duration of local control,survival advantage,complete response and duration of local control,local pelvic tumour recurrence,3-year overall survival,quality of life,Five-year survival rate,Complete response (CR) and partial response (PR,complete-response rate with radiotherapy plus hyperthermia,maximum tumour temperature,survival and cumulative incidence of pelvic site of first progression,Intratumour temperatures,Intracavitary temperatures|Five-year survival rate was 66.7% (24/36) in group A, 50% (14/28) in group B and 40.5% (15/37) in group C. Percentage of survival at 5 years was 73.7% (14/19) for 40 Gy plus heat, 57.1% (8/14) for 40 Gy alone, 58.8% (10/17) for 30 Gy plus heat, and 42.9% (6/14) for 30 Gy alone.
not found|quality of life|Within each state and age group, consumers were not more susceptible to adverse health outcomes or injuries under Cash and Counseling.
                
39|overall survival,disease progression,levels of hepatic copper,Progressive symptoms, deterioration in serial hepatic laboratory values, or histologic progression on sequential liver biopsy specimens|Progressive symptoms, deterioration in serial hepatic laboratory values, or histologic progression on sequential liver biopsy specimens were similar in both groups, occurring in greater than 80% of the entire study population.
35|treatment failure and secondary efficacy outcomes were late clinical and parasitological failures, fever clearance time, and time to oral intake,Efficacy and pharmacokinetics,fatal outcome and coma recovery time,fever clearance time,Clinical and parasitological status,Cmax,tolerated and no anal irritation,Tmax,residual pain,Mean fever clearance times,lethality of severe malaria,efficacy and safety,approximate bioavailability of intrarectal quinine,Local pain,blood concentration-time profiles of quinine,parasite clearance time, fever clearance time, coma recovery time, time to sit unsupported, time to begin oral intake, time until oral quinine was tolerated, and death,clinical and parasitological outcomes,diarrhoea,parasitaemia,safety and efficacy,parasite clearance time,Cmax. and the area under the concentration-time curve,Body temperature and parasitaemia,Mortality,blood quinine concentrations,tolerated,Blantyre coma score,tolerability,presence of blood in stools and secondary safety outcome was diarrhoea,Parasitaemia expressed as a percentage of initial values,efficacy outcomes (late clinical failure, late parasitological failure, fever clearance time, time to starting oral intake and rate of deterioration to severe malaria,transient impairment of mobility,temperature clearance,Safety and efficacy,negative blood slide results,Fever recurrence,hyperthermia, hypoglycemia, anemia and seizures,efficacy and tolerance,Mean parasite clearance times,Blood in stools and diarrhoea,died; mean coma recovery times,Residual blood quinine concentrations,parasitaemia ,ulceration or necrosis of the anorectal mucosa,parasitemia,coma recovery time,mortality|The intrarectal route has been shown to be an alternative to parenteral therapy for the treatment of acute uncomplicated malaria.
not found|support person self-efficacy,level of negative (nonsupportive) social interactions,6-month smoking abstinence rate,abstinence rates,adherence to the quitting protocol and quit rates,smoking behavior,feasibility, acceptability, and potential efficacy,smoking abstinence rates or quit attempts,quit rates,low-moderate levels of motivation to quit,level of support and program material use (reading the manual and watching TV,outcome expectancies,Study retention rates,Abstinence rates|Intent-to-treat analyses showed no significant differences by condition in women's reports of abstinence at any follow-up.
323|episode of candidiasis,safe and effective in preventing oropharyngeal and vaginal candidiasis,vaginal candidiasis,relative risk of experiencing an episode of VC,Vaginal candidiasis (VC,esophageal candidiasis,Lactobacillus acidophilus,estimated median time to first episode VC,oropharyngeal candidiasis,Absolute risk reduction,resistance,safety and effectiveness|Weekly fluconazole was effective in preventing oropharyngeal candidiasis (RR, 0.50 [Cl, 0.33 to 0.74]; P < 0.001) and vaginal candidiasis (RR, 0.64
not found|Postoperative apnea, bradycardia, and oxygen desaturation,postoperative minimum SpO2,no prior history of apnea,minimum heart rate,length of hospital stay,postoperative bradycardia, prolonged apnea, or periodic breathing,unacceptable number of post-operative cardiorespiratory complications,postoperative hemoglobin oxygen desaturation and bradycardia,postoperative respiratory complications,prolonged apnea with bradycardia,Postoperative apnea,Respiratory pattern and heart rate,Cardiorespiratory function,incidence of postoperative central apnea,apnea spells, periodic breathing, and episodes of hemoglobin oxygen desaturation and bradycardia,bradycardia and apnoea,postoperative minimum SpO2 and minimum heart rate,inpatient hospital stay,incidence of apnea,respiratory rate (chest wall impedance), electrocardiogram (ECG), and hemoglobin O2 saturation (SpO2,apnoea, hypoxaemia or bradycardia,inguinal hernia,postoperative respiratory morbidity,respiratory morbidity|When infants with no prior history of apnea were analyzed separately, there was no statistically significant increased incidence of apnea in children receiving general versus spinal anesthesia with or without ketamine sedation.
8|mean number of collected oocytes,number of obtained oocytes,Complex hormonal status,Overall clinical pregnancy rates,overall fertilization rate,ovarian stimulation and in vitro fertilization,vitro fertilization (IVF), altered follicle stimulating hormone (FSH) requirement,risk of ovarian hyperstimulation syndrome,total number of follicles on the day of human chorionic gonadotropin treatment,median number of oocytes retrieved per cycle,clinical pregnancy rates,Mean total FSH dose,total dose of rFSH required per cycle,pregnancy rates following IVF,pregnancy rates,risk of OHSS,cancelled cycles,number of cleaved embryos,per embryo transfer,risk of ovarian hyperstimulation syndrome development,insulin sensitivity,primary end-points: duration of FSH stimulation,vitro fertilization/intracytoplasmic sperm injection (IVF/ICSI) outcomes,FSH requirement,incidence of severe ovarian hyperstimulation syndrome (OHSS,mean number of mature oocytes,incidence of ovarian hyperstimulation syndrome,estradiol levels,reproductive function,secondary end-points number of oocytes, fertilization rates, embryo quality, pregnancy rates and clinical pregnancy rates,vitro fertilization (IVF)-embryo transfer (ET) outcomes,number of ampoules of rFSH,overall fertilization rates,estradiol blood levels,intraovarian androgen levels,IVF/ICSI outcomes|administration of metformin is therefore likely to increase the number of oocytes collected after ovarian stimulation in insulin-resistant women with PCOS but is unlikely to reduce the requirement for FSH.
not found|toxicity,Survival,CD4 cells,relative hazard ratios for progression to an AIDS-defining event or death,relative risk of disease progression or death,survival,gastrointestinal adverse effects,disease progression,Virologic and immunologic benefits,serum HIV-1 RNA,safety and efficacy,relative hazard ratios for death,time to disease progression or death,CD4 cell count, development of the acquired immunodeficiency syndrome (AIDS), or death,CD4 cell counts,Disease progression, survival, toxic effects, and the CD4 cell response,progression rates,estimated 12-month event-free rates,disease progression or death,progression of HIV disease,time to first AIDS-defining event or death,Severe toxic effects,CD4 cell count,mortality|However, combination therapy resulted in a significant increase in CD4 cells through 72 weeks compared with zidovudine monotherapy and a greater and more sustained decline in serum HIV-1 RNA.
not found|knowledge, clinic visits, or testing or treatment for syphilis,social marketing campaign materials,syphilis infections,number of MSM testing|There was a 4.5-fold rise (p < 0.001) in MSM testing at the campaign clinic.
18816|mortality rate ratio,HCC mortality,number of HCC,5-year survival rate,HCC mortality rate|Thirty-two people died from HCC in the screened group versus 54 in the control group, and the HCC mortality rate was significantly lower in the screened group than in controls, being 83.2/100,000 and 131.5/100,000, respectively, with a mortality rate ratio of 0.63 (95%CI 0.41-0.98).
                
277|recurrence-free interval and overall survival (OS,risk of recurrence,survival probability,overall survival differences,median duration,therapy morbidity,overall survival,risk of progression or death,risk of recurrence and prolongs progression-free survival,tumor size|Pelvic radiotherapy after radical surgery significantly reduces the risk of recurrence and prolongs progression-free survival in women with Stage IB cervical cancer.
247|safety, tolerance, and efficacy,UPDRS total scores, subscores part II, III (activities of daily living and motor examination), and IV (complications of therapy,advanced PD,safety data,Unified Parkinson's Disease Rating Scale (UPDRS) parts II and III,activities of daily living, motor function,efficacy, safety,severity of "off" periods, decreased disability and PD severity,Safety and tolerability,motor function,total score of the unified Parkinson's disease rating scale (UPDRS,Unified Parkinson Disease Rating Scale,time spent in "off" periods,gastrointestinal and cardiovascular tolerability,Mean UPDRS total score,Efficacy, safety, and tolerance,fatigue, dyskinesia, and vivid dreams,dyskinesia and nausea,adverse events, vital signs, laboratory measurements, and ECG recordings,UPDRS part II|The UPDRS part III showed improvements of 34% for pramipexole (p = 0.0006) and 23.8% for bromocriptine (p = 0.01) versus 5.7% for placebo.
20|Performance measures of impairment (Fugl-Meyer Assessment), strength (isometric torque), and function (Functional Test of the Hemiparetic Upper Extremity [FTHUE,sway during static standing,walking ability,mobility and upper limb function early,Standing (Functional Reach), walking (MAS Item 5) and quality of life (SA-SIP30,isometric muscle torque,area under the curve (AUC) and inserting AUC values into Mann-Whitney U tests,JTHFT dexterity scores,functional outcomes,movement time, distance reached, vertical ground reaction forces through the feet, and muscle activity,Nine-Hole Peg Test, maximal grip strength, the Test d'Evaluation des Membres suprieurs des Personnes Ages (TEMPA) and the Stroke Rehabilitation Assessment of Movement,Gait improved earlier in DG,MAS and SMES,number of repetitions of the step test,Performance of reaching in sitting,Barthel ADL Index,FIM scores,Wolf Motor Function Test (WMFT,spatial cognition deficits,dynamic reaching, sitting and standing, and static standing balance,Fugl-Meyer motor scores,mobility and quality of life,length of stay in the hospital, use of assistive devices for mobility, and the patient's accommodation after discharge from the hospital,ability in ADL (Barthel index), walking ability (functional ambulation categories), and dexterity of the paretic arm (Action Research arm test,Rivermead Motor Assessment and the Motor Assessment Scale,Six-minute walk test (SMWT), 5-m walk (comfortable and maximum pace), Berg Balance Scale, timed 'up and go,quality of life,Lower-limb function,lateral weight transference,motor function,isometric torque,movement abilities or functional independence,Motor Assessment Scale (MAS), the Sdring Motor Evaluation Scale (SMES), the Barthel ADL Index and the Nottingham Health Profile (NHP,walking speed and endurance, force production through the affected leg,FTHEU and isometric torque,locomotor ability,functional independence, walking speed, arm function, muscle tone, and sensation,voluntary movement or manual dexterity,time to return to their original position during dynamic reaching,Jebsen Taylor Hand Function Test (JTHFT), two arm items of the Motor Assessment Scale (MAS), and three mobility measures, the Timed Up and Go Test (TUGT), Step Test, and Six Minute Walk Test (6MWT,severe walking deficit,walking,standing,reaching or sit-to-stand,life quality test (NHP), use of assistive devices or accommodation after discharge from the hospital,walking speed and endurance, peak vertical ground reaction force,functional recovery of activities of daily living (ADL), walking ability, and dexterity,activation of affected leg muscles|After training, experimental subjects were able to reach faster and further, increase load through the affected foot, and increase activation of affected leg muscles compared with the control group (P < .01).
2|maximal mid-expiratory flow rate,daily steroid requirement,nausea and headache,mean forced expiratory volume,liver function tests,toxicities,Symptom scores and spirometry,corticosteroid requirements,Daily diary cards of symptoms, peak expiratory flow rate and medication requirements,Pneumocystis carinii pneumonia and died,wheezing, dyspnoea and coughing,symptom scores, pulmonary function data, and exacerbations,steroid requirement,Mean serum theophylline levels,Adverse events,pulmonary function and reduction of prednisone requirement,steroid requirements,Pulmonary function,forced vital capacity and forced expiratory volume,methotrexate,adverse events,steroid consumption,steroid dose,Lung function,blood taken for full blood count, urea and electrolytes and liver function tests,severe nausea,steroid use, asthma symptom scores, pulmonary function, airway reactivity, blood cellular components, and immunoglobulin E levels,Adverse effects,peak expiratory flow rate (PEF) 1-s forced expiratory volume (FEV1) values,subjective symptom scores,FEV1,lung function,serum MTX concentration and clinical improvement,transient nausea,mean prednisone requirements,airway reactivity and symptom scores,anorexia, alopecia, and stomatitis,Symptom scores, peak flow rates, spirometry, and beta-agonist frequency|There were no significant differences in symptom scores, pulmonary function data, and exacerbations between active and placebo treatments.
                
61|postural performance and reduced neck pain scores,postural performance or pain intensity,cervical pain,postural performance or pain scores,postural performance,Decreased muscular tension|There were no significant evoked potential and clinical group changes after 6 months and 2 years in the mild myelopathy group treated either surgically and conservatively, whereas patients with severe myelopathy displayed significant improvement in clinical and evoked potential parameters after surgery.
108|gametocyte clearance time,gametocyte carriage, of CQ or SP monotherapy against the respective combinations (PQ or AS,gametocyte carriage rates,gametocyte clearance,Haemoglobin levels (Hb,Pfs25 QT-NASBA gametocyte prevalence,Gametocyte prevalence and density,children harboured gametocytes,Clinical recovery,Gametocyte clearance rates,Mean Cmax,Failure rates,Gametocytemia,Gametocyte elimination,vomiting and dizziness,appearance of gametocytemia,Clinical response and parasite elimination efficacy,Adverse events,Mean t1/2, Cl/f and Vd,cleared parasitaemia and remained aparasitaemic,serious side effects,tolerated,63 day recrudescence rate,cure of asexual stage parasitaemia,failure rates,efficacy and gametocytocidal activity,Plasmodium vivax infection,parasite clearance times,parasitemia and fever,Hazard ratios for re-infection,reinfection-adjusted cure rates,density of gametocyte and infectivity,therapeutic response,gametocyte count,clearing gametocytaemia,Parasitaemia,shorter gametocyte clearance times,fever clearance times, rates of P. falciparum reappearance, or recurrent vivax malaria,recrudescent P falciparum infections,elimination of parasitaemia and prevention of gametocyte carriage,Mixed falciparum and vivax infections,trophozoite and gametocyte clearance (read by light microscopy), and clinical and parasitological failure,Hb levels,gametocytaemia and gametocyte viability|Pfs25 QT-NASBA gametocyte prevalence was 88-91% at enrolment and decreased afterwards for both treatment arms.
193|seizure-free,total number of premature discontinuations,tolerability reasons,tolerability,number of premature discontinuations,memory, attention and simple psychomotor speed,number of premature discontinuations due to adverse experiences|The number of premature discontinuations due to adverse experiences was statistically significantly lower in the OXC group than in the PHT group.
17|cognitive subscale of the Alzheimer's Disease Assessment Scale,incidence and severity of adverse events,one section of an implicit memory test,Cognitive Drug Research (CDR) efficacy assessments|D-Cycloserine was associated with significant improvement in scores on the cognitive subscale of the Alzheimer's Disease Assessment Scale (improvement of 3.0 points) when given at a dose of 100 mg/day.
                
286|proportion of Montgomery-Asberg Depression Rating Scale (MADRS) responders,Children's Depression Rating Scale-Revised total score,efficacy, safety, and tolerability,suicidal thinking,Serious adverse events,Kiddie-SADS,suicidal ideation,HAM-D total score < or = 8, HAM-D depressed mood item, K-SADS-L depressed mood item, and CGI score,Efficacy,headache, nausea, and insomnia,efficacy and safety,Children's Depression Rating Scale-Revised (CDRS-R) score,Withdrawal rates for adverse effects,response rate,Rates of discontinuation due to adverse events,suicidal thoughts and tendencies,Headache and abdominal pain,effective and well tolerated,Children's Depression Rating Scale-Revised (CDRS-R) scores,Adverse events,safety and efficacy,Discontinuation rates,score on the Children's Depression Rating Scale-Revised; the response criterion,adverse events,complete symptom remission (Children's Depression Rating Scale,moderate clinical global improvement,Children's Depression Rating Scale-Revised,Mean Children's Depression Rating Scale-Revised scores,Clinical Global Impression-Improvement (CGI-I) response rate,tolerated,CDRS-R scores,endpoint response (Hamilton Rating Scale for Depression,incidence of suicidality,Equivalent response rates,headache, menstrual cramps, insomnia, and nausea; only influenza-like symptoms,depressive symptoms,CDRS-R score,tolerated and effective,adverse effects,duration of treatment, time of onset, or dosage,Remission (MADRS score,Clinical Global Impressions scale,Montgomery Asberg Depression Rating Scale (MADRS,weekly ratings of the Children's Depression Rating Scale--Revised,global improvement of the Clinical Global Impressions scale and the Children's Depression Rating Scale--Revised, a measure of the severity depressive symptoms,Mean CDRS-R score,parent- or self-rating measures,Complete remission of symptoms,Rhinitis, nausea, and abdominal pain,HAM-D depressed mood item; (2) depression item of the Schedule for Affective Disorders and Schizophrenia for Adolescents-Lifetime version (K-SADS-L); (3) Clinical Global Impression (CGI) improvement scores of 1 or 2; (4) nine-item depression subscale of K-SADS-L; and (5) mean CGI improvement scores|A post hoc analysis of AEs related to suicidal behavior suggested a greater incidence of these events for paroxetine than for placebo (4.4% versus 2.1%); however, this difference was not statistically significant (odds ratio, 2.15, 95% Confidence Interval 0.45, 10.33; p = 0.502).
                
71|Intervention efficacy and cost-effectiveness,safe and feasible,contamination" of standard care,number of deaths,higher "dose" of mobilization achieved in VEM,adverse events (including falls and early neurologic deterioration), compliance with physiologic monitoring criteria, and patient fatigue after interventions,ischemic strokes,number of deaths at 3 months|The intervention protocol was successfully delivered, achieving VEM dose targets (double SC, P=0.003) and faster time to first mobilization (P<0.001).
                
405|rate of maternal fever,Mode of delivery, duration of labour, and maternal satisfaction,Labour duration, mode of delivery,rate of cesarean section and labor outcomes,shortened first stage of labor and total duration of labor,rate of caesarean section,spontaneous vaginal delivery rate,infectious complications,rate of cesarean section and other labor outcomes,frequency of dystocia (arrest of labor,Labour,neonatal outcome,rates of newborn nursery admission, neonatal acidosis, low Apgar scores, or postpartum haemorrhage,median duration of labor,Caesarean section rate,dystocia,length of labor,cesarean section rate,cesarean-section rate,rate of delivery by cesarean section,maternal infectious morbidity, uterine hyperstimulation syndromes, ruptured uterus or neonatal Apgar scores,Satisfaction with labour care,average length of labor,Prolonged labour,maternal or neonatal morbidity,Maternal satisfaction with labour care,caesarean risk,length of first stage of labour,caesarean section,Maternal characteristics,percentage of women in whom labor lasted longer,cesarean delivery rates,relative risk of prolonged labour,rate of caesarean section, maternal satisfaction, or other maternal or newborn morbidity,rate of caesarean section and prolonged labour without influencing maternal satisfaction,rate of vaginal delivery without increasing maternal or neonatal morbidity,epidural analgesics,rate of cesarean section,rate of cervical dilation,length of labor persisted despite the use of epidural analgesics|Fifty-five percent of patients received epidural analgesics; a reduction in length of labor persisted despite the use of epidural analgesics (active management 11.2 hours vs control 13.3 hours, p = 0.001).
960|101-point numerical rating scale (NRS-101,pain (100-mm visual analogue scale), disability (100-point disability scale), and cervical range of motion,neck pain,disability,active cervical range of motion and neck pain,headache NRS score, frequency, lasting time,motion and pain scale measurements,active cervical ROM,100-point Modified Von Korff pain and disability scales, and headaches in last 4 weeks,elbow extension,pressure pain,Neck Disability Index, and (3) three visual analogue scales of local pain intensity,range of motion,measured rotation,Pain intensity, active cervical ROM, and global perceived effect,pressure pain threshold (PPT,pain relief,pain and active range of motion (ROM,neck-shoulder pain,Neck Disability Index, visual analog scale, and posttreatment response questionnaire,visual analog scale,response rate of manipulation treatment,pain levels,Muscle tenderness and tender thoracic levels,pain and range of motion,discomfort or an unpleasant reaction,neck pain and neck mobility,Neck Disability Index,lateral flexions,headache intensity per episode,subjective (Numerical Pain Rating Scale 101, McGill Short-Form Pain Questionnaire, and Neck Disability Index) and objective (goniometer cervical range of motion) measurement parameters at specific intervals,pain, mobility, and disability,subjective (Numerical Pain Rating Scale 101, McGill Short-Form Pain Questionnaire and the Canadian Memorial Chiropractic College,ROM scores,pain improvement,pain and disability,cervical inclinometer (CROM), and cervical pain status,pain improvement scores,Active cervical rotation range of motion,flexion,area of symptom distribution,pain/paraesthesia,Pain levels,headache degree (numeric rating scale, NRS), frequency, lasting time and the range of motion (ROM) of the cervical spine,spinal manipulation,pain and/or discomfort,neck mobility,headache NRS scores , frequency, lasting time and the ROM scores,neck pain and active range of motion,cervical rotation ROM,lateral flexion,mean visual analog scales for pain and activity,cervical pain and cervical active motion restriction,cervical pain and range of motion,Decreased neck pain and increased range of motion,range of elbow extension, symptom distribution, and pain intensity,cervical spine range of motion,MDC(95,neck disability index, and (3) reductions on the visual analogue scale,pain or stiffness in the neck, and pain/paraesthesia,pain and active cervical ROM,immediate analgesic effects,scores of the (1) Oswestry Back Pain Disability Index, (2,Pain Disability Index,Neck Disability Index) and objective (cervical range of motion goniometer and algometer) measurement parameters,cervical rotation and pain,cervical pain,local paraspinal pain threshold levels,pressure pain thresholds,headache NRS score,pain intensity,history of neck pain or level of disability,number of headache hours per day,change in left rotation,pain,neck pain at rest and pain on most painful movement|Mean reductions in pain and disability were similar in the manipulation and mobilization groups through 6 months.
                
458|intermenstrual bleeding,report amenorrhea,rate of occurrence,total hormonal ingestion,intermenstrual bleeding (IMB,report leg cramps,IMB|Cycle control was good with all three regimens but the incidence of intermenstrual bleeding was higher with the triphasic.
40|EDSS,safety, tolerability, and clinical efficacy profiles of the 2 routes of administration,gadolinium-enhancing lesions,number of gadolinium-enhancing lesions,mean area under the concentration-time curve (AUC), the main component of bioavailability,efficacy, tolerability, and safety,Adverse effects,Kurtzke's expanded disability status scale (EDSS), Hauser's Ambulatory Index, and an arm-function index,disability or functional scores,EDSS over time,reduction of Gd-enhancing lesions,acute relapse of MS,number of Gd-enhancing lesions,Expanded Disability Status Scale (EDSS) and brain MRI (dual-echo and postcontrast T1-weighted scans,tolerated and adverse events|Both groups showed an improvement of EDSS over time (p < 0.001) without between-group difference at week 4.
9|Blood flow through muscle and skin vessels,vascular resistance,Heart rate,dilatation of muscle and skin arteries,systemic blood pressure to the handgrip and cold pressure tests,systemic blood pressure,systolic and diastolic blood pressures,blood pressure, heart rate, response to cold pressure and handgrip tests, as well as blood flow in the calf and finger vessels,systemic blood pressure, limb blood flow,sitting systolic and diastolic blood pressure,orthostatic response|Spironolactone did not significantly change the response of systemic blood pressure to the handgrip and cold pressure tests.
64|relapse rate,small bowel and colon disease,withdrawal rate,Clinical relapse, recurrence, and extension of the disease,Crohn's disease activity index (CDAI,response of active symptomatic disease,radiological recurrence or extension of disease,small bowel disease|Prednisone did not improve the relapse rate, nor did it affect recurrence or extension of disease.
344|Young-Mania Rating Scale (Y-MRS) total score,Clinical Global Impression (CGI) improvement scale,remission of mania symptoms,nausea,Extrapyramidal symptoms (Simpson-Angus Scale, Barnes Akathisia Scale, Abnormal Involuntary Movement Scale,HAMD-21 scores,average weight gain,patients' YMRS total scores,severe depressive symptoms,Hamilton depression scale score,mean Young Mania Rating Scale score,treatment-emergent somnolence,Somnolence, dizziness, dry mouth, and weight gain,weight gain and cases of dry mouth, increased appetite, and somnolence,Completion rates,SD) weight gain,Safety,response and remission rates,efficacy and safety,CGI-severity scale,mean total score on the Young Mania Rating Scale,parkinsonism, akathisia, and dyskinesias,EPSs,mean improvement of mania ratings,dry mouth, increased appetite, and somnolence,Young Mania Rating Scale score,adverse events,21-item Hamilton Depression Rating Scale (HAMD-21) total scores,Young Mania Rating Scale and the Hamilton Depression Rating Scale,tolerated,SD) improvement in Y-MRS total score,Young Mania Rating Scale total score,proportion of patients achieving protocol-defined remission,Clinical response rates,YMRS,rate of response,total score on the Young Mania Rating Scale,Young Mania Rating Scale (YMRS) scores,Mania Scale,Brief Psychiatric Rating Scale,efficacy,somnolence, dry mouth, weight gain, increased appetite, tremor, and slurred speech,adverse events, Extrapyramidal Symptom (EPS) rating scales, laboratory values, electrocardiograms, vital signs, and weight change|Olanzapine cotherapy improved 21-item Hamilton Depression Rating Scale (HAMD-21) total scores significantly more than monotherapy (4.98 vs 0.89 points; P< .001).
40|retention in treatment,opiate withdrawal syndrome and depressive symptoms,intensity of opioid craving and self-reported opioid and alcohol use,opioids and alcohol use according to urinalysis and self-report ratings, intensity of opioid craving assessed with a visual analogue scale, opioid withdrawal symptoms as measured by the Short Opiate Withdrawal Scale and depression scores on the Hamilton inventory,rates of opioid-positive urine tests,Completion rates,Treatment retention|Non-significant, but generally favorable responses were seen in the baclofen group with other outcome measures including intensity of opioid craving and self-reported opioid and alcohol use.
420|shorter procedure time and less patient discomfort,global ratings,discomfort and pain scores,discomfort and pain,esophageal intubation, procedure duration and completeness, and request for assistance,average procedure time, patient satisfaction, and discomfort associated with the procedure,percentage of colon visualized,procedure duration, completion, ability to perform retroflexion, and level of patient comfort/discomfort,time, technique (intubation, pyloric passage, J-maneuver), and diagnosis of pathological entities,objective competence overall,superior technical skill (reduced simulated pain scores, correct use of abdominal pressure, and loop management,objective competency rates,shorter completion times,diagnostic accuracy,Resident self-evaluation scores,directional errors,Median scores,faster insertion times,hand-eye skill measures,length of procedures,time taken to reach the duodenum,median Patient Discomfort ratings,Discomfort scores,examination times and hand-eye skill measures,complete procedures,splenic flexure,difficulty with initial endoscope insertion and negotiation of the rectosigmoid junction,performance of upper gastrointestinal endoscopy,discomfort experienced during endoscopy (1, no pain; 10, worst pain of life,viewing quality of examination,technical accuracy,residents' procedural skill scores,Technical ability,performance of endoscopy,shorter mean length of examination,median number of cases needed to reach 90% competency,completion rates,Discomfort and pain,Retroflexion,median patient discomfort score|The computer-based simulator is effective in providing novice trainees with the skills needed for identification of anatomical landmarks and basic endoscopic maneuvers, and in reducing the need for assistance by instructors.
1021|total avoidance of pacifier use,prevalences of breast-feeding,cry/fuss behavior,prevalence and duration of breastfeeding,mean number of pacifier insertions,breastfeeding frequency and duration,prevalence of exclusive and any breastfeeding at different ages and duration of any breastfeeding,prevalence of exclusive breastfeeding at 3 months,frequency of exclusive and any breastfeeding,prevalence or duration of breastfeeding,24-hour infant behavior logs detailing frequency and duration of crying, fussing, and pacifier use|Furthermore, the recommendation to offer a pacifier did not produce a significant decrease in the frequency of exclusive and any breastfeeding at different ages or in the duration of lactation.
                
315|risk of febrile nonhemolytic transfusion reactions,effective rate of preventing transfusion febrile reactions,transfusion reactions,blood transfusion febrile reactions,overall risk of transfusion reactions,risk of transfusion reactions,reaction symptoms,risk of febrile reactions|There was no significant difference in the overall risk of transfusion reactions between the two groups.
not found|treatment compliance rate,waiting time,Compliance,patients' compliance,level of real compliance|The intervention, which tended to improve both case and drug management at facilities, was well accepted by health staff and did not involve them in additional working time.
                
181|safety knowledge,pedestrian competence|There was no statistical difference in the change between pretest and posttest scores of children who participated in the Safety City program and those in the control group (crossing the street, P = .29; calling 911, P = .41; stranger avoidance, P = .57).
                
234|Fibrinogen, protein C, and antithrombin,DIC resolution rate,Aggravation of bleeding,severe adverse events,DIC and alleviates bleeding symptoms,rate of death,clinical course of bleeding symptoms and mortality rate at 28 days,activated partial thromboplastin time and thrombin time,time courses of the coagulation and fibrinolysis markers for DIC,safety and efficacy,incidence of bleeding-related adverse events,Fibrinogen-fibrin degradation products, D-dimer, thrombin-antithrombin complex (TAT), and plasmin-plasmin inhibitor complex (PIC,Efficacy and safety,alleviation of bleeding,clinical course of bleeding symptoms,DIC,Improvement of coagulation/fibrinolysis,DIC-related organ dysfunction,Platelet count,death rate|The incidence of bleeding-related adverse events up to 7 days after the start of infusion was lower in the ART-123 group than in the heparin group (43.1% vs. 56.5%, P = 0.0487).
                
49|Deep wound infection or dehiscence,overall wound infection,severe sepsis,Non-wound infectious morbidity,intra-abdominal infection,septic complications,Severe sepsis,Postoperative wound infection,overall postoperative morbidity,hospital stay,Insufficiency of the anastomosis,respiratory tract infections,postoperative wound infection rates,safety and effectiveness,anastomotic leakage,risk of surgical site infection,success rates,rates of wound sepsis,total infectious episodes,serious postoperative bleeding and no serious adverse reactions,septic and sepsis-related deaths,postopertive infectious complications nor mortality,duration of hospitalization,overall incidence of operation-related infection,incidence of wound infections,postoperative septic complications,equivalent prophylactic effectiveness,Colorectal cancer,overall incidence of Clostridium difficile infection,presence of pus), death, or discharge from hospital,Primary wound infections,Severe sepsis included: septicaemia, peritonitis, intra-abdominal abscess and extra-abdominal infections with death,rates of wound dehiscence, intra-abdominal abscess or anastomotic leakage,overall wound infection rates,successful clinical response rates,Postoperative complications,incidence of wound infection,mortality of patients receiving Timentin prophylaxis,type of sepsis,Mean concentrations of cefotetan in plasma, specimens of colon, and subcutaneous fat,abnormal bleeding,Postoperative septic complications related to colorectal surgery,Perineal wound sepsis,anastomotic leakages,blood transfusion,incidence of postoperative infectious complications,incidence of perineal wound and intra-abdominal infections,nausea, vomiting and abdominal pain,suture dehiscence,Clostridium difficile,nonwound infectious morbidity,number of urinary tract infections,anastomotic dehiscence,incidence of intra-abdominal abscesses,Nausea,demographic details, type and duration of surgery, risk factors associated with surgical procedures and postoperative management,deep infection,incidence of major wound infection,rate of surgical infections,deep infections,total costs,postoperative wound infectious morbidity rates,Colorectal operations,infectious morbidity or adverse reactions,infection rate,Septic complications,frequency of all wound infections,Surgical wound healing,total infection rate,deep sepsis or anastomotic leak rates,tolerated and no adverse events,sensitivity patterns,wound infection rates,annualized cost savings,MRSA infection,surgical site infection,anastomosis developed leaks,deep surgical infection,septicaemia,septic complication rate,risk of wound infection,abdominal wound sepsis, intra-abdominal complications and septicaemia,Intra-operative wound contamination,microbial concentrations,deep wound infections,Abdominal wound sepsis,surgical procedure,intra-abdominal abscesses,mean hospital stay,Colectomy, mucosal proctectomy, and ileal pouch-anal anastomosis,overall incidence of intra-abdominal septic complications,rate of septic complications,blood loss,Adverse reactions,postoperative wound infections,wound fat,serious side effects,overall infection rate,uncomplicated postoperative course,wound sepsis rate,incidence of operation-related infection,24-hour systemic antibiotic prophylaxis,Anaerobic sepsis,rates of postoperative septicemia,postoperative wound infection rate,frequency of septic and nonseptic complications,frequency of surgical wound infection, intra-operative wound contamination and other postoperative infections,body mass index (BMI,mean postoperative hospital stay,Urinary tract infections (1 case) and respiratory tract infections,Intra-abdominal infections,Postoperative diarrhoea,SD,time of hospital discharge,non-fatal deep sepsis, length of postoperative hospital stay, duration of postoperative fever or the use of antibiotics for postoperative infection,Positive reaction,transient skin rashes,incidence of superficial wound infections,respiratory infections,perioperative blood loss, duration of the operation, type of operation and drainage,Postoperative infection,haematological or biochemical abnormalities,rate of postoperative wound infections,Death,delayed cutaneous hypersensitivity,Surgical infections,number of postoperative urinary tract and respiratory tract infections,perineal sepsis,postoperative anaerobic infection,remote infection rates (pneumonia, urinary tract, and central venous line,Operation-related infection of any type,bacterial infections,septic complication or mortality rates,major anastomotic failures,Minor wound sepsis,Severe wound infection,Intra-abdominal abscesses,local wound infection, septicemia, anastomotic dehiscence or death,operative site infection rate,Aerobic bacteria,abdominal wound infection,urinary infections, pneumonia, postoperative ileus or intra-abdominal abscess,time of hospitalization,septic deaths,postoperative infectious complications,Prolongation of prothrombin time,postoperative infections,Diabetes mellitus,Death rates,effectiveness and safety,overall incidence of post-operative septic complications,incisional wound infections,frequency of abdominal septic complications,wound infections and wound fat,risks of postoperative sepsis,extended hospital stay,wound infections,wound infection rate,total wound infection rate,occurrence of postoperative sepsis,nosocomial infections,urinary infections,adverse reaction,incidence of abdominal and of perineal wound infections,acceptable rate of postoperative infections,Overall infection rates,infective complications,adverse reactions,Postoperative infectious complications,clinical bleeding,rates of other infective complications,Abdominal pain,antibiotic concentrations in samples of serum, subcutaneous fatty tissue, and colonic wall,Deep wound infection,Wound infection,adverse ecological effects,clinical anastomotic leakage rate,postoperative abdominal wound infections,overall wound infection rate,reduction of anaerobic bacterias,risk of infection,total number of septic complications (wall abscesses, fistulas, subdiaphragmatic abscesses, septicemia, peritonitis,minimal toxicity,anaerobic bacteria,rate of wound infection,Episodes of sepsis, urinary tract infection and pneumonia,abdominal abscess,incidence of other major or minor infective or non-infective postoperative complications,tolerated,severity of sepsis,corresponding mortality,total number of surgically related infections,rate of overall prophylactic failure,adverse effects,overall abdominal infection rates (wound, deep, and septicaemia,intra-abdominal, pelvic, or wound infections,rate of postoperative wound infection,infection rates,wound infection,isolations of enterococci,postoperative wound infection,serious infections,Abnormally elevated prothrombin times,subsequent infection rate,non-fatal deep sepsis,Wound sepsis,Sepsis,occurrence of infection of intestinal origin, either minor (wound cellulitis) or major (abscess, peritonitis, septicaemia,non-fatal intra-abdominal complication,Side effects,Vomiting,lower infection rates,mortality,median increase in oral body temperature,overall mortality,septic complications, possibly caused by opening of the colon (wound infection, anastomotic failure, colocutaneous fistula,surgical infection,Perineal wound infection,frequency of the grade II wound infections alone,operative mortality,rates of infective complications,surgical sepsis,appearance of post-surgical infections (abdominal, urinary, respiratory and wound infections,abdominal wound infection rate,number of patients with infections at nonsurgical sites (respiratory and urinary tract, phlebitis, and septicemia,superficial SSIs,primary site infections,Abdominal wound healing,infectious complications,postoperative infection,Rupture of the wound,appendicitis, wound infection rates,anaerobic pathogens,number of colony-forming units (CFU,wound sepsis develop,incidence of sepsis,Postoperative abdominal wound infections,incidence of abdominal wound infection,Septic wound complications,adverse side effects,therapeutic intraoperative serum levels,postoperative sepsis,incidence of a surgical site infection,Perineal sepsis,efficacy and safety,incidence of intra-abdominal abscess,type of hospital, public or private, wound infection rate,Specific drug toxicity,failure rate,incidence of MRSA infection including at surgical and remote sites,deep surgical site infection (SSI) rates,frequencies of anastomotic dehiscences, intra-abdominal abscesses, sepsis, and pulmonary infections,incidence of postoperative complications, the median duration of hospital stay (12 days), and antibiotic tolerance,mean duration of hospital stay,overall postoperative infection rate,degree of wound contamination and the occurrence of wound infection,Intra-abdominal abscess,incidence of infection,prolonged hospital stay,Timentin associated wound infection rate,poor performance status, operative contamination and wound infections,overall septic complication rate,adverse events,Rates of postoperative surgical site infections: risk differences, risk ratios (RRs) and 95% confidence intervals (CIs,beta-lactamase [corrected,absence of surgical-site infection, anastomotic leakage, or antibiotic use 4 weeks postoperatively,Rates of postoperative infection,infectious complications, reoperations, additional use of antibiotics, and a shorter hospital stay,rate of sepsis,median postoperative hospital stay,surgical infection rate,proportion of patients with wound infections and other infective complications,Antibiotic plasma concentrations,cent infection rate,wound abscess,satisfactory bacteriologic response rates,intraabdominal abscess,Postoperative sepsis,abdominal wound sepsis rate,rate of anastomotic leakages,Major life-threatening sepsis,significant wound sepsis,wound sepsis,rate of postoperative infection,incidence of operation-related infection, chest or urinary tract infection,Incidence of all types of infection, mortality, and side effects,sterile cultures,overall incidence of wound sepsis,Wound infection rates,Wound infections,surgical site infections|No septic complications occurred in the 26 patients (0%) receiving metronidazole/fosfomycin (p less than 0.01).
44|therapeutic effectivity,carnitine,urinary estrogen excretion,Better therapeutic effects,birth weights,Maternal blood IGF-I and amniotic fluid IGF-I and IGF-II levels,IGF-I levels in maternal blood,IGF-I and IGF-II levels,insulin-like growth factors (IGFs) and fetal growth restriction (FGR,spontaneous improvement of fetal growth,levels of IGF-I and IGF-II|Better therapeutic effects were achieved in the treatment group than in the control group (P<0.01), and the birth weights of the neonates in the treatment group were basically normal.
                
60|gastrointestinal haemorrhage,Cardiac output,Hepatic venous pressure gradient,APACHE score,degree of liver failure, severity of the bleeding episode, activation of the endogenous vasopressor systems, and hemodynamic parameters,Cardiopulmonary pressures,hospital stay neither the rate of organs failure,blood hemoglobin,systemic vascular hindrance (resistance/blood viscosity,Kaolin Cephalin Clotting Times (KCCT,Systemic and portal hemodynamics, and rheological and hormonal parameters,hematocrit value,total blood volume and suppression of vasopressor systems,wedged hepatic venous pressure|We did not see differences between the groups in the hospital stay neither the rate of organs failure.
45|CGI, BPRS, and NOSIE-30,Hostile-suspiciousness" (BPRS) and "Social interest" (NOSIE-30,psychopathological and somatic symptoms,AMP-syndromes of hostility, hypochondria, and autonomic symptoms|A significant difference with regard to perphenazin-enanthate was found in the AMP-syndromes of hostility, hypochondria, and autonomic symptoms.
2|squeeze pressure,ability to postpone defecation,quality of life,fecal incontinence diaries, anorectal physiological tests, and quality-of-life assessments (SF-36 health survey,Quality-of-life measurements,resting pressure and rectal threshold and urge volumes,fecal incontinence,frequency of fecal incontinence episodes,anal sphincter function,score for symptom severity,number and severity of episodes of incontinence,frequency of fecal incontinence and urgency episodes, delay in postponing defecation, score severity, feeling of improvement, preference for ON or OFF, quality of life, and manometric measurements,FI|There was an increase in squeeze pressure (Patient 1, 70 vs. 100 cm H2O; Patient 2, 60 vs. 90 cm H2O; off vs. on), with moderate increases in resting pressure and rectal threshold and urge volumes.
100|Incidence of spontaneous preterm birth (SPTB,endometritis,neonatal deaths,length of evaluation in triage,mean latency period,initial cervical length,length of evaluation,neonatal infection,cervix longer,incidence of chorioamnionitis,mean time for evaluation,incidence of maternal infection|The knowledge of CL and FFN was associated with reduction in length of evaluation in women with CL > or = 30 mm and in incidence of SPTB in all women with PTL.
||
36|nausea,therapeutic efficacy and safety,Systolic and diastolic blood pressures,clinical effectiveness,frequency and intensity of side effects,probabilities of induction of cervical ripening,headache,baseline cervical dilatation and cumulative force required to dilate the cervix,cervical dilatation,Baseline cervical dilatation, duration of operation and operative blood loss,vaginal bleeding,blood loss,Adverse events,blood pressure,cumulative force required to dilate the cervix,Cervical ripening,abdominal pain,cumulative force to dilate the cervix,relative risk (RR,mean systolic and diastolic blood pressure,headaches,mainly pelvic pain,cervical resistance,Vital signs and symptoms,number of women remaining asymptomatic,Cervical dilation, adverse effects, termination complications, and patient satisfaction,visual analogue scale,incidence of non-serious adverse events,cervical ripening,cervical diameter,efficacy and patient satisfaction,Cervical resistance,high frequency of side effects,baseline cervical dilatation, cumulative force, and operative blood loss,Blood pressure,Adverse events, such as headache, abdominal pain, pelvic pain, backache, nausea and vomiting,Mean cervical dilation,Operative blood loss,Side effects,values of cervical resistance,Mean operative time|Women treated with both doses of nitroprusside gel showed values of cervical resistance significantly lower than those treated with placebo gel, at any tested diameter.
206|operative time and length of hospital stay,analgesic requirements,incisional hernias,Postoperative pain,analgesic requirement and pain scores,incisional hernia,failure rate,pain and low VAS scores,wound sepsis, wound dehiscence, and subsequent incisional hernia development,wound integrity,pain with visual analogue scale (VAS) scores,postoperative pain,narcotic requirements, pain scores, or wound complications,burst abdomens and 7 wound hernias|No incisional hernias have developed in patients in whom a lateral paramedian incision was performed and the peritoneum was closed, and one incisional hernia has occurred in the patients in whom the peritoneum was left open.
39|muscle action potentials,neuropathy disability score,vibratory detection threshold, summed motor-nerve conduction velocity, and sensory-nerve action potentials,weakness score,average neuropathy disability score,plasma exchange,muscle action potentials of motor nerves|Changes in the vibratory detection threshold, summed motor-nerve conduction velocity, and sensory-nerve action potentials did not differ significantly between the treatment groups.
476|incidence of asthma-like symptoms,6-month nicotine levels,Asthma severity,quit rate,knowledge of ETS effects,readiness to quit and attitude toward and knowledge of ETS,cotinine levels,Asthma symptom days,self reported 24 h point prevalence quit rate and self-reported continuous quit rate and bio-chemically validated quit rate,mean cotinine level,small airway function,parental smoking,tobacco smoke,24-hour quit attempts,quit rate, cigarettes/day, or stage of change,daily smoking and smoking quantity,behavioral contracting, self-monitoring, problem solving, and positive reinforcement,maternal smoking behavior,maternal smoking and relapse,abstinence rates,absolute risk reduction,pediatric asthma caregiver quality-of-life score,serum cotinine concentration,asthma-like symptoms,Serum cotinine concentrations,caregiver quality-of-life score,relapse,nicotine levels,Cotinine prevalence,Smoking outcomes,prevalence of persistent lower respiratory symptoms,smoking behavior,Children's mean urine cotinine concentrations,maternal depression,maternal quitting or relapse,Children's cotinine values,Salivary cotinine concentrations,cigarettes/day, location smoking occurred, and knowledge of ETS effects,maternal smoking,secure attachment, maternal mood and child health,Saliva cotinine samples,Cotinine,7-day abstinence,social class and smoking behavior,smoking behaviour,passive smoking,cotinine concentration,acceptable test-retest reliability and validity of measures,having banned smoking,Parenting Stress Index and the Edinburgh Post Natal Depression Scale,consumption of tobacco products,Parents' smoking,Response rates,total daily consumption or consumption in front of the child, children's urinary cotinine level, or parental smoking cessation,crude odds ratio of quitting,Tobacco consumption,Smoking experimentation,rate of cessation of smoking and smoking location change,attempt quitting, and quitting behavior,Household nicotine levels,mean cotinine levels,infant urine cotinine excretion,feasibility and acceptability,Children's urinary cotinine concentrations,maternal mood,cotinine-confirmed 7-day abstinence rates,total and specific immunoglobulin E,prevalence quit rate,salivary cotinine concentrations,detectable serum cotinine concentration,Follow-up urine cotinine measurements,quality of maternal-infant attachment,concentrations of the nicotine metabolite cotinine,school absenteeism,infant passive smoking and lower respiratory illness,mean log ratio of the follow-up to initial urine cotinine measurements,quality of maternal-infant attachment, maternal mood and child health parameters,ETS exposure and children's urine cotinine,medical visits, theophylline levels, or records of asthma symptoms,proportion of mothers who stopped smoking,Mothers' smoking rates,cigarette smoking|No significant differences in total and specific immunoglobulin E were found between the groups.
70|clinically significant agitation (Cohen-Mansfield Agitation Inventory [CMAI]) and quality of life indices (percentage of time spent socially withdrawn and percentage of time engaged in constructive activities, measured with Dementia Care Mapping,frequency of excessive motor behaviour,agitation,Chinese versions of Cohen-Mansfield Agitation Inventory (CCMAI) and Neuropsychiatric Inventory (CNPI,mean CCMAI total scores,CNPI scores,CMAI score,motor behaviour,Behavioral and psychological symptoms,Quality of life indices,agitated behaviours,side effects|In summary, lavender is effective as an adjunctive therapy in alleviating agitated behaviours in Chinese patients with dementia.
116|femur length, head circumference and abdominal circumference of fetus,fetal growth restriction,risk of clinical negative outcomes,Biparietal diameter of fetus,relative risk for fetal growth restriction,reduced risk of preterm deliveries and severe fetal growth retardation,Bleeding problems or thrombocytopenia,Rate of one minute Apgar score,hypertension or pre-eclampsia,resistance indexes of both uterine arteries,maternal blood pressure values,Systolic,Pulsatile index (PI) and resistance index (RI,recurrence of preeclampsia, of negative outcomes, and the resistance of uteroplacental flow,maternal blood pressure increase,recurrence rate of preeclampsia,diastolic (P=0.002) blood pressures,non-severe pre-eclampsia, newborn weight at the 6-10th percentile and gestational age at delivery,Gestational age,body weight,composite of one or more of: severe pre-eclampsia, newborn weight <or= 5th percentile or major abruptio placentae,relative risk for preeclampsia,fetal growth indices, biophysical score, umbilical blood, neonatal outcome,6-keto PGF1 alpha concentration,Fetal growth indices, biophysical score, umbilical artery blood flow, count of platelet (PLT), prothrombin time (PT), activated partial thromboplastin time (APTT), 1-minute Apgar score, body weight and gestational age of the neonates,Body weight of the neonates,placenta function,Umbilical blood S/D ratio,PLT, PT and APTT,circulating eicosanoid concentrations,recurrence of placental-mediated complications of pregnancy,1) Height of fundus of uterus,2) Biophysical score|In this pilot study, dalteparin is effective in decreasing the recurrence of placental-mediated complications in women without thrombophilia.
110|waist circumference, BMI, blood pressure, resting heart rate, self-reported physical activity and dietary variables, and physical activity and dietary cognitions,moderate or vigorous physical activity,insulin resistance-related metabolic parameters,waist circumference,total APFT score and 2-mile run time/score,BMI,physical activity-related cognitions,physical activity levels,weight loss and improved health-related outcomes and behaviours,systolic blood pressure,PA improved modestly and coronary risk profile,resting heart rate,metabolic parameters,body weight, body mass index, fasting plasma glucose, insulin and homeostasis model assessment of insulin resistance changes (p<0.01,physical activity,physical activity, fitness, and coronary heart disease risk,weight loss,physical activity (PA), Army Physical Fitness Test (APFT), and coronary heart disease risk factors,moderate and vigorous physical activity and walking|The WP program was feasible and efficacious and resulted in significant weight loss and improved health-related outcomes and behaviours in overweight male shift workers.
                
800|progression of disability,motor performance,median time to reach,severe dyskinesias,worsening of rigidity,UPDRS total score,therapeutic efficacy,UPDRS score,mean dosage of levodopa,revised diagnosis, disability rating scores, autonomic or cardiovascular events, other clinical features, or drug interactions,Disease progression,possible dementia and a history of falls before death,ratings for Parkinson's disease,average time until L-dopa,occurrence of motor fluctuations,motor complications,rates of dystonias and on-off fluctuations,safe and well tolerated,progression of disease disability,Unified Parkinson Disease Rating Scale (UPDRS) total score,initiation of additional dopaminergic therapy,frequency of adverse experiences,parkinsonian disability,rigidity,Kaplan-Meier survival curves,Time course of physical and psychological responses,Deterioration in Unified Parkinson's Disease Rating Score (UPDRS,Activities of Daily Living,onset of disability prompting the clinical decision to begin administering levodopa,extent of deterioration,incidence of dyskinesias,mortality in PD,pretreatment disability levels,disability scores,severity of parkinsonism, levodopa requirements and the development of end-of-dose motor fluctuations,severe parkinsonism,excess mortality,hazard ratio,mortality, disability, and adverse events,mortality|The ratings for Parkinson's disease improved during the first three months of deprenyl treatment; the motor performance of deprenyl-treated patients worsened after the treatments were withdrawn.
                
325|realistic expectations about the risk of stroke and hemorrhage,intention-to-treat analysis of a composite score combining the variance (median square of the standard deviation) of the International Normalized Ratio (INR) value (using a blinded control sample analyzed monthly by a reference laboratory), death, major complications, or discontinuation from the study,time within therapeutic INR target range using the standard INR values from the coagulometer and laboratory measurement,Self-management,time within therapeutic INR target range,Decision conflict,major bleeding,warfarin knowledge,frequency of major bleeding,anxiety, knowledge, decision-making preference, treatment decision, use of primary and secondary care services and health outcomes,OAT quality,numbers of thromboembolic and hemorrhagic complications,quality of OAT,Death and recurrent venous thromboembolism,Major bleeding, death, recurrent venous thromboembolism, and therapeutic control of anticoagulant therapy,decision conflict scale,Decisional conflict and satisfaction,major bleeding complications,number of patients receiving therapy appropriate to their stroke risk,proportion of total treatment time,number of patients receiving appropriate care,median duration of NVAF,maintenance of the INR value in the individual target range, INR variance, the course of complications over time, and the cost efficiency of self-management,change in antithrombotic therapy|Throughout 6 months, the proportion of total treatment time during which the international normalized ratio was within the therapeutic range was higher in the intervention group than in the usual care group (56% vs. 32%; P < 0.001).
23|Adverse event rates,Predose PTH levels,plasma parathyroid hormone (PTH) and serum calcium levels,plasma parathyroid hormone levels,plasma PTH levels,Plasma PTH levels,effective in rapidly and safely reducing PTH, Ca x P, calcium, and phosphorus levels,Gastrointestinal events,parathyroid hormone (PTH) secretion,PTH, serum calcium, phosphorus, and calcium x phosphorus,Calcium x phosphorus levels,Serum phosphorus levels,Blood ionized calcium levels,parathyroid hormone levels,safety and effectiveness,incidence of vomiting,efficacy and safety,plasma parathyroid hormone (PTH,plasma PTH, serum calcium, serum phosphorus, and calcium x phosphorus levels,Serum total and blood ionized calcium concentrations,parathyroid hormone and calcium,Mean PTH,Median oral clearance,percentage of patients with values in this range during a 14-week efficacy-assessment phase,PTH ,nausea and vomiting,safe and well tolerated,adverse events,plasma parathyroid hormone (PTH) levels,maximal plasma concentration (Cmax ) of cinacalcet,incidence of adverse events,predose PTH levels,mean baseline PTH,Pharmacokinetics, pharmacodynamics, and safety,PTH and calcium x phosphorus levels,serum calcium, phosphorus, and Ca x P levels,PTH,plasma PTH concentrations,mean parathyroid hormone values,Plasma concentration, median area under the plasma concentration-time curve,serum calcium-phosphorus product,ionized calcium concentrations,Pretreatment PTH levels,intact parathyroid hormone levels,PTH levels fell,Plasma PTH and blood ionized calcium levels,Serum calcium concentrations,pharmacokinetics, pharmacodynamics, safety, and tolerability,calcium|Cinacalcet HCl was reasonably tolerated, and the incidence of adverse events was similar between groups (76%, cinacalcet; 80%, placebo).
not found|Functional capacity and disease activity,Disease activity and bone mass,bone loss,Radiographic scores,disease activity and bone mass,Bone mass|Functional capacity and disease activity improved significantly in both groups and did not differ significantly between the groups, except for a greater improvement in the prednisone group at 1 month.
not found|minuscule relapse rate,schizophrenic relapse,relapse rate,severity of caregiving difficulties,baseline Global Assessment Scale score, Positive and Negative Syndrome Scale scores,hospitalization outcomes,positive symptoms and in symptom exacerbations,time-to-relapse,illness and social functioning,Rehospitalization rates and psychotic symptoms,relapse rates,Brief Psychiatric Rating Scale, social activity according to the Strauss-Carpenter Outcome Scale and an interactive test,index hospital discharge,Monthly Brief Psychiatric Rating Scale (BPRS) ratings,adverse outcomes,relatives' satisfaction,BPRS ratings,stress-appraisal-coping' model of caregiving,knowledge of schizophrenia,recurrent psychotic episodes,levels of family burden,duration of rehospitalisation,number of medium and long-term poor clinical outcomes,Relatives' social contacts and perception of professional support,rate of psychiatric hospitalization,Outcome rates,schizophrenia subscore of the Brief Psychiatric Rating Scale,functional outcomes of schizophrenia,antipsychotic medication,extensive changes,patient social functioning,number of relapse episodes; the presence and severity of symptoms, as measured by the Brief Psychiatric Rating Scale (BPRS) and the Scale for the Assessment of Negative Symptoms; and social functioning, as measured by the Family Burden Scale, the Health of the Nation Outcome Scale, and the Quality of Life Scale,Reduction in EE,Changes in criticism and marked emotional over-involvement (EOI,compliance, insight into psychosis, psychosocial function (General Assessment of Function) or in relatives' expressed emotion scores postintervention,number of days spent,relapse and symptoms,Psychotic relapse, symptom status, medication compliance, rehospitalization, and employment,psychotic decompensations,levels of family burden and increased family functioning,extensive psychiatric histories,patients' clinical status, personal and social functioning, and social network as well as relatives' burden, social resources, and perception of professional support,Verona Service Satisfaction Scale Scores,family service utilization,duration of employment,knowledge, relapse, compliance, insight and satisfaction, and relative outcome measures were knowledge and satisfaction,2-year cumulative relapse rates,relapse hazard ratio,Relapses,rate of psychotic relapse,Relapse rates,outcome measures: psychological morbidity, negative appraisal, coping or social support,psychotic and affective relapse,Psychological distress, coping behavior, and family satisfaction,social relationships, interests in obtaining a job, maintenance of social interests, and management of social conflicts,patients' general functioning,rehospitalization rates,Reduction of hostility,knowledge of schizophrenia and greater satisfaction with health care services,relapse and rehospitalization rates,duration of patient re-hospitalization (the total number of days of psychiatric hospitalization,number of patients with poor or very poor global personal and social functioning,levels of expressed emotion (EE|To test further the highly successful outcomes of a controlled study of in-home behavioural family management (BFM) for schizophrenic patients, a clinic-based version of this intervention was compared with customary care alone for 41 schizophrenic patients in a Veterans Administration (VA) mental health clinic.
not found|abdominal pain,number of migraine headache days,pain lasts,frequency and intensity of migraine,headache frequency,Mild adverse effects,tolerated; adverse events (somnolence, dizziness, tremor, fatigue and ataxia,number of attacks,brain GABA levels,effectiveness and safety,dizziness,asthenia,drowsiness|GEn did not significantly differ from placebo for migraine headache prophylaxis.
42|CR,toxicity,Median OS,response rate, response duration, or survival,therapeutic efficacy and tolerability,Survival,haematological recovery,haematological toxicity,complete response rate and survival,number of complete remissions,survival,serious adverse events,febrile leukopenia,squamous cell carcinoma,objective responses,graft-vs.-host reaction,recurrent time,fungal infections,incidence, duration and severity of clinically or bacteriologically documented infection,Myelosuppression, fever and documented infectious episodes,recurrent rate,lymphocyte levels,complete remission (CR) rate,efficacy and safety,hematological toxicity,toxicity and long-term survival,duration of response, overall survival (OS), and progression-free survival (PFS,distant metastases,T cell numbers or function,Median survival duration,normalization of T cell function,recurrent rate, recurrent time and median survival period,rates of survival and tumor response, including transplant candidacy,incidence of febrile episodes and other treatment-related toxicities,overall response rate,relapse-free and overall survival,slightly longer disease-free-survival interval,3-yr survival,normal hemoglobin levels,hematological tolerance to chemotherapy, skin reactions and number and severity of infections registered,median duration of response,Duration of response,survival rates,PFS,incidence of chemotherapy-related fever and leukopenia,median survival,pattern of toxicity,hematological tolerance,median duration of survival,neutropenic fever,Median overall survival time,febrile episodes,NK activity,overall response,mucositis and diarrhoea,mild nausea and generalized bone pain,median time to reach a neutrophil count|Placebo-treated patients did not show any improvement in T cell numbers or function over 15 weeks of serial immune monitoring, and exhibited gradual depressions of helper T lymphocyte percentages.
not found|intracranial pressure (ICP) control and reversal of brain and cerebrospinal fluid (CSF) acidosis,mean Glasgow Coma Scale score,cerebral blood flow (CBF,occurrence of cerebral ischemia|Accordingly, cerebral blood flow (CBF) was lower in the HV + THAM group than in the control and HV groups, but neither CBF nor arteriovenous difference of oxygen data indicated the occurrence of cerebral ischemia in any of the three groups.
not found|low hemoglobin,neutrophil count,alive without evidence of disease,alopecia,five-year survival rate,recurrence,adverse drug reactions (ADRs|The five-year survival rate was 87.5% in the BAP group and 83.3% in the BEP group, and the difference was not significant (p=0.5954).
400|expulsion, bleeding problems, pain, pelvic inflammatory disease and other medical reasons,effectiveness and complication rates,rate of adverse events,overall performance of the IUD equals,tolerated,pregnancy rate for Nova-T,expulsion/displacement rates,removal rates for bleeding and/or pain,Gross cumulative life-table accidental pregnancy rates,cumulative expulsion gross rate for NovaT,final gross rate|Differences in removal rates for bleeding and/or pain were not significantly different at any of the follow-up intervals.
not found|initial coercive attitude scores,anxiety scores,efficacy expectations,knowledge scale, the State-Trait Anxiety Inventory for Children, a videotape vignettes measure, a parent questionnaire, and disclosure data,knowledge levels of both Inappropriate Touch,global skill scores,knowledge and skills,preventive knowledge and skills relative,Acquisition of self-protective behaviors,33-item Children's Knowledge of Abuse Questionnaire-Revised (CKAQ-R,ongoing or past sexual abuse,knowledge regarding sexual abuse and self-protection skills,children's safety discrimination skills,child abuse knowledge,knowledge of correct actions,knowledge of maltreatment prevention information,preventive skills,sexual attitude scales|Treatment children exhibited significantly greater knowledge and better ability to discriminate safe from unsafe situations on the video measure than control children at posttesting.
28|HAM-D score,treatment response,Hamilton Rating Scale for Depression (HAM-D,fatigue, anxiety and self-reported quality of life,Hamilton Rating Scale for Depression|Clinical judgments indicated that patients treated with desipramine improved significantly more than the placebo group.
87|effective biliary drainage,biliary infection, bacteremia and intraoperative bleeding,intrabiliary pressure,hyperbilirubinaemia, indocyanine green retention and serum albumin concentration,level of biliary obstruction,preoperative biliary drainage,mortality rate,incidence of cholangitis and failed endoscopic drainage,incidence of early complications,liver function,overall morbidity rate|The overall morbidity rate (18 patients versus 16) and mortality rate (six patients in each group) were similar in the two treatment arms irrespective of the level of biliary obstruction.
52|relapse rate,heroin relapse,Opioid use,opioid positive urine tests,retention and relapse,time to heroin relapse,HIV risk behaviours,degree of treatment acceptance, percentage of relapse in heroin consumption, presence of side effects, and overall retention on naltrexone,socio-demographic data and toxicological history,urine testing three times per week, were days to first heroin use, days to heroin relapse (three consecutive opioid-positive urine tests), maximum consecutive days of heroin abstinence, and reductions in HIV risk behaviours,opioid-free,compliance or ratio of adverse effects,greater time to first heroin,relapse to heroin addiction and for reducing HIV risk, psychiatric symptoms, and outcome,acceptance of treatment, retention rates, opioid and other drug consumption, drug compliance or side effects,reabuse of heroin,heroin-positive urine tests,retention rate,HIV risk, psychiatric symptoms,overall efficacy,most psychological parameters|Significant differences in retention and relapse favoring naltrexone were seen beginning at 1 month and continuing throughout the study.
64|pain of infiltration and effectiveness of anesthesia,Pain scores,5-point scale to rate the perceived pain on injection and the pain felt,intensity of pain using a 100 mm visual analog scale (VAS,pain score,Demographic data,lowest mean pain scores,Pain,pain of digital nerve blockade,amount of superficial bleeding at the catheter site, pain during local anesthetic infiltration and epidural catheter movement during labor,pain on skin infiltration,Visual Analogue Scale (VAS,pain with infiltration,Linear analogue pain scores,pain of injection for digital nerve blockade,pain of skin infiltration,preference ratio,pain of injection and suturing according to a 10-cm visual analog scale (VAS,onset of action, hemostasis, or duration of action,Visual analogue pain scores,Pain on needle insertion and on infiltration,hemostasis or duration of action,VAS readings,epidural catheter movement,pain of infiltration,catheter insertions pain scores,injection pain,superficial bleeding,pain on intravenous and epidural catheterization,pain of skin infiltration and intravenous catheterization,pain on needle insertion,VAS score on epidural needle insertion,Pain of infiltration,mean intraoperative pain scores,pain of intradermal injection,infiltration pain,pain scale,VAS scores on skin infiltration,mean injection pain scores,painful and better tolerated,severity of pain,mean pain score,tolerated and caused no cardiovascular disturbances,visual analogue scale,pain of infiltration or pain of cannulation,10-point pain score,median VAS,obliterating pain,10-cm visual analog pain scale (VAPS,superficial bleeding and pain,VAS score on intravenous needle insertion,highest mean pain scores,Superficial bleeding,Adult visual analog scores,median nurse-rated pain score,visual analog pain score (VAS,mean pain scores,pain on infiltration,pain, while bicarbonate reduced it [verbal score,catheter gauge and pain,pain,pain scores,bacteriostatic saline modified solution,verbal analog scale (VAS|The results showed no statistical difference in the pain scores reported by patients.
not found|positive urine culture,Recurrence of infection,therapeutic efficacy,relapse rates,Upper and lower urinary tract infections,bacteriologic cure rate,efficacy and safety,Urinary tract infection,Complete symptom resolution,urinary tract infections,radiological abnormality,Persistence of infection,actuarial percentage recurrence-free curves,reinfection rates,erythrocyte sedimentation rate,Urinary Tract Infections,tolerated,clinical symptoms, fever, and erythrocyte sedimentation rate,reinfection,cure rate,Candida vaginitis,cure rates,induction of resistant organisms,suppression upon rectal,bacterial sensitivity pattern,immediate cure rates,positive cultures,Side effects,side effects|A significant difference in the induction of resistant organisms was seen between treatment groups (P less than .05).
not found|trough, sitting, and standing measurements of diastolic and systolic BP,adverse events and number of patients discontinuing therapy,mean supine DBP and SBP,change in sitting systolic blood pressure (SSBP) and response rates,baseline plasma renin activity and reduction in peak and trough blood pressure,supine DBP,trough seated diastolic blood pressure,trough mean sitting DBP and systolic blood pressure (SBP,lowering sitting diastolic blood pressure,headache and dizziness,control blood pressure (BP,SBP goal,Systolic and diastolic blood pressure,mean seated trough cuff DBP and SBP measurements, and response and control rates,diameter or distensibility,fasting plasma glucose and glycosylated haemoglobin levels,SeDBP and seated systolic BP,mean ambulatory systolic and diastolic pressure,mean trough sitting diastolic blood pressure,All-causality adverse events,seated systolic blood pressure,SeDBP,trough blood pressures,SBP,change in mean trough SeDBP,lowering SiSBP and SiDBP,efficacious and well tolerated,diastolic and systolic blood pressures,frequency of drug related cough,SiDBP,safe and well tolerated,lipid profile and glucose metabolism,mean ambulatory systolic blood pressure,diastolic trough-to-peak ratios,reductions in early morning BP by COER-verapamil,Blood pressure (BP,MSDPB and MSSBP,percentage achieving the target fall in SBP and the change from baseline in seated trough DBP,trough SBP,trough mean supine diastolic blood pressure (MSuDBP,Trough/peak DBP ratios,supine systolic blood pressure (SBP,vascular function,incidence of dizziness,Headache incidence,radial but not carotid artery wall thickness,trough SeDBP,rebound hypertension or adverse events,augmentation index (valsartan,blood pressures,antihypertensive effect,Tolerability,Ambulatory Blood Pressure Monitoring (ABPM), mean daytime DBP,Angiotensin II and aldosterone levels,rate of response (SiDBP,mean blood pressure,Ambulatory blood pressure monitoring (ABPM,blood pressure lowering,blood pressure changes,incidence of clinical adverse events,baseline sitting systolic blood pressure (SBP)/DBP,Antihypertensive efficacy and safety,levels of triglycerides, high-density lipoprotein cholesterol, very low-density lipoprotein (VLDL) triglycerides, VLDL cholesterol and apolipoprotein B,antihypertensive efficacy,isolated systolic hypertension,ambulatory blood pressure monitoring,office systolic BP,severe blood pressure elevations,total and LDL cholesterol levels,adverse events (AE) and discontinuations because of AE,Ambulatory blood pressure (BP) monitoring,sitting diastolic and systolic BP,augmentation index,blood pressure decrements,efficacy, safety and tolerability,Seated systolic and diastolic blood pressures,Plasma renin activity and safety parameters, including treatment-emergent adverse events, physical findings, electrocardiograms, and serum electrolyte levels,sitting systolic blood pressure (SSBP) and percentage of 'successful' responders,24-hour blood pressure control,safety and tolerability,Plasma irbesartan concentrations,BP, heart rate, and the heart rate systolic BP product,Responder rates,systolic and diastolic blood pressures,morning heart rate, the rate-pressure product, and the rate-of-rise of BP,SDBP or SSBP,response rate,effective and well tolerated,early-morning blood pressure, heart rate, and the rate-pressure product,efficacy, safety, pharmacokinetics, and pharmacodynamics,mean sitting DBP,adverse experiences,trough mean supine systolic blood pressure (MSuSBP), responder rates and trough/peak ratio,sitting diastolic and systolic blood pressures,mean 24-h diastolic blood pressure (DBP,Ambulatory and cuff blood pressure,antihypertensive efficacy and tolerability profiles,mean supine trough SBP/DBP,incidence of adverse experiences (AE,reduction in sitting SBP,MSDBP and MSSBP,MSDBP,mean sitting diastolic blood pressure (SDBP,Ambulatory BP,Efficacy and tolerability,trough office seated diastolic blood pressure and seated systolic blood pressure,mean blood pressures,SBP and DBP,levels of both low-density lipoprotein (LDL) cholesterol,Augmentation index reduction,Pharmacokinetic and pharmacodynamic parameters,24-hour efficacy,MSDBP to baseline levels,tolerated and effective,mean sitting diastolic blood pressure (MSDBP,SeDBP and SeSBP,Tolerability and safety profiles,SEM,24-h change in BP,Blood pressure,mean supine DBP,Mean reductions in ambulatory and seated BP,laboratory values,All clinic blood pressure measurements,Dizziness and headache,Antihypertensive efficacy,Responder rates (trough sitting diastolic BP,proportion of patients responding (SitDBP,serious adverse events,mean supine SBP,Sitting diastolic blood pressure,systolic and diastolic ABPM,efficacy and tolerability,BP,radial artery wall thickness,mean 24-hour BP,systolic and diastolic blood pressure (SBP, DBP,systolic and diastolic sitting blood pressures,antihypertensive effects,Blood pressure effects,SitSBP,trough sitting DBP,mean 24-hour blood pressure reduction,blood pressure,trough DBP,placebo corrected trough/peak ratio,incidence of adverse events,blood pressure reductions,Clinical and 24-hour ambulatory blood pressures,tolerated,sitting systolic blood pressure (SBP,response rate with losartan/ HCTZ,telmisartan plasma concentrations,incidence of clinical and laboratory Adverse events and evaluating mean changes in pulse, body weight, electrocardiographic parameters, and laboratory test results,total cholesterol,ambulatory and seated DBP and SBP,Response rates,diastolic and systolic blood pressure,Office DBP,efficacy, tolerability, and safety,Carotid wall thickness and diameter,DBP,safety and tolerability profile,supine SBP,Sitting systolic blood pressure (SiSBP,antihypertensive efficacy and tolerability,symptomatic orthostatic hypotension,Safety and tolerability variables included data on adverse experiences, rebound hypertension, and clinical laboratory evaluations,blood pressure (BP), heart rate, and the heart rate systolic BP product,circadian rhythm of BP and heart rate,ambulatory blood pressure measurements,trough-to-peak ratio,BP reduction,ambulatory systolic blood pressure,24-h ambulatory blood pressure monitoring (ABPM) and by seated cuff blood pressure (BP) measurements,augmentation index in essential hypertension,ambulatory blood pressure and trough office blood pressure lowerings,responder rates,seated trough SBP,mean sitting diastolic blood pressure (SiDBP,mean sitting systolic blood pressure (MSSBP,antihypertensive efficacy and safety,MSuDBP and MSuSBP,systolic blood pressure (SBP,mean SiDBP,mean sitting systolic blood pressure (MSSBP) and responder rates,SitDBP(-7.5+/-0.8 mm Hg) and sitting systolic blood pressure (SitSBP,headache,Mean changes in BP,supine heart rate,diastolic blood pressure,Hypokalaemia,antihypertensive efficacy and systemic tolerability,efficacy and safety,central aortic pressure wave and augmentation index,pulse pressure,peak ratios,mean 24-h ambulatory systolic blood pressure (SBP,cardiovascular hypertrophy,trough mean sitting office DBP,mean diastolic blood pressure (DBP,supine diastolic pressure,SD values for Cmax,Mean sitting systolic blood pressure (SitSBP,Adverse events,tolerability and safety,number of responders,incidence of coughing,baseline levels of active renin, and angiotensin I and II,adverse events,Mean ,total number of adverse events,blood pressure reduction,SeDBP and seated systolic blood pressure (SeSBP,Radial artery pressure,trough seated diastolic blood pressure (SeDBP) and trough seated systolic blood pressure (SeSBP,mean trough sitting systolic blood pressure,changes in 24-h and trough blood pressure (BP,systolic blood pressure,BP reductions,24-h mean blood pressure,Office SBP,SiSBP and SiDBP,Blood pressure reduction,orthostatic changes in diastolic or systolic blood pressure,supine systolic/diastolic pressure,potential blood pressure response,trough seated blood pressure,supine trough DBP,mean 24 h ADBP and ambulatory systolic blood pressure, and were well tolerated,Incidence and severity of adverse events and physical examination and laboratory parameters,24-hour ambulatory systolic/diastolic blood pressure measurements,mean 24-hour ambulatory diastolic blood pressure,SDBP,daytime and night time mean ABPM,clinical diastolic blood pressure,rebound hypertension,ambulatory SBP/DBP,antihypertensive effect, and tolerability and safety,mean trough sitting SBP,trough concentrations,seated diastolic blood pressure (DBP|Moreover, significant (P < .05) placebo-adjusted differences in ambulatory SBP/DBP and a significant dose-response relationship (P < .001) were observed with all tasosartan dosages during the 24-h, daytime, and nighttime periods.
not found|mortality rate,leakage rate of pancreaticojejunostomy,hospital stay,Pancreatic fistula,delayed gastric emptying,rate of pancreatic fistula,overall morbidity,incidence of pancreatic fistula,PF and overall morbidity rates,Pancreatic Fistula criteria,morbidity,demographic data, underlying pathologies, pancreatic consistency, and duct diameter,overall PF,pancreatic fistula rate,Hospital stay,Mortality, morbidity, and PF rates,hospital mortality,median stay,median postoperative hospital stay,fistula rates,PF rate defined as amylase-rich fluid (amylase concentration >3 times the upper limit of normal serum amylase level,Pancreatitis,pancreatic fistula, mortality, and postoperative hospital stay,pancreatic fistula,pancreatic fistulas|The median postoperative hospital stay was 21 days (range, 8-163 d) in the internal drainage group, which was shorter than the median stay of 24 days (range, 21-88 d) in the external drainage group (P = .016).
                
36|nausea,somnolence,bodily pain,Roland Disability Questionnaire,nausea, dizziness, somnolence, and headache,pain visual analog [PVA] score ,mean final pain relief scores,adverse event,activity or hours asleep,health transition,scores on the Pain Relief Rating Scale (PRRS), Short-Form McGill Pain Questionnaire (SF-MPQ), Roland Disability Questionnaire (RDQ), and 36-Item Short-Form Health Survey (SF-36); the incidence of discontinuation due to insufficient pain relief (Kaplan-Meier analysis); and overall assessments of medication by the patients and investigators,physical functioning and quality of life, and in overall medication assessments,RDQ scores,constipation,cumulative incidence of discontinuation due to insufficient pain relief,pain relief, quality of life and physical functioning, efficacy failure, and overall medication assessments,McGill Pain Questionnaire,emotional distress,pain, activity, mood, medication, hours awake, and adverse effects,role-emotional,efficacy and safety,Mean baseline pain VAS score,final PVA scores,activity and sleep,total score,mean pain visual analog scores,signs of abuse behavior,adverse events,pain,role-physical,pain and improved mood,pain and mood,chronic back pain,time to discontinuation due to inadequate pain relief,distribution of time to therapeutic failure,final PRRS scores,final pain VAS score,mean final pain VAS scores,cumulative discontinuation rate due to therapeutic failure,mental health,mean baseline PVA score,analgesic efficacy and safety,efficacy failures,PVA score,Roland Disability Questionnaire scores and physical-related subcategories of the McGill Pain Questionnaire and the Medical Outcome Study Short Form-36 Health Survey,dizziness,pain reduction,Analgesic efficacy and safety|Weekly reports during the experimental phase showed the titrated-dose group to have less pain (P < 0.001) and less emotional distress (P < 0.001) than the other two groups.
298|extended overall recanalization,rate of recurrent DVT,duration of hospital stay,ultrasonographic clot volume score (an index of recanalization,Quality of life,overall incidence of major events (mortality, DVT recurrence, pulmonary embolism, major bleeding, heparin-induced thrombocytopenia,bleeding events and adverse events,Hospitalization,Major bleeding,Thrombus regression, reflux distribution and the incidence of complications,cost consequences,incidence of venous thromboembolism recurrence, pulmonary embolism, or major bleeding,pulmonary emboli,efficacy and safety,Total costs,Thrombus regression,major bleeding,clinical outcome,recurrent DVT (confirmed by venography or ultrasonography), and safety endpoints included bleeding and serious adverse events,recurrent venous thromboembolism, major bleeding, quality of life, and costs,Physical activity and social functioning,deep-vein thrombosis and pulmonary embolism,rates of primary efficacy outcome,recurrent thromboembolism,rate of pulmonary embolism (PE,longer plasma half-life, better bioavailability,recurrent deep-vein thromboses|The incidences of bleeding events and adverse events in the enoxaparin and unfractionated-heparin groups were similar.
                
558|self-efficacy and mastery,Self-efficacy,likely to complete a first visit,completion of a visit to the tuberculosis clinic within 1 month of release and completion of therapy,overall rate of treatment completion|Those in the education group were twice as likely to complete therapy compared with controls (adjusted odds ratio, 2.2; 95% confidence interval, 1.04-4.72; P =.04).
10|clinical attachment gain,attachment levels and probing depths, as well as index values for plaque and bleeding on probing,PD reduction and clinical attachment gain,probing attachment levels and fill of intrabony defects,mean probing attachment gain,mean probing attachment loss,clinical attachment level gain,Probing pocket depth reduction,PAL gain and PD reduction,clinical attachment level (CAL) and probing depth (PD) changes,PAL gain,Probing bone level gain,predictability of CAL gains,clinical attachment level (CAL) and probing depths (PD,CAL gains,gingival recession,probing depth reduction, attachment gain and defect depth,Probing attachment level (PAL) gain, probing depth (PD) reduction and gingival recession (REC) variation,Preoperative measurements of clinical attachment, probing depth, and recession,postoperative complications, edema,PPD reduction and PAL gain, and superior to open flap curettage alone,Clinical attachment level (CAL) gains,change of probing attachment levels and amount of bone fill,probing depths and gaining new attachment,gain in probing bone levels,Baseline clinical measurements (plaque, gingivitis, PPD, PAL and soft tissue recession,gain of bone in test lesions,probing depth (PD) reduction,baseline tooth mobility,clinical attachment levels (CAL) and reductions in probing depths,clinical attachment level gain nor bone gain,Reduction in probing pocket depth (PPD,gains in clinical attachment (CAL) and reductions in probing depth,Baseline probing pocket depths,residual probing depths,Initial PD,probing attachment level gains,clinical efficacy,probing attachment alteration,Gains in probing attachment level (PAL,mean PPD reduction,probing pocket depth reductions,CAL gain ,probing bone level (PBL,baseline oral hygiene and defect characteristics,clinical attachment levels (CAL) and reduction in probing depth (PD,PPD reduction and CAL gain,feeling moderate pain,blinded examiner: Plaque index (PlI), gingival index (GI), bleeding on probing (BOP), probing pocket depth (PPD), gingival recession (GR) and clinical attachment level (CAL,mean CAL gain,linear CAL gains,CAL gain,probing bone level gain,frequency distribution of CAL changes,Full thickness flaps,25 visual analog scale (VAS) units,reduced PD and improved attachment levels,bone fill|0.95 mm, while no gain was observed in the control lesions (P less than 0.01).
28|six symptom exacerbations,urgent physician visits for asthma,severity of asthma,histamine responsiveness,symptoms and quality of life (QOL,Cardiopulmonary fitness,Maximal inspiratory pressure (MIP) and maximal expiratory pressure (MEP,PC,mean (SD) maximum % fall in forced expiratory volume,PFT, PEF and severity of asthma,asthma symptoms,asthma symptom severity scores,Aerobic capacity and the degree of EIB,PEF,pulmonary function tests (PFT), PEF and severity of asthma,ventilatory threshold (VTh) intensity level,PC values,cardiorespiratory fitness,MEP,symptoms and pulmonary function tests (PFTs,elastic recoil of the chest wall,asthma symptoms or PFTs,aerobic capacity, exercise induced bronchoconstriction (EIB), and bronchial responsiveness,bronchial hyperresponsiveness,aerobic capacity and exercise induced bronchoconstriction,parental QOL,MIP,mean (SD) aerobic capacity at LT,safety, parental satisfaction, asthma symptoms, quality of life, and urgent asthma physician visits,spirometric parameters and bronchial hyperresponsiveness,childhood asthma symptoms and physician office visits and improved parental QOL,aerobic capacity|Participants and parents reported reduced childhood asthma symptoms and physician office visits and improved parental QOL.
190|Adverse events, predominantly injection-site reactions,concentrations of progesterone,rate of metaphase II oocytes, a number of metaphase II oocytes with mature cytoplasm and a rate of metaphase II oocytes with mature cytoplasm calculated from total MII oocytes,rate of mature oocytes,IVF outcome,Moderate ovarian hyperstimulation syndrome (OHSS,Ovarian response and IVF outcome (pregnancy rate,serum HCG concentrations,Mean numbers of oocytes,efficacy and safety,Serum and FF E(2), P, hCG, and T levels,Mean arterial pressure, cardiac output, peripheral vascular resistance, and serum levels of progesterone, plasma concentrations of aldosterone, norepinephrine, and plasma renin activity,peripheral vascular resistance,moderate or severe OHSS,adverse events,number of oocytes retrieved per follicle,rate of metaphase II oocytes, the number and the rate of MII oocytes,serum and follicular fluid (FF) hormone levels,oocyte maturity, embryo development, and luteal function, as well as pregnancy and pregnancy outcome,serum progesterone concentrations,incidence of adverse events,clinical pregnancy rate,tolerated,mean number of mature oocytes,number of oocytes retrieved per patient receiving either compound,OHSS,incidence of injection-site reactions,Stimulation parameters, serum and follicular E(2), P, T, and hCG levels,number of oocytes retrieved per follicles aspirated; the number of mature oocytes; normally fertilized oocytes; and cleaved embryos,Serum progesterone concentrations,numbers of 2PN fertilized oocytes,number of oocytes,Serum and FF hormone measurements,mean number of oocytes,total number of oocytes retrieved, percentage of mature oocytes, number of injected oocytes, fertilization rates and number of embryos transferred,number of total, biochemical, and clinical pregnancies; and the embryo implantation rate,Adverse safety events, laboratory changes, local tolerance, and immunogenicity,live birth rate,numbers of oocytes,proportion of mature oocytes, fertilization rate, and pregnancy rate (PR|The incidence of injection-site reactions was significantly lower in the rHCG group (P = 0.0001).
1000|Rates of postpartum haemorrhage,Median blood loss,postpartum hemorrhage and manual removal of the placenta,maternal nausea, vomiting, headache and rise in blood pressure,nausea, vomiting, headache and hypertension,postpartum blood loss,rate of post partum haemorrhage,blood loss,incidence of manual removal of the placenta,risk of postpartum haemorrhage,diastolic and systolic blood pressures,nausea, vomiting and headache,need for manual removal of the placenta,nausea, vomiting, and increased blood pressure,Postpartum haemorrhage, nausea, vomiting, and increased blood pressure,duration of the 3rd stage of labor,primary postpartum hemorrhage,nausea, vomiting, and raised blood pressure,postpartum haemorrhage, hypertension, nausea/vomiting and retained placenta,Postpartum blood loss, the length of the 3rd stage of labor, and the need for manual removal of the placenta|The two drugs did not differ in their effect on the duration of the third stage.
not found|smoking behaviour,continued abstinence from smoking at 3 and 12 months,rates of continued abstinence,consumption of tobacco,Number of quit attempts and future quit intentions,Cessation rates,smoking cessation,report quitting|Seventy-six per cent of the nicotine patches group and 51% of the brief intervention only group had reduced their consumption of tobacco.
not found|locoregional recurrences,Toxicities,median survival time,systemic relapse rate,OS,rates of radiotherapy for boosting parapharyngeal disease or residual lymph nodes,survival and toxicity analysis,year failure-free survival (FFS) and overall survival (OS,overall survival or disease free survival,time to first distant failure,5-year overall survival and relapse-free survival rates,metastasis free survival,locoregional recurrence free survival rate,disease free survival or overall survival,DMR,degree of mucositis,2-year overall survival,overall survival,overall incidence of recurrence,RFS,myelosuppression, nephrotoxicity, and nausea and vomiting,moderate to severe mucositis,locoregional relapse rate, distant metastatic rate, and median time to relapse,median progression-free survival (PFS) time,2-year disease-free survival,proportion of local and/or regional metastases,locoregional failure free survival,3-year survival rate,progression-free survival (PFS,overall response rate,survival and toxicity,tumor response and survival,5-year overall survival rate,disease free survival,toxicities, including mucositis, myelosuppression, and weight loss,DMR and LRFR,2-year PFS,PFS and overall survival,relapse free survival (RFS) or overall survival (OS,Locoregional failure rates (LRFR,Distant metastases rate (DMR,hazard rates ratio,3-year OS rate,overall complete response rate,3-year PFS rate,5-year disease free survival rate,incidence of leukopenia,OS with CRT,overall survival or relapse-free survival,progression-free survival|DMR and LRFR were not reduced with AC (P =.34
958|incidence of postpartum hemorrhage, retained placenta, manual removal of placenta, and the need for blood transfusion,Placental cord drainage shortens the duration of third stage labour,duration of third stage of labour in vaginal deliveries,postpartum hemorrhage, uterine atony, hypovolemic shock, or the need for blood transfusion,placental cord drainage,mean duration of third stage of labor,mean age, parity, gestation and birth weight,duration of third stage|The mean duration of third stage of labor was 3.24 min and 3.2 min in the placental drainage group in contrast to 8.57 min and 6.20 min in controlled cord traction method in primigravida and multigravida respectively.
                
16|Trough plasma theophylline concentration,sleep quality and cognitive performance,SML,peak expiratory flow (PEF) variability, forced expiratory volume in 1 sec (FEV1), asthma symptom scores (daytime and night-time), supplemental terbutalin use, asthma exacerbations and adverse events,lung function data and symptom scores,Sleep quality global scores,Side-effects,day- and night-time symptoms,subjective assessment of efficacy,sleep latency, total sleep time, percentage of total sleep time spent in Stages 1, 2, and 3/4 and in REM sleep,improving morning and evening peak expiratory flow (PEF,patient perceptions of sleep,otherwise daytime cognition,number of nights,efficacy and tolerability,FEV1 and FVC,Efficacy and tolerance of SML,gastrointestinal adverse events,rare nocturnal symptoms and c) none or rare early morning symptoms,nocturnal spirometry, nocturnal polysomnography, sleep questionnaires, and daily measurements of lung function and symptoms,daytime symptoms,PEF, symptoms or additional salbutamol medication,nocturnal FEV1 levels,Efficacy,Sleep architecture,efficacy and safety,PEF,percentage of days and nights with no albuterol use and decreased daytime albuterol,sleep quality, quality of life, and daytime cognitive function,effective and better tolerated,sleep quality,nights with none or rare symptoms,serum theophylline level,mean morning PEF,sleep architecture,adverse events,mean morning peak expiratory flow (PEF,efficacy, safety,quality of life,total number of adverse events,daytime and nocturnal pulmonary symptoms and lung dysfunction,maximum side effect,additional salbutamol requirement,forced expiratory volume in one second (FEV1) or peak expiratory flow (PEF,polysomnographic measures of sleep quality,tolerated,asthma symptom score (night-time,overall asthma control,success/failure, success being defined as the complete disappearance of nocturnal symptoms/awakening,Visual vigilance,clinical efficacy,SML and TK,lung function, asthma symptom scores and supplemental terbutalin use criteria,peak expiratory peak flow rate (PEFR,night-time awakenings,number of nights with an overnight fall in PEFR,mean serum theophylline concentration,nocturnal asthma symptoms,Overnight PEFR falls,nocturnal arousals,asthma symptom score (daytime,incidence of gastrointestinal symptoms (gastric irritation, nausea and vomiting,Mean predose FEV1,asthma symptoms, reducing nighttime awakenings, and reducing the daily use of albuterol,overall satisfaction with their asthma medication,Nocturnal cough and wheeze,median percentage of nights with no asthma symptoms|12 patients preferred salmeterol over theophylline (p < 0.05).
48|gait speed, number of falls, daily activity (Barthel index scores), social activity (Frenchay activities index), hospital anxiety and depression scale, and emotional stress of carers (general health questionnaire 28,muscle strength and all functional measures,gains in cardiorespiratory fitness, mobility, and paretic leg muscle strength,walking ability,lower limb motor function,Gait performance,patients' daily activity, social activity, anxiety, depression, and number of falls, or on emotional stress of carers,mobility including gait speed, functional ambulation categories, the Nottingham extended activities of daily living index, and individual items from the Barthel activities of daily living index and the Frenchay activities index,walking speed and endurance, peak vertical ground reaction force,time taken to walk 10 m,gait speed,number of repetitions of the step test,muscle strength changes,mobility measured by the Rivermead mobility index,cardiorespiratory fitness, mobility, leg muscle strength, balance, and hip bone mineral density (BMD,functional performance,mobility and gait speed,performance of activities of daily living (ADL) and motor function,manual dexterity, depression, and anxiety,Femoral neck BMD of the paretic leg,Six-minute walk test (SMWT), 5-m walk (comfortable and maximum pace), Berg Balance Scale, timed 'up and go,Lower-limb function,walking speed, cadence, stride time, stride length, and temporal symmetry index,extremity muscle strength,Cardiorespiratory fitness (maximal oxygen consumption), mobility (6-minute walk test), leg muscle strength (isometric knee extension), balance (Berg Balance Scale), activity and participation (Physical Activity Scale for Individuals with Physical Disabilities), and femoral neck BMD (using dual-energy x-ray absorptiometry,walking speed and endurance, force production through the affected leg,Barthel Index (BI) and Stroke Rehabilitation Assessment of Movement (STREAM,Lower extremity muscle strength, gait velocity, cadence, stride length, six-minute walk test, step test, and timed up and go test,Rivermead mobility index,muscle strength and functional performance,severe walking deficit,motor function of upper limbs, mobility, and ADL performance,strength gain,Muscle strength,Gait speed,balance, activity and participation, nonparetic leg muscle strength, or nonparetic femoral neck BMD|In the control group, the number of repetitions of the step test significantly decreased (-20.3%) with no change in other functional tests.
not found|prevalence of the high-risk patterns (P2 and DY,false-positive screen,breast cancer mortality,odds ratio (OR) of having a high-risk pattern,rates of false-positive mammography,Axillary metastases,ratio of the proportions of death from breast cancer,mortality reduction,Satisfactory initial biopsies,relative risks (RR) for breast cancer death and mortality,invasive breast cancer,highest survival rate,rate of death,511 breast cancer deaths,cardiovascular disease and lung cancer,detection rates,rates of false-positive recall,Mortality,cumulative number of advanced mammary carcinomas,total rate of breast cancer,total mortality,lead time, sensitivity, and predicted mortality,false-positive rates,survival rates,rate of screen-detected breast cancer on first examination,cumulative breast cancer mortality,cumulative mortality,node-positive tumours,false-positive recall rates,cumulative false-positive rate,Rates of referral from screening, rates of detection of breast cancer from screening and from community care, nodal status, tumour size and rates of death,Breast cancer detection and death rates|Mortality from all causes, cardiovascular disease and lung cancer over the first 5 year period of follow up are examined.
2499|Detectable blood levels,Nausea,incidence of HIV,rates of serious adverse events|Nausea was reported more frequently during the first 4 weeks in the FTC-TDF group than in the placebo group (P<0.001).
not found|VAS values,High pain scores,Analgesics,indirect costs,discomfort,healing frequencies,Postoperative discomfort,success rate for surgery,pain and swelling,Postoperative symptoms,swelling and discoloration of the skin,degree of swelling and pain on horizontal 100-mm visual analog scales (VAS,healing rate|The success rate for surgery was higher than for conventional retreatment, but the difference was not statistically significant.
                
123|5-year and 10-year survival rate,colorectal cancers,curative effects,intraoperative tumor reduction,hepatic cryosurgical procedures,survival,disease-free survival,5-year survival rate,3-year survival rate|During a follow-up period, recurrence in the liver was observed in 54 patients (85%) in group 1 and in 57 patients (95%) in control subjects.
36|proportion of patients with ACR20 improvement,ACR20 response rates,proportion of patients with ACR50 improvement,progression of structural joint damage, and improved physical function,mean radiographic progression,efficacy and safety,RA signs and symptoms,response rate,physical function|CDP870 is effective, was very well tolerated in this small study, and has an extended duration of action following one or more intravenous doses.
270000|Survival,survival rates and neurological prognosis,resuscitation success,Return of spontaneous circulation, admission to the intensive care unit, survival to hospital discharge, and neurological function at hospital discharge,return to baseline neurological function at hospital discharge,Return of spontaneous circulation, admission to the intensive care unit (ICU), return of baseline neurological function (alert and oriented to person, place, and time), survival to hospital discharge, survival to hospital discharge with return of baseline neurological function, and complications,proportion of patients receiving bystander CPR,24-h survival,survival,cerebral performance category score at discharge,hospital discharge rates,Rate of patients regaining a spontaneous circulation (ROSC), hospital discharge rate, and mean carbon dioxide content,survival to hospital discharge,long-term survival rates,return of spontaneous circulation and 24-h survival,hospital admission,Complication rates,spontaneous return of circulation, 24-h survival and survival to hospital discharge,interval between collapse and defibrillation,survival rates and neurological outcome,return of spontaneous circulation (ROSC), hospital admission and discharge rates,ROSC rates,cardiopulmonary hemodynamic function,hospital discharge,mean score,rate of hospital discharge without neurologic impairment,mean emergency medical services call response interval,prevalence of bystander CPR,median MMSE score of survivors,ROSC,hospital discharge rate,asystole or pulseless electrical activity,return of spontaneous circulation,survival until hospital discharge,return to baseline neurological function,Spontaneous return of circulation,downtime, survival to the ICU,active compression-decompression CPR, neurologic status,return of spontaneous circulation, survival to be admitted to the intensive care unit, survival to hospital discharge, and neurological outcome,Neurological outcome,ventilation and coronary perfusion,standard scoring systems (cerebral and overall performance categories (CPC and OPC,one-year survival rate,rate of survival to hospital discharge without neurologic impairment and the neurologic outcome,Cerebral outcome,Return of spontaneous circulation, ICU admission, and neurological recovery,survival or neurologic outcomes|No statistically significant differences were found between hospital discharge rates (12 [23%] of 53 for ACD CPR vs 13 [17%] of 77 for standard CPR), return to baseline neurological function (10 [19%] of 53 for ACD CPR vs 13 [17%] of 77 for standard CPR), or return to baseline neurological function at hospital discharge (nine [17%] of 53 for ACD CPR vs 12 [16%] of 77 for standard CPR).
10|Survival,ALS Health State scale,biochemical markers of oxidative stress,adverse reaction: worsening depression,12-month survival,survival and motor function,superoxide dismutase (CuZn SOD), catalase (CAT), glutathione reductase (GR,muscle strength, pulmonary function, disability, and bulbar function,activity of GSH-Px,rate of progression,Cell death,Rates of disease progression,Appel ALS total score,survival and disease progression,baseline characteristics and mean Appel ALS total score,severe state B,rate of clinical progression or outcome of ALS,glutathione peroxidase activity in plasma,Biochemical markers of oxidative stress,patients given alpha-tocopherol,activity of both GSH-Px and CuZn SOD,plasma levels of thiobarbituric acid reactive species,disturbed oxidative/antioxidative balance,rate of change of the Appel ALS total score, an index of disease severity that incorporates strength and function in limbs, respiratory function, and bulbar function,monthly rate of change,MAO-B activity in blood platelets,still alive,ALS Functional Rating Scale-revised (ALSFRSr) score,rate of deterioration of function assessed by the modified Norris limb scale,activity of glutathione peroxidase (GSH-Px|In the preliminary analysis performed so far, no obvious retardation in the progress of the disease could be observed with deprenyl treatment.
30|bone level,Crestal bone response,HDD,bone healing and crestal bone changes,implant stability quotient,Bone healing,reduction over time,facial gingival margin position,Implant survival, mean Implant Stability Quotient (ISQ) values, gingival aesthetics, radiographic bone loss, and microbiologic characteristics of periapical lesions,Implant stability,marginal mucosa and bone levels,Horizontal resorption,Vertical defect height (VDH) reductions,Mucosal recession,VDH and HDD reduction,position of the facial gingival margin with a more apical position of the facial gingival margin,vertical defect height (VDH), horizontal defect depth (HDD) and horizontal defect width (HDW,horizontal defect depth (HDD) reductions,mean reductions in parallel width, perpendicular width, and depth of the largest defect of each implant,Mean ISQ, gingival aesthetics and radiographic bone resorption, and periapical cultures,healing of marginal defects,VDH,horizontal resorption of buccal bone,capacity of spontaneous healing,implant integration or crestal interdental bone movement,VDH, HDD and HDW,bone healing,survival rates,crestal bone levels,implant stability quotient values,soft tissue measures compared with method,BG+M,HDW reduction,labial plate resorption,survival rate|Mucosal recession was significantly associated (P=0.032) with buccally positioned implants (HDD 1.1+/-0.3 mm) when compared with lingually positioned implants (HDD 2.3+/-0.6 mm).
40|carotenoid status, clinical diagnostic markers of prostate proliferation, and symptoms of the disease,International Prostate Symptom Score questionnaire,Serum lycopene levels,Serum PSA and lycopene,PSA response,progression of prostate enlargement,PSA levels,digital rectal examination,inhibition or reduction of increased serum prostate-specific antigen (PSA) levels,plasma lycopene concentration,Serum PSA,serum prostate specific antigen (PSA|Lycopene is an effective chemopreventive agent in the treatment of HGPIN, with no toxicity and good patient tolerance.
6|pain frequency,verbal pain rating scale,frequency of pain,overall pain status,efficacy and tolerability,tolerated,trigeminal neuralgia symptoms,surgery because of persistent pain,frequency of trigeminal neuralgia attacks,relieved of their pain,Pain response,visual analog scale (VAS) and the overall efficacy,pain rating scales,analgesic effect,adverse effects|The results indicate that tizanidine was well tolerated, but the effects, if any, were inferior to those of carbamazepine.
118|postoperative liver injury and intraoperative blood loss,operative blood loss,resection time, the need of blood transfusion, ICU, and hospital stay as well as postoperative complications and mortality,feasibility, safety, efficacy, amount of hemorrhage, postoperative complications, and ischemic injury of selective clamping,demographics, ASA score, type of hepatectomy, duration of inflow occlusion (range, 30-75 minutes), and resection surface,bilirubin ratio (serum total bilirubin level,Operative mortality,amount of hemorrhage,pH,hospital stay,apoptotic activity,operative procedures, and area of liver transection plane,postoperative liver enzymes and serum bilirubin levels,liver tissue pH, partial pressure of carbon dioxide (P(L)CO(2)), and partial pressure of oxygen (P(L)O(2,operative blood loss and incidence of blood transfusion,occlusion of hepatic blood inflow,overall liver ischemic times,Blood loss during liver transection,portal pressure and the hepatic venous pressure gradient (HVPG,hospital deaths,ALT,liver transection areas,Intraoperative blood loss during liver transsection,surgical parameters, aspartate transaminase levels, and apoptosis,amount of blood loss, measurement of liver enzymes, and postoperative progress,postoperative complications,operative findings,hemodynamic intolerance,transection area per unit transection time,Operative blood loss, need for blood transfusion, and postoperative morbidity,blood loss,postoperative morbidity,higher caspase-3 levels,transection-related blood loss,incidence of blood transfusion,median ICU,Major postoperative deterioration of liver function,minimized bleeding, limited hepatic function damage, and low rate of postoperative complications,peak values of AST (alanine aminotransferase) and ALT (aspartate aminotransferase), as well as the area under the curve (AUC) of the postoperative transaminase course,mean length of postoperative hospital stay,Overall liver ischemic and total operative times, postoperative morbidity, and postoperative changes in liver enzyme levels,Intraoperative blood losses,blood aspartate transaminase levels,blood loss and shorter transection time,Postoperative liver injury,Postoperative abdominal collections and pulmonary complications,blood loss, measurements of liver enzymes alanine aminotransferase (ALT), aspartate aminotransferase (AST), and postoperative evolution,liver enzyme changes, bilirubin, or morbidity,liver tissue pH, carbon dioxide, and oxygen partial pressures,Mean operative duration and mean clampage duration,bilirubin ratio,high central venous pressure, HVPG >10 mm Hg, and intraoperative blood loss,postoperative liver function tests and coagulation profile|Thus, incidence of blood transfusion was significantly greater in patients of the CIO group (P=0.041).
210|school achievement, accidents, or satisfaction with glasses,progression of myopia,axial length (secondary,axial length,included myopia progression and ocular biometry,axial elongation,changes in central cycloplegic auto-refraction and eye axial length, respectively,prismatic bifocals,myopia progression,myopia,Axial length,pattern of change in myopia,refractive error or axial length,steep corneal meridian,occurrence of adverse events,Peripheral refraction,baseline spherical equivalent refraction,rate of progression,change in axial length of the eyes, as assessed by A-scan ultrasonography,efficacy and safety,mean myopic progression,myopia and axial length,spherical equivalent refraction as measured by cycloplegic autorefraction and change in ocular axial length,axial growth of the eyes,mean progression of myopia and of axial elongation,progression of myopia, as determined by autorefraction after cycloplegia,fast myopic progression,corneal curvature,number of prescription changes,rate of myopic progression,Myopic progression,safety and efficacy,slow myopia progression,controlling myopia,rapid myopia progression and axial elongation,progression of myopia in COMET children,axial length of eyes of children,adverse events,average reading distance,spherical equivalent refractive error and axial length (both measured using a cycloplegic agent,tolerated and effective in slowing the progression of low and moderate myopia and ocular axial elongation,degree of myopia,3-year change in spherical equivalent cycloplegic autorefraction,rates of progression,mean progression of myopia,spherical equivalent,mean SE refraction,Safety and efficacy,Axial length and refraction,Cycloplegic subjective refraction, keratometry, and axial length,corneal power (r=-0.09), anterior chamber depth,spherical equivalents,intra-ocular pressure ,vitreous chamber growth,adverse effects,prescription change,myopia progression and axial elongation,myopic progression,Mean changes in axial length,depth of vitreous chamber,rate of progression of myopia,rate of myopia progression,myopia progression, as determined by cycloplegic autorefraction,progression,axial growth|There were no statistically significant differences in the rate of progression of myopia between the control and novel lens wearing eyes for the age group 6 to 16 years.
79|tear stability,lid margin vascular injection, tarsal telangiectasis, and fluorescein staining,rate of recurrence of their symptoms,secretion turbidity,ocular symptoms, ocular findings, and serum and meibomian gland contents,eradication or reduction of potentially pathogenic bacteria,clinical signs, bacterial count, cure rate, and improvement rate,Safety and stability tests,clinical cure rate,meibomian gland secretion quality,symptoms, and signs of inflammation,symptoms, tear interference grade, tear evaporation, fluorescein and rose bengal scores, tear break-up time (BUT), and meibomian gland orifice obstruction,ocular symptoms,symptoms using visual analogue scales, appearance of the eyelids and reduction in numbers of pityrosporum yeasts on the eyelids,change in tear breakup time (TBUT), meibum score, and overall OSDI score,MG plugging, MG secretions, and eyelid redness,lipid expression,overall clinical impression,resolution of lid telangiectasia,symptomatology,average Schirmer increase rate,degree of symptomatic improvement,signs and symptoms composite score,meibomian gland dysfunction,number of meibomian gland inclusions,VAS scores for symptoms, BUT values, fluorescein, and rose bengal staining scores,mean TFLLT,FBUT and Schirmer scores,mean MG secretion score, tear break-up time, corneal staining score, number of MGs yielding liquid secretion and symptom scores,Schirmer test, tear film break-up time,ocular symptoms, lid margin vascularity, tarsal telangiectasis, meibomian gland inclusions, tear breakup time, and fluorescein staining,subjective symptoms and objective signs including meibomian gland inclusions, lid margin vascular injection, tarsal telangiectasis, fluorescein staining, tear breakup time, and Schirmer scores,Posterior blepharitis,safety and clinical and quantitative microbiologic efficacy,Changes in meibum content,BUT and dry-eye symptoms,overall symptomatic relief,blepharitis and meibomian gland dysfunction,tear break-up time,meibomian gland obstruction,safety and efficacy,Efficacy and safety,tolerated and safe,effective and safe,Eyelid health,itching symptom,Blepharitis and meibomian gland dysfunction (MGD,VAS scores of ocular fatigue,BUT), DR-1 tear film lipid layer interferometry, fluorescein staining, and rose bengal staining,incidence of meibomian gland obstruction,Symptoms of ocular fatigue,serious side-effects,adverse reactions,symptoms,Patient symptoms, slit lamp findings, and overall preferences,IOP,skin of the closed eyelids increases TFLLT,tolerated,Symptom scores, tear interference grade, tear evaporation test results, rose bengal scores, tear BUT, and orifice obstruction scores,RBC and plasma ratios of omega-6 to omega-3,Ocular Surface Disease Index (OSDI) objective clinical measures, including tear production and stability, ocular surface and meibomian gland health, and biochemical plasma, red blood cell (RBC), and meibum evaluation,MG secretion,symptom of itching,TBUT, OSDI score, and meibum score,mild discomfort and stinging,TFLLT,lid edema, lid erythema, debris, and pouting of Meibomian glands; patients rated their subjective complaints,symptoms of ocular burning, foreign body sensation, and intermittent filmy or blurred vision,tear function and ocular surface status,symptoms of blepharitis,clinical cure or improvement,moderate edema and discomfort,normal or markedly improved lids,tear film lipid layer interference patterns, BUT, meibomian gland secretion, and dry-eye symptoms,incidence of normal tear lipid layer,corneal staining,eyelid edema, eyelid margin hyperemia, meibomian secretion appearance, meibomian gland obstruction, foam collection in the tear meniscus, conjunctival hyperemia, conjunctival papillae, and corneal staining,overall OSDI score, TBUT, and meibum score,number of symptoms,mean ocular symptoms, Schirmer's test scores, and FBUT values,tear break-up time (BUT) and dry-eye symptoms,symptoms of blurred vision, burning, and itching,efficacy and safety,omega-6 to omega-3 fatty acid ratios in RBCs and plasma,eyelid edema,total objective signs,meibomian gland dysfunction (MGD,Schirmer's scores,eyelid margin inflammation,Eyelid temperature measurements, slit lamp examination, tear film break-up time, Schirmer test, vital staining, tear film lipid layer interferometry, and dry eye symptomatology scoring with visual analog scales,tear film lipid layer thickness,signs and symptoms composite score using a non-inferiority metric to compare LE/T to DM/T. Safety endpoints included visual acuity (VA), biomicroscopy, intraocular pressure (IOP) assessments, and adverse events,subjective symptoms,Pityrosporum numbers,stability and uniformity of the tear lipid layer,visual analog scales (VASs,FBUT,severity of five clinical signs: eyelid debris, eyelid redness, eyelid swelling, meibomian gland (MG) plugging, and the quality of MG secretion,acute conjunctivitis,blepharitis and associated rosacea,TFLLT of the control eye,side effects,mean ocular symptoms, fluorescein break-up time (FBUT) values, and Schirmer scores|Lid cultures showed that the combination and gentamicin were significantly superior to placebo or betamethasone in freeing the lids of staphylococcus.
not found|mean time to delivery,rates of preterm delivery,mean gestational age at delivery|Terbutaline by pump, saline by pump, and oral terbutaline appear equivalent for the prevention of preterm delivery.
19|gut colonization by yeasts or gram-negative bacilli, or infections, use of antimicrobials, days with fever and total societal costs,adherence rate,major infection,Time to major infection and survival time,risk of mortality (ERM) score,major infection (pneumonia, bacteremia, or fungemia) and death; if the true probability of either event,febrile neutropenia,Infection rates,major infection or death,colonization of the digestive tract with aerobic gram-negative bacilli and yeasts,Fever of unknown origin,infections and total societal costs,adherence and diet tolerability,infection rate|Infection rates for children with cancer on the neutropenic diet were similar to those for patients following food safety guidelines.
12|dyspnoea and change in IC,walking distance while breathing Heliox28,Dyspnea,quality of life indices,end-inspiratory (EILV) and end-expiratory (EELV) lung volume changes,dyspnea at submaximal exercise and the increases in QO2LEG and VO2LEG,HRQL (Chronic Respiratory Questionnaire (CRQ), 36-item Short-Form Health Survey, Hospital Anxiety and Depression Scale) except for CRQ emotion domain,Exercise time, inspiratory capacity (IC), work of breathing, and exertional symptoms,Breathing oxygen,Breathlessness,severe airflow obstruction,resting ventilation, hyperinflation and dyspnoea,lung emptying,resting saturation,O(2) administration reduced dyspnea,normoxic helium,laboratory exercise performance,dyspnoea and perceived exertion,Walking distance,QLEG, VO2LEG, and leg fatigue,hyperinflation associated with functional and symptomatic improvement,heart rate, minute ventilation, or RVSP.(ABSTRACT TRUNCATED AT 250 WORDS,dyspnea,Hyperoxia improved dyspnoea,breathing rate,Duration of exercise,mild hypoxaemia,Wmax, peak carbon dioxide production (V'CO2) and 6MWD while breathing oxygen,exercise tolerance and respiratory mechanics,exertional breathlessness,endurance walking distances,IC,Ventilation (V'E,time of ascent, desaturation, and dyspnoea associated with the ascent,6MWD or steps achieved while breathing supplemental oxygen,peak exercise capacity,dynamic hyperinflation,Mean values,Exercise tolerance,endurance walking distance,mean walk distance,6MWD and steps,PDOD,acceptability or tolerability,mean ,lower dyspnea with O2,mean speed,peak VO2LEG,Peak exercise capacity,dyspnoea rating,breathlessness,dyspnoea nor improved performance,maximum exercise performance and relieve exertional dyspnoea,mean breathlessness scores,room air, endurance time increased with FI,lower limb blood flow and O2 uptake,greatest desaturation whilst walking with the air cylinder,duration of exercise,Breathlessness ratings (Borg scale), endurance time, respiratory drive (change in mouth occlusion pressure over the first 0.1 s of inspiration, P0.1), ventilation (VE), breathing pattern, operational lung volumes, gas exchange, and metabolic parameters,endurance time,interaction effect of gender with O2 for dyspnea,expiratory flow resistance,breathlessness on submaximum exercise,endurance shuttle walking distance, resting and exercise oxygen saturation, and end-exercise dyspnea (Borg scale,Oxygen relieves breathlessness,Six minute walking distance (6MWD), stair-climbing, weight-lifting exercise ,Slopes of Borg/VE, Borg/lactate, and VE/lactate,exercise capacity,reduced dyspnea,health-related quality of life,exercise performance and quality of life,peak QO2LEG,mean arterial oxygen saturation (SaO2,health-related quality of life (HRQL,anxiety and depression and in certain domains of the SF-36,lower limb blood flow (QLEG), O2 delivery (QO2LEG), and O2 uptake (VO2LEG,Exercise ability and breathlessness,blood lactate levels,6-minute walking distance,degree of airflow obstruction and change in IC,smaller V'E and fR decreases,Breathing air, arterial saturation at rest,O(2,compressed air, PaO2,tidal volume,perception of breathlessness and walk distance,arterial oxygen saturation measured by pulse oximetry (SpO(2,Degree of desaturation,exercise time,peak exercise work rate,QLEG, QO2LEG, and VO2LEG,Heart rate and breathlessness score on a visual analogue scale,exercise dyspnoea score,training work rate,dyspnea and endurance,CRQ,Lung function, endurance time (cycle ergometer), dyspnoea score, blood gases and LTOT compliance,dyspnoea for oxygen,distance walked and reduce dyspnea,five-breath averages of respiratory rate, tidal volume, and ventilation (VE), dyspnea and leg fatigue scores, arterial and venous blood gases, and QLEG,resting pulmonary hyperinflation,hyperinflation and exercise endurance,walking distance (mean+/-SD, 147+/-150 m) and reduced Borg score,distance walked using oxygen,dyspnea score and VE,endurance in constant work rate tests,mean time-to-resting Borg score for air and oxygen,rise in dyspnea scores,quality of life,slopes of P0.1 and lactate over time,6MWD or steps,Exercise capacity,resistive work of breathing,cardiac frequency and dyspnoea and a significant increase in SpO(2,arterial oxygen desaturation,walking distance,intrinsic positive end-expiratory pressure,Dyspnoea,mean (SD) distance walked on continuous flow oxygen,mean endurance walking time,Endurance time,acute healthcare utilisation,exercise performance while breathing air and oxygen, and on quality of life,resting pattern of ventilation and dyspnoea in COPD,BWT and CAWT,maximal dyspnoea,severity of dyspnea with right ventricular systolic pressure (RVSP,delta PaCO2/time,distance walked,endurance and symptom perception,exertional dyspnoea,endurance,Measurements of dyspnoea (Borg score), oxyhaemoglobin saturation (SpO(2)), inspiratory capacity (IC), minute ventilation, tidal volume, breathing and cardiac frequency,visual analogue scale, reduced desaturation (oxygen,exercise tolerance,IC and tidal volume,endurance time for cycling at a constant work load,maximum distance walked or maximum heart rate, or in the breathlessness score or heart rate,SEM) and mild hypoxemia,breathing room air) and quality of life,mild exercise hypoxemia, relief of exertional breathlessness,Inspired oxygen fraction (FI,O2,mean endurance walking distances,respiratory gymnasium and undertook four 6-min walk (6MW) tests,6-minute walk distance,exercise performance,exercise performance (step tests and 6 min walking distance [6MWD,visual analogue scales (VAS,exercise duration,Oxygen saturation (SpO2), 6-minute walk distance, and end of walk dyspnea,flow rate of supplemental oxygen and cycling endurance time,Improved endurance time,dyspnea at iso-exercise intensity,mean 6MW distance,helium-hyperoxia,mean of individual Borg/time slopes fell,dyspnoea score, EELV, EILV, V'E and respiratory frequency (fR,dyspnea scores by numeric rating scale,recovery times,Dyspnea management,Chronic Respiratory Questionnaire (CRQ), Hospital Anxiety and Depression scale and the short form (SF)-36,Maximum workload (Wmax,SD work rate,dyspnoea,breathlessness and exercise tolerance,endurance time and mortality,Time to readmission|With endurance testing on compressed air, PaO2 did not change significantly in the group as whole (postexercise PaO2 63 +/-
not found|analgesic effects,total analgesic consumption,pain score on fracture manipulation,Pain,longer time before first additional analgesia,fracture manipulation,Colles' fracture,highest individual prilocaine plasma concentration,Blocking efficacy and acute toxicity,overall A&E transit time,cuff discomfort,swelling or pain,pain assessment,Systemic toxicity,dorsal angulation,Duration of motor blockade,lower pain scores,quality of analgesia,initial radiological outcome,grip strength,cost of adding (and risk of allergy,successful fracture reductions,Onset-time and the duration of the sensory block,analgesia,waiting and manipulation times and resource costs,distal radius fractures,overall success rate for analgesia,moderate pain,pain,severe pain,visual analogue scale, radiological position, waiting time, procedure time and cost|We describe the proximal cranial needle approach for brachial plexus blockade; clear surface markings and cranial direction of the needle lead to satisfactory results with a low incidence of complications.
114|rates of specific complications, blood loss and the need for secondary procedures to complete the abortion,pain,numbers of women with one or more complications,pain, noise disturbance and overall satisfaction with the abortion procedure,rate of complications with MVA,level of pain with visual analog scales,mean procedure times,Patient pain perception,incidence of cannula obstruction,amounts of anesthesia required and complication rates,pain level with cervical dilatation,level of pain,pain levels or satisfaction,pain, anxiety or bleeding,blood loss,Estimated blood loss,frequency of complete abortion,pain perception and procedure time|The level of pain after aspiration did not vary significantly in patients who had abortions performed by residents or faculty.
203|velopharyngeal insufficiency,frequency of residual velopharyngeal insufficiency after palatal closure,mean size of the gap at the velopharyngeal sphincter during speech,residual size of the gap at the velopharyngeal sphincter,frequency of residual velopharyngeal insufficiency|The mean size of the gap at the velopharyngeal sphincter during speech was not significantly different in both groups of patients before surgery (23 percent versus 22 percent; p > 0.5).
114|Mild intraoperative hypothermia,Neurological status,postoperative neurologic deficits,frequency of neurological deterioration,excess morbidity or mortality,postoperative critical care requirements, respiratory and cardiovascular complications, duration of hospitalization, and discharge disposition,incidence of good long-term outcomes,neurologic outcome,frequency of discharge to home,Mild hypothermia,total length of hospitalization, the rates of death,intubation and rewarming,Postoperative bacteremia,Glasgow Outcome Score|Although not achieving statistical significance, patients with SAH randomized to the hypothermic group, when compared with patients in the normothermic group, had the following: 1) a lower frequency of neurological deterioration at 24 and 72 hours after surgery (21 versus 37-41%), 2) a greater frequency of discharge to home (75 versus 57%), and 3) a greater incidence of good long-term outcomes (71 versus 57%).
not found|Energy expenditure for total daily physical activities,lifestyle factors (energy intake; fat intake; time spent on leisure-time physical activity; walking, bicycling, and sports; and smoking behavior,fat mass index,rates of walking and moderate physical activity in the past week,International Physical Activity Questionnaire (IPAQ) data,hypertension, obesity, high cholesterol, smoking, and exercise,moderate physical activity,exercise, or prevalence of physical inactivity,risk factor levels and mortality rates,mean change in lifestyle factors,physical activity knowledge, attitudes, and behavior,health-related behaviour,Self-reported and objective risk factor measurements,rate of walking-trail use,comparison community,physical activity knowledge, attitudes, or self-efficacy,Average daily steps,diastolic blood pressure,high-density cholesterol concentrations,energy intake,fruit consumption, vegetable consumption, physical activity, smoking, alcohol consumption and intermediate outcomes of behaviour (i.e. attitudes, self-efficacy, awareness, knowledge and stages of change,Leisure time devoted to physical activities,BMI,TV/video viewing,Body mass index (BMI), body composition, physical activity by questionnaire, plasma lipids and glucose, insulin resistance,Beneficial effects,smoking, eating and exercise behaviours,Body mass index,physical activity levels, reduced weight gain,vigorous activities,total leisure-time physical activity,glucose levels,high-density lipoprotein cholesterol and triglycerides,excessive weight gain,mean dietary score,nonfasting serum levels of lipids and glucose,Systolic blood pressure,cholesterol-to-HDL cholesterol ratio,Daily smoking,knowledge levels,energy intake, fat consumption, walking, and bicycling,supervised physical activity,systolic blood pressure,physical activity since,rates of walking-trail use, total number of minutes walked in the past week, and total minutes walked for exercise,walking behavior,physical activity knowledge, attitudes, self-efficacy, and behavior,CVD morbidity and mortality,Smoking prevalence,cholesterol and smoking,vegetable consumption, physical activity, smoking and alcohol consumption,Food consumption, physical exercise and smoking behaviours,blood pressure and active and passive smoking on health,physical activity,body mass,triglyceride levels,time spent bicycling,Physical assessments determined lipid, lipoprotein, apolipoprotein, and blood pressure levels,quitting smoking,physical inactivity|The project had a slightly favorable intervention effect on cholesterol and smoking, but failed to have an effect on other risk factors for cardiovascular disease.
300|PID and febrile complications,febrile complications,incidence of PID,Positive culture (gonorrhea,PID,removal rate,morbidity,morbidity associated with IUD insertion,PID infection and febrile complications,risk of developing PID,risk of infection,diagnostic criteria for acute PID,fever with or without leucocytosis and none required hospitalization,occurrence of PID,overall infection rates,rate of IUD removal,rate of this infection,rate of unscheduled IUD-related visits,risk of post-insertion pelvic inflammatory disease (PID,overall three-month retention rate,rate of an unplanned IUCD-related visit to the clinic,Rate of PID infection|The overall infection rates for group 1 and 2 were 2.1% and 2.9%, respectively and this difference was not significant.
not found|reversible side effects,Faecal iron excretion,initial serum ferritin levels,Local reactions,skin reactions (DFX alone), nausea and arthralgia (combined therapy,Ferritin levels,urinary iron excretion,liver iron content,Mean (SD) daily urinary iron excretion,variation of the Ishak fibrosis stage,serum ferritin levels,serum ferritin,mean urinary iron excretion,reduction of liver and heart iron content,mean serum ferritin reduction,Serum ferritin,Urinary iron excretion,24-hr urinary iron excretion (UIE) and measurement of serum ferritin levels,mean urine iron excretion,Liver and heart iron contents,Liver iron content and fibrosis stage variations|Deferiprone plus DFX produced a greater mean urine iron excretion (1.01 mg/kg/24 h) than iron intake from blood transfusion in each patient.
337|Pruritus scores,nausea,median daily percentage of escape medication use,complete resolution of itching,Quality of life,VAS,partial response,Serum naltrexone and 6 beta-naltrexol concentrations,prolonged antipruritic effect,itching intensity,neuropathic pain,geometric mean of tryptase,Serum levels of intact PTH,relieved pruritus subjectively,visual analog pruritus score,perception of pruritus and its behavioral manifestation, scratching, in cholestasis,efficacy and tolerance,nighttime itching,mean of pruritus score,idiopathic generalized pruritus,Adverse effects and patient satisfaction and preferences,fasting total serum bile acids,Geometric mean of serum tryptase,excoriations,investigator's global assessment and improvement in skin hydration,pruritus by scoring a daily 100 mm visual analogue scale (VAS; 0 = no itch, 100 = severe, continuous, day and night intolerable itch,perception of pruritus,pruritus intensity scores,Pruritus, quality of sleep, fatigue (using visual analogue scales), side effects, and liver function,severity of pruritus and treatment-related side effects (cutaneous burning/stinging sensations, dryness, or erythema,plasma histamine levels,suffered nausea,itch intensity,incidence of adverse drug reactions (ADRs,VAS quality of life,daytime itching,pruritus score,mean (+/- SE) pruritus score,reduction in itch intensity,VAS scores,sleep disturbances,pruritus scores,predialysis biochemistry test results or dialysis efficacy,mean score,serious side effects,Plasma histamine and beta-endorphin levels,pruritus of cholestasis,Efficacy and safety,insomnia (sleep disturbance,elevated plasma histamine concentrations,plasma histamine concentrations,intensity of itching and serum levels of intact PTH,Mean basal VAS,VAS pruritus score,serum tryptase level,visual analogue scale (VAS,gastrointestinal disturbances,Plasma histamine levels,intensity of pruritus,complained of drowsiness,sedation,serum biochemistry,CKD-associated pruritus and serum tryptase level,pruritus in response to rifampin,hemoglobin level,median daily pruritus score,individual global response,serum concentrations of albumin, calcium, phosphorus, alkaline phosphatase, or intact parathyroid hormone,severity of pruritus,complete remission of pruritus,severity of pruritus of cholestasis,efficacy and tolerability,active, scratch-induced skin lesions,adverse reactions,biochemical tests or side effects,visual analog score (VAS) of pruritus,Pruritus,paraneoplastic pruritus,quality of life,Relief of idiopathic generalized pruritus,tolerated,Subjectively, pruritus,serum bile acid levels,intensity of pruritus daily on a 0-to-10 visual analogue scale,mean VAS scores,adverse effects,Mild side effects,mean serum bile acid levels,Hourly scratching activity (HSA,visual analogue scale (VAS) and weekly by a detailed score assessing scratching activity, distribution of pruritus, and frequency of pruritus-related sleep disturbance,mean HSA,mild and easily reversible constipation,antipyrine plasma half-life,Mean pruritus score using visual analogue scale and scratching activity,Uremic pruritus,cholestatic pruritus,Antipyrine elimination rates and serum bile acids,Plasma beta-endorphin levels,alleviating uremic pruritus,pruritus and plasma histamine levels,degree of relief,marked relief or complete resolution of itching,liver function tests, antipyrine clearance or serum total bile acids,effectiveness against renal itch,rate of decline in itching,Pruritus intensity,Subjective outcome,marked relief,proportion of patients with at least a 40% reduction in pruritus visual analogue scale scores,perception of pruritus and in HSA,efficacy and safety,renal itch,Changes in itch distribution, duration, direction, and physical evidence,serum concentrations of standard laboratory variables, including lipids, alkaline phosphatase, phosphorus, or calcium,baseline pruritus score,visual analogue scale, and scratching activity,mean daily scores,mean pruritus score,daily visual analogue scales, quality-of-life scores, and evaluations of cutaneous scratch lesions,Adverse events,Serum tryptase levels,Level of pruritus,pruritus severity,median pruritus scores,Complete resolution of pruritus,basophil histamine-release,relief of pruritus,uremic pruritus,onset of anti-pruritic action,Visual analogue scale pruritus scores,mean pruritus perception or scratching activity,antipruritic effect,pruritus scores, quality-of-life scores, and severity of cutaneous scratch lesions,patient preference, changes in a daily visual analogue scale pruritus score, and amount of cholestyramine ingested,success rate,6 beta-naltrexol levels,Moderate to severe ADRs,mean VAS,Adverse events (mainly nausea and sleep disturbances,side effects,pruritus|The most common ADR was insomnia (sleep disturbance), seen in 24 of the 226 nalfurafine patients.
                
152|Direct costs of care,overall mortality,bleeding rates,Overall mortality,variceal eradication,hepatic failure,serious complications of variceal ligation,bleeding and death,bleeding-related mortality,variceal hemorrhage,cumulative mortality rate,variceal bleeding,variceal hemorrhage or a severe medical complication requiring discontinuation of therapy,failure rates of failure, first esophageal varix hemorrhage, and cumulative mortality,rate of esophageal variceal bleeding,mean number of sessions needed to complete variceal ligation,actuarial probability of bleeding,major complication or interval bleeding,actuarial risks of bleeding,actuarial risk for first variceal bleed,initial variceal hemorrhage,2-year cumulative bleeding rate,efficacy and safety,variceal obliteration,actuarial risks of variceal bleeding,Variceal obliteration,Direct costs,Gastroesophageal variceal bleeding,Variceal bleeding,Mean costs,Adverse events,mean daily dosage,Deaths and bleeding related deaths,bleeding,varices,2-year actuarial risks,adverse events,Mortality,Direct costs of medical care,failure rate of propranolol,Fatal bleeding,variceal bleeding, mortality,2-year cumulative mortality rate,Minor complications,bleeding incidence nor mortality,actuarial probability of death,rates of the first variceal bleed,rate of first esophageal variceal bleeding,mean (+/-SD) duration,bleeding before their varices,survival, source of bleeding and serious adverse events,recurrent varices,2-year actuarial risks for first variceal bleed,upper-GI bleeding,bleeding rate,esophageal variceal hemorrhage,serious complication,Esophageal variceal bleeding,heart rate,rate of subcardial variceal bleeding,mortality rates,uncontrollable variceal hemorrhage,prevention of first variceal bleeding,postbanding ulcers,variceal hemorrhages,pulse rate,side effects,actuarial risk for bleeding,mortality|Carvedilol, a non-cardioselective vasodilating beta-blocker, is more effective in reducing portal pressure than propranolol; however, there have been no clinical studies assessing the efficacy of carvedilol in primary prophylaxis.
not found|hepatic or hematologic abnormalities,response probabilities,alcohol withdrawal symptoms,Symptom Checklist-90, side effects, and adverse outcomes,duration of mechanical ventilation and major intercurrent complications, such as pneumonia, sepsis, cardiac disorders, bleeding disorders, and death,uneventful withdrawals,risk of having a first drink,withdrawal symptoms,pruritus but no rash,symptoms of alcohol withdrawal,sleep continuity and sleep architecture variables,recurrent seizures,withdrawal symptoms or psychological distress,delirium tremens,primary effectiveness measure: amount of CLO,rate tremor, speech and coping,recurrence of alcohol withdrawal seizures,response rates,Tolerability,severity of alcohol withdrawal syndrome,fever, tachypnea, and tachycardia,Clinical Institute Withdrawal Scale--Alcohol (CIWA-A,Mainz Alcohol Withdrawal Scores,total symptom score,hostility/aggression,mechanical ventilation,Self-reports of depression (Beck Depression Inventory,sleep disturbances, decreased libido,Drug efficacy,progression in severity of withdrawal symptoms,recurrent alcohol-related seizures,verbal memory performance,frequency of pneumonia,Syndromkurztest (SKT), Nurses' Observation Scale for Inpatient Evaluation (NOSIE), NGI; the Webster scale,disturbed sleep,Four major AWS symptoms (tremor, sweating, nausea, restlessness,Lumbar cerebrospinal fluid,AWS score,cardiac complications,Revised Clinical Institute Withdrawal Assessment for Alcohol Scale,sympathetic activity, the renin-aldosterone system, and clinical symptoms,relative risk of recurrence,Subjective and objective ratings of abstinence symptoms and subjective mood disturbance,sedative side effects,total number of recorded adverse events (AEs,Symptom reduction,Adverse reactions,safety and efficacy,dizziness, motor incoordination, or ataxia,serious side effects,Efficacy and safety,polysomnographic variables of sleep continuitiy and sleep architecture,Equivalent diphenylhydantoin serum levels,baseline characteristics (eg, demographic data, severity of AWS,efficacy,cognitive processing speed,rebound symptoms,Comprehensive Psychopathological Rating Scale,sleep disturbances and daytime sleepiness,Revised Trauma and Injury Severity Score and Acute Physiology and Chronic Health Evaluation II score on admission,craving for alcohol,serious adverse events,standard alcohol withdrawal rating-scale,efficacy and tolerability,total symptoms, score and visual analogue scale assessment,ratings of alcohol withdrawal symptoms nor requests for additional medication,seizures,observer-rated and self-rated withdrawal severity, dysphoric mood,duration of patient withdrawal,Rapid Eye Movement (REM) sleep variables,withdrawal symptoms, or craving for alcohol,tolerated,global psychological distress,Mean total milligrams of oxazepam received, progression of withdrawal symptoms, psychological distress,alcohol withdrawal seizures,clinical efficacy,Blood pressure, body temperature and pulse rate,recurrent seizure,drinking behaviors,Daily drinking,symptomatic orthostatic hypotension,Overall tolerability,levels of HVA and auditory and visual hallucinations,Side effects,occurrence of seizures and other withdrawal symptoms (tremulousness, nausea, sweating, disorientation,ICU stay,demographics or substance use parameters,Levels of HVA in the cerebrospinal fluid,initial impairments in some neuropsychological tests (d2, Zahlen-Verbundings test, Beck Depression Inventory, Anxiety Sensitivity Index,Hostility scores,sleep disturbances and sleepiness,rebound withdrawal symptoms,sociodemographic or drinking data,efficacy and safety,duration of ICU stay,Recurrent alcohol-related seizures,acute alcohol withdrawal,breakthrough signs and symptoms of alcohol withdrawal,adverse clinical events,side effects, normalization of vegetative parameters, craving, or improvement of psychopathological parameters,plasma catecholamines, blood pressure, and pulse rate fell,Oxcarbazepine--efficacy and tolerability,Cardiac complications,daytime sleepiness using the Epworth Sleepiness Scale,diurnal vigilance,white blood counts,alcoholic hepatitis and/or cirrhosis|However, plasma catecholamines, blood pressure, and pulse rate fell more rapidly and to a greater extent during clonidine than following chlormethiazole, findings which could have therapeutic implications.
not found|Standard haematological and biochemical profiles,Hamilton Depression Scale and a global rating of depression,Plasma amitriptyline and nortriptyline levels,free or total plasma tryptophan concentration,mean heart rate|Side-effects necessitated withdrawal of more patients from the amitriptyline group than from the other active treatment groups, but this difference was not significant.
110|Mean change in QTc interval,Extrapyramidal symptoms (EPS), weight gain, serum prolactin level, QTc interval, and self-reported adverse events,Efficacy improvements,serum prolactin level elevation,weight gain,efficacy, safety, and tolerability,CGI-S score,mean weight loss,total treatment costs,mean CGI-I score,effectiveness and lower total costs,safety and tolerability,Mean prolactin levels,dropout rate,clinically significant weight gain,neurocognitive effects,Incidence and severity of adverse events (AEs,efficacy and favorable safety and tolerability profiles,Clinical Global Impression of Severity scale (CGI-S) and Brief Psychiatric Rating Scale (BPRSd) total (derived from the Positive and Negative Syndrome Scale,efficacy and safety,Positive and Negative Syndrome Scale (PANSS) total, positive, and negative scores and Clinical Global Impressions-Severity of Illness (CGI-S) and -Improvement scale scores,Body weight, Positive and Negative Syndrome Scale, and Clinical Global Impressions-Improvement scale (CGI-I) assessments,overall response,Cost-effectiveness,Safety and tolerability evaluations included extrapyramidal symptoms and effects on weight, prolactin, and corrected QT (QTc) interval,fasting plasma levels of total cholesterol, high-density lipoprotein cholesterol, and triglycerides,cost-effectiveness,extrapyramidal symptoms (EPS)-related adverse events,general cognitive functioning, executive functioning, and verbal learning,BPRSd total score,response rates and preference of medicine (POM) ratings,medication acquisition cost,EPS liability,weight gain or increased lipid levels,Efficacy and safety,mild weight gain,Positive and Negative Syndrome Scale (PANSS) and treatment-emergent adverse events,Total scores,mean weight change,extrapyramidal symptom rating scales,Positive and Negative Syndrome Scale (PANSS) scores and Clinical Global Impression scores,body weight,fasting glucose and lipid levels,incremental cost-effectiveness ratio,QTc interval prolongation,CGI-I scores and responder rates,EPS,efficacy measures,PANSS total, PANSS positive, PANSS negative, and CGI-S scores,plasma lipid profile,weight change,Clinical Global Impression-Improvement (CGI-I) score,efficacy and tolerability profiles,Positive and Negative Syndrome Scale (PANSS,total utility scores,Weight gain,fasting glucose and triglycerides,Cognitive deficits,metabolic and cardiovascular risk,total cholesterol, low- and high-density lipoprotein,Neurocognitive data,Significant weight gain,patients' weight|Olanzapine was associated with significantly greater weight gain than aripiprazole at all time points (week 52 [LOCF]: +2.54 vs +0.04 kg; p < 0.001).
1024|incidence of neonatal pneumonia, culture proven neonatal sepsis, and use of the antibiotics in the neonate,clinically diagnosed maternal peripartal infection: chorioamnionitis or endometritis,Rates of infection (chorioamnionitis + endometritis,adverse reaction,sepsis rates,rates of nulliparity,adverse maternal or neonatal reactions,Rates of peripartal infection,length of ruptured membranes,neonatal infection,intrauterine pressure catheter usage,Major and minor neonatal morbidities,combined rate of chorioamnionitis and endometritis (which were mutually exclusive diagnoses|Rates of infection (chorioamnionitis + endometritis) did not differ significantly between the groups, chlorhexidine 10% versus placebo 13% (relative risk 0.8, 95% confidence interval 0.5 to 1.1).
||
677|CRBSI rates,rate of ventilator-associated pneumonia,VAP incidence rates,incidence of VAP,ventilator-associated pneumonia,bloodstream infection,catheter-related bloodstream infections,relative rate (RR) and confidence intervals (CIs,bloodstream infections,rate of CA-BSIs,percentage of incorrect practices,CRBSI rate,average incidence,incidence of gram-negative septicemia,episodes of ventilator-associated pneumonia,total cost,ventilator-associated pneumonia rates,mortality, prolonged hospitalization and costs,Staff compliance,umbilical vein catheter,VAP rates,rate of catheter-associated bloodstream infection,hospital stay and drives up hospital costs,Average CA-BSI rates,ICU length of stay,average cost of a VAP,occurrence of ventilator-associated pneumonia,number of primary bloodstream infections,incidence of central line-associated bloodstream infection (CLABSI,Ventilator-associated pneumonia rates,incidence of CRB fell,medical-care costs and patient morbidity,VAP infection rates,risk of acquiring ventilator-associated pneumonia,incidence of ventilator-associated pneumonia,cost, morbidity, and mortality,infection rates,incidence of ventilator-associated pneumonia ranges,hospital rate of ventilator-associated pneumonia,incidence rates of VAP,infection rate|VAP infection rates reduced by 51%, from a mean of 13.2+/-1.2 in the pre-intervention period to 6.5+/-1.5/1000 device days in the post-intervention period (mean difference 6.7; 95% CI: 2.9-10.4, P =0.02).
210|complication rates,length of hospital stay,postoperative fatigue,need for narcotics and in visual analog score,Perceived postoperative pain,Operative costs,hospital stay,Mean time to return to work,length of operation, complications, hospital stay, and recovery time,ovulation bleeding, ovarian cyst, Meckel's diverticulum, ectopic pregnancy and leiomyoma of the uterus,Number of days in hospital and time to full recovery,evaluation of pain and activity scores at base line preoperatively and on every postoperative day, as well as resumption of diet and length of stay,lost workdays, postoperative pain, or operative time with laparoscopic appendectomy,median hospital stay,visual analog scale,Appendicitis,incidence of wrong diagnosis,Cost-effective appendectomy,short hospital stay,relative risk of removing a healthy appendix,Length of in-hospital stay,complications,total hospital charges,lost workdays, postoperative pain, or operative time from,gastrointestinal quality of life index,Avoidance of unnecessary appendicectomy, length of operating time, and length of stay in hospital,postoperative intramuscular narcotic analgesic usage,morbidity,surgical and general complications, operating time, consumption of analgesics and antibiotics, and return to work,appendix rate,shorter duration of parenteral analgesia,duration of sick leave,total costs of treatment (direct and indirect costs,hospital cost,pain scores and medications, resumption of diet, length of stay, or activity scores,operative but less global cost,operating time, postoperative morbidity, duration of convalescence and cosmesis,anesthetic time,Mean hospital stay,Postoperative complications,mean number of the analgesic doses,shorter time until return to normal physical activity, and a shorter duration of complaints,hospital stay, less postoperative pain, and earlier return to usual activities (work,intraperitoneal abscesses,postoperative recovery (analgesic requirement, postoperative hospitalisation, return to normal activity, return to work,Activity scores and quality of life,Intraabdominal abscesses,operative expenses,Length of stay,mean postoperative hospitalisation,wound-complication rate and ileus,Patient demographics, pathological findings, operative time, postoperative course, and cost,Operative findings, operating time, postoperative complications, and length of hospital stay,postoperative morbidity rate,cosmesis,activity or pain scores, but physical health and general scores on the short-form 36 (SF36) quality of life assessment,total costs,anaesthetic time,mean hospital stay for LA,operating room charges,pain scores,Operative time and technique, reintroduction of diet, postoperative pain, use of analgesia, hospital stay, and complications,demographic data (particularly macroscopic aspect of appendix) analgesia, sedation, delay before eating and walking, incidence of urinary retention, nausea, vomiting,Billed charges and direct costs,postoperative pain and shorter hospital stay,mean time to return to normal activities,median operating time,normal activity,mean operating times,mean total hospital bill,pain medication,vomiting postoperatively,wound infection rates,length of hospitalization, interval until resumption of a regular diet, or morbidity,Negative appendectomy rate,unnecessary appendectomies,longer operating times and increased cost,acute appendicitis,hospital costs,Mean duration of surgery,aggregate incision length,Postoperative ileus,mean number of narcotic injections,postoperative complications,demographic variables including age, body weight,and duration of symptoms,postoperative analgesia,intra-abdominal abscesses,complication rate,rate of misdiagnosis,delay of postoperative recovery (walking and feeding), pain assessment by visual analog scale during the 3 subsequent days, amount of nalbuphine administered via a patient-controlled analgesia system during the first 48 h and responses by children, parents, and nurses on the overall quality of analgesia,conversion to OA because of technical difficulties,morphine-equivalent milligrams of parenteral narcotic,postoperative pain,operating time, complications, hospital stay and functional status,Hospital stay,mean operative times,Wound infection incidence,shorter anesthesia and operative time,Length of stay in hospital,mean duration of hospital stay, period off work (indirect costs), and time to complete recovery,comfortable postoperative course (oral resumption, postoperative stay, and analgesia,Diagnostic accuracy, rate of negative appendectomies, safety, and final outcome,pain medications overall,earlier return to full activity,mean length of postoperative hospital stay,operative morbidity and time to return to work,Average postoperative length of stay without any complications,mean postoperative hospital stay,shorter hospital stay, fewer postoperative complications,Morbidity,mean operative time for LA,quality of life scores,diagnostic errors,postoperative narcotic requirement (P<0.05), quicker reintroduction of diet and quicker return to normal activity,actual operating time,Length of operative times, hospital stay, lost work days, visual analog pain scores, and operative costs,physical activity,postoperative pain on a visual analogue scale,operating time, time until return to a general diet, time until return to normal activity and work, length of hospital stay, billed charges, and postoperative complications,Rates of readmission,operative time, hospital stay,Blood samples,Recovery and duration of work disability,bacteriological risk of appendectomy,body temperature, hematocrit, leukocytecount, or any of the inflammatory markers,recovery of bowel function,Higher operative cost,wound infections, faster recovery, earlier return to work and improved cosmesis,histologic confirmation of appendicitis,mean time to complete recovery,emesis,Length of the operation, intraoperative and postoperative complications, postoperative pain control, length of hospitalization, postdischarge recovery time, and hospital charges,wound infections,LA and OA in time to full recovery,rapid return to full activities, and LAS required shorter hospital stays,risk of bacteraemia,median hospital costs,return to normal activity,complications of laparoscopy,pain control,age, ASA score, symptoms or macroscopic aspect of the appendix,global cost,Wound infection,billed charges,Operating time,postoperative death,complications, hospital stay, cost, return to activity, and return to work,quality of life,length of hospitalization,shorter postoperative hospital stay,median time to return to normal activity,unnecessary appendicectomy,negative for appendicitis,postoperative pain or fatigue, but return to normal life,Severe infection,Operative time,intraoperative complications,billed charges, total costs, direct costs, and indirect costs associated with treatment,pain relief, length of stay, return to normal activities, or morbidity,shorter duration of analgesic use and return to full activities sooner postoperatively,mean durations of hospitalization,relative brevity of OA,medians of operative times,regular activities sooner,shorter time until return,duration of hospital stay and the time to return to normal activities,counts of T-lymphocytes and monocytes expressing HLA-DR,time to full recovery,Visual Analogue Scale (VAS) in lying, standing and moving position and the postoperative consumption of analgesics,operating time,wound infection incidence,operating room costs,mortality,histological abnormality,Mean operative time,postoperative pain, less hospital stay,postoperative hospital stay, pain assessment or complications,length of the operation, complications, postoperative pain control, length of hospitalization, postdischarge recovery time, and hospital charges,risk of unnecessary appendicectomy,total costs (including indirect costs) of laparoscopic appendectomy,Pain,rate for overall complications,total operation room times,demographic data, complications and gastro-intestinal quality of life index scores,shorter length of stay and abbreviated recuperative period,Body temperature,leukocyte count, hematocrit and serum levels of the inflammatory markers c-reactive protein, interleukin (IL)-6, tumor necrosis factor (TNF)-, sTNF-R, IL-1Ra, sIL-2R, and IL-8,mean oral intake durations,incidence of post-operative morbidity,plasma potassium concentration,Total costs,histologic classification of normal, catarrhal, inflamed, suppurative, and gangrenous appendicitis,operative time,pelvic inflammatory disease,gynecologic diagnosis,postoperative complication rate or surgical time,inflammatory parameters,analgesia and postoperative recovery,operative mortality rate,items operative, anesthesia, length of stay, post-operative pain, medicine, wound healing, days to return to normal activity,Inflammatory response,pain,Hospital stay and complications,recovery time (time necessary before returning to work or school,postoperative analgesia, resumption of oral intake, length of hospitalization, return to normal activities, or morbidity,Immunologic function,postoperative stay,narcotic analgesia, and an earlier return to normal activity,Diagnostic accuracy,Age, sex, body mass index (BMI), American Society of Anesthesiology (ASA) rating, job status as well as histologic degree of inflammation of the appendix,duration of postoperative convalescence,postoperative pain and fewer wound infections,time to resumption of fluid and diet intake and length of hospital stay,duration of anesthetic and operation times, postoperative pain, duration of ileus, and length of hospital stay,plasma potassium concentrations,clinical parameters, duration of anaesthesia, operative time, duration of ileus and length of hospital stay,positive blood cultures,complications, postoperative pain control, length of hospitalization, and recovery time,time to full recovery after LA and OA,Postoperative morbidity and hospital readmissions,hospital stays, less postoperative pain,Duration of postoperative convalescence,shorter operative time and lower operating room and hospital charges,Postoperative morbidity,positive bacterial culture,Postoperative pain,postoperative hospital stay,time until return to work; minor endpoints were postoperative pain, fatigue, operative time and postoperative morbidity,hospital stay for LA,Functional status,mean operation durations,Wound infections,perforative appendicitis,median time to discharge of 3 days,overall complication rate|Mean operative time was longer in the LA group (p < 0.05).
124|CDAI score,quality of life,experience musculoskeletal pain, injection site reactions and dyspnoea,disease severity,Mild-to-moderate injection-site reactions and bone pain,corticosteroid-free remission (Crohn's Disease Activity Index (CDAI,rates of either type of clinical response and of remission,health-related quality of life,corticosteroid-free remission,serious adverse events,disease severity and the health-related quality of life and adverse events,corticosteroid-free response (CDAI decreased by > or =100) and induction of remission,clinical response, defined by a decrease from baseline of at least 70 points in the Crohn's Disease Activity Index (CDAI|Mild-to-moderate injection-site reactions and bone pain were more common in the sargramostim group, and three patients in this group had serious adverse events possibly or probably related to treatment.
                
not found|pain with chewing,experience postextraction pain,Kruskal-Wallis and Mann-Whitney U tests,2011 BSPD, IAPD and Blackwell Publishing Ltd,pain reaction,Self-report scores,pain,postextraction pain,pain scores,postoperative pain,pain relief|There is a trend toward reduced postoperative pain in the acetaminophen pretreatment groups.
not found|Acquisition of gram-negative bacilli,single-agent gram-negative bacteremias,fever onset during neutropenia,Localized infections and fever episodes,gram negative bacilli (GNB,mean duration of severe granulocytopenia,incidence of fever, hospitalization, or infection,median duration of on-study time prior to documentation of first infection,rate of fungal infection,testicular cancer,deaths due to infection,mean number of days of fever,time to endpoint, occurrence of fever, type and number of microbiologically documented infections, and administration of intravenous antibiotics,bacteriemias,Febrile neutropenia (FN,frequency of bacteremia and febrile episodes,number of patients with bloodstream infections,occurrence of infection or bacteremia,microbiologically documented infections,incidence of fever, probable infection, and hospitalization,number of acquired gram-negative bacillary organisms,fever and infection,episodes of fever and infection,Incidence of infection,failure of prophylaxis, defined as the first occurrence of either the need to change the prophylactic regimen or the initiation of intravenous broad-spectrum antibiotics,Infection,respective rates of probable infection,combined frequency of disseminated candidiasis, candidemia, and esophagitis of presumed fungal etiology,incidence of febrile or infectious episodes,occurrence of documented septicemia, documented coccus Gram-positive infections, or fever of unknown origins during aplasia,occurrence of fever during neutropenia, time to onset of first fever, or overall infection rates,grade IV leukopenia,febrile neutropenic episodes,acquisition of potential pathogens,Staphylococcus aureus infections,Gram-negative bacteremia,days of fever,morbidity,incidence of gram-positive bacterial,rectal flora and temporarily destroyed the colonization resistance,bacterial infections and delays the onset of fever,proportion of neutropenic febrile days,respective rate of severe infection,Gram-negative bacterial infections,infectious mortality,recurrence of FN,signs or symptoms of arthropathy,episodes of bacteremia,Colonization by newly acquired gram-negative bacilli,Septicemia,time before the onset of the first fever, the number of episodes of fever,died of infection,occurrence of neutropenia and fever, incidence and cause of bacterial infection, time to onset and duration of fever, requirement for intravenous antimicrobials, and length of hospital admission,duration of fever,Bacteremia, microbiologically documented infections, and fever of unknown origin,death rate from infection,risk of Gram-positive sepsis,gram-positive bacterial or Pneumocystis carinii infection,incidences of bacteremias,efficacy and tolerance,bacteremia,numbers of deaths, duration of broad-spectrum antibiotics, or incidence of neutropenic fever,hospitalizations to treat fever or infection,incidence of total infection, bacteremias, pneumonias, rectal abscesses, urinary tract infection, and pharyngitis,duration of neutropenia,bioavailability,overall incidence of infectious complications, number of febrile days, use of parenteral antibiotics, or number of days following randomization to first infectious episode,number of days to first fever, total number of febrile days, length of stay, and number of transfusions,Microbiologically proven major infections,isolation of the pathogenic bacteria,number of bacteremias and the mean proportion of study time on broad-spectrum antibiotics,Corresponding rates,infectious morbidity and/or mortality,median interval between the onset of neutropenia and the onset of fever,Risk factors for infection,incidence of all probable infections, severe infections, and hospitalization but did not include a systematic evaluation of antibacterial resistance,number of days with fever > 38.5 degrees C,incidence of febrile episodes,febrile neutropenia,gram-negative septicemia,certain bacterial infections,Fever,streptococcal bacteremia,pyrexial episodes,mean number of days,parenteral antibiotics,gram-positive organisms,Aerobic gram-negative rods,proportion of patients developing fever,incidence of fever,duration of severe granulocytopenia and thrombocytopenia,number of septicemias,mean duration of granulocytopenia,Gram-negative infections,Clostridium difficile enterocolitis,deaths from infection,neutropenic days on intravenous antibiotics,days without fever and without bacteremia,mean ANC and mean length of hospital stay for neutropenic fever,total interval of hospitalization, time to engraftment, or all-cause mortality,bacterial infection,streptococcal bacteremic episodes,proportion of neutropenic days with fever,Adverse reactions,marrow suppression,Fever or infection (without fever,gastrointestinal side effects,neutropenia and fever,time interval between initiation of chemotherapy and onset of fever, white blood cell (WBC) count at the onset of fever, duration of leukopenia (WBC < 1,000/mm3), duration of systemic antibiotic therapy, mortality due to infection and hospitalization period,overall infection rate,gram-negative bacillary infections,incidence of rash or organ toxicity,infectious source,episodes of bacteraemia and central venous line infections,incidence of FL, the number of infections,occurrence of febrile days, febrile episodes, the duration of antibiotic treatment, the number of sepsis,occurrence of fever and streptococcal and other gram-positive coccal bacteremic infections,bacteremias,skin rashes,fever, days of antibiotic administration, days of hospitalization, or gram-negative rod bacteremia,catheter associated infection,infection-related mortality rate,occurrence of infection,survival rates,episodes of pneumonia,infective events,infection acquisition,year survival and the complications,number of days with fever,infections,incidence and severity of graft-versus-host disease or incidence and duration of fever,febrile morbidity,median survival,mean duration of hospital stay to treat fever or infection,mean number of days of agranulocytosis,fever,neutropenic fever,granulocytopenia,Gram-negative,frequency of febrile episodes,bacterial infections,occurrence of infection or infection associated death,median duration of aplasia,frequency of patients with surveillance cultures positive for coagulase-negative staphylococci,number of infectious deaths,gram positive bacteria,incidence of gram-positive infections,Mortality and tolerability,mean duration of fever,longer durations of granulocytopenia at AGC levels,Reduction of fever and streptococcal bacteremia,mortality rate,infection and fever rate,gram negative bacteria,Gram-positive,incidence of gram-positive bacteremia,mean time to the first infection-related febrile episode,overall incidence of febrile illness,Hospitalization,Seventeen febrile episodes,rate of infection,WHO grade IV leukopenia,median of study time to the first acquired infection,reduction of infection,infective complications,Gram-positive and gram-negative infections,fever during granulocytopenia,gram-positive bacteremias,streptococcal infections,staphylococcal bacteremia,number of patients with fever,incidence of FL,Pneumocystis carinii infections,infection,incidence of bacteremia,afebrile,rate of microbiologically documented infections,lower fever incidence,adverse reactions,overall risk for bacterial infection,overall alimentary tract microbial suppression,leukemic remission rate,febrile leucopenia,20 febrile episodes,profound granulocytopenia,Pseudomonas aeruginosa,bacteremia and septicemia,long term survival rates,prophylactic efficacy,episodes involving Gram-negative bacilli,length of hospitalization,hematologic malignancy, duration and severity of neutropenia,tolerated,number of febrile episodes,major local infection,Gram-positive bacteremia,incidence of Gram-positive infections,fever, signs or symptoms of infection, serious adverse effects, or recovery of the absolute granulocyte count (AGC,Infections,incidences of superficial skin and overall infections,mortality, incidence of severe infections, proportion of neutropenic episodes without fever, empiric use of amphotericin B or fungal infections,neutropenic febrile episodes,gram-negative bacterial infection,number of infection-free neutropenic episodes,mean incidence of febrile complications,incidence of clinically documented febrile episodes (temperature of more than 38 degrees C) attributed to infection,duration of severe neutropenia,Duration of administration of parental antibiotics,subsequent infection,microbial resistance,median duration of leukopenia,rate of bacteremias,time spent febrile,Side effects,survival rate,absolute granulocyte count,febrile or infectious episodes,toxicity,empiric antibiotic therapy,prevention of gram-positive bacteremias,risk of infection-associated complications (including prolonged or secondary fever, pneumonia, septic shock, need for mechanical ventilation, and/or infection-related death), and antimicrobial usage for therapy,percentage of patients with a gram-negative bacterial infection,Faecal anaerobes,infection-related deaths,complete remission rates,Bacteremia,probability of failure-free survival,total numbers,invasive fungal infection,disease status and risk factors for neutropenia,Mean peak and trough serum levels of CIP,granulocyte count,Infectious deaths,myelosuppression,efficacy and safety,Gram-positive cocci,percentage of febrile granulocytopenic days,neutropenia,infection morbidity,incidence of febrile days and of days on parenteral antibiotic therapy,incidence of febrile leucopenia (FL,Streptococcus infections,overall infections,number of major acquired infections,absolute neutrophil count (ANC,Adverse events,intestinal GNB colonization,Disseminated candidiasis,incidence of infection,geometric mean of the neutrophil nadir,therapeutic antibiotics,septic shock,Gram-negative rod bacteremias,number of deaths from infection,overall incidence of bacteremia,frequency of febrile neutropenia and Gram-negative infections,median time,Gram-negative bacilli,Zero gram-positive infections,time elapsed to the onset of fever, incidence of febrile episodes, amphotericin B use, and length of hospital stay,median number of days of fever, the time to onset of fever,gram-positive infections,mean of febrile days and the mean of days with systemic antibiotics,Occurrence of fever and/or infection,overall number of days of hospitalization,infectious morbidity,overall infection rates,median time of decontamination,complete remission rate,frequencies of confirmed bacteremia,lung cancer,Throat and rectal surveillance cultures,number of patients without any infection,total number of acquired infections,febrile episode,mean number of days of empiric antibiotic therapy,delay or dose reduction of chemotherapy,Gram-negative bacteria infection,survival, frequency of bacteremia, overall infections, use of systemic antimicrobial therapy, or adverse effects, including myelosuppression,No death,episodes of afebrile aplasia,Gram-negative bacteremias,febrile episodes,fungal infection,number of gram-negative bacilli resistant to co-trimoxazole isolated from stools,number of unexplained fevers,streptococcal bacteremias,compliance problems, skin reactions or gastrointestinal intolerance|Bacteraemia due to resistant gram-negative rods occurred only in the co-trimoxazole-colistin group though both regimens were effective for selective gastrointestinal tract decontamination.
670|Repeat angiotensin sensitivity test,Preeclampsia,Baseline blood pressure measures,mean systolic and diastolic blood pressures,higher intakes of Ca,duration of pregnancy,systolic and diastolic blood pressure,breast-milk calcium concentrations or infant birth weight, growth, or bone mineral status,infant whole-body bone mineral content and bone area,early preterm delivery,Blood pressure (BP,reduction of pre-eclampsia,incidence of pregnancy-induced hypertension,incidence or severity of preeclampsia or delay its onset,incidence of preterm delivery,frequency of pregnancy-induced hypertension, preeclampsia and preterm birth,blood pressure patterns,prevalence of pregnancy-associated hypertension without preeclampsia,hypertensive disorders of pregnancy,nonproteinuric PIH,risk of pregnancy-induced hypertension,preeclampsia and preterm delivery; secondary outcomes focused on severe morbidity and maternal and neonatal mortality rates,risk of preeclampsia,Blood pressure values, gestational age at delivery, newborn weights, incidence of low Apgar scores, and umbilical arterial blood gases,systolic BP,rates of hypertensive disorders of pregnancy,Bone density of the neonate,average daily calcium intake,hypertensive disorders,Cord blood,preeclampsia,Compliance,pregnancy-induced hypertension,incidence of proteinuric PIH,pregnancy induced hypertension,breast-milk calcium concentrations and infant birth weight, growth, and bone mineral accretion,Infant birth weight and gestational age,neonatal mortality rate,systolic/diastolic blood pressure,diagnosis of preeclampsia,rate of pregnancy induced hypertension,occurrence of pre-eclamsia,Growth and bone mineral accretion,incidence of gestational hypertension,total body calcium,severe maternal morbidity and mortality index,blood lead levels,urinary tract infection, and chlamydial infection,incidence of both proteinuric and nonproteinuric PIH,low birth weight,Urinary excretion of calcium and creatinine,risk of preeclampsia and preterm birth,risk of hypertension and preeclampsia,higher maternal vitamin D and folate serum levels and higher newborn weight and bone mineralization,low ratios of urinary calcium to urinary creatinine,Ca, phosphate (P), magnesium (Mg), and vitamin 25-hydroxyvitamin D (D,incidence of pregnancy induced hypertension,Ca tablets,blood pressure,breast-milk calcium concentration, infant birth weight, or growth or bone mineral status,bone density,incidence of preeclampsia,preeclampsia, pregnancy-associated hypertension, or adverse perinatal outcomes,Dietary calcium intake,severe gestational hypertension,diastolic and systolic blood pressure,severe preeclamptic complications index,hypertension,risk of preterm birth,blood pressure values,preterm birth,Pre-eclampsia,incidence of PIH,frequency of pregnancy-induced hypertension,serum ionized calcium levels,maternal blood lead levels,hypertensive disorders of pregnancy (gestational hypertension and preeclampsia,incidence of any type of hypertension,Maternal and infant weight, length, and blood pressure (BP,Infant bone mineral status,blood pressure and urinary protein excretion,diastolic blood pressure,blood levels of calcium, magnesium, phosphorus, and proteins,severity, maternal morbidity, and neonatal mortality,severe preeclampsia,Eclampsia,risk of both gestational hypertension and preeclampsia,demographic characteristics, initial blood pressure measurements, and amount of proteinuria,higher intakes of P, D, and Mg, higher serum folate and D, and higher cord D levels,numbers of preterm deliveries, small-for-gestational-age births, or fetal and neonatal deaths,spontaneous labor and preterm delivery,mean duration of calcium supplementation|This reduction was more evident in the second trimester (-14%, p < 0.001) than in the third (-8%, p = 0.107) and was strongest in women who were most compliant (those who consumed > or = 75% calcium pills; -24%, p < 0.001), had baseline blood lead > 5 microg/dL (-17%, p < 0.01), or reported use of lead-glazed ceramics and high bone lead (-31%, p < 0.01).
                
not found|weight, coronary heart disease (CHD) risk factors, and incidence of diabetes,total carotenoid concentration,total blood or high-density lipoprotein cholesterol,Glycemia,baseline serum cholesterol levels,mean reduction in serum LDL-C,Anthropometry (weight, body mass index); metabolic fitness (blood pressure, blood lipids); energy expenditure; eating behavior (restraint, eating disorder pathology); psychology (self-esteem, depression, body image); attrition and attendance; and participant evaluations of treatment helpfulness,measures of eating, exercise, and fitness; weight losses,dietary fat,glucose tolerance,total and low density lipoprotein cholesterol concentration,serum levels of total cholesterol, LDL-C, HDL-C, and triglycerides,mean fasting serum triglyceride,blood cholesterol levels,risk of type 2 diabetes,Serum cholesterol,behavior, weight, or physiological parameters,serum cholesterol levels,mean total cholesterol concentration fell,cholesterol,maximum cholesterol decrease,blood cholesterol and dietary changes,Patient satisfaction,Two factors-length of time to follow-up measurement and change in weight,serum cholesterol,body weight and glycemia,Weight losses,FPG, dietary compliance by body weight and food diaries, and fitness compliance by bicycle ergometer assessment and exercise diaries,Serum cholesterol levels,insulin sensitivity,Body weight,mean concentrations of lipids, lipoproteins, and antioxidants or body mass index,Initial mean cholesterol,metabolic fitness, psychology and eating behavior,total cholesterol,lipid profiles,body weight,low density lipoprotein cholesterol,mean cholesterol level fell,body weight, smoking, and dietary fat consumption,Cognitive restraint,gradual deterioration of behavioral and physiological changes,serum lipids, lipoproteins, and antioxidants,modest weight loss,fasting serum triglycerides,total cholesterol level reduction,Weight,metabolic fitness, psychological well-being and eating and activity behaviors,many metabolic fitness, psychological and eating behavior variables,calculated maximal oxygen uptake,relative to initial level,risk factors (smoking, weight, level of physical activity) and patients' cholesterol/saturated fat index,Concentrations of total cholesterol and low density and high density lipoprotein cholesterol,physical activity,blood cholesterol and dietary intake,FPG, glucose tolerance, or hemoglobin A1c (HbA1c), and (4) showed a greater tendency to withdraw,Cholesterol reduction,weight loss,Total serum cholesterol and intervention costs,risk of developing diabetes, and weight loss,mean cholesterol response|The mean reduction in serum LDL-C was 0.08 mmol/L (1.8%) in Group I, 0.07 mmol/L (1.6%) in Group II, and 0.28 mmol/L (6.3%) in Group III (P = 0.94).
107|average caries increment of 2.1 surfaces,caries development,cariostatic effect,proximal caries progression,caries progression,caries-protective efficacy,caries reduction,inhibition of caries increment,mean caries increment, including initial lesions,Absolute and percent caries reductions,caries-free,still caries-free,caries-preventive effect,mean caries increment,Percentage caries reduction,progression of proximal caries lesions,Caries reduction|The study showed that topical application of fluoride varnish every third month significantly (P less than 0.05) reduced the progression of proximal caries lesions in premolars and molars.
60|continence and defecation,length of hospital stay,Mean inpatient stay,return to pain-free defecation and normal activities,faecal urgency,reduced pain, shorter length of stay, and earlier resumption to work,Operation time,median hospital stay,Average pain,complications,Overall complication rates,average pain,Patient satisfaction,resolution of symptoms,Persistence of itching,anal pressures and sphincter anatomy,control of hemorrhoidal symptoms one year after operation,intra-/postoperative conditions, hospital stay, pain intensity scoring, time off work, and procedure-related morbidity) and over a follow-up period of minimum 18 months (mid-term, i.e., relapse of prolapse and/or bleeding, anal stricture, anal sepsis, and the acceptability of the procedures to the patients,postoperative pain, shorter hospital stay,Mean hospital stay,Postoperative bleeding requiring haemostatic procedures,postoperative pain scores (visual analog score,Mean length,satisfaction scores,persistent or recurrent symptoms,episodes of bleeding,operative time, intraoperative blood loss, postoperative pain intensity, and return to work,postoperative pain scores and satisfaction scores,Return to normal activity,pain score,normal activity sooner,pain relief and disappearance of bleeding,continence problems,Grade III or IV hemorrhoids,Resumption of pain-free defecation,Postoperative pain, wound healing,VAS score,median (range) symptom severity score,postoperative pain, earlier recovery time and return to work, and a similar recurrence rate,postoperative pain,Hospital stay,visual analog scale (VAS,prolapse and hemorrhoids,Operative data and complications,rectal evacuation,Operation time for stapled hemorrhoidectomy,pain during bowel movement,postoperative pain, early discharge, less time off work, complications,pain overall,Resting and squeeze pressures,total number of complications, the length of absence from work or control of symptoms,Patient satisfaction scores,late complications, and functional outcome,maintaining normal continence to liquid stools,Hospital stay and time to first bowel motion,Visual analog scale,operation time, blood loss, day of first bowel movement after surgery, and complication rates,overall incidence of complications,symptom load, symptom severity or the disease severity,shorter anaesthesia time,reduced postoperative pain, a reduced hospital stay,total analgesic requirement,Mean pain intensity,Demographic parameters, hemorrhoid symptoms, preoperative pain scores, and bowel habits,Postoperative morbidity and time off work,Operating time, postoperative pain, time to return to work, postoperative complications and effectiveness of haemorrhoidal symptom control,Average pain relative,overall symptom control and safety,hospital stay or symptom control,normal activities sooner,Late complications,Impaired sphincter function,immediate postoperative period (e.g., type of anesthesia, mean duration of operation, mean hospitalization time, analgesic administration, time before returning to work) and over a long-term follow-up period of 48 months (later complications such as prolapse relapse, bleeding, stenosis, incontinence,Postoperative pain, symptom control, complications, re-treatment rates, patient satisfaction, and quality of life,average pain experience,acute postoperative pain, and hemorrhoid symptom recurrence requiring additional treatment at one-year follow-up from surgery,appearance of a new symptom, tenesmus,Surgical and functional outcome,bleeding control,Recurrent prolapse starting,rate of recurrent prolapse,shorter operating time, less frequent postoperative analgesia intake, shorter hospital stay and earlier return to normal activity,Operating time, postoperative pain (measured by the visual analog scale), hospital stay, histologic features, morbidity, defecation habit, continence, recovery time (return to work), and hemorrhoid recurrence at 1 year,tenesmus,Healing time,recurrence rate,Mean duration of inability to work,Endoanal ultrasound,hemorrhoidal prolapse,smooth muscle incorporation and postoperative continence function,moderate pain,intraoperative bleeding,hemorrhoidal prolapse recurrences,occasional pain,operating time,severe pain,work or routine activities earlier,Median (range) V.A.S. scores,clinical efficacy, safety and patient acceptability of SA,shorter length of stay,Postoperative pain, analgesic use, symptoms, disability, early and late complications, and patient satisfaction,blood loss, pain scores and requirement of analgesics,control prolapse, discharge, and bleeding, with no stenosis or significant incontinence,external hemorrhoidal thrombosis,prolapse, discharge and bleeding,operative time, pain scores, complications, day of discharge, return to work, and level of satisfaction,serious complications,partial residual prolapse,prolapse and hemorrhoids required additional anorectal procedures,Length of surgery and disability, postoperative pain, and use of analgesics,adverse events,complained of recurrent external swelling and/or prolapse,hemorrhoid symptoms,length of the operation,late complications, patient-assessed symptom control, and functional outcome,hemorrhoidal recurrence,Operating time, frequency of postoperative analgesic intake, hospital stay, time to return to normal activity and postoperative complications,mean operative time,postoperative pain/discomfort,pain at first bowel movement, and need for postoperative analgesics,Median range of VAS score,Postoperative pain,continence score,rate of residual symptoms, prolapse control,pain,frequency of late complications|Stapled hemorrhoidectomy may be associated with less pain and faster recovery than conventional hemorrhoidectomy for prolapsing hemorrhoids.
30|low autonomic liability,efficacy and safety,tolerated,akathisia, Parkinsonism and autonomic side effects,MIA left/right and WPV left/right,Akathisia,social activities,intensity of the symptoms (total Brief Psychiatric Rating Scale (BPRS) score|No significant side effects occurred.
not found|average aggression score, a global severity index from the Overt Aggression Scale,Retention,psychiatric symptoms and personal adjustment problems,amplitudes of P300 ERP waveforms,urine toxicology tests,consecutive weeks of abstinence and less craving,alcohol consumption,Aggression,P300 ERP waveforms,impulsive aggressive acts,average OAS-M Aggression scores,urine toxicologies,OAS-M Aggression score, including verbal assault and assault against objects, as well as OAS-M Irritability score, and Clinical Global Impression (CGI)-Severity,impulsive aggression, irritability, and global severity,impulsive aggression,percentage of cocaine-free urines,drinking behavior and psychiatric symptoms,psychiatric symptoms, alcohol craving, g-GGT levels and adverse events,Medication compliance,impulsive and premeditated aggression,frequency of impulsive-aggressive outbursts,Overt Aggression Scale (OAS) and the Profile of Mood States (POMS,overall premature discontinuation rate,Psychophysiological measures (evoked potentials,P1 amplitude|Analysis showed a significant reduction in impulsive aggression during all 3 anticonvulsant conditions compared with placebo.
306|survival advantage|Following palliative sigmoid colectomy for carcinoma at Dukes' stage D, 306 patients were randomized to the control group or to electrocoagulation of liver secondaries alone or with allopurinol (50 mg by mouth 4 times a day) or DMSO (500 mg by mouth 4 times a day).
not found|Serum IgG,IVIG acquired nosocomial sepsis,Nosocomial infections of the blood, meninges, or urinary tract,mean days of hospitalization,mortality rate,Bacteremia,frequency of infection and serum immunoglobulin concentrations,risk of nosocomial infection,tolerated; mild, reversible adverse reactions,incidence of hospital-acquired infections,Serum total IgG and group B streptococcus-, Escherichia coli-, and CMV-specific IgG levels,gram-positive cocci,nosocomial sepsis,incidence of necrotizing enterocolitis,safety and effectiveness,risk of a first nosocomial infection,infection rate,serum IgG concentration,incidence of sepsis, mortality due to sepsis, total mortality, and minor infections,episodes of certain infection,nosocomial infections,low serum immunoglobulin G levels,serum IgG levels,overall mortality rate or mortality rate,red blood cell concentration,infection rate or severity of infection,episodes of sepsis,change in serum IgG or half-life of IgG,number who developed sepsis,perinatal and neonatal characteristics,serum IgG,rate of nosocomial infections,Adverse reactions,serum IgG values,IgG levels,IgG concentrations,blood pressure,incidence of infection,Mortality,occurrence of sepsis,Serum IgG levels,late-onset sepsis,blood-culture-proven septicaemia,respiratory distress syndrome, bronchopulmonary dysplasia, intracranial hemorrhage, the duration of hospitalization, or mortality,incidence of certain or probable infection,rate of hospital-acquired infections,incidence of infection or septicemia,Sepsis, death, and death as a result of infection,sepsis,death,adverse effect,Septicemia,immunoglobulin concentrations,episodes of probable infection,Maternal and neonatal risk factors for infection,Infection rate,median peak level of serum IgG,mean length of the hospital stay,frequency of proven sepsis,nosocomial infection,persistent hepatic or renal abnormalities,heart rate, respiratory rate, urine output, blood glucose, serum osmolality, BUN, SGPT, pH, blood gasses, serum electrolytes, total or direct bilirubin, blood leukocyte concentration, absolute neutrophil count, or blood platelet concentration,Mortality, morbidity, and nosocomial infection,overall mortality rates,side effects,neonatal sepsis,mortality rate attributable to infection|The serum IgG concentration was increased (p < 0.05) in IVIG-treated patients for 8 weeks.
not found|elimination of parasites, deaths attributed to treatment, and rate of encephalopathy,Plasma DFMO concentrations,Skin reactions,Encephalopathic syndromes,frequency of adverse events,plasma and CSF DFMO concentrations,Plasma and CSF concentrations of DFMO,V(z)/F, CL/F and t(1/2z) values,CSF concentrations,efficacy and safety,plasma, cerebrospinal fluid (CSF) levels and pharmacokinetics of eflornithine (DFMO,complications of melarsoprol therapy or in relapse rate,Average trough (C(ss-min)) and average (C(ss-ave)) plasma DFMO concentrations,safety and efficacy,C(max), t(max) and AUC(0- infinity ) values,number of patients with encephalopathic syndromes,adverse events,good initial response, but relapse,Parasitological cure,2-year probability of relapse,convulsions,cure rates and adverse events,efficacy and toxicity,M+E,cure rates,concentration-time profiles of DFMO,therapeutic plasma and CSF levels,cure (defined as absence of trypanosomes in body fluids and a leucocyte count,relapse, severe adverse events, and death attributed to treatment,unacceptable toxicity,morbidity and death associated with melarsoprol-induced encephalopathy,Cure rates,gambiense sleeping sickness,2-year probability of cure|In the PP population, 122 (91.7%) of 133 patients in the eflornithine group and 129 (97.7%) of 132 in the NECT group were cured at 18 months (difference -6.0%, one-sided 95% CI -1.5; p<0.0001).
15|RV,forced expiratory volume,FEV1.0,maximum FEV1 and in area under the time-response curve (AUC-FEV1,peak expiratory flow (PEF,safety and efficacy,maximum FEV1 and AUC-FEV1,bronchodilatory effect,FVC, and s-Gaw|Inhalation of terbutaline in different doses and from different devices induced a decrease in RV, an increase in FVC, and s-Gaw and a less pronounced increase in FEV1.0.
40|operative time,Hernia formation,Incision size, hospital stay and time to normal daily activity,shorter hospital stay,number and size of the trocars used, length of incision, specimen weight, pathologic stage, operative time, need for additional procedures such as adrenalectomy and/or lymph node sampling, estimated blood loss, need for blood transfusions, analgesic requirement, length of hospital stay, or the incidence of minor or major complications,narcotic use,age, American Society of Anesthesiologists class, body mass index or tumor size,blood loss,greatest risk of hernia formation,Mean operative time|No statistically significant differences were found between the two approaches in terms of the number and size of the trocars used, length of incision, specimen weight, pathologic stage, operative time, need for additional procedures such as adrenalectomy and/or lymph node sampling, estimated blood loss, need for blood transfusions, analgesic requirement, length of hospital stay, or the incidence of minor or major complications.
not found|total costs of care,Conversion to open cholecystectomy,Visual analogue scale scores of health,hospital stay time,Conversion to open cholecystectomy, operative time, postoperative hospital stay, costs, and complications,Quality-adjusted life year (QALY) gains,Mean operative time|Visual analogue scale scores of health were 72.94 versus 84.63 (P = 0.012) and the mean(s.d.)
1650|antepartum seizure rates,total length of labor,eclamptic convulsions,acceptable serum phenytoin levels,oxytocin use, change in hematocrit, frequency of maternal infection, progression to severe preeclampsia, incidence of cesarean delivery, and Apgar scores,development of eclampsia, as defined by a witnessed tonic-clonic seizure,risk factors for eclampsia,adjusted risk ratio for eclampsia,risk of eclampsia,hiporreflexia, flaccidity or neonatal respiratory distress,disease progression,dyspnea and weakness,neonatal outcome,cesarean deliveries,eclampsia and, for women randomised before delivery, death of the baby,rates of cesarean delivery,diastolic blood pressure,endometritis,systolic and diastolic blood pressure,rates of cesarean delivery, infectious morbidity, obstetric hemorrhage, or neonatal depression,side-effects,gestational age at delivery, birth weight, Apgar scores and pH in umbilical cord blood,postpartum hemorrhage,signs or symptoms of severe preeclampsia, eclampsia, or laboratory abnormalities of full or partial HELLP (hemolysis, elevated liver enzymes, low platelets) syndrome,blood pressure,risk of maternal death,severe preeclampsia,rate of cervical dilation,Maternal mortality,Mild preeclampsia,maternal or neonatal morbidity,blood pressure measurements,length of the active phase of labor,risk of the baby dying,cerebral vasoconstriction and ischemia,hot flushes,systolic blood pressure,rapid cervical dilation,mean Apgar scores,eclamptic seizures,chorioamnionitis,eclampsia,eclampsia or thrombocytopenia,fetal distress,control blood pressure,High blood pressure,duration of labor,prolongation or failure of labor induction,babies with poor apgar score,diastolic,materno-fetal effects,rate in cesarean section,overall incidence of eclampsia,length of labor induction,side effects associated with magnesium sulfate therapy: hours and maximum dose of oxytocin, incidence of progression to severe preeclampsia, incidence of cesarean delivery, change in maternal hematocrit, incidence of postpartum hemorrhage, incidence of maternal infection, and Apgar scores,incidence of postpartum hemorrhage,rate of postpartum seizures,occurrence of eclampsia|More women in the magnesium sulfate group than in the nimodipine group needed hydralazine to control blood pressure (54.3 percent vs. 45.7 percent, P<0.001).
                
50|MSFC score, T2 lesion volume and TI lesion volume,severe flulike reactions and raised liver enzymes,rate of accumulation of T2 lesion load,rate of ventricular enlargement,time to sustained progression in disability,timed 10-meter walk, nine-hole peg test, and on MRI, T2 and T1 brain lesion loads and brain and spinal cord atrophy|Subjects on interferon beta-1a 30 microg had a lower rate of accumulation of T2 lesion load than controls (p = 0.025); subjects on 60 microg had a greater rate of ventricular enlargement than controls (p = 0.025).
                
100|Alanine aminotransferase ALT, haemoglobin and reticulocyte percentage,Alpha-tocopherol levels,erythrocyte activities of antioxidative enzymes (glutathione reductase, superoxide dismutase and catalase) or plasma levels of oxidative markers (malondialdehyde and 2-amino-adipic semialdehyde,Platelet count, serum albumin, ALT, and total cholesterol,cumulative incidence of hemorrhage,Cumulative tumor-free survival and cumulative survival rate,thiobarbituric acid reactants, which reflects lipid peroxidation,hepatic or systemic hemodynamics,Alcohol ingestion and hospitalization rates,micronutrient status indicators,ribavirin concentration,hepatic venous pressure gradient,viral load,hospital stay, serum indicators,Retinopathy,re-appearance of detectable hepatitis C virus (HCV) RNA and/or re-elevation of ALT-activity,Symptoms and health-related quality of life,HCV-RNA levels,selenium (Se) level and regional cancer incidence,molar proportion of linoleic acid,ALT levels,serum level of alpha-tocopherol,Changes in histology, normalization of ALT, reduction of viral RNA, serum levels of glutathione, selenium, vitamin E, erythrocyte glutathione peroxidase, trolox equivalent antioxidative capacity (TEAC), thiobarbituric acid reactive substances (TBARS,alanine aminotransferase (ALT) and aspartate aminotransferase (AST,lycopene changes,ascorbic acid levels,rate of resolution of a serum marker of free radical activity and abnormal serum biochemistry,serum alanine aminotransferase and log10-transformed plasma hepatitis C virus-RNA,Fisk scores,mean serum concentration of alpha-tocopherol,5.7)--a mean rise,parallel vitamin E plasma levels and plasma lipids,hepatitis C viral load, transaminases and oxidative status,hepatic laboratory parameters, mortality or hospitalization rates,impaired selenium status, lipid peroxidation, and liver function,liver damage,fatigue,response rate,mean 14C aminopyrine breath test, an indicator of liver function,oxidative stress,safety and efficacy,serum concentrations of vitamin C,white cell count,serum retinol, alpha-tocopherol, vitamin C, carotenoids, xinc and selenium,Adverse effects,Plasma selenium,vitamin E levels,complete response (normal ALT and negative HBV-DNA,14C aminopyrine breath test,levels of ascorbic acid and increased levels of MDA,liver histology,biochemical indicators of vitamin, carotenoid and trace element levels,hemoglobin levels,HBV-DNA negativization,Prothrombin time,lowest platelet counts,aminotransferase status,hemoglobin level,recurrence of viremia,Sustained viral response,MDA levels,rate of fall between serum aspartate transaminase (AST) concentration,low serum concentrations of vitamin E,haemoglobin and ALT reduction,retinol and alpha-tocopherol concentrations decreased; zinc and selenium levels,intrahepatic endothelial dysfunction,partial or full recovery of sexual functioning,mortality within 6 months,EPA in erythrocytes,HBV infection,cumulative survival,serum vitamin E levels,sexual functioning,liver function, suppress hepatocarcinogenesis,activity of erythrocyte glutathione peroxidase,luteinizing hormone,Oxidative stress,PLC incidence,eicosapentaenoic acid (EPA,serum aminotransferases and serum bilirubin,6-month survival,Health-related quality of life,fatigue scores,180-day survival,Outcome: Vitamin C, retinol, alpha-tocopherol, zeaxanthin/lutein, beta-cryptoxanthin, lycopene, alpha- and beta-carotene, zinc and selenium,plasma selenium,alanine aminotransferase, viral load or oxidative markers,endothelial dysfunction,mortality,haemolytic anaemia,Histology activity index (HAI) score,survival,haemoglobin and reticulocyte percentage,concentrations in erythrocytes or plasma,median platelet counts,hepatic and systemic hemodynamics, ascorbic acid, and malondialdehyde (MDA,postprandial increase in portal pressure,alanine aminotransferase (ALT) normalization,sustained biochemical response rates,rapid relapse of ALT and AST elevation,serum alanine aminotransferase, plasma hepatitis C viral load as well as oxidative and antioxidant markers,cumulative incidence of cotton-wool spots,Serum levels of alpha-tocopherol, albumin, alanine aminotransferase (ALT), and total cholesterol and platelet count,plasma levels of the alpha-tocopherol,plasma ascorbic acid and alpha-tocopherol,liver enzymes, HCV-RNA levels and histology,serum hyaluronic acid,serum creatinine,Monocyte nuclear nuclear factor-kappa B binding activity,EPA level|In part II of the trial, oral administration of antioxidants was not associated with significant alterations in any of the end points.
                
not found|rate of anatomic closure 3 months after surgery,mean gain in visual acuity,mean size of macular holes,mean VA,Progression of cataract and the rate of other complications,corrected visual acuity (VA), fundus examination, and macular optical coherence tomography,overall anatomic success rate,ETDRS scores,Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity, progression of cataract, and frequency of complications,Closure rates|The success rate of surgery for idiopathic macular holes of 400 m or smaller is not significantly reduced if facedown positioning is replaced by simply taking care to avoid the supine position.
300|HIV risk behavior reduction,methamphetamine use and sexual risk behaviors,UAV,median number of unprotected sex acts,levels of risky behavior,Transmission-risk behaviors,sexual risk,audio computer-assisted self interview (A-CASI) assessments,transmission risk behavior and serostatus disclosure,HIV transmission risks,mean percentage of occasions of anal intercourse,depression, hostility, and somatization,unprotected anal intercourse,number of sexual partners,sexual risk behavior,sexual behavior and immune functioning,high-risk sexual behavior,satisfying counseling experience,mean transmission risk acts,unsafe sexual activity,number of episodes of unprotected anal intercourse (UAI) with any nonprimary partner of nonconcordant HIV serostatus,making sexual choices, physical safety, HIV and STI transmission knowledge, and sexual negotiation skills,HIV transmission rates,retention,methamphetamine dependence and HIV-related sexual risk behaviors,transmission risk,gain-frame arm,HIV and STI transmission knowledge and comfort with sexual choices,HIV risk reduction,sexual health behaviours,emotional distress,Sexual behavior, psychological distress and psychological help seeking, and immune function,HIV transmission behaviors,Sexual risk behaviors,sexual partners,risky sexual behavior,risk of HIV transmission,levels of HIV nonconcordant UAI,Population-level of risk behaviour,paid, unprotected sexual intercourse and oral sex,greatest reduction,sexual risk behaviors of HIV+individuals,unprotected sex acts,Stay Healthy" module, number of positive lifestyle changes and active coping styles,Acceptability,Risk reduction,proportion of men who engaged in any unprotected anal intercourse,Self-reported unprotected anal or vaginal intercourse (UAV,receptive anal intercourse,HIV risk,HIV high-risk sexual behavior,mean frequency of unprotected anal intercourse,transmission risk or serostatus disclosure,number of partners,sexual risk behaviors,symptoms of distress,substance use, HIV transmission risk, physical health, psychological status, and quality of living situation,sexual behavior,risk of transmission,Social support coping,self-efficacy, communication skills, social norms, and enjoyment of unprotected anal intercourse,incidence of sexual activity,UAI,hepatitis B vaccination; HIV testing; unprotected anal intercourse (UAI) with casual partners; negotiated safety; and amongst men reporting UAI with a regular partner, the proportion who knew their own and their partner's HIV status,frequency of unprotected anal intercourse,HIV risky behaviors and health practices,proportion of men engaging in any unprotected anal intercourse,behavior change,maladaptive interpersonal sensitivity, anxiety, and frequency of unprotected receptive anal intercourse,lymphocyte numbers and function,knowledge, skills, attitudinal or behavioural differences,unprotected receptive anal intercourse (URAI,sexual risk-taking,overall psychiatric symptoms,efficacy and acceptability,unprotected anal intercourse (UAI|No significant changes occurred in the comparison community over the same period.
                
not found|Spatial working memory performance,Hamilton depression scale ratings,neurocognitive functioning,Psychotic major depression (PMD,Brief Psychiatric Rating Scale (BPRS,normal afternoon cortisol release,Hamilton Depression Rating Scale (HDRS) and the Brief Psychiatric Rating Scale (BPRS,number of responders and the time to onset of action,elevated cortisol and ACTH levels,Responder rates,Brief Psychiatric Rating Scale scores,plasma concentrations of corticotropin and deoxycortisol,neurocognitive and neuroendocrine function,verbal fluency and spatial recognition memory,Hamilton Rating Scale for Depression,Cortisol and ACTH,Hamilton Depression Rating Scale,effective and well tolerated,measures of depression,Mood symptoms,Hamilton Rating Scale for Depression scores,adverse events,cortisol and ACTH,Montgomery-Asberg Depression Rating Scale scores,depression ratings,Hamilton Depression Rating Scale scores,Hamilton Rating Scale for Depression (HAM-D), the Beck Depression Inventory (BDI), and the Clinical Global Impression Scale (CGI,BPRS positive symptom subscale, an index of psychotic symptoms,dehydroepiandrosterone and testosterone levels and increased pregnenolone and pregnenolone-sulfate levels,lower HDRS and BPRS scores,depressive symptoms,adverse effects,baseline Hamilton Rating Scale for Depression scores,HAM-D, BDI, or CGI scores,BPRS Positive Symptom Scale (PSS,tolerated without serious adverse effects,neurocognitive function and mood|The treatment resulted in a significant reduction in depressive symptoms.
79|Clinical Institute Withdrawal Assessment of Alcohol Scale, Revised (CIWA-Ar); lorazepam|We found that the use of baclofen was associated with a significant reduction in the use of high doses of benzodiazepine (lorazepam) in the management of symptomatic AWS.
not found|Fruit juice consumption,Eating habits,body composition,social support across time,BMI, BMI z-score, waist circumference, sum of skinfolds and fat-free mass,daily Physical activity and academic achievement,cardiovascular disease (CVD) risk profile,hours of screen activities, body mass index, mode of transport to school and teachers' views of the intervention,physical activity and eating behaviours,feasibility, acceptability, and potential efficacy,waist circumference,BMI z-score,daily saturated fat intake and percentage of calories from fat,number of servings of fruits and vegetables,blood lipids and blood pressure,screen-viewing activities,physical activity or body mass index,fat and sugar intake,Recruitment and retention goals,body composition and behavior,mean body mass index,HOMA index,Body Mass Index,high-density cholesterol concentrations,energy intake,cardiovascular disease risk factors,physical activity, self-efficacy for physical activity and aerobic fitness,heart rate response to a bench-stepping task.%BF and bone density,apolipoprotein (apo) B levels,Fat intake, fruit, water and soft drink consumption,percentage of body fat,TV/video viewing,Cardiovascular disease (CVD,BMI SDS,body mass index z-score,body mass index,BMI, consumption of fruits and vegetables, and physical activity,consumption of snacks or active commuting to school,BMIs,consumption of sweetened beverages,Obesity prevention,fat intake and in food- and health-related knowledge and behaviors,incidence of overweight,Body Mass Index for Physical Activity,weight and height (WHZ score and weight-for-height percentile for children), dietary intake (3-day food records), physical activity (measured by accelerometers), parental feeding style (Child Feeding Questionnaire), and maternal outcome expectations, self-efficacy, and intention to change diet and exercise behaviors,median triceps skinfolds,body weight,cardiovascular fitness (20-m Shuttle Run), blood pressure (BP), and body mass index (BMI, wt/ht(2,consumption of fruits and vegetables and increased physical activity levels,child sex (for fruit and vegetable consumption, physical activity, and weight status), family involvement (for fruit and vegetable consumption), and child body mass index (for screen time,adiposity and physical fitness,insulin levels and insulin resistance,Response rates to questionnaires, teachers' evaluation of training and input, success of school action plans, content of school meals, and children's knowledge of healthy living and self reported behaviour,higher performance in movement skills tests,physical activity participation,normal weight,prevalence and remission of overweight and obesity, BMI z score, total energy and fat intake, fruit and vegetable consumption, body dissatisfaction, and hours of activity and inactivity,nutritional intake, body mass index (calculated as weight in kilograms divided by height in meters squared), fat mass, physical activity, blood indicators, and quality of life,percentage of protein intake,PA,lower likelihood of having an increasing BMI slope,body mass index (BMI) (kg/m 2 ,weight,reduced household television viewing,SPSS (SPSS, Inc., Chicago, IL,recreational physical activity,level of moderate-to-vigorous activity,healthy eating habits,children's fruit and vegetable consumption and minimizing screen time,nutrition knowledge and dietary behaviour,fitness or percent body fat,weight gain,WHZ scores,Fitness Improvement and Lifestyle Awareness,feasibility, perceived acceptability, and efficacy,Physical activity (PA,percentage of overweight,screen time,TST,physical fitness parameters,Implementation and attendance rates,body mass index, waist circumference, and body composition,BMI,daily Physical activity and academic achievement scores,dietary intake, including daily fat intake, daily saturated fat intake, percentage of daily calories from fat, and daily cholesterol intake,television/video viewing,overweight prevalence,diminution of insulin levels,parent-reported screen time,fat-free soft tissue,child television/video viewing and measured growth variables,physical activity and screen time,physical activity level,Children's growth, nutrition knowledge, diet and physical activity,change in BMI,supervised physical activity,Body mass index (BMI), triceps skin-fold thickness (TST) and percentage body fat,rates of overweight and obesity,triceps and calf skinfolds, and body mass index (BMI,percentage of risk of overweight or overweight,body mass index (BMI,body weight (mean,overweight prevalence and BMI z-scores,restriction subscale of the Child Feeding Questionnaire,physical activity, eating patterns, self-perceptions, and body mass index (BMI,levels of PA and TV viewing,physical activity,Standard-Deviation-Score of the BMI (BMI SDS,nutrition knowledge,fruit and vegetable consumption,screen-viewing behavior,social support,Total energy intake,motor skills,parent-reported fruit and vegetable consumption while child-reported fruit and vegetable consumption,nutritional intakes and weight control,BMI Z,Body height and weight, waist circumference, 4 skinfold thickness measurements, and dietary and physical activity behavior data,Blood lipid results,fat mass index,school grades,BMI gain,nutritional intakes and body weight control,healthy eating, physical activity and reducing TV viewing,fruit consumption,Adiposity indices (BMI, BMI Z-score, triceps skinfold thickness (TSF), waist circumference and physical fitness (20 m shuttle run test and lower back flexibility,percentage of overweight/obese schoolchildren,aerobic fitness and percent body fat (%BF,percentage of children watching television/videos,Adiposity,food intake/physical activity,BP,higher score for knowledge, attitudes, and self reported behaviour for healthy eating and physical activity,BMI reduction,SSB consumption,self-efficacy for physical activity,percentage BMI-for-age and percentage body fat for target children and weight, BMI, and percentage body fat for parents,prevalence of overweight and obesity,overweight and obesity,body composition and dietary and physical activity behavior,change in BMI (BMI = weight (kg)/height (m2,waist/height,total weekday physical activity,apo A-I levels,activity levels,recreational activity increased their median daily steps,daily consumption of carbonated drinks,school physical activity,gain in BMI z-score,higher levels and greater enjoyment of PA,fundamental movement skills,bone density,physical activity, eating patterns, and self-image,excess weight gain, reduce time spent in screen behaviours, promote participation in and enjoyment of physical activity (PA,eating behavior,behavioral change for physical activity,total skinfold,Percent body fat,elevated risk factor (fitness, BP or BMI,percentage body fat; other outcomes included dietary intake, physical activity, and knowledge, attitudes, and behaviors,incidence or prevalence of obesity,concern about weight,adjusted body mass index (BMI) z score,dietary intake and physical activity,fitness and body fat,BMI, and secondary outcomes included waist circumference, percentage body fat, cardiorespiratory fitness, objectively measured physical activity and small screen recreation time,dinners eaten while watching TV,Mean changes in body mass index,Physical Activity,physical activity (accelerometer data), and in consumption of sweetened beverages and water,fitness and body composition,unhealthy weight gain,daily MET-weighted minutes of moderate-to-vigorous physical activity (MET-weighted MVPA,intake of prohibited foods, such as mass-produced snacks,vigorous physical activity,Adiposity indices,mean weight-for-height z (WHZ) scores,Body mass index (BMI), consumption of fruit, 100% fruit juice, and vegetables (FJV), physical activity,nutritional intake,physical activity levels and body mass index (BMI,levels of body fat,diastolic blood pressure,prevalence of overweight, BMI z-score and change in BMI z-score,Eating disorders,time spent in small screen recreation,anthropometric variables,Weight, height, and triceps skinfold thickness,prevalence of overweight,physical activity and sedentary behaviour; fundamental movement skills; and evaluation of the process,Consumption of sugar-containing beverages,Body mass index (BMI), body composition, physical activity by questionnaire, plasma lipids and glucose, insulin resistance,Body mass index,cardiorespiratory fitness,excessive weight gain,BMI change,percentage body fat,physical activity and sedentary behaviour by accelerometry,adiposity indices (except TSF,Overall, fruit and vegetable intake,physical activity and healthy eating,reduced television, videotape, and video game use,Consumption of SSBs,prevalence of obesity and anthropometric characteristics,total cholesterol (TC), total:high-density cholesterol (TC:HDL-C), low-density lipoprotein, apolipoprotein B, C-reactive protein and fibrinogen on a subset of volunteers (n=77,Physical activity,Changes in underweight and attempted weight loss,mean BMI z score,Implementation and process measures, body mass index, waist circumference, physical activity measured by accelerometry, self-reported media use, and meals eaten with TV,insulin levels,dietary intake, 2) increase in physical activity, 3) a classroom curriculum focused on healthy eating and lifestyle, and 4) a family-involvement program,weight change and baseline BMI,insulin, homeostatic model assessment (HOMA) index, glucose, HDL-C, LDL-C, triglycerides, and body mass index,intake of artificial juice,total cholesterol, triglycerides or blood pressure,key behaviors and body mass index,physical fitness,response of body mass index (BMI) to exercise,sedentary behaviors,percentage of energy from fat|Each field center developed its own intervention(s) and corresponding control, and tailored its study to the specific hypothesis being tested.
61|larger systemic absorption of salbutamol,clinical score and variation of forced expiratory volume,heart rate, respiratory rate, pulsus paradoxus, arterial blood gas analysis (all cases) and peak expiratory flow rate (wherever possible,clinical and functional respiratory parameters (PEFR and SaO2,mean FEV1, FVC, or PEFR,mean percentage of improvement in FVC and FEV1,mean clinical scores,Pulmonary index, hospitalization, ease of use, acceptability, and pulse oximetry saturation,respiratory rate and percent predicted PEFR,mean baseline clinical score,rate of improvement of clinical score, respiratory rate, arterial oxygen saturation, or FEV1,salbutamol absorption and higher plasma level,PEFR,severe dyspnea and intercostal muscle retraction (subjective assessment,pulmonary index values,clinical score, respiratory rate, and oxygen saturation,clinical severity score,heart rate,bronchodilator response,initial spirometry,Clinical score, heart rate, respiratory rate, auscultatory findings, and oxygen saturation,clinical features, oxygen saturation (SaO2) and the best of three peak expiratory flow rate (PEFR) measurements,side-effect,maximum mean FEV1,maximal bronchodilation,cost of treatment,rates of tremor or hyperactivity,heart rate response,Clinical score, forced expiratory volume in one second and side effects,mean (SD) oxygen saturation,incidence of tremor,population demographics, baseline FEV1, and arterial blood gas values on air,Efficacy and safety,wheezing,frequency of oxygen desaturation,Serum theophylline levels,costs and effectiveness,recovery parameters,episodes of vomiting,All variables (dyspnoea, use of accessory muscles, cyanosis, respiratory rate, heart rate, blood pressure, oxygen saturation, pulsus paradoxus, and wheeze) and Peak Expiratory Flow Rate (PEFR,Drug costs,cardiovascular adverse events,Costs and effectiveness,respiratory rate,rates of spirometric improvement and duration of hospitalization,bronchodilation,SaO2,forced expiratory volume,salbutamol plasma levels,Baseline characteristics and asthma severity,FEV1,respiratory rate and percent predicted peak expiratory flow rate (PEFR,admission,costs for medication and spacer devices,Heart rate,Asthma severity score, peak expiratory flow rate in children 5 years or older, and oxygen saturation,Asthma disability scores,clinical effectiveness, acceptability, and cost benefit,Median hospital stay,mean FEV1,efficacy, side effects, and cost of treatment of acute asthma attacks,mean changes in respiratory rate, asthma severity score, and peak expiratory flow rate, oxygen saturation, number of treatments given, administration of steroids in the ED, and admission rate,clinical score, respiratory rate, arterial oxygen saturation, and FEV1,Peak-flow meter,anxiety,efficacy and safety,forced expiratory volume in 1 s (FEV1), forced vital capacity (FVC), and peak expiratory flow rate (PEFR,PEF,FVC and FEV1,peak expiratory flow (PEF,PEFR and FEV1,FEV1 and dyspnea scores,spirometry, pulse oximetry, and clinical severity scoring system,frequency of side effects,pulmonary function,hospitalization,baseline mean FEV1, FVC, or PEFR,morbidity and re-admission rates,daily rates of spirometric improvement and duration of hospitalization,mean cost of each emergency department presentation,Mean peak expiratory flow rate (PEFR) and FEV1,side effects|Large volume spacers are an acceptable, cost effective alternative to nebulisers in treating children admitted with acute asthma, provided that the children can use the mouthpiece, and symptoms are not severe.
21|Radiographic signs of loosening,mean DASH score,telephone interview, written questionnaire, and radiographic examination,pain relief and range of motion (ROM) improvement,total shoulder arthroplasty (TSA,pain and abduction,moderate or severe pain,active elevation,superior migration of the humeral component,medial migration,external rotation,preoperative condition of the rotator cuff,Glenoid loosening,rheumatoid arthritis,Active elevation,endoprosthetic loosening, glenohumeral subluxation, and glenoid bone loss,durable pain relief and patient satisfaction,8-year survivorship,8-year and 11-year survivorship rates,Satisfactory pain relief,survivorship rates,quality of the repair of the ruptured cuff,proximal migration,Constant scores,Glenoid erosion,postoperative complications,risk for revision,complication rate,Glenoid periprosthetic lucency,Level of Evidence,range of motion and strength,shoulder function,Shoulder instability,localized lucencies,average Constant score,Preoperative and postoperative scores,pain, functional outcome, and overall patient satisfaction,revision to total shoulder arthroplasty,radiographic evidence of definite loosening,degree of superior subluxation,progressive radiographic loosening,incidence of radiolucency and upward migration of shoulder components,revision or complication,overall pain,Satisfactory deltoid arm level,proximal humeral migration,nonprogressive osteolysis,range of movement and function,pain relief, improvement in abduction, and lower risk of revision surgery,Active abduction,mean range of active flexion,functional gains,juvenile rheumatoid arthritis,pain relief, range of movement, abduction force, nor function,Total shoulder arthroplasty: long-term survivorship, functional outcome, and quality of life,rheumatoid shoulder (nonprogressive, arthrosis-like, erosive, collapse, and mutilating patterns,mean range of active elevation,mean strength,active abduction,satisfactory performance of the activities of daily living,mean preoperative Constant score,satisfaction,average pain relief, range of movement, abduction force, or function,shoulder function or pain,postoperative clinical score,median Constant score,Shoulder and Hand (DASH) questionnaire,relief of pain, shoulder range of motion, and strength,disabling pain,pain relief and ROM improvement,pain and motion,loosening of the prosthesis or changes in cup position,mean Constant score,Complications requiring reoperation,good pain relief,Constant score,survival,Humeral component loosening,Pain,pain on unusual activity,pain relief,Median Constant-Murley score,annual cumulative survivorship values,4-year survivorship,rotator cuff,glenoid depth,median duration of follow,septic implant loosening (1 shoulder), aseptic glenoid loosening (2), and failed acromion osteosynthesis following the transacromial approach (3,mean proximal migration,Accelerated deterioration of function of shoulder arthroplasties,average rotation,Proximal migration and glenoid erosion,Constant-Murley and Association of Shoulder and Elbow Surgeons score,probability of implant survival,bone-cement radiolucencies,humeral component,Relief from moderate or severe pain,pain,shoulder function and radiographic deterioration|Patients with both partial and full-thickness rotator cuff tears had significant improvements in terms of overall pain (p < 0.05) and satisfaction (p < 0.05).
72|early complication rates,total peritonitis-free period,catheter survival, episodes of peritonitis and exit-site infections,cumulative probability of not developing ESI,exit site infection,Dialysate leak,rates of complications related to Staphylococcus aureus and Pseudomonas infections,number of ESI,exit site leak,Fluid leakage,better survival,catheter survival,rate of infection,incidence of the first episode of peritonitis,Simultaneous peritonitis and exit site infection,catheter-related mechanical or infectious complications,Overall probability of catheter survival,number of CAPD patient dropouts,Catheter-tip migration,catheter survival without mechanical failure,mechanical complications, catheter survival, probability of episodes of peritonitis, and probability of exit-site infections,ESI rate,survival rate,incidence of peritonitis and exit-site infections (ESI,probability of developing first episode of peritonitis or exit site infection,lowest incidence of peritonitis,incidence of peritonitis and exit-site infection,Complications (early/late) and catheter survival,probability of episodes of peritonitis, or probability of exit-site infections,infectious complication,Peritonitis, exit site infection, simultaneous peritonitis and exit site infection, and complication related to Staphylococcus or Pseudomonas infections,number of technique failures,Dialysate leak, catheter migration, or tunnel infection,duration of surgery, hospital stay, pain scores, and analgesic requirements,episodes of ESI,skin exit,operative discomfort, complication rates, and catheter survival,cumulative probability of not developing peritonitis,mean operative time,Technique survival,Peritonitis rate,Peritonitis,rate of exit site leak and early infection,transfer to haemodialysis,infection rates,Catheter survival,peritonitis rate,rate of exit-site infections,Total duration of observation,risk of contracting peritonitis or exit-site infection,Early peritonitis episodes,incidence of ESI,Tip migration,rate of exit-site infection|Significantly higher (p < 0.01) survival rate of the curled as compared to the straight catheter.
not found|Weekly drop seizure rates,somnolence,total seizure frequency,tonic-atonic ("drop attack") seizure frequency with rufinamide,seizure rate,abnormal biochemical or hematologic findings,GIR was "slightly to markedly improved,Nondrop seizures,total seizures,seizure frequency,frequency of refractory partial-onset seizures,efficacy, and adverse reactions,major seizures (drop attacks and tonic-clonic seizures,efficacy and safety,severe seizures or both, or improved behavior or improved motor skills or both. ,Adverse events,plasma levels,frequency of atonic seizures,adverse events,incidence of adverse events, except for colds or viral illnesses,vomiting,frequency of side effects,seizure severity,global improvement rating (GIR) based on changes in seizure frequency, EEG findings, and nonparoxysmal clinical manifestations,median frequency of all major seizures,frequency of seizures,tonic-atonic seizures,number of drop attacks and major motor seizures,Seizure frequency,global-evaluation scores,total frequency of seizures,overall symptoms,number of tonic-clonic seizures,total number of seizures counted during a four-hour period of video recording, parents' or guardians' global evaluations of the patients' quality of life, and the total number of atonic seizures, as reported by parents or guardians,seizure reduction or global evaluations|None of the children studied showed abnormal biochemical or hematologic findings, or changes in plasma levels of concomitantly administered AEDs.
                
not found|GDM,Oxygen consumption,gestational weight gain,Nutrition knowledge,submaximal exercise capacity evaluated by oxygen uptake at the anaerobic (first ventilatory,gestational diabetes and weight gain,cesarean deliveries,Maternal weight gain, fresh placental volumes, and histomorphometric indices of placental function,fetoplacental growth,energy intake,weight gain in pregnancy,maternal health perception,intake of dietary fiber,regular or good cardiorespiratory capacity,deliveries,incidence of GDM as assessed by OGTT (maternal outcome) and newborns' birthweight adjusted for gestational age (neonatal outcome,substrate utilization (glucose oxidation v. lipid oxidation), and insulin resistance and sensitivity,insulin resistance (HOMA-IR,gestational duration,average gestational weight gain,Better glucose tolerance,intensity activity,highest quantitative insulin sensitivity check index,Postpartum weight retention,gestational weight gain patterns and postpartum weight retention,mean glucose levels,gestational weight gain/postpartum weight retention patterns,rate of weekly weight gain,Compliance and acceptability,Maternal perception of health status and several pregnancy outcomes,PA,rates of prevalence of excessive weight,weight,nutritional habits,weight development,triglycerides,Weight and height,maternal perception of health status,IOM adherence,weight gain,exercise-based activity,maternal weight gain and the need for insulin treatment during pregnancy,pregnancy outcomes,baseline in exercise (+28 min), intake of fruits and vegetables, whole grains, fish, avocado and nuts, and significant decreases in intake of sugary foods, refined grains, high fat meats, fried foods, solid fats, and fast food,frequency of insulin therapy,controlling weight gain,mean (SD) per-week weight gain,pre-gestational nutritional status,reduced risk of elevated glucose concentration,Adjusted head circumference,LGA newborns,Mean birthweight,body weight, body mass index, health-promoting behaviour and psycho-social variables (self-efficacy, body image, depression and social support,Blood glucose concentrations,body mass index (BMI,percentage of NW women who exceeded IOM recommendations,perinatal outcomes,adherence to IOM guidelines, rate of cesarean delivery, preeclampsia, GDM, operative vaginal delivery, or vaginal lacerations,fasting plasma glucose and glucose tolerance,physical activity,intake of saccharose (adjusted coefficient,average weight retention,postpartum weight retention,Both s-insulin and s-leptin,percentages of NW and OW/OB,weight gain during pregnancy categorized as above the IOM recommendations,Maternal carbohydrate intake and pregnancy outcome,kg(-1,Key obstetric and fetal outcomes,substrate level or flow alter feto-placental growth rate,Fasting levels of beta-hydroxybutyrate,polyunsaturated fatty acids,gestational weight gain and glucose metabolism,prevalence of clinical complications,Neonatal birthweight,infant anthropometric measurements, gestational duration, maternal weight gain, and maternal metabolic parameters,ketonemia,Fat content and daily caloric content,fat mass,Fat intake,placental growth rate, birth weight, and placental volume at term,Excessive weight gain,Fasting glucose and insulin and homeostasis model assessment of insulin resistance (HOMA-IR,risk of GDM,proportion of patients whose gestational weight gain,submaximal cardiorespiratory capacity,birthweight of newborns,total cholesterol,higher ponderal index,excessive gestational weight gains,percentage of normal-weight,lowest insulin concentration,physical activity (weekly metabolic equivalent task (MET) minutes) and diet (intake of total fat, saturated and polyunsaturated fatty acids, saccharose, and fiber,intake of saturated fatty acids,weight retention,GWG and obstetrical or neonatal outcome,Calcium intake and vegetable consumption,Oxygen uptake,gestational diabetes mellitus (GDM,Energy restriction,mean diet GI fell,excessive gestational weight gain,fasting b-glucose,homeostasis model assessment,gain weight speed,exercise and dietary behaviors,postprandial glucose and insulin responses,submaximal exercise capacity,Metabolic effects,protein intake,obstetric outcomes,Maternal obesity and excessive gestational weight gain (GWG,higher birth centile,Fasting plasma insulin,excessive weight gain,mode of delivery, rate of operative vaginal delivery, neonatal weight, and the incidence of preeclampsia, gestational diabetes mellitus (GDM), vaginal/perineal lacerations, and shoulder dystocia,dietary habits, physical activity, and gestational weight gain,incidence of gestational diabetes,Nutritional habits,urine ketones,fetal size,birth weight z score,longer pregnancy duration, greater infant head circumference, and improved maternal cardiovascular risk factors,C-reactive protein,Energy intake,Weight gain,deterioration of glucose tolerance,dietary habits, increase physical activity (PA), and reduce GWG|Both s-insulin and s-leptin were reduced by 20% in the intervention group compared to the control group at week 27, mean difference: -16 pmol l(-1)
not found|hand function,kinaesthesia sense and position sense,upper extremity (UE) function and independence,level of impairment (Brunnstrm-Fugl-Meyer test) and disability (Action Research Arm test, Barthel Index,Recovery rates,functional independence and UE function (fine motor, sensory discrimination, and musculoskeletal performance,sensory and motor functional outcomes,Brunnstrom stage, modified motor assessment scale, grasping strength, angles of wrist extension and flexion, sensation by monofilament, and muscle tone by modified Ashworth scale,performance of Brunnstrom stage and wrist extension and sensation,hand movement scores,adverse effects|Both groups showed improvement in hand movement scores (P< 0.05), whereas hand function improved only in the TENS group (P< 0.05).
                
not found|Risk and protective behaviors,rates of alcohol and marijuana use,Externalizing and internalizing problems, diagnosed mental disorders, drug and alcohol use, and number of sexual partners,high-risk behaviors,alcohol or cigarettes,Student self-reports of violence, provocative behavior, school delinquency, substance use, and sexual behaviors (intercourse and condom use,mental health problems,areas of parent skills, parent drug use, deviant peers and family management,rates of the other risk behaviors and intentions,relapse and problem-solving skills, self-report measures of family management practices, deviant peer networks, domestic conflict and drug use,parental coping skills,multiple risk behaviors,self-report measures of rules, family attachment, parental involvement, school attachment and misbehavior, negative peers, substance use and delinquency,tobacco use and violence,Outcome assessment batteries measured youths' reported use of smoked and smokeless tobacco, alcohol, and marijuana,prevalence of weekly cigarette use,drug consumption and perceptions of drug-related risk and harm,substance initiation index (SII) measuring lifetime use of alcohol, cigarettes, and marijuana and by rates of each individual substance,prevalence of smokeless tobacco,sexual partners,provoking behavior,social skills,violent behavior,Incidence of new drug users,social competence and self-regulation and parents' parenting skills,symptoms of mental disorder; rates of diagnoses of mental disorder; levels of externalizing problems; marijuana, alcohol, and other drug use; and number of sexual partners,HIV/AIDS knowledge and attitudes and recognition of drug problems,smokeless tobacco, alcohol, and marijuana,school delinquency,rates of substance use,externalizing problems,1-year prevalence of diagnosed mental disorder,rates of sexual intercourse, sex without a condom, alcohol use, and cigarette use and marginally lower rates of "risky sexual behavior,substance use and risky sexual behavior,rates of tobacco, alcohol, and marijuana use,cigarette use and overall risk intention,symptoms of mental disorder,rate of increase in condom use,levels of externalizing problems,attitude, sexual self-efficacy, and resilience scores,fewer symptoms of mental disorder,children's behavior or attitudes,knowledge, attitudes, intentions, and behaviors to prevent and/or reduce substance use and risky sexual behaviors,recent sexual intercourse,prevalence of alcohol and any drug use|The interventions also produced effects on 3 of the 4 predictor variable domains: children's social competence and self-regulation and parents' parenting skills.
not found|disease-specific quality of life,pm major symptom score,symptom improvement,resolution of facial pain and the resumption of daily activities,time to recover,Respiratory complications requiring antibiotic treatment,Global response,exacerbation of symptoms,major symptom score,Diarrhea,rate of clinical success,adjusted hazard ratio,disease recurrence,Kaplan-Meier curves and hazard ratios,duration of general illness or pain,Duration of purulent rhinorrhea,adverse events,mean change in Sinonasal Outcome Test-16 scores,rhinosinusitis symptoms,diarrhea,median time before resolution of symptoms,pain, fever, cough, and nasal congestion to use as needed,patient's retrospective assessment of change in sinus symptoms and functional status, recurrence or relapse, and satisfaction with and adverse effects of treatment,severe symptoms,time to cure,general illness, pain, and purulent rhinorrhea,Side effects,disease recurrence or bacterial infection,duration and severity of symptoms,resolution of symptoms within a 14-day follow-up period and the time to improvement (days,total symptom score,time to cure (primary outcome), number of days during which rhinosinusitis restricted activities at home or work, and frequency of adverse effects (secondary outcomes,resolution of pain,history of purulent nasal discharge and maxillary or frontal pain|No significant difference was found in time to recover between the doxycycline-treated group and the placebo-treated group.
32|Pa(O2)/FI(O2,Frequency of reversal of ALI,mortality, the number of days alive and off mechanical ventilation, and the number of days alive after meeting oxygenation criteria for extubation,systemic oxygenation (PaO2/FIO2,length of stay or Therapeutic Intervention Scoring System points,Lipid peroxide concentrations,percentage of patients alive and off mechanical ventilation,DR curve,alive and weaned from mechanical ventilation,mortality rate, the number of days alive and off mechanical ventilation, or the number of days alive after meeting oxygenation criteria for extubation,PaO2/FiO2,inhaled concentration of nitric oxide,oxygenation and hemodynamic parameters,DR curves of PaO2/FIO2,Nitric oxide synthase activity,oxygenation and survival,ratio of pulmonary to systemic vascular resistance and improved oxygenation indexes,activity of nitric oxide synthase,oxygenation indexes,lung function, morbidity, and mortality,frequency of reversal of ALI,low quality of life,total nitrite,hypoxia score,Pao2/Fio2 ratio,Nitric oxide synthase activity was measured spectrophotometrically, and myeloperoxidase, elastase, interleukin-8, and leukotrienes,Healthcare costs,oxygenation index,severe respiratory failure,Oxygenation indexes,duration of mechanical ventilation or stay,acute response,30-d mortality rate,mean pulmonary arterial pressure, intensity of mechanical ventilation, and oxygenation index,reversal of ALI,Oxygenation indexes acutely,Pao /Fio ratio,equivalent improvement in Pa(O2)/FI(O2,Total nitrite and lipid peroxides in serum,mean inspired nitrogen dioxide concentration,peak improvement in PaO2/FIO2,PaO2/FIO2 ratio,Hospital costs,FI(O2,venous admixture,Hemodynamic and blood gas measurements,number or type of adverse events,mortality|Nitric oxide synthase activity decreased (p = .01) and total nitrite increased (p = .02) in patients receiving inhaled nitric oxide.
351|Hemoglobin responses,serious TEEs,toxic effects,hemoglobin levels, improves quality of life (QOL), and reduces transfusions,Plt counts,Functional Assessment of Cancer Therapy scale,percentage of patients achieving a haemoglobin response,median average increase in Hb levels,proportion of patients with complete or partial response,incidence of transfusion,CS domain scores,overall survival,symptomatic anemia,FACT-An subscale scores,incidence of transfusions,incidence of cardiovascular and thromboembolic events and more deaths,primary cancer- and anemia-specific QOL domains, including energy level, ability to do daily activities, and fatigue,Hb concentration,proportion of patients transfused while secondary end points were changes in Hb and QOL,Plt transfusions,number of patients with metastatic disease,mean change in EXIT25 score,QOL measures,Pretreatment serum erythropoietin levels,executive function,transfusion requirements, hematopoietic parameters, quality of life (QOL), and safety,fatigue and QOL,haematopoietic response,hemoglobin/hematocrit, transfusion requirement, and quality of life,Hb overall,health-related quality of life (HRQOL), hemoglobin (Hb), transfusions, and tolerability,mean hematocrit,haemoglobin (Hb) level, transfusion requirements, and QOL,transfusion requirements,transfusion,energy level and ability to perform daily activities,Impaired cognition, fatigue, and diminished quality of life (QOL,proportion of patients transfused,hematocrit level, transfusion requirements, and quality of life,hemoglobin concentration,Hematologic parameters,anemia, transfusion need, and quality of life (QOL,endogenous Epo production,12-month survival,blood transfusion requirements,hematologic parameters and quality of life,haemoglobin concentrations,quality of life, hematologic end points, and safety,transfusion requirements, hemoglobin level (Hb), quality of life (QOL,median CLAS scores (Energy Level, Ability to Do Daily Activities, Overall QOL) and the median average CLAS score,response rate,tolerability and hematologic benefits,haemoglobin,onset of anemia,safety and efficacy,overall survival favoring epoetin alfa,longer time to first erythrocyte transfusion,red blood cell transfusions,transfusion requirement, hemoglobin level and survival,Epo level,diarrhea,overall quality of life,Efficacy and safety,health-related quality of life,progression/relapse-free survival, overall survival, response to RCT, hemoglobin (Hb) response, and safety,PedsQL-GCS total score,hemoglobin and survival,Hb level without need of transfusion,tumor response to chemotherapy or survival,hematopoietic responses,hospitalization rate,hemoglobin levels,mean units of blood transfused per patient,Hemoglobin,Percentage transfused,QoL,experience nadir haemoglobin levels,median Hb,Transfusion-free (P =.0012) survival and transfusion- and severe anemia-free survival,Survival,median serum,Functional Assessment of Cancer Therapy-Anemia,progression-free survival, transfusion- and severe anemia-free survival, Hb response, safety, and quality of life (QoL,SF-36 PCS, FACT-F and VAS scores,Shorter survival,darbepoetin alpha maintained hemoglobin levels,hospitalization days, transfusion requirements, hemoglobin levels, and fatigue,Quality-of-life assessment,Cognitive function,hemoglobin concentration, and decreased fatigue,Mean hemoglobin levels,quality of life,QOL,tolerated,median overall survival,cognitive impairment and fatigue,Safety and efficacy,Executive Interview (EXIT25) and Clock Drawing Tasks; mood by Profile of Mood States; anemia-related symptoms, including fatigue, by the Functional Assessment of Cancer Therapy-Anemia,FACT-Fatigue scores,progression/relapse-free survival,mean baseline Hb level,transfusions, haemoglobin (Hb) and quality of life (QOL,cancer control or survival,FACT-An subscale score,Bone marrow progenitors,RBC transfusion requirements,quality of life (QoL,transfusion requirement,Functional Assessment of Cancer Therapy-Fatigue score,QOL, maintaining hemoglobin level,Transfusion incidence,hematocrit level,hemoglobin,progression-free survival,pediatric health-related quality-of-life generic scales (GS) and cancer-specific scales (CS,performance scores,Overall tumor response,mean total number of units transfused,overall mortality,thromboembolic events,mean Hb,haematologic and quality of life (QOL) parameters,safety, haemoglobin endpoints and red blood cell (RBC) transfusions,survival,Mean change in EXIT25 scores,time to locoregional progression and survival,overall complete response,HRQOL changes,locoregional progression-free survival,transfusion- and severe anemia-free survival,subscale scores,poorer survival,efficacy and safety,change in hemoglobin concentration,anaemia and transfusion dependency,Adverse events,anemia correction and treatment failure (no complete response or relapsing,Mean final values for GS total score,improvement in QoL as measured using the Short-Form-36 physical component summary (SF-36 PCS) score and the Functional Assessment of Cancer Therapy fatigue and anaemia subscales (FACT-F and FACT-An,Median Hb level,Hemoglobin responses, transfusion requirements, and prognostic factors for responses,HRQOL,Kaplan-Meier analyses, Cox proportional hazards analyses, and chi-square tests,hemoglobin (Hb) levels and RBC and platelet (Plt) transfusions,transfusion-free and transfusion- and severe anemia-free survival,hematocrit and quality of life,serum Epo levels,haemoglobin and reduced red blood cell transfusions,cognitive function,thromboembolic events (TEEs,hematocrit,transfusion risk,diaphoresis,occurrences of transfusions,hemoglobin and QOL,hemoglobin concentration (i.e., hematopoietic response), adverse events, antibody formation to darbepoetin alfa, hospitalizations, Functional Assessment of Cancer Therapy (FACT)-Fatigue score, and disease outcome,chronic lymphocytic leukemia,incidence of adverse events and survival,Hemoglobin improvements,overall survival; statistical testing of survival,transfusions,cumulative response frequency,A visual analogue scale (VAS,neutralising antibodies|For locoregional progression the relative risk was 1.69 (1.16-2.47, p=0.007) and for survival was 1.39 (1.05-1.84, p=0.02).
                
not found|endpoint Y-MRS change scores,baseline Y-MRS total scores,attention, concentration and memory problems, fatigue, sedation, transient paraesthesias, nausea, and anorexia,Weight loss|Adverse effects of topiramate in bipolar subjects include attention, concentration and memory problems, fatigue, sedation, transient paraesthesias, nausea, and anorexia.
not found|nausea,nausea and vomiting and pruritus,serious respiratory depression,abnormal dorsal column function,Pruritus and headache,CSE technique (Visual Analogue Pain Score (VAPS,epidural labor analgesia quality,motor blockage at time of delivery or mode of delivery,rate of cervical dilatation, delivery type or duration of delivery,duration of analgesia,relief of labor pain,visual analog scale, extension of sensory and motor block, maternal hemodynamic constants, number of boluses of bupivacaine used, total doses of bupivacaine and oxytocin, instruments needed for childbirth, and side effects (pruritus, nausea and vomiting,lower limb motor weakness,anthropometric measurements, gestational age, cervical dilation, length of time between the blockade and absence of pain according to the visual analogic scale, ability to walk, length of time between analgesia and complete cervical dilation, duration of the expulsive phase, maternal hemodynamic parameters, and vitality of the newborn,duration of the first stage of labor and the total duration of labor,sensory block, motor block or dorsal column function,uterine hypertonus,efficacy and side effects,epidural catheter manipulation and replacement rate, sacral sparing, unilateral block, number of top-up doses, average hourly epidural drug usage, highest sensory blockade level, and labor analgesia quality,analgesic efficiency, side effects and obstetrical repercussions,consumption of bupivacaine,Durations of second stage and expulsion,patient satisfaction,Visual analog scale scores,labor epidural catheter function,prolonged deceleration (PD) of fetal heart rate,fetal heart rate (FHR) abnormalities,pain scores,mean initial cervical dilation rates,catheter replacement rate,number of top-up doses requested to treat breakthrough pain,CSEA,uterine basal tone,itching,cervical dilation, pain, sensory level, and motor blockade,Mild motor weakness,Efficacy and adverse effects,probability of uterine hypertonus and FHR changes,Pain relief,motor impairment, hypotension, or nausea or vomiting,Adverse effects,Apgar scores,Visual analog scores (VAS) for pain,Overall, 5 min APGAR scores,time from analgesic to delivery, incidence of operative or assisted delivery, or cervical dilation,time required to obtain satisfactory analgesia (visual analog score,Analgesic efficacy,respiratory depression, maternal hypotension, pruritus, nausea, and vomiting,analgesia,Hypotension,Duration of labour, quality of analgesia and side-effects,Verbal numeric pain scores (VNPS), onset time to pain relief times of additional analgesia and other side effects,rate of cervical dilation,FHR abnormalities, elevation of uterine tone,cerebral spinal fluid return,somnolence,time to first analgesic demand,Uterine tone,Mean,VAS for pruritus,peripartum nausea and vomiting (N/V), pruritus, postdural puncture headache, and respiratory depression,Analgesia,motor blockade,length of the first stage of labour,Mean (SD) onset times to the first pain-free contraction,mean duration of analgesia,respiratory depression,length of time between the beginning of analgesia and complete cervical dilation,rates of instrumental deliveries and Caesarien sections,oxytocin use, hypotension, and speed of pain relief,Pruritus,adequate pain relief,epidural catheter function,rate of PD or other adverse outcomes,rapid cervical dilation,Analgesia, course of labour, obstetrical outcome, and neonatal status,rate of cesarean delivery, or mean epidural duration,pain or maternal satisfaction scores,adverse effects,urinary retention,Elevation of uterine basal tone and fetal heart rate abnormalities,incidence of technique failure and side-effects,incidence of posterior presentation,High-level resuscitation,spinal anaesthesia for Caesarean section,rate of mean initial cervical dilation,FHR abnormalities,analgesic efficacy and incidence of maternal, fetal and neonatal side-effects,Side effects,motor block,catheter manipulation rate,hypotension,SD) onset time to the first pain free contraction,unilateral analgesia,time to first top-up,normal lower limb motor power and dorsal column function,analgesia, pain scores and side effects,motor weakness and proprioceptive deficit,pain relief,hypotension, mode of delivery, and efficacy of analgesia by visual analog pain scale (VAPS,nausea, vomiting, and pruritus,efficacy and safety,incidence of pruritus,analgesic efficacy,rate of PD,pain-free,quality of analgesia, incidence and severity of pruritus, lower limb motor blockade, and the ability to ambulate,duration of the expulsive phase, incidence of cesarean section related to the analgesia, maternal hemodynamic parameters, and vitality of the newborn,excellent analgesia,elevation of baseline uterine tone and occurrence of FHR prolonged decelerations or bradycardia after analgesia,onset of analgesia,incidence of maternal or neonatal side effects,labour length,Uterine contractions and FHR,instrumental vaginal delivery,VAPS ratings,uneventful, moderate headache compatible with postdural puncture headache,mode of delivery, and secondary outcomes were progress of labour, efficacy of procedure, and effect on neonates,Additional analgesia,VAS pain scores,normal vaginal delivery rate,postdural puncture headache,Overall mean cervical dilation rates,side effects,pruritus|79 sec, p < 0.05), excellent analgesia, using less bupivacaine (23.5 +/-
not found|dihomogamma-linolenic acid (DGLA,skin changes,overall severity and grade of inflammation,intensity, itching, and dryness), clinical evaluation,eczema,efficacy and tolerability,Plasma levels of TXB2, 6-keto-PGF1 alpha and PGE1, and the amount of TXB2 released into serum during clotting,efficacy and safety,erythrocyte dihomo-gamma-linolenic acid levels,GLA metabolites,red cell membrane microviscosity,erythema, scale, excoriation, lichenification, or overall severity,proportion of long chain polyunsaturated fatty acids,inflammation,eczema symptoms,Peak expiratory flow was measured and disease activity,tolerated,adverse effect,visual analogue scales; topical corticosteroid requirement, assessed on a five point scale; global assessment of response by participants; adverse events and tolerability,atopic dermatitis (SASSAD) score,Efficacy and tolerability,plasma concentrations of essential fatty acids,topical steroid requirement, and symptom scores,total sign score,mean SASSAD score fell,overall severity of the clinical condition,adverse effects,Disease activity,Red cell membrane microviscosity|A significant improvement in the overall severity of the clinical condition was seen in children treated with gamma-linolenic acid, independent of whether the children had manifestations of IgE-mediated allergy.
37|Infection resolution rate,urinary beta 2-microglobulin,clinical data, hepatic and renal function tests and Child Pugh score,therapeutic efficacy,Hospital survival rate,Hospitalization mortality,infection resolution rate,hospital stay,cost of antibiotic and antibiotic administration,hospitalization mortality,Infection,24 ascitic fluid infections,spontaneous peritonitis and/or bacteremia,Peak serum levels,efficacy and safety,Recurrence rates,renal impairment,cost of antibiotics,Incidence of complications and hospital mortality,duration of treatment, incidence of complications, time of hospitalization and hospital mortality,spontaneous bacterial peritonitis resolution,antibiotic concentration in ascitic fluid/MIC ratio,spontaneous bacterial peritonitis,Peak serum levels and trough serum and ascitic fluid levels of ofloxacin and cefotaxime,renal impairment or nephrotoxicity,adverse events,duration of antibiotic therapy,Spontaneous bacterial peritonitis resolution,Infection-related mortality,infection resolution and patient survival,hospital survival,Hospital survival,Infection resolution,positive ascitic fluid culture,rate of infection resolution,patient's death,colonizations with Enterococcus faecalis or Candida albicans,prophylactic norfloxacin, infection resolution,Nephrotoxicity (impairment of renal function,bacteriologic cure,Resolution of infection,hepatorenal syndrome,Blood urea nitrogen and hepatic encephalopathy,recurrence of ascitic fluid infection|Infection was cured in 15 of 19 patients (78.9%) treated with cefotaxime and in 11 of 18 (61.1%) treated with amikacin.
147|rate of perineal wound complications,postpartum perineal wound complications,parity, incidence of diabetes, operative delivery, or third-degree,perineal wound complication,gross disruption or purulent discharge at site of perineal repair by 2 weeks postpartum|There were no differences between groups in parity, incidence of diabetes, operative delivery, or third-degree compared with fourth-degree lacerations.
                
58|Gleason score,continence rates,urine loss,absolute risk difference [RD,Urinary continence,rate of return,number of patients with incontinence episodes and post-micturition dribbling,time to continence,subjective and objective voiding and incontinence parameters and four tests of the pelvic floor muscle: function; strength; static endurance; and dynamic endurance,Spontaneous recovery of normal urinary control,20-minute pad test and a urine symptom inventory,overall continence or the rate of return of urinary control,Quality-of-life measures,Urinary incontinence,continence and quality of life,rate of urinary incontinence,bladder diaries, 24-hour pad weight testing, and a quality-of-life survey,static endurance,proportion of men still incontinent,Pelvic floor muscle function,prostate-specific antigen level,proportion of patients with severe/continual leakage,urine loss with coughing,urine losses,1) length of time urine loss was experienced; 2) episodes and frequency of urine loss; and 3) ounces of urine lost and number of pads used,relevant storage or voiding improvements,urinary continence,duration and severity of incontinence, and improving quality of life,postoperative urinary incontinence questionnaires,leakage weight,overall spontaneous continence rate,urinary continence overall or the rate of return of continence,number of pathologic prostates,urinary incontinence and incremental cost per quality-adjusted life year (QALY,grams of urine loss on pad test; secondary outcomes were International Prostate Symptom Score (IPSS), Incontinence Impact Questionnaire (IIQ-7) score, cost, and perception of urine loss as a problem,severe incontinence,total score on the Danish Prostatic Symptom Score questionnaire,overall objective spontaneous continence rate,episodes, frequency, ounces of urine lost by UI, and pad usage,urinary continence recovery,duration of incontinence (time to continence), as derived from bladder diaries, incontinence severity (the proportion with severe/continual leakage), pad use, Incontinence Impact Questionnaire, psychological distress (Hopkins Symptom Checklist) and health related quality of life (Medical Outcomes Study Short Form Health Survey,Incontinence,severity of incontinence,pelvic floor muscle endurance,urinary symptoms and of quality of life,visual analogue scale,24 hr Pad test, a visual analogue scale (VAS) and a single question of QoL. Results,micturition parameters, urinary incontinence, post-micturition dribbling, and quality of life,urinary continence earlier,pad test results or voiding diary,adverse effects,grade of muscle contraction strength,times of urinary continence recovery,overall subjective spontaneous continence rate (questionnaire,American Urological Association Symptom Score,average 24-hour leakage weight,obtained consent rate,average quality of life score,sneezing,continence recovery time,IPSS, IIQ-7 score, pad test, or voiding diary,length of time urinary incontinence (UI,return to work and usual activities or quality of life measures,VAS and the response to the QoL question,degree of incontinence,mean leakage weight,continence rate|Our results show that pelvic floor muscle re-education produces a quicker improvement of urinary symptoms and of quality of life in patients after TURP.
13|relapse rate,Expired CO,neurobiological and cognitive biomarkers,relapse rates,Expired CO measures,longer duration of abstinence,Cotinine and CO levels,Positive schizophrenia symptoms,Continuous Performance Test hit reaction time,Stroop Interference,cognitive functioning,saliva cotinine quit rates,number of cigarettes smoked,total scores on the Positive and Negative Syndrome Scale,cotinine levels,highest quit rates,treatment retention, rate of smoking abstinence, and expired-breath carbon monoxide level,tobacco abstinence and change from baseline in expired air carbon monoxide (CO) and psychiatric symptoms,smoking abstinence rates,smoking cessation responses,7-day point prevalence smoking abstinence,executive function,short-term smoking abstinence,sustained tobacco abstinence,positive or negative symptoms of schizophrenia,self-reported smoking behavior, clinical status (Positive and Negative Syndrome Scale, Hamilton Rating Scale for Depression; Clinical Global Impression Scale for Psychosis), subjective quality of life (Quality of Life Enjoyment and Satisfaction Questionnaire-abbreviated version), and weight,mean tau-b correlation between expired CO level and visit,Prepulse inhibition, sensory gating, antisaccade, spatial working memory, eye tracking, processing speed, and sustained attention,abstinence rates,highest plasma clozapine level,weight gain,Cigarette craving and psychiatric symptom levels,cognitive impairments,depressive and negative symptoms,antisaccadic error rate,negative symptoms and greater stability of psychotic and depressive symptoms,smoking behavior,startle reactivity,cigarette smoking,Smoking abstinence rates,carbon monoxide levels,Smoking activity,carbon monoxide smoking indices,7-day point-prevalence of 50% to 100% smoking reduction,weight loss,smoking behavior and stability of psychiatric symptoms,rate of smoking cessation,worsening of clinical symptoms,continuous abstinence,7-day point prevalence abstinence at 6 months post-target quit date (TQD,reduced CO levels,feasibility and efficacy,reduction in smoking, as measured by self-report verified by expired-air carbon monoxide,nicotine plasma level or CO level,cigarette consumption,exacerbation of psychiatric symptoms, psychosis, depression, or suicidality,treatment retention, smoking abstinence rates, expired breath carbon monoxide (CO) levels, psychotic symptoms, and medication side effects,tolerated,Nicotine levels,Neuropsychological, clinical, and safety assessments,Abstinence rates,dry mouth, gastrointestinal symptoms, headache, and insomnia,efficacy of CM,continuous and point-prevalence abstinence rates, smoking reduction status, and changes in symptoms and functioning,spatial working memory, predictive and maintenance pursuit measures, processing speed, or sustained attention by Conners' Continuous Performance Test,quit rates,Psychiatric symptoms, carbon monoxide and cigarettes,Carbon monoxide in expired air, self-reported cigarettes per day, nicotine plasma levels, and psychiatric ratings,continuous abstinence rate,carbon monoxide (CO) levels, and to report number of cigarettes smoked per day, nicotine withdrawal symptoms, cigarette craving, and psychiatric symptoms,7-day point prevalence abstinence,Dyskinesias,continuous smoking abstinence,Mean FTND scores,daily cigarette consumption,P50 sensory gating deficit,trial endpoint 7-day point prevalence smoking abstinence rates,higher rate of 4-week continuous abstinence,expired carbon monoxide,Digital Symbol Substitution Test,plasma cotinine levels,Quit rates|The patients smoked significantly fewer cigarettes while receiving nicotine than while receiving placebo.
16|perioperative complications,cardiopulmonary parameters,exercise performance and health perception,intact AV conduction (antegrade conduction capacity,Resting plasma concentrations of atrial natriuretic peptide,quality-of-life scores,plasma level of brain natriuretic peptide,Quality of life,Dizziness, breathlessness and fatigue,stroke and atrial fibrillation,heart-failure scores,cardiac function and quality of life,Prevalence of atrial fibrillation and stroke,atrioventricular synchronous pacing,ventricular rate,Pacemaker syndrome,Palpitation and general wellbeing,mean symptom score in DDD mode,pacemaker syndrome,paced rhythm, either DDD or VVI,Overall quality-of-life and cardiovascular symptoms,atrial rate during VVI,R pacing,Symptomatic assessment (by diary card and monthly symptom scores) of "shortness of breath", "palpitation", and "general well-being,episodes of hypotension,body weight,atrial natriuretic peptide,Mitral regurgitation estimated by Doppler color flow imaging,Quality-of-life,paroxysmal atrial fibrillation,cerebral ischemia and/or atrial fibrillation,corresponding mean (SE) pacemaker syndrome symptom scores,incidence of atrial fibrillation and stroke,DDD and dual sensor VVIR (QT and activity) pacing modes,Beat to beat variability of cardiac output,Left ventricular systolic function,Arterial lactate, respiratory rates and perceived exertion ratings during submaximal levels of exercise,atrioventricular node ablation, DM,cardiac output,symptom scores for dyspnoea, fatigue, and mood disturbance; exercise time; and maximal oxygen consumption,symptomatic questionnaire score,death from any cause, atrial fibrillation, and hospitalization for heart failure,Paced ventricular rate,Perceived "general well-being," exercise capacity, functional status and symptoms,mean total quality-of-life score,exercise tolerance and improves symptoms,Exercise treadmill time,Exercise duration,physiological responses, arrhythmias, symptomatology and quality of life,death from any cause or nonfatal stroke,DM,retrograde atrioventricular block, symptoms and maximal exercise performance,exercise capacity,quality-of-life,ventriculoatrial (VA) conduction,health-related quality of life,sense of general well-being during DDD pacing,activity of daily living questionnaire, in atrioventricular synchronous and ventricular pacing,hospitalization for heart failure, (i) overall symptoms scores; (ii) exercise tests related to daily activities; and (iii) perceived level of difficulty (Borg score,annual rate of atrial fibrillation,quality of life and cardiovascular functional status,larger left ventricular end-diastolic dimensions,mean maximal exercise tolerance,composite of death, stroke, or hospitalization for heart failure; atrial fibrillation; heart-failure score; the pacemaker syndrome; and the quality of life,quality-of-life and cardiopulmonary performance,Resting plasma catecholamine concentrations,risk of atrial fibrillation, reduces signs and symptoms of heart failure,maximal and submaximal exercise tolerance,dyspnea on effort, dizzy spells, palpitation, sweating, fatigue, lethargy, emotional functioning, and self-perceived health,tricuspid regurgitation,atrial rate adaptive (AAIR), dual chamber rate adaptive (DDDR) and ventricular rate adaptive (VVIR) modes,treadmill times,adverse symptoms,mean exercise time to submaximal exertion (Borg 5/10), exertion ratings and respiratory rate,rates of hospitalization for heart failure and of death, stroke, or hospitalization for heart failure,strong preference for DDD pacing,Blood pressure, LV function, presence of ventriculoatrial conduction, and ability to override the pacemaker,DDD and dual sensor VVIR (activity and QT) pacing modes,Mean (SE) total symptom scores during VVI, VVIR, and DDD pacing,Shortness of breath,episodes of dizziness,variability of left atrial antegrade,stroke-free survival,Mean (SD) total Borg scores in DDD mode and VVI mode,oxygen consumption,quality-of-life benefits,exercise performance, cardiac chamber size, cardiac output, functional status and health perception,arterial pressure,Patient preference, symptom scores, "daily activity exercises," and perceived level of exercise (Borg score,blood pressure,incidence of stroke,DDD pacing,Symptom scores, maximal exercise performance on a treadmill, and the plasma concentrations of atrial natriuretic peptide, adrenaline, and noradrenaline,quality of life,shortness of breath, dizziness, fatigue, pulsations in the neck or abdomen, cough, and apprehension,stroke volume,exercise peak systolic blood pressure,quality of life or prespecified clinical outcomes (including cardiovascular events or death,incidence of atrial fibrillation,incidence of stroke and atrial fibrillation,rate of atrial fibrillation,exercise time, Borg ratings, and respiratory rate during submaximal exercise,Exercise performance and Borg scores,DDD pacing (mean (SD) daytime systolic blood pressure,symptoms of general well-being, palpitations, dizziness, pulsating sensation in the neck or abdomen, shortness of breath at rest and during effort, chest pain, and NYHA classification,risk of atrial fibrillation,breathlessness, fatigue, and dizziness,VVIR (ventricular demand rate-responsive), DDIR (dual chamber demand rate-responsive), DDD (dual chamber universal) or DDDR,left atrial diameter,VVI and DDD modes maximal atrial rates,annual rate of stroke or death due to cardiovascular causes,Quality of life and clinical outcomes,quality of life and cardiac function,mitral and tricuspid regurgitation,Bloodflow variability,exercise performance,Systolic blood pressure,chamber dimensions, left ventricular fractional shortening or pulmonary artery pressure,chest pain,A quality-of-life and cardiovascular symptom questionnaire,Perceived general well-being and exercise capacity,maximal effort tolerance,submaximal exercise tolerance, atrial synchronous (DDD) and activity rate modulated ventricular (VVI,R) pacing,health-related quality of life as measured by the 36-item Medical Outcomes Study Short-Form General Health Survey,paced rate,ability to climb stairs,symptom scores,Cardiac output,Maximal symptom limited exercise,Change in subjective (general health perception, symptoms) and objective (clinical assessment, treadmill exercise, and radiological and echocardiographic indices,incidence of ventricular pacing and arrhythmias (Holter recording), diurnal blood pressure changes (ambulatory blood pressure recording), and symptom and quality of life level (questionnaires and interviews,stroke or death due to cardiovascular causes,Mean distance walked,Symptom scores during VVI and VVIR pacing,DDD pacing and no patient preferred VVI pacing,cardiovascular symptoms, physical activity, psychosocial and emotional functioning, and self-perceived health|Ventricular demand pacing in elderly patients with complete heart block is associated with higher symptom scores, reduced exercise ability and greater perceived exercise difficulty compared with dual-chamber pacing.
395|Self-efficacy,substance abuse aftercare participation,adherence and lowering blood pressures,Return rates for reaction readings,Self-reported adherence,Adherence,asthma morbidity and mortality,compliance levels,Compliance levels,overall rate of treatment completion,compliance rates,opiate positives,antabuse compliance,systolic and diastolic blood pressure,Reduction of lower extremity clinical abnormalities,blood pressure,adherence to requests for regular medical care, Max L,self-efficacy and mastery,AUDIT and Addiction Severity Index alcohol scores,blood pressure levels,use of JP,longer periods of continuous abstinence,dermatologic abnormalities,slower weight gain,BSE frequency,BSE adherence,pain, functional disability, grip strength, self-efficacy or helplessness,weight,serious foot lesions,1-year abstinence rates,diastolic blood pressures,lowering blood pressures,Adherence with JP|An intervention designed to reduce risk factors for lower extremity amputations positively affected patient self-foot-care behavior as well as the foot care given by health care providers and reduced the prevalence of lower extremity clinical disease in patients with diabetes.